

**Funding Opportunities Monthly Edition
Oct 2024 Due Dates**

Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in Oct 2024. The opportunities are organized in the following order:

1. [National Institutes of Health \(NIH\)](#)
2. [National Science Foundation \(NSF\)](#)
3. [Other Federal](#)
4. [Non Federal](#)

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
121794	Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-23-308	09-Sep-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Sandra L. San Miguel-Majors, DrPH, M.S.</p> <p>Contact Telephone 240-276-5977</p> <p>Contact Email sandra.sanmiguel@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Sep-2024 [Optional][LOI/Pre-App], 09-Oct-2024 , 09-Sep-2025 [Optional][LOI/Pre-App], 09-Oct-2025</p> <p>Synopsis This funding opportunity seeks to support the Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) Program. The CPACHE Program develops and maintains comprehensive, long-term, and mutually beneficial partnerships between institutions serving underserved health disparity populations and underrepresented students (ISUPs) and NCI-designated Cancer Centers (CCs). The program aims to achieve a stronger national cancer program and address challenges in cancer and cancer disparities research, education, and outreach, as well as cancer's impact on underserved populations. The institutions in each partnership are expected to work collaboratively to: 1) increase the cancer research and cancer research education capacity of the ISUPs; 2) promote the diversity of the cancer research workforce; 3) improve the effectiveness of CCs in developing and sustaining research programs focused on cancer health disparities and increase the number of investigators and students conducting cancer health disparities research; and 4) develop and implement cancer-related outreach and education initiatives that benefit the surrounding underserved communities.</p>				
122679	RFA-CA-24-011 -- Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-24-011	01-Sep-2024 [Optional][LOI/Pre-App]	900,000 USD
	<p>Contact Name Kelly Crotty, Ph.D.</p> <p>Contact Telephone 240-255-0917</p> <p>Contact Email kelly.crotty@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Sep-2024 [Optional][LOI/Pre-App], 01-Oct-2024</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This NOFO will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing to use existing technologies where the novelty resides in the application of the technology or the biological or clinical question being pursued, and not the technical capabilities being developed, are not appropriate for this NOFO and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

122678	RFA-CA-24-010 -- Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA- 01-Sep-2024 24-010 [Optional][LOI/Pre-App]	01-Sep-2024	450,000 USD
--------	--	------------------------------------	---	-------------	----------------

Contact Name	Kelly Crotty, Ph.D.
Contact Telephone	240-255-0917
Contact Email	kelly.crotty@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	01-Sep-2024 [Optional][LOI/Pre-App], 01-Oct-2024
Synopsis	This Notice of Funding Opportunity (NOFO) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This NOFO will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, or address

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

122672	RFA-CA-24-008 -- Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-24-008	01-Sep-2024 [Optional][LOI/Pre-App]	450,000 USD
--------	--	------------------------------------	---------------	-------------------------------------	-------------

Contact Name | Kelly Crotty, Ph.D.
 Contact Telephone | 240-255-0917
 Contact Email | kelly.crotty@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 01-Sep-2024 [Optional][LOI/Pre-App], 01-Oct-2024

Synopsis | This Notice of Funding Opportunity (NOFO) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic, clinical, or epidemiological cancer research. The emphasis of this NOFO is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

122688	RFA-CA-24-014 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-24-014	01-Sep-2024 [Optional][LOI/Pre-App]	150,000 USD
--------	--	------------------------------------	---------------	-------------------------------------	-------------

Contact Name | Kelly Crotty, Ph.D.
 Contact Telephone | :240-255-0917
 Contact Email | kelly.crotty@nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Sep-2024 [Optional][LOI/Pre-App], 01-Oct-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to encourage revision applications from currently funded NCI P50 specialized centers proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this NOFO are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this NOFO aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.</p>				
122686	<p>RFA-CA-24-013 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)</p>	National Cancer Institute/NIH/DHHS	RFA-CA- 24-013	01-Sep-2024 [Optional][LOI/Pre-App]	150,000 USD
	<p>Contact Name Kelly Crotty, Ph.D.</p> <p>Contact Telephone :240-255-0917</p> <p>Contact Email kelly.crotty@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Sep-2024 [Optional][LOI/Pre-App], 01-Oct-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to encourage revision applications from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this NOFO are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this NOFO aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.</p>				
122683	<p>RFA-CA-24-012 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)</p>	National Cancer Institute/NIH/DHHS	RFA-CA- 24-012	01-Sep-2024 [Optional][LOI/Pre-App]	150,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Kelly Crotty, Ph.D.</p> <p>Contact Telephone :240-255-0917</p> <p>Contact Email kelly.crotty@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Sep-2024 [Optional][LOI/Pre-App], 01-Oct-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to encourage revision applications from currently funded NCI R01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this NOFO are meant to incentivize independent validation and accelerate the adoption of these emerging technologies by appropriate research communities. As a component of the NCI IMAT program, this NOFO aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.</p>				
122738	<p>RFA-CA-24-009 -- Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)</p>	National Cancer Institute/NIH/DHHS	RFA-CA-24-009	01-Sep-2024 [Optional][LOI/Pre-App]	900,000 USD
	<p>Contact Name Kelly Crotty, Ph.D.</p> <p>Contact Telephone 240-255-0917</p> <p>Contact Email kelly.crotty@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Sep-2024 [Optional][LOI/Pre-App], 01-Oct-2024</p> <p>Synopsis This Notice of Funding Opportunity Announcement (NOFO) invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic, clinical, or epidemiological cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.</p>				
122689	RFA-CA-24-015 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P30 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-24-015	01-Sep-2024 [Optional][LOI/Pre-App]	150,000 USD
	<p>Contact Name Kelly Crotty, Ph.D. Contact Telephone :240-255-0917 Contact Email kelly.crotty@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 01-Sep-2024 [Optional][LOI/Pre-App], 01-Oct-2024 Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to encourage revision applications from active P30 Cancer Center Support Grants (CCSG) to support an expansion of cancer research conducted in a cancer center by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program into a pilot cancer research project. As a component of the NCI IMAT program, this NOFO is meant to promote interdisciplinary collaboration in the development of innovative tools and methods as well as incentivize independent validation and accelerate the suitability of these emerging technologies to enable cancer research and accelerate scientific discovery.</p>				
120726	Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-23-259	05-Oct-2024	2,499,995 USD
	<p>Contact Name Darrell Tata, Ph.D. Contact Telephone 240-276-5894 Contact Email Darrell.Tata@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Oct-2026</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, or treatment of cancer. A distinguishing feature of each application to this NOFO will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the NOFO acts more as a funding mechanism for driving translational research in imaging than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or establish new ones that would drive the field of imaging, as a whole, further than if they had not been formed. This NOFO defines innovation as the likelihood to deliver a new capability to end users. This funding announcement will support clinical trials that test functionality or validate performance in the chosen setting. However, this NOFO is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation.</p>				
114325	<p>Mechanistic Links Between Diet, Lipid Metabolism, and Tumor Growth and Progression (U01 Clinical Trial Not Allowed)</p>	National Cancer Institute/NIH/DHHS	PAR-23-051	23-Oct-2024	2,500,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Kristine Willis, Ph.D.</p> <p>301-792-1338</p> <p>Kristine.Willis@nih.gov</p> <p></p> <p>Link to program URL</p> <p>23-Oct-2024 , 14-Feb-2025 , 23-Oct-2025</p> <p>The purpose of this funding opportunity announcement is to request applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking diet with the biology of cancer; bridge the historically divided fields of nutrition and molecular metabolism; and stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry.</p>			
114326	<p>Mechanistic Links Between Diet, Lipid Metabolism, and Tumor Growth and Progression (UH2 Clinical Trial Not Allowed)</p>	National Cancer Institute/NIH/DHHS	PAR-23-052	23-Oct-2024	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p>	<p>Kristine Willis, Ph.D.</p> <p>301-792-1338</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email Kristine.Willis@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Oct-2024 , 14-Feb-2025 , 23-Oct-2025</p> <p>Synopsis The purpose of this funding opportunity announcement is to request applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking diet with the biology of cancer; bridge the historically divided fields of nutrition and molecular metabolism; and stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry. For this announcement, unpublished preliminary data are limited to one figure, comprising no more than one-half page, to facilitate the entry of qualified new investigators to the field.</p>				
121292	Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-23-298	21-Oct-2024	Not Specified
	<p>Contact Name Alexa Romberg Ph.D.</p> <p>Contact Telephone 301-435-0264</p> <p>Contact Email alexa.romberg@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Oct-2024 , 07-Jan-2025 , 21-Oct-2025 , 07-Jan-2026 , 25-Oct-2026 , 07-Jan-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support research on interventions to improve health in Native American populations. This includes 1) etiologic research that will directly inform intervention development or adaptations, 2) research that develops, adapts, or tests interventions for health promotion, prevention, treatment, or recovery, and 3) where a sufficient body of knowledge on intervention efficacy exists, research on dissemination and implementation that develops and tests strategies to overcome barriers to the adoption, integration, scale-up, and sustainability of effective interventions. Through this initiative, intervention and related research is sought to build upon community knowledge, resources, and resilience to identify and rigorously test culturally appropriate solutions to reduce morbidity and mortality. Interventions should be designed with a consideration for sustainability within the communities where they are tested, and have the flexibility to be readily adapted, disseminated, and scaled up to other communities where culturally appropriate. This NOFO is part of the Intervention Research to Improve Native American Health (IRINAH) initiative, which also</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	includes NOFOs using the R21 Exploratory/Developmental Research Grant mechanism (PAR-23-299) and the Clinical Trial Planning Grant mechanism (PAR-23-285). For the purposes of this NOFO, Native Americans include the following populations: Alaska Natives, American Indians (whose ancestral lands fall at least partially within the U.S. mainland border), and Native Hawaiians. The term 'Native Hawaiian' means any individual any of whose ancestors were natives, prior to 1778, of the area which now comprises the State of Hawaii.				
121293	Intervention Research to Improve Native American Health (R21 Clinical Trials Optional)	National Cancer Institute/NIH/DHHS	PAR-23-299	21-Oct-2024	275,000 USD
	<p>Contact Name Alexa Romberg Ph.D.</p> <p>Contact Telephone 301-435-0264</p> <p>Contact Email alexa.romberg@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Oct-2024 , 07-Jan-2025 , 21-Oct-2025 , 07-Jan-2026 , 25-Oct-2026 , 07-Jan-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support developmental/exploratory research to improve health in Native American populations. This includes 1) etiologic research that will directly inform intervention development or adaptations, 2) research that develops, adapts, or tests interventions for health promotion, prevention, treatment, or recovery, and 3) where a sufficient body of knowledge on intervention efficacy exists, research on strategies to overcome barriers to the adoption, integration, scale-up, and sustainability of effective interventions. Through this initiative, culturally appropriate and community-engaged exploratory/developmental research is sought that builds upon Native community knowledge, resources, and resilience to provide foundational knowledge that will inform effective and scalable interventions. This NOFO is part of the Intervention Research to Improve Native American Health (IRINAH) initiative, which also includes PAR-23-298, which uses the Research Project Grant (R01) mechanism and PAR-23-285, which uses the Clinical Trial Planning Grant (R34) mechanism. For the purposes of this NOFO, Native Americans include the following populations: Alaska Natives, American Indians (whose ancestral lands fall at least partially within the U.S. mainland border), and Native Hawaiians. The term 'Native Hawaiian' means any individual any of whose ancestors were natives, prior to 1778, of the area which now comprises the State of Hawaii.</p>				
106546	Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-21-329	05-Oct-2024	Not Specified
	<p>Contact Name Kelly Filipski PhD, MPH</p> <p>Contact Telephone 240-276-6841</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email Filipskikk@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and/or clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on 1) mechanistic studies with translational endpoints; and/or 2) longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.</p>				
108548	Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22-083	05-Oct-2024	Not Specified
	<p>Contact Name Tram Kim Lam, Ph.D., MPH</p> <p>Contact Telephone 240-276-6967</p> <p>Contact Email Tram.Lam@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.</p>				
108551	Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-099	05-Oct-2024	2,000,000 USD
	<p>Contact Name Steven Becker, Ph.D.</p> <p>Contact Telephone 240-276-6210</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email steven.becker@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this FOA will collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.</p>				
109909	Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22-139	05-Oct-2024	2,500,000 USD
	<p>Contact Name Michael Graham Espey, Ph.D.</p> <p>Contact Telephone 240-276-7619</p> <p>Contact Email SP@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to solicit R01 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.</p>				
111847	Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-164	05-Oct-2024	2,500,000 USD
	<p>Contact Name Kelly D. Blake, ScD</p> <p>Contact Telephone 240-281-5934</p> <p>Contact Email kelly.blake@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.</p>				
111859	Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-198	05-Oct-2024	Not Specified
	<p>Contact Name Michael Graham Espey, Ph.D.</p> <p>Contact Telephone 240-276-5609</p> <p>Contact Email SP@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R01 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.</p>				
117334	Impacts of Climate Change Across the Cancer Control Continuum (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-23-153	05-Oct-2024	Not Specified
	<p>Contact Name Curt DellaValle, Ph.D., MPH</p> <p>Contact Telephone 240-276-7225</p> <p>Contact Email curt.dellavalle@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026</p> <p>Synopsis This notice of funding opportunity (NOFO) aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control and behaviors.</p>				
107221	Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22-061	05-Oct-2024	Not Specified
	<p>Contact Name Phillip J. Daschner, M.Sc.</p> <p>Contact Telephone 240-276-6227</p> <p>Contact Email PD93u@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites target immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter its effectiveness and thus those parameters should be rigorously addressed in the application.</p>				
110471	Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-131	05-Oct-2024	Not Specified
	<p>Contact Name Sudhir Srivastava, Ph.D., MPH</p> <p>Contact Telephone 240-276-7028</p> <p>Contact Email srivasts@mail.nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other -omic integration strategies for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions in a technology agnostic manner by improving sensitivity and specificity of applied tests. N-dimensional co-registered, cross-correlated imaging results integrated with multiplexed biomarker data and digital pathomics using analytic strategies such as artificial intelligence and virtual reality visualization for improving discovery are encouraged. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false negatives.</p>				
112619	Biology of Bladder Cancer (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-218	05-Oct-2024	Not Specified
	<p>Contact Name Ron Johnson, Ph. D.</p> <p>Contact Telephone 240-276-6250</p> <p>Contact Email rjohnso2@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications that investigate the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression and malignancy of bladder cancer. Furthermore, our understanding of the biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and contribute to the future development of new interventions.</p>				
114678	Co-infection and Cancer (R01 Clinical Trial Not Allowed)	National Cancer	PAR-23-	05-Oct-2024	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Institute/NIH/DHHS	055		Specified
	<p>Contact Name Tram Kim Lam, Ph.D., MPH</p> <p>Contact Telephone 240-276-6967</p> <p>Contact Email lamt@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.</p>				
120755	Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-23-264	05-Oct-2024	Not Specified
	<p>Contact Name Suzanne Forry, Ph.D.</p> <p>Contact Telephone 240-276-5922</p> <p>Contact Email forryscs@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate research in discovery and development of novel, small molecules for cancer. Molecules discovered through this NOFO may be used to probe cancer biology, to validate cancer targets, or as the basis for optimized drugs. Stages of discovery research covered by this NOFO include: 1) development of the primary screen assay(s) and testing in an initial pilot screen; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.</p>				
120756	Understanding Expectancies in Cancer Symptom Management (R01 Clinical	National Cancer	PAR-23-	05-Oct-2024	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Trial Required	Institute/NIH/DHHS	273		Specified
	<p>Contact Name Rebecca Ferrer</p> <p>Contact Telephone 240-276-6914</p> <p>Contact Email ferrerra@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) will solicit mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. Expectancies are defined in this context as beliefs about future outcomes, including one's response to cancer or cancer treatment. Expectancies can be evoked by social, psychological, environmental, and systemic factors. Expectancy effects are the cognitive, behavioral, and biological outcomes caused by expectancies. Expectancy effects can be generated by expectancies held by patients, clinicians, family members, caregivers, and/or dyadic/social networks. Program is particularly interested in applications that enroll individuals and groups from populations historically underrepresented or excluded from biomedical and behavioral research.</p>				
126403	<p>RFA-CA-24-027 -- Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers (R01 Clinical Trial Optional)</p>	National Cancer Institute/NIH/DHHS	RFA-CA-24-027	12-Sep-2024 [Optional][LOI/Pre-App]	2,495,000 USD
	<p>Contact Name Lynn S. Adams, PhD</p> <p>Contact Telephone 202-570-5079</p> <p>Contact Email adamsls@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Sep-2024 [Optional][LOI/Pre-App], 11-Oct-2024</p> <p>Synopsis Through this notice of funding opportunity (NOFO) as a request for applications (RFA), the NCI intends to support multi-level intervention studies that address individual and system level barriers to transition from pediatric to adult care for survivors of childhood and adolescent cancers. The goal of this opportunity is to support the development and testing of interventions and strategies that promote high-quality transitional care and continued engagement of survivors of childhood and adolescent cancers to ensure these survivors receive appropriate surveillance and care into adulthood. Overall, it is</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		anticipated that this research will provide critical evidence for establishing best practices and standards of care that can be widely disseminated and adopted.			
120897	Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-23-281	05-Oct-2024	2,495,000 USD
	<p>Contact Name: Joanna Watson, Ph.D.</p> <p>Contact Telephone: 240-276-6206</p> <p>Contact Email: Joanna.Watson@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis: Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. The NCI, through this NOFO encourages submission of projects devoted to demonstrating that mammalian models, including organoids, tumoroids and cell models, used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patient benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this NOFO could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.</p>				
120973	Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-23-279	05-Oct-2024	Not Specified
	<p>Contact Name: Edward R. Sauter, MD, PhD</p> <p>Contact Telephone: 240-276-7657</p> <p>Contact Email: edward.sauter@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer. Investigators wishing to study incretin mimetics other than GLP-1 RAs or GLP-1/GIP-1 RAs, such as dipeptidyl peptidase (DPP)-4 inhibitors, must justify why the agent(s) they propose to study are more effective and/or have a more favorable side effect profile than GLP-1 or GLP-1/GIP-1 RAs. Route of agent administration (oral vs. other) is, by itself, not an adequate justification.</p>				
123579	Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-24-122	05-Oct-2024	1,250,000 USD
	<p>Contact Name Scott Rogers, MPH</p> <p>Contact Telephone 240-276-6932</p> <p>Contact Email rogerssc@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024</p> <p>Synopsis This notice of funding opportunity (NOFO) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, digital health and data science, and implementation science.</p>				
123053	National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-24-085	07-Sep-2024	2,499,995 USD
	<p>Contact Name Lori A. Henderson, Ph.D.</p> <p>Contact Telephone 240-276-5930</p> <p>Contact Email hendersonlori@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) is soliciting research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of DCTD and OHAM. The proposed project must involve at least 1 clinical trial related to the scientific interests of one or more of the following research programs: Cancer Therapy Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, Radiation Research Program, Complementary and Alternative Medicine Program and/or the HIV and AIDS Malignancies Research Programs. Applicants may propose to conduct an early phase trial by itself, or in combination with another research aim(s) as appropriate. This NOFO does not accept Phase III clinical trials.</p>				
123051	Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-24-072	07-Sep-2024	Not Specified
	<p>Contact Name Brandy Heckman-Stoddard, Ph.D., M.P.H.</p> <p>Contact Telephone 240-276-7048</p> <p>Contact Email heckmanbm@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 05-Jan-2027</p> <p>Synopsis Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this NOFO must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this NOFO and the application instructions. This NOFO does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients.</p>				
112622	Biology of Bladder Cancer (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-219	16-Oct-2024	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Ron Johnson, Ph. D.</p> <p>Contact Telephone 240-276-6250</p> <p>Contact Email rjohnso2@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications that investigate the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression and malignancy of bladder cancer. Furthermore, our understanding of the biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and contribute to the future development of new interventions.</p>				

114679	Co-infection and Cancer (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-23-056	16-Oct-2024	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

	<p>Contact Name Tram Kim Lam, Ph.D., MPH</p> <p>Contact Telephone 240-276-6967</p> <p>Contact Email lamt@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.</p>				
--	--	--	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
121014	Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-23-280	16-Oct-2024	275,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Edward R. Sauter, MD, PhD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-276-7657</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>edward.sauter@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer.</td> </tr> </table>					Contact Name	Edward R. Sauter, MD, PhD	Contact Telephone	240-276-7657	Contact Email	edward.sauter@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026	Synopsis	Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer.
Contact Name	Edward R. Sauter, MD, PhD																		
Contact Telephone	240-276-7657																		
Contact Email	edward.sauter@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026																		
Synopsis	Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer.																		
114360	Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-22-256	17-Oct-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Wynne E. Norton, PhD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-276-6875</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>wynne.norton@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>17-Oct-2024 , 14-Feb-2025 , 14-Jun-2025 , 17-Oct-2025</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) intends to accelerate the development of evidence-based cancer-related interventions that reflect the diversity of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.</td> </tr> </table>					Contact Name	Wynne E. Norton, PhD	Contact Telephone	240-276-6875	Contact Email	wynne.norton@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	17-Oct-2024 , 14-Feb-2025 , 14-Jun-2025 , 17-Oct-2025	Synopsis	Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) intends to accelerate the development of evidence-based cancer-related interventions that reflect the diversity of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.
Contact Name	Wynne E. Norton, PhD																		
Contact Telephone	240-276-6875																		
Contact Email	wynne.norton@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	17-Oct-2024 , 14-Feb-2025 , 14-Jun-2025 , 17-Oct-2025																		
Synopsis	Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) intends to accelerate the development of evidence-based cancer-related interventions that reflect the diversity of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.																		
106892	Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)	National Cancer	PAR-21-	08-Oct-2024	275,000														

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Institute/NIH/DHHS	341		USD
	<p>Contact Name Mukesh Verma, Ph.D.</p> <p>Contact Telephone 240-276-6889</p> <p>Contact Email vermam@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Oct-2024 , 08-Nov-2024</p> <p>Synopsis Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, interventions, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical).</p>				
122281	<p>Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)</p>	National Cancer Institute/NIH/DHHS	PAR-23-313	08-Oct-2024	Not Specified
	<p>Contact Name Tracy G. Lively, Ph.D.</p> <p>Contact Telephone 240-276-5944</p> <p>Contact Email livelyt@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Oct-2024 , 14-Feb-2025 , 11-Jun-2025 , 15-Oct-2025 , 13-Feb-2026 , 10-Jun-2026 , 14-Oct-2026</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

increasingly combined with immunotherapies to enhance durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this NOFO supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this NOFO supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays. Investigators responding to this NOFO must address both UH2 and UH3 phases. Milestones to be accomplished in the UH2 phase for transition to the UH3 phase must be proposed by the investigators.

122288	Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-23-314	08-Oct-2024	750,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	Tracy G. Lively, Ph.D.
Contact Telephone	240-276-5944
Contact Email	livelyt@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Oct-2024 , 14-Feb-2025 , 11-Jun-2025 , 15-Oct-2025 , 13-Feb-2026 , 10-Jun-2026 , 14-Oct-2026

Synopsis
 Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other trials, observational studies, or

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multidisciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.

106230	NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-21-296	12-Oct-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name | Mulualem E. Tilahun, D.V.M., Ph.D
 Contact Telephone | 240-276-7360
 Contact Email | mulualem.tilahun@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 12-Oct-2024

Synopsis | This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA.

108550	Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22-084	16-Oct-2024	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name | Tram Kim Lam, Ph.D., MPH
 Contact Telephone | 240-276-6967
 Contact Email | Tram.Lam@nih.gov
 Sponsor Website |

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024 , 16-Feb-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.</p>				
108359	Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-091	16-Oct-2024	275,000 USD
	<p>Contact Name Miguel R. Ossandon, Ph.D.</p> <p>Contact Telephone 240-276-5714</p> <p>Contact Email ossandom@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024</p> <p>Synopsis The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA</p>				
113074	The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22-234	23-Sep-2024 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name Joanna M. Watson, Ph.D.</p> <p>Contact Telephone 240-276-6206</p> <p>Contact Email watsonjo@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Sep-2024 [Optional][LOI/Pre-App], 23-Oct-2024 , 20-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The National Cancer Institute's (NCI) Metastasis Research Network (MetNet) is a collection of U54 Research Centers that support using systems-level approaches to understand pressing questions in metastasis. The overall goal of the MetNet is to advance our understanding of metastasis as a whole body, systems-level problem to develop a comprehensive and cohesive picture of the processes involved. Through this Funding Opportunity Announcement (FOA), the NCI invites applications for MetNet Research Projects. These Research Projects should be defined as discrete entities that use systems-level approaches to address gaps and opportunities in metastasis research to integrate into the MetNet and complement ongoing research across the Network.</p>			
114550	NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-23-058	07-Sep-2024	100,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email				
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Sep-2024 , 17-Oct-2024 , 07-Jan-2025 , 24-Feb-2025 , 07-May-2025 , 20-Jun-2025 , 07-Sep-2025 , 17-Oct-2025 , 07-Jan-2026			
	Synopsis	<p>This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.</p>			
122437	NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)	National Cancer Institute/NIH/DHHS	PAR-23-288	15-Oct-2024	Not Specified
	Contact Name	Sergey Radaev, PhD			
	Contact Telephone	240-276-5630			
	Contact Email	sradaev@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Oct-2024 , 14-Feb-2025 , 16-Jun-2025 , 14-Oct-2025 , 17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p>Synopsis</p>	<p>The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-23-286). This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>			
--	-----------------	---	--	--	--

122436	NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-23-287	15-Oct-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Sergey Radaev, PhD
Contact Telephone	240-276-5630
Contact Email	sradaev@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	15-Oct-2024 , 14-Feb-2025 , 16-Jun-2025 , 14-Oct-2025 , 17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026
Synopsis	The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This notice of funding opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-23-286).

122435	NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-23-286	15-Oct-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Sergey Radaev, PhD
Contact Telephone	240-276-5630
Contact Email	sradaev@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	15-Oct-2024 , 14-Feb-2025 , 16-Jun-2025 , 14-Oct-2025 , 17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026

Synopsis The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFOs (PAR-23-287 or PAR-23-288).

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
109910	Systematic Testing of Radionuclides in Preclinical Experiments (STRIFE) (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22-140	16-Oct-2024	275,000 USD
	<p>Contact Name: Michael Graham Espey, Ph.D.</p> <p>Contact Telephone: 240-276-7619</p> <p>Contact Email: SP@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 16-Oct-2024 , 16-Feb-2025</p> <p>Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to solicit R21 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.</p>				
110931	Notice of Special Interest (NOSI): Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer	National Cancer Institute/NIH/DHHS	NOT-CA-22-085	07-Sep-2024	Not Specified
	<p>Contact Name: Ron Johnson, Ph.D.</p> <p>Contact Telephone: 240-276-6250</p> <p>Contact Email: rjohnso2@mail.nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 07-Sep-2024 , 05-Oct-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 12-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 12-Oct-2026 , 16-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 12-Feb-2027 , 16-Feb-2027 , 07-May-2027</p> <p>Synopsis: The purpose of this Notice of Special Interest (NOSI) is to promote research in understanding the mechanisms by which cannabis and cannabinoids affect cancer biology, cancer interception, cancer treatment and resistance, and management of cancer symptoms.</p>				
106319	Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21-330	11-Oct-2024	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Claire Zhu, Ph.D.</p> <p>Contact Telephone 240-276-7013</p> <p>Contact Email zhucla@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Oct-2024</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from both the screened and the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens and may include other resources; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research on non-cancer outcomes, especially those related to aging (e.g., Alzheimer’s, depression, hip fracture, osteoporosis and rheumatoid arthritis) may also be supported. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.</p>				
115306	Notice of Special Interest (NOSI): Research on the Etiology, Early Detection, Screening and Prevention of Early-Onset Colorectal Cancer	National Cancer Institute/NIH/DHHS	NOT-CA-23-018	07-Sep-2024	Not Specified
	<p>Contact Name Gary Della’Zanna</p> <p>Contact Telephone 240-276-7042</p> <p>Contact Email Gary.DellaZanna@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 25-Sep-2024 , 08-Oct-2024 , 10-Oct-2024 , 12-Oct-2024 , 25-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to solicit applications directed toward identifying, characterizing, and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	mitigating risk factors, identifying biomarkers for early detection, best screening modalities, and preventive interventions for early-onset colorectal cancer (EOCRC), defined as occurring before 50 years of age.																		
115286	Notice of Special Interest (NOSI): Career Development Opportunities for Research Within the Mission of the Division of Cancer Prevention at the National Cancer Institute	National Cancer Institute/NIH/DHHS	NOT-CA-23-035	07-Sep-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%; padding-right: 5px;">Contact Name</td> <td>Jessica Faupel-Badger</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>240-276-7296</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>Jessica.Faupel-Badger@nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>07-Sep-2024 , 12-Oct-2024</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>This NOSI from the NCI expresses continued interest in receiving Career Development Award applications from early career scientists conducting research within the mission of the Division of Cancer Prevention.</td> </tr> </table>					Contact Name	Jessica Faupel-Badger	Contact Telephone	240-276-7296	Contact Email	Jessica.Faupel-Badger@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024	Synopsis	This NOSI from the NCI expresses continued interest in receiving Career Development Award applications from early career scientists conducting research within the mission of the Division of Cancer Prevention.
Contact Name	Jessica Faupel-Badger																		
Contact Telephone	240-276-7296																		
Contact Email	Jessica.Faupel-Badger@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024																		
Synopsis	This NOSI from the NCI expresses continued interest in receiving Career Development Award applications from early career scientists conducting research within the mission of the Division of Cancer Prevention.																		
123027	RFA-CA-24-016 -- Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-24-016	16-Oct-2024 [Optional][LOI/Pre-App]	275,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%; padding-right: 5px;">Contact Name</td> <td>Juli Klemm, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>202-853-7889</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>juli.klemm@nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>16-Oct-2024 [Optional][LOI/Pre-App], 15-Nov-2024</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The purpose of this Notice of Funding Opportunity (NOFO) is to invite exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, the emphasis of this NOFO is on supporting the development of novel informatics capabilities that involve a high degree of innovation that have the potential</td> </tr> </table>					Contact Name	Juli Klemm, Ph.D.	Contact Telephone	202-853-7889	Contact Email	juli.klemm@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	16-Oct-2024 [Optional][LOI/Pre-App], 15-Nov-2024	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to invite exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, the emphasis of this NOFO is on supporting the development of novel informatics capabilities that involve a high degree of innovation that have the potential
Contact Name	Juli Klemm, Ph.D.																		
Contact Telephone	202-853-7889																		
Contact Email	juli.klemm@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	16-Oct-2024 [Optional][LOI/Pre-App], 15-Nov-2024																		
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to invite exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, the emphasis of this NOFO is on supporting the development of novel informatics capabilities that involve a high degree of innovation that have the potential																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

to accelerate or enhance research. To be successful, there must be a clear rationale for how the proposed informatics method or algorithm is novel and how it will benefit the cancer research field. Projects with a significant level of data generation and/or data analysis will not be considered responsive to this funding opportunity.

123041	RFA-CA-24-019 -- Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-24-019	16-Oct-2024 [Optional][LOI/Pre-App]	Not Specified
--------	--	------------------------------------	---------------	-------------------------------------	---------------

Contact Name | Juli Klemm, Ph.D.
 Contact Telephone | 202-853-7889
 Contact Email | juli.klemm@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 16-Oct-2024 [Optional][LOI/Pre-App], 15-Nov-2024

Synopsis | The purpose of this Notice of Funding Opportunity (NOFO) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR NOFOs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justification for why the research resource should be maintained and how it has benefited and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and deep engagement between the resource and the targeted research community should be described.

123034	RFA-CA-24-018 -- Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-24-018	16-Oct-2024 [Optional][LOI/Pre-App]	3,000,000 USD
--------	--	------------------------------------	---------------	-------------------------------------	---------------

Contact Name | Juli Klemm, Ph.D.
 Contact Telephone | 202-853-7889
 Contact Email | juli.klemm@nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024 [Optional][LOI/Pre-App], 15-Nov-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. To be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult the companion NOFOs listed above.</p>				
123030	RFA-CA-24-017 -- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-24-017	16-Oct-2024 [Optional][LOI/Pre-App]	900,000 USD
	<p>Contact Name Juli Klemm, Ph.D.</p> <p>Contact Telephone 202-853-7889</p> <p>Contact Email juli.klemm@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024 [Optional][LOI/Pre-App], 15-Nov-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this NOFO as initial tool development or the significant modification of existing tools for new applications. The central mission of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

108323	Notice of Special Interest (NOSI): Disparities Affecting Healthcare Utilization and Health Outcomes Among Childhood Cancer Survivors	National Cancer Institute/NIH/DHHS	NOT-CA-22-029	25-Sep-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name | Veronica Chollette, RN, MS
 Contact Telephone | 240-276-6969
 Contact Email | cholletv@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 25-Sep-2024 , 08-Oct-2024

Synopsis | The purpose of this Notice is to highlight the interest of the National Cancer Institute (NCI) Division of Cancer Control and Population Sciences (DCCPS) in receiving applications to understand and address the full spectrum of factors that contribute to disparities in survivorship care, healthcare utilization, and health outcomes among childhood cancer survivors. Studies that focus on factors that extend beyond the individual (e.g., survivor, caregiver, clinician) to include an examination or intervention that involves healthcare teams, healthcare system, community, payer, and/or policy-level factors that contribute to disparities in health outcomes and result in inequitable survivorship care are strongly encouraged.

107760	Notice of Special Interest (NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment	National Cancer Institute/NIH/DHHS	NOT-CA-22-014	07-Sep-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name | Sallie J. Weaver, PhD, MHS
 Contact Telephone | 240-276-6254
 Contact Email | sallie.weaver@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 07-Sep-2024 , 25-Sep-2024 , 05-Oct-2024 , 08-Oct-2024

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This Notice of Special Interest (NOSI) highlights the NCI Healthcare Delivery Research Program's interest in receiving applications focused on understanding and improving interprofessional teamwork and coordination during cancer diagnosis and treatment.			
107222	Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22-062	16-Oct-2024	275,000 USD
	Contact Name	Phillip J. Daschner, M.Sc.			
	Contact Telephone	240-276-6227			
	Contact Email	PD93u@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Oct-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites target immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter their effectiveness and thus those parameters should be rigorously addressed in the application.			
111848	Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-165	16-Oct-2024	275,000 USD
	Contact Name	Kelly D. Blake, ScD			
	Contact Telephone	240-281-5934			
	Contact Email	kelly.blake@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025			
	Synopsis	Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>communication pilot interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.</p>				
111860	Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-199	16-Oct-2024	275,000 USD
	<p>Contact Name Michael Graham Espey, Ph.D. Contact Telephone 240-276-5609 Contact Email SP@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R21 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.</p>				
115117	Notice of Special Interest (NOSI): Adaptive Biomaterials for Cancer Biology	National Cancer Institute/NIH/DHHS	NOT-CA-23-030	07-Sep-2024	Not Specified
	<p>Contact Name Eric M. Johnson Chavarria, Ph.D. Contact Telephone 240-276-7416 Contact Email eric.johnsonchavarria@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 Synopsis The purpose of this Notice of Special Interest (NOSI) is to promote research focused on the development, adaptation, or</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	integration of innovative biomaterials for cancer biology. The applications of these new materials are expected to enable new insights into basic cancer research.				
117338	Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-23-152	16-Oct-2024	275,000 USD
	<p>Contact Name: Curt DellaValle, Ph.D., MPH</p> <p>Contact Telephone: 240-276-7225</p> <p>Contact Email: curt.dellavalle@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026</p> <p>Synopsis: This Notice of Funding Opportunity (NOFO) aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control and behaviors.</p>				
117714	Notice of Special Interest (NOSI): RNA Modifications in Cancer Biology	National Cancer Institute/NIH/DHHS	NOT-CA-23-060	07-Sep-2024	Not Specified
	<p>Contact Name: Stefan Maas, Ph.D.</p> <p>Contact Telephone: 240-276-6230</p> <p>Contact Email: stefan.maas@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 07-Sep-2024 , 05-Oct-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis: Through this Notice of Scientific Interest (NOSI), the National Cancer Institute intends to stimulate research on the role of RNA modifications in the area of cancer biology. Despite the recognition that RNA modifications and editing exert a substantial impact on gene expression and function, there is a lack of mechanistic insights into the dynamic regulation of RNA</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>modifications and their de-regulation as drivers of cancer formation. A better understanding of the extent, diversity, and crosstalk between different types of RNA modification, and the elucidation of the molecular players that read and interpret the modification code are needed to reveal the mechanisms of RNA modifications that underlie cancer formation and the cancer phenotype.</p>				
106228	NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21-295	12-Oct-2024	Not Specified
	<p>Contact Name Mulualem E. Tilahun, D.V.M., Ph.D Contact Telephone 240-276-7360 Contact Email mulualem.tilahun@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 12-Oct-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or a separate ancillary clinical trial as lead investigator, should apply to the companion FOA.</p>				
112021	Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)	National Cancer Institute/NIH/DHHS	PAR-22-174	07-Sep-2024	Not Specified
	<p>Contact Name Brandy Heckman-Stoddard, Ph.D., M.P.H. Contact Telephone 240-276-7048 Contact Email heckmanbm@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025 , 25-Feb-2025 , 07-May-2025 , 25-Jun-2025</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
112019	Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)	National Cancer Institute/NIH/DHHS	PAR-22-173	07-Sep-2024	Not Specified

Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns this can include a pilot/feasibility clinical trial if necessary, improving trial design and rigor.

Contact Name Brandy Heckman-Stoddard, Ph.D., M.P.H.
 Contact Telephone 240-276-7048
 Contact Email heckmanbm@mail.nih.gov
 Sponsor Website
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025 , 25-Feb-2025 , 07-May-2025 , 25-Jun-2025

Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns this can include a pilot/feasibility clinical trial if necessary, improving trial design and rigor.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
103024	Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-21-206	05-Oct-2024	2,495,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Miguel Ossandon MS</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-276-5714</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>ossandom@mail.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>05-Oct-2024 , 05-Nov-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td> <p>The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. This FOA is not intended to support straight clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA. This FOA does not propose to support commercial production or basic research projects.</p> </td> </tr> </table>					Contact Name	Miguel Ossandon MS	Contact Telephone	240-276-5714	Contact Email	ossandom@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Oct-2024 , 05-Nov-2024	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. This FOA is not intended to support straight clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA. This FOA does not propose to support commercial production or basic research projects.</p>
Contact Name	Miguel Ossandon MS																		
Contact Telephone	240-276-5714																		
Contact Email	ossandom@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Oct-2024 , 05-Nov-2024																		
Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. This FOA is not intended to support straight clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA. This FOA does not propose to support commercial production or basic research projects.</p>																		
112442	NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-216	10-Oct-2024	275,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>William C. Timmer, Ph.D</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-276-6130</td> </tr> </table>					Contact Name	William C. Timmer, Ph.D	Contact Telephone	240-276-6130										
Contact Name	William C. Timmer, Ph.D																		
Contact Telephone	240-276-6130																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email william.timmer@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Oct-2024 , 01-Nov-2024 , 13-Feb-2025 , 01-Mar-2025 , 12-Jun-2025 , 01-Jul-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among underserved populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative correlative studies in cancer patients with age, gender, racial/ethnic, or health disparities are encouraged to explore mechanisms underlying their differential responses (efficacy and toxicity) and resistance to therapeutic interventions. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways, molecular mechanisms, or mechanisms of metastasis), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed (see below for a more detailed description of studies that are not responsive for this FOA). The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to breakthroughs in particular areas, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research (preclinical or clinical).</p>				
113746	Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers	National Cancer Institute/NIH/DHHS	NOT-CA-23-004	05-Sep-2024	Not Specified
	<p>Contact Name Matthew Young, Ph.D.</p> <p>Contact Telephone 240-276-5846</p> <p>Contact Email matthew.young@nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Sep-2024 , 07-Sep-2024 , 01-Oct-2024 , 05-Oct-2024 , 10-Oct-2024 , 11-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 13-Feb-2025 , 01-Mar-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 01-Jul-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to encourage research studies leveraging partnerships between biomarker technology developers with assays for early cancer detection, and population-based researchers, including cohort and biorepository researchers. Proposals that facilitate early cancer biomarker assay development, verification, qualification, and validation utilizing statistically powered retrospective cohorts and/or through prospective studies in the appropriate populations with a sound study design are responsive to this NOSI.</p>				
113232	Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22-242	07-Sep-2024	Not Specified
	<p>Contact Name Rao Divi, Ph.D.</p> <p>Contact Telephone 240-276-6913</p> <p>Contact Email divir@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025</p> <p>Synopsis The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) develop, integrate, optimize, validate, translate or accelerate adoption of promising tools, methods and techniques: a) that fulfill an unmet need and address specific research or clinical problem in basic, translational, and/or clinical science and practice, b) capable of enhancing our understanding of health and disease, and/or c) improve practice of medicine. Applications may propose design-directed, developmental, discovery-driven, or hypothesis-driven research, and this FOA is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.</p>				
113233	Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-243	07-Sep-2024	Not Specified
	<p>Contact Name Rao Divi, Ph.D.</p> <p>Contact Telephone 240-276-6913</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email divir@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025</p> <p>Synopsis The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical, or translational science. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. This FOA is not intended to support conventional clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of research are not sought by and will not be supported through this FOA. This FOA does not propose to support commercial production.</p>				
105645	Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-21-290	07-Sep-2024	499,999 USD
	<p>Contact Name Shane Woodward</p> <p>Contact Telephone 240-276-6624</p> <p>Contact Email woodwars@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025</p> <p>Synopsis National Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
121826	Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-24-047	08-Oct-2024	450,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Sumana Dey, Ph.D.</p> <p>Contact Telephone 240-276-5748</p> <p>Contact Email sumana.dey@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Oct-2024 , 14-Feb-2025 , 11-Jul-2025 , 14-Oct-2025 , 13-Feb-2026 , 10-Jul-2026 , 13-Oct-2026</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose projects that are expected to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of applications submitted in response to this NOFO should be on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer prevention and control. Applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed in response to this NOFO encourage multidisciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.</p>				
127223	RFA-CA-24-029 -- RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA- 05-Oct-2024 24-029 [Optional][LOI/Pre-App]	05-Oct-2024	3,250,000 USD
	<p>Contact Name Stefan Maas, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email stefan.maas@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 [Optional][LOI/Pre-App], 04-Nov-2024</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for the RNA Modifications Driving Oncogenesis (RNAMoDO) initiative. This NCI initiative aims to promote fundamental studies in the</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>emerging area of RNA modifications that underlie the oncogenic process, focusing on the central role of RNA modifications in translational reprogramming of cancer cells. RNA modifications have been recognized to exert a substantial impact on gene expression and function and their de-regulation has been linked to the cancer phenotype. In particular, recent insights point to a crucial role for mRNA, tRNA, and rRNA modifications in translational reprogramming during tumor initiation, progression, and adaptation to therapy. However, the molecular mechanisms underlying this reshaping of the transcriptome caused by dynamic changes in RNA modifications, as well as the interplay between different RNA modifications within and/or across RNA molecules during translation, are not understood and represent the focus of this initiative. This new program will be composed of up to five U01 grants that will be supported by this NOFO.</p>				
123791	NCCIH Natural Product Mid Phase Clinical Trial Cooperative Agreement (U01 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24-115	21-Oct-2024	1,750,000 USD
	Contact Name	Sekai Chideya, M.D., MPH			
	Contact Telephone	301-827-1916			
	Contact Email	sekai.chideya@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	21-Oct-2024 , 13-Nov-2024 , 23-Jun-2025 , 17-Jul-2025 , 23-Feb-2026 , 17-Mar-2026 , 20-Oct-2026 , 13-Nov-2026			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) invites cooperative agreement applications for investigator-initiated mid-phase clinical trials of natural products. All applications submitted under this FOA must be supported by sufficient preliminary data of bioavailability and documentation that the natural product produces a replicable and measurable impact on a biological signature (i.e., measure of the mechanism of action). Only in cases when it is not possible/practical to measure a biological signature in the patient population of interest or when there is a fundamental understanding of the product's mechanism of action will this preliminary data requirement be waived. Applications submitted to this FOA should propose a mid-phase clinical trial to do the following: determine the optimal dose or formulation of a given natural product for use in a future multi-site clinical trial; or determine which patient phenotypes will be responders versus non-responders to the natural product to inform inclusion/exclusion criteria of a future efficacy study. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This FOA will not support single-site or multi-site efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
126574	Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24-238	01-Oct-2024	1,750,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Hye-Sook Kim, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-827-6910</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>hye-sook.kim@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>01-Oct-2024 , 02-Jun-2025 , 02-Feb-2026 , 01-Oct-2026 , 02-Jun-2027</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td> <p>The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate the development of effective precision probiotic interventions using a milestone-driven, biphasic award mechanism. It aims to identify, understand, and develop strategies to address barriers in precision probiotic interventions to account for the heterogeneity in humans that often causes inconsistent probiotic therapeutic responses. Specifically, this NOFO solicits applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders, which may then help enhance probiotic clinical outcomes. The first phase, funded by the R61 mechanism, will provide 1 or 2 years of support to identify host biological patterns (e.g., native microbiome, immune system, sex and/or gender, diet, age, genetic background, lifestyle, or health history) that are correlated with differences in probiotic clinical effects using observational or secondary data analysis studies. The second phase, funded under the R33 mechanism, will support studies to assess the causality of the factors identified in the R61 phase that impact probiotic responsiveness through rigorous mechanistic study designs in animal models or human subjects. This NOFO will not support efficacy or effectiveness clinical trials. The combined R61/R33 should not exceed 5 years. Transition to the R33 phase requires administrative review by NIH staff and is not guaranteed. Approval of the transition to the R33 phase will be based on the original R61/R33 peer review recommendations, successful completion of transition milestones, any proposed changes to the R33 research based on R61 findings, program priorities, and availability of funds. It is not expected that all applications will continue to the R33 phase. Support for a single phased award that does not need the R61 Exploratory phase is available in the companion (R33) NOFO, PAR-24-239. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p> </td> </tr> </table>					Contact Name	Hye-Sook Kim, Ph.D.	Contact Telephone	301-827-6910	Contact Email	hye-sook.kim@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	01-Oct-2024 , 02-Jun-2025 , 02-Feb-2026 , 01-Oct-2026 , 02-Jun-2027	Synopsis	<p>The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate the development of effective precision probiotic interventions using a milestone-driven, biphasic award mechanism. It aims to identify, understand, and develop strategies to address barriers in precision probiotic interventions to account for the heterogeneity in humans that often causes inconsistent probiotic therapeutic responses. Specifically, this NOFO solicits applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders, which may then help enhance probiotic clinical outcomes. The first phase, funded by the R61 mechanism, will provide 1 or 2 years of support to identify host biological patterns (e.g., native microbiome, immune system, sex and/or gender, diet, age, genetic background, lifestyle, or health history) that are correlated with differences in probiotic clinical effects using observational or secondary data analysis studies. The second phase, funded under the R33 mechanism, will support studies to assess the causality of the factors identified in the R61 phase that impact probiotic responsiveness through rigorous mechanistic study designs in animal models or human subjects. This NOFO will not support efficacy or effectiveness clinical trials. The combined R61/R33 should not exceed 5 years. Transition to the R33 phase requires administrative review by NIH staff and is not guaranteed. Approval of the transition to the R33 phase will be based on the original R61/R33 peer review recommendations, successful completion of transition milestones, any proposed changes to the R33 research based on R61 findings, program priorities, and availability of funds. It is not expected that all applications will continue to the R33 phase. Support for a single phased award that does not need the R61 Exploratory phase is available in the companion (R33) NOFO, PAR-24-239. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>
Contact Name	Hye-Sook Kim, Ph.D.																		
Contact Telephone	301-827-6910																		
Contact Email	hye-sook.kim@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	01-Oct-2024 , 02-Jun-2025 , 02-Feb-2026 , 01-Oct-2026 , 02-Jun-2027																		
Synopsis	<p>The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate the development of effective precision probiotic interventions using a milestone-driven, biphasic award mechanism. It aims to identify, understand, and develop strategies to address barriers in precision probiotic interventions to account for the heterogeneity in humans that often causes inconsistent probiotic therapeutic responses. Specifically, this NOFO solicits applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders, which may then help enhance probiotic clinical outcomes. The first phase, funded by the R61 mechanism, will provide 1 or 2 years of support to identify host biological patterns (e.g., native microbiome, immune system, sex and/or gender, diet, age, genetic background, lifestyle, or health history) that are correlated with differences in probiotic clinical effects using observational or secondary data analysis studies. The second phase, funded under the R33 mechanism, will support studies to assess the causality of the factors identified in the R61 phase that impact probiotic responsiveness through rigorous mechanistic study designs in animal models or human subjects. This NOFO will not support efficacy or effectiveness clinical trials. The combined R61/R33 should not exceed 5 years. Transition to the R33 phase requires administrative review by NIH staff and is not guaranteed. Approval of the transition to the R33 phase will be based on the original R61/R33 peer review recommendations, successful completion of transition milestones, any proposed changes to the R33 research based on R61 findings, program priorities, and availability of funds. It is not expected that all applications will continue to the R33 phase. Support for a single phased award that does not need the R61 Exploratory phase is available in the companion (R33) NOFO, PAR-24-239. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>																		
126576	Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24-239	01-Oct-2024	1,400,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Hye-Sook Kim, Ph.D.</td> </tr> </table>					Contact Name	Hye-Sook Kim, Ph.D.												
Contact Name	Hye-Sook Kim, Ph.D.																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-827-6910</p> <p>Contact Email hye-sook.kim@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024 , 02-Jun-2025 , 02-Feb-2026 , 01-Oct-2026 , 02-Jun-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate the development of effective precision probiotic interventions. The NOFO aims to identify, understand, and develop strategies to address barriers in precision probiotic interventions' development to account for human heterogeneity resulting in inconsistent responses to probiotic treatments. Specifically, this NOFO solicits R33 applications that will assess the causality of person-specific features or patterns affecting probiotic responses and identify subgroups of probiotic responders in order to enhance therapeutic outcomes. This NOFO will support studies that assess whether host biological patterns (e.g., native microbiome, immune system, sex and/or gender, diet, age, genetic background, lifestyle, or health history) that are correlated with clinical probiotic effects can modulate responsiveness to probiotic interventions. Well-suited applications must offer rigorously designed mechanistic studies using relevant/innovative animal models or human subjects. This NOFO is intended to support projects where potential host biological patterns that are correlated with probiotic usage or interventions have been identified, as demonstrated with supportive preliminary data, which require further mechanistic studies to test for causality. This NOFO will not support efficacy or effectiveness clinical trials. Applicants pursuing early-stage research to identify host biological patterns that may affect probiotic health outcomes should consider the companion (R61/R33) PAR-24-238. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
126608	RFA-AT-24-010 -- Whole Person Research and Coordination Center (Whole Person RCC) (U24 Clinical Trial Not Allowed)	National Center for Complementary and Integrative Health/NIH/DHHS	RFA-AT-24-010	01-Oct-2024 [Optional][LOI/Pre-App]	7,500,000 USD
	<p>Contact Name Elizabeth Ginexi, Ph.D.</p> <p>Contact Telephone 301-827-0160</p> <p>Contact Email elizabeth.ginexi@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024 [Optional][LOI/Pre-App], 01-Nov-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the establishment of the Whole Person Research and Coordination Center (Whole Person RCC) under the NIH Whole Person Initiative. This center will be integral in</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>coordinating the initial and future research programs in whole person health research. Its creation is driven by the goal to seamlessly integrate current and emerging biomedical knowledge about human health, thereby forming a comprehensive, multi-scale human knowledge network. This NOFO aims to accomplish two major objectives with the first objective of the highest priority. The first objective is to build a healthy human whole person physiome conceptual map to represent all physiological organ system functions and identify Common Data Elements (CDEs) appropriate for each major physiological function. It is expected that the conceptual map will not be built from data using computational methods [e.g., artificial intelligence/machine learning (AI/ML)], but will be mapped by a team of content experts using existing established knowledge of healthy human physiology, linking all physiological systems into a whole. The second objective is to select and test existing datasets for the conceptual map and CDEs and build at least one prototype in silico model of whole person. The Whole Person RCC's role will additionally include fostering multidisciplinary collaboration and providing the logistical support infrastructure for the entire NIH Whole Person Initiative.</p>				
123153	Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24-086	21-Oct-2024	Not Specified
	Contact Name	Beda Jean-Francois, Ph.D.			
	Contact Telephone	202-313-2144			
	Contact Email	beda.jean-francois@nih.govr01			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	21-Oct-2024 , 13-Nov-2024 , 20-Feb-2025 , 10-Mar-2025 , 20-Jun-2025 , 14-Jul-2025 , 20-Oct-2025 , 17-Nov-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 13-Jul-2026 , 20-Oct-2026 , 13-Nov-2026			
	Synopsis	<p>This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH- designated areas of high research priority. Applications submitted under this NOFO are expected to propose a remotely delivered and conducted fully powered clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies. Applicants must provide justification for the remotely delivered approach and provide preliminary data on the feasibility and safety of the approach, along with evidence that the intervention has promise of clinical benefit. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

123147	NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24-083	21-Oct-2024	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Pete Murray, Ph.D.
Contact Telephone	301-496-4054
Contact Email	peter.murray@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	21-Oct-2024 , 13-Nov-2024 , 20-Feb-2025 , 20-Jun-2025 , 15-Jul-2025 , 20-Oct-2025 , 18-Nov-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 14-Jul-2026 , 20-Oct-2026 , 17-Nov-2026
Synopsis	<p>This notice of funding opportunity (NOFO) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this NOFO are expected to propose a multisite feasibility clinical trial that will provide new information that is scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIH’s mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R01) research is scientifically necessary to design or plan the subsequent fully powered, full-scale clinical trial. Under this R01, the data collected should be used to fill gaps in scientific knowledge, including, but not limited to the following: assessing whether the intervention can be delivered with fidelity across sites; demonstrating feasibility of recruitment, accrual, and randomization of participants across sites; demonstrating participant adherence to the intervention, as well as retention of participants throughout the study across sites; refining and assessing the feasibility of protocolized multimodal interventions, and/or demonstrating feasibility of data collection across sites in preparation for a future fully powered, multisite efficacy or effectiveness trial. The need for multisite feasibility trials is expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s) or the published literature. The data collected should be used to fill gaps in scientific knowledge and be necessary to develop a competitive fully powered multisite clinical trial that has the potential to make a significant impact on public health. Prior to submitting to this NOFO, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

123152	Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24-084	21-Oct-2024	450,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Jennifer N. Baumgartner, Ph.D.
Contact Telephone	301-402-4084
Contact Email	jennifer.baumgartner@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	21-Oct-2024 , 13-Nov-2024 , 20-Feb-2025 , 10-Mar-2025 , 20-Jun-2025 , 14-Jul-2025 , 20-Oct-2025 , 17-Nov-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 13-Jul-2026 , 20-Oct-2026 , 13-Nov-2026
Synopsis	<p>The goal of this notice of funding opportunity (NOFO) is to support feasibility trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions that have been identified by NCCIH as high-priority research topics. This funding opportunity is intended to support feasibility clinical trials that provide new information that are scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIH's mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent competitive full-scale clinical trial. Under this R34, the data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: examining feasibility and acceptability of interventions lacking published data; tailoring or adapting the content or structure of an intervention to a specific population, modality, or setting; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention, and data collection procedures; refining and assessing the feasibility of protocolized multi-component interventions; or examining acceptability and adherence of control conditions. The subsequent full-scale clinical trial should have the potential to make a significant impact on public health. Prior to submitting to this NOFO, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
117409	Notice of Special Interest (NOSI): Development of Innovative Informatics and Data Science Technologies, Tools, and Methods for Vision Research	National Eye Institute/NIH/DHHS	NOT-EY-23-005	05-Sep-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>James Gao, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-594-6074</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>james.gao@nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>05-Sep-2024 , 07-Sep-2024 , 16-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026 , 16-Feb-2026</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants that the National Eye Institute (NEI) is interested in supporting research to develop innovative informatics and data science methods, algorithms, and tools to improve data acquisition, analysis, visualization, annotation, integration, and interpretation. The emphasis will be on innovation and its potential impact on vision research, including discovery biology, population studies, as well as clinical and translational research.</td> </tr> </table>					Contact Name	James Gao, Ph.D.	Contact Telephone	301-594-6074	Contact Email	james.gao@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Sep-2024 , 07-Sep-2024 , 16-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026 , 16-Feb-2026	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants that the National Eye Institute (NEI) is interested in supporting research to develop innovative informatics and data science methods, algorithms, and tools to improve data acquisition, analysis, visualization, annotation, integration, and interpretation. The emphasis will be on innovation and its potential impact on vision research, including discovery biology, population studies, as well as clinical and translational research.
Contact Name	James Gao, Ph.D.																		
Contact Telephone	301-594-6074																		
Contact Email	james.gao@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Sep-2024 , 07-Sep-2024 , 16-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026 , 16-Feb-2026																		
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants that the National Eye Institute (NEI) is interested in supporting research to develop innovative informatics and data science methods, algorithms, and tools to improve data acquisition, analysis, visualization, annotation, integration, and interpretation. The emphasis will be on innovation and its potential impact on vision research, including discovery biology, population studies, as well as clinical and translational research.																		
109678	NEI Regenerative Medicine Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed)	National Eye Institute/NIH/DHHS	PAR-22-135	07-Sep-2024	300,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Donald Everett, MA</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-435-8181</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>everettd@mail.nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The National Eye Institute (NEI) supports regenerative medicine clinical trials. Before a research team undertakes a clinical trial, it is critical to have clear delineation and documentation of the trial's rationale, design, analytic techniques, protocols, and procedures in a Manual of Procedures (MOP). Additionally, there are other elements essential to the launching of a trial, such as obtaining regulatory authorizations or approvals and establishing agreements with requisite partners including cell manufacturing and production facilities, assay or cell analysis centers, and data coordinating centers. These activities are often costly and time-consuming, and they may involve collection of preliminary data to assess feasibility. The Regenerative Medicine Clinical Trial Planning Grant may be used by applicants to support the preparation of a clinical trial</td> </tr> </table>					Contact Name	Donald Everett, MA	Contact Telephone	301-435-8181	Contact Email	everettd@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025	Synopsis	The National Eye Institute (NEI) supports regenerative medicine clinical trials. Before a research team undertakes a clinical trial, it is critical to have clear delineation and documentation of the trial's rationale, design, analytic techniques, protocols, and procedures in a Manual of Procedures (MOP). Additionally, there are other elements essential to the launching of a trial, such as obtaining regulatory authorizations or approvals and establishing agreements with requisite partners including cell manufacturing and production facilities, assay or cell analysis centers, and data coordinating centers. These activities are often costly and time-consuming, and they may involve collection of preliminary data to assess feasibility. The Regenerative Medicine Clinical Trial Planning Grant may be used by applicants to support the preparation of a clinical trial
Contact Name	Donald Everett, MA																		
Contact Telephone	301-435-8181																		
Contact Email	everettd@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025																		
Synopsis	The National Eye Institute (NEI) supports regenerative medicine clinical trials. Before a research team undertakes a clinical trial, it is critical to have clear delineation and documentation of the trial's rationale, design, analytic techniques, protocols, and procedures in a Manual of Procedures (MOP). Additionally, there are other elements essential to the launching of a trial, such as obtaining regulatory authorizations or approvals and establishing agreements with requisite partners including cell manufacturing and production facilities, assay or cell analysis centers, and data coordinating centers. These activities are often costly and time-consuming, and they may involve collection of preliminary data to assess feasibility. The Regenerative Medicine Clinical Trial Planning Grant may be used by applicants to support the preparation of a clinical trial																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	MOP and procedures necessary for implementing a clinical trial to evaluate interventions (or new treatments) that restore vision in humans through regeneration of cells.				
109530	NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)	National Eye Institute/NIH/DHHS	PAR-22-128	07-Sep-2024	300,000 USD
	<p>Contact Name Donald Everett, MA</p> <p>Contact Telephone 301-435-8181</p> <p>Contact Email everettd@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The NEI supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies on eye/vision conditions. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This clinical research planning grant funding opportunity supports applicants in their planning efforts to conduct collaborative clinical research. The grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.</p>				
109824	NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)	National Eye Institute/NIH/DHHS	PAR-22-141	07-Sep-2024	275,000 USD
	<p>Contact Name Donald Everett, M.A.</p> <p>Contact Telephone 301-435-8181</p> <p>Contact Email everettd@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis This FOA encourages applications from institutions/organizations that propose to conduct vision-related secondary data</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally-intended purpose. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest. The purpose of this FOA is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, but this FOA must not be used to support the collection of new data.

111645	NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-194	17-Oct-2024	Not Specified
--------	---	--	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Pankaj Qasba, Ph.D.</p> <p>gasbap@nhlbi.nih.gov</p> <p>Link to program URL</p> <p>17-Oct-2024 , 07-Jan-2025</p> <p>This Funding Opportunity Announcement (FOA) invites applications to use NHLBI-funded TransOmics for Precision Medicine (TOPMed) program to generate a large volume of integrated genetic and multi-omics data to facilitate discovery of the molecular mechanisms of Heart, Lung, Blood, and Sleep (HLBS) disorders. No funding will be provided under this FOA. The omics data and related phenotypic data will be deposited in a public NIH-designated controlled-access database such as the database for Genotypes and Phenotypes (dbGaP) and NHLBI's BioData Catalyst (BDC).The overall goal is to transition the program from genetic Map to Mechanism (M2) and to fill knowledge gaps that have not been sufficiently covered by existing TOPMed datasets, enabling functional genomics research that will accelerate mechanistic personalized medicine.</p>
---	---

125805	RFA-HL-25-009 -- Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-25-009	17-Oct-2024	Not Specified
--------	---	--	---------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p>	<p>Karin F. Lidman, Ph.D.</p> <p>301-435-0535</p>
--	---

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email karin.fredriksson@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Oct-2024 , 07-Jan-2025 , 11-Feb-2025 , 07-May-2025 , 15-Oct-2025 , 07-Jan-2026 , 11-Feb-2026 , 07-May-2026 , 14-Oct-2026 , 07-Jan-2027 , 11-Feb-2027 , 07-May-2027</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites applications to provide career development activities for a diverse pool of highly trained investigators in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This NOFO is designed specifically to support candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial to support the lead investigator should apply to the companion NOFO (RFA-HL-25-008).</p>				
114386	Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-23-036	28-Oct-2024	150,000 USD
	<p>Contact Name Ruth Kirby, RN, BS</p> <p>Contact Telephone 301-435-0401</p> <p>Contact Email kirbyr@nhlbi.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Oct-2024 , 07-Jan-2025 , 28-Feb-2025 , 07-May-2025 , 28-Oct-2025 , 07-Jan-2026</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses using existing human datasets in areas relevant to the National Heart, Lung, Blood Diseases and Sleep Disorders Institute (NHLBI) scientific mission. The FOA aims to stimulate the use of existing human datasets to investigate novel scientific ideas, and/or generate new models, systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. Generation of new primary data is not allowed.</p>				
125802	RFA-HL-25-008 -- Mentored Career Development Award to Promote Faculty	National Heart, Lung, and Blood	RFA-HL-	17-Oct-2024	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Diversity in Biomedical Research (K01 Independent Clinical Trial Required)	Institute/NIH/DHHS	25-008		Specified
	<p>Contact Name Karin F. Lidman, Ph.D.</p> <p>Contact Telephone 301-435-0535</p> <p>Contact Email karin.fredriksson@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Oct-2024 , 07-Jan-2025 , 11-Feb-2025 , 07-May-2025 , 15-Oct-2025 , 07-Jan-2026 , 11-Feb-2026 , 07-May-2026 , 14-Oct-2026 , 07-Jan-2027 , 11-Feb-2027 , 07-May-2027</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites applications to provide career development opportunities for a diverse pool of highly trained investigators by providing eligible faculty members with the opportunity to undertake special study and supervised research under an accomplished investigator in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This NOFO is designed to support candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must work with their institutes to apply to companion NOFO (RFA-HL-25-009).</p>				
125098	NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R61/R33 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24-173	03-Sep-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Sumita Khatri, MD</p> <p>Contact Telephone 301-402-9673</p> <p>Contact Email sumita.khatri@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Sep-2024 [Optional][LOI/Pre-App], 07-Sep-2024 , 02-Oct-2024 , 04-Jan-2025 [Optional][LOI/Pre-App], 07-Jan-2025 , 03-Feb-2025 , 05-May-2025 [Optional][LOI/Pre-App], 07-May-2025 , 04-Jun-2025 , 03-Sep-2025 [Optional][LOI/Pre-App], 07-Sep-2025 , 02-Oct-2025 , 04-Jan-2026 [Optional][LOI/Pre-App], 07-Jan-2026 , 03-Feb-2026 , 05-May-2026 [Optional][LOI/Pre-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	App], 07-May-2026 , 04-Jun-2026 , 03-Sep-2026 [Optional][LOI/Pre-App], 07-Sep-2026 , 02-Oct-2026 , 07-Jan-2027 The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This FOA will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.			
125065	NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24-172	03-Sep-2024 [Optional][LOI/Pre-App]	4,545,000 USD
	Contact Name	Sumita Khatri, MD			
	Contact Telephone	301-402-9673			
	Contact Email	sumita.khatri@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-Sep-2024 [Optional][LOI/Pre-App], 07-Sep-2024 , 02-Oct-2024 , 04-Jan-2025 [Optional][LOI/Pre-App], 03-Feb-2025 , 05-May-2025 [Optional][LOI/Pre-App], 07-May-2025 , 04-Jun-2025 , 03-Sep-2025 [Optional][LOI/Pre-App], 07-Sep-2025 , 02-Oct-2025 , 04-Jan-2026 [Optional][LOI/Pre-App], 07-Jan-2026 , 03-Feb-2026 , 05-May-2026 [Optional][LOI/Pre-App], 07-May-2026 , 04-Jun-2026 , 03-Sep-2026 [Optional][LOI/Pre-App], 07-Sep-2026 , 02-Oct-2026 , 07-Jan-2027			
	Synopsis	The objective of this Notice of Funding Opportunity (NOFO) is to support investigator-initiated, Phase 1 clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multi-site. Applicants applying for funding under this NOFO should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other pre-clinical and/or trial readiness activities are desired, applicants should consider the companion NOFO PAR-24-173, which utilizes an R61/R33 phased approach.			
113286	Notice of Special Interest (NOSI): Basic and Translational Research on Circadian Regulation of Heart, Lung, Blood, and Sleep Disorders (R01)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-043	07-Sep-2024	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Ravi Balijepalli, Ph.D.</p> <p>Contact Telephone 301-435-0504</p> <p>Contact Email ravi.balijepalli@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>Synopsis This NOSI aims to stimulate research on understanding how circadian rhythms regulate cell function and metabolism of peripheral tissues, and to find new avenues for the investigation of heart, lung, and blood disease risk, pathogenesis, diagnosis, treatment, and prevention. Basic, translational, and clinical research applications to elucidate circadian-dependent mechanisms contributing to the pathophysiology of HLBS disorders are invited. This NOSI encourages multidisciplinary and multiple investigator teams of experts in heart, lung, and blood research fields to synergistically work with circadian biologists and sleep researchers to provide a comprehensive understanding of the circadian biology in relation to HLBS conditions. The purpose is to facilitate translational research to identify potential applications of circadian science to the diagnosis, prevention and treatment of HLBS conditions. Mechanism-based studies investigating the circadian rhythm dysregulation, clinical markers, and/or therapeutic targets of HLBS conditions are encouraged. Behavioral, physiological, pharmacological, molecular, and genomic studies aimed at elucidating the relationship between circadian-dependent mechanisms and disease are appropriate. Studies to delineate circadian-based mechanisms, therapeutic targets, epidemiological risk and clinical trials to assess therapeutic safety, efficacy, effectiveness, or implementation may be proposed.</p>				
114141	<p>Notice of Special Interest (NOSI): Advancing Research in Lipoprotein(a) and Cardiovascular Disease (R01 Clinical Trials Allowed) and (R01 No Clinical Trials Allowed)</p>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-052	07-Sep-2024	Not Specified
	<p>Contact Name Lijuan Liu, PhD</p> <p>Contact Telephone 301-435-0582</p> <p>Contact Email liliu@nhlbi.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | The purpose of this NOSI is to stimulate research on lipoprotein(a) [Lp(a)] and its role in cardiovascular disease (CVD). We encourage multidisciplinary collaborations to conduct basic, preclinical, and mechanistic clinical studies on Lp(a) and CVD.

106202	Notice of Special Interest (NOSI): Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence Through Adolescence to Young Adulthood	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-015	07-Sep-2024	Not Specified
--------	--	--	---------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Alison G.M. Brown, PhD, MS, RDN 301-435-0583 Alison.brown@nih.gov Link to program URL 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 This Notice of Special Interest (NOSI) calls for research to understand and promote cardiovascular and cardiometabolic health during transitional phases across the lifecourse, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years). This initiative would support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitional phases from pre-adolescence into adolescence and adolescence into young adulthood, and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitional phases.
--	---

112260	Notice of Special Interest (NOSI): Studies of Cellular/Molecular Pathobiological Mechanisms of Lung Diseases Using Human 3-Dimensional Cellular Systems (R01)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-030	07-Sep-2024	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Qing Lu, Ph.D. 301-480-9158 qing.lu@nih.gov Link to program URL 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025
--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The purpose of this NOSI is to promote research characterizing the pathobiological processes and mechanisms that drive the onset and progression of lung diseases at a molecular/cellular level, providing a systems-level understanding by studying experimental systems with cellular heterogeneity and 3-D architecture. It is expected that projects supported by this NOSI will utilize ex vivo preparations (e.g., thin human lung slices) or 3-D multi-cellular in vitro systems (e.g., organoids) of human lung cells and will employ state-of-art multi-omics measures (e.g., spatial or single cell/nucleus omics) to better understand specific pathobiological processes in systems of interacting cell types.</p>				
115585	<p>Notice of Special Interest (NOSI): Development of Functional Assay Sites to Evaluate Candidate -Omics Variants Associated with Heart, Lung, Blood, or Sleep Disease (R01, R41, R42, R43, R44)</p>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-23-066	05-Sep-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Charlene Schramm, Ph.D.</p> <p>301-402-3793</p> <p>schrammc@nih.gov</p> <p></p> <p>Link to program URL</p> <p>05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 07-May-2025 , 05-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 05-Jan-2026 , 07-Jan-2026 , 05-Feb-2026 , 05-Apr-2026 , 07-May-2026 , 05-Jun-2026 , 05-Sep-2026 , 07-Sep-2026</p> <p>The NHLBI is issuing this Notice of Special Interest (NOSI) to highlight interest in receiving grant applications focused on HLBS disorders in the following area(s): Development and/or application of moderate- or high-throughput functional assays to provide biological validation of candidate human variants associated with HLBS disorders Defining causal relationships between genotypes and phenotypes Development and validation of functionally informed risk predictions</p>			
116586	<p>Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)</p>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-23-067	07-Sep-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p>	<p>James Luo, Ph.D.</p> <p>301-435-0533</p> <p>luoja@nih.gov</p> <p></p> <p>Link to program URL</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in recent years, yet an understanding of the molecular mechanisms underlying many of these diseases has remained elusive. Furthermore, in most cases the impact of genetic variation on severity of disease and treatment outcomes remains unknown. Therefore, the NHLBI has created the Trans-omics for Precision Medicine (TOPMed) program, which aims to utilize genomics data to characterize a variety of HLBS diseases. TOPMed is well on its way to collecting whole genome sequence (WGS) from over 194,270 well-phenotyped individuals and is currently generating multi-omics data (e.g., over 31,852 RNA sequences, over 44,342 DNA methylation profiles, and 26,124 metabolomics profiles) from many of these individuals to complement whole genome sequence information. Having produced an unprecedented volume of high-throughput data, TOPMed now seeks to turn its attention to effectively leveraging this resource to uncover biological function and disease pathobiology through novel systems biology analyses and the power of artificial intelligence (AI) and Machine Learning (ML). Although lower costs and technological improvements in sequencing technology have vastly expanded our ability to generate large volumes of omics data, the ability to analyze such large datasets to extract biologically meaningful insights remains challenging. Systems level models incorporating trans-omics analyses will be an important step in uncovering the underlying biological networks and the gene-gene and gene-environment interactions influencing disease and treatment outcomes. Thus, advanced analyses that incorporate genotype and phenotype datasets from thousands to tens of thousands of individuals are essential to move TOPMed to the next phase of discovery.</p>				
107287	<p>Notice of Special Interest (NOSI): Heart, Lung, Blood and Sleep Focused Ancillary Studies to Large Ongoing Clinical Studies (Revised)</p>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-030	07-Sep-2024	Not Specified
	<p>Contact Name Jue Chen, Ph.D.</p> <p>Contact Telephone 301-435-0550</p> <p>Contact Email jue.chen@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis This Notice of Special Interest (NOSI) seeks to expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within the mission of the National Heart, Lung, and Blood Institute (NHLBI) by leveraging ongoing clinical research studies through ancillary studies. The purpose of this NOSI is to invite research project applications to conduct focused ancillary studies to large ongoing clinical trials (including late-stage T4 implementation clinical trials),</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

observational studies, and registries. This NOSI also serves as a replacement for NOT-HL-20-755 (expired as of November 6, 2021).

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
107093	Notice of Special Interest (NOSI): DEA2Health: Innovative Data Evaluation and Analysis to Health	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-001	07-Sep-2024	Not Specified

Contact Name	Lucy L. Hsu, M.P.H.
Contact Telephone	301-402-3276
Contact Email	lucy.hsu@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to stimulate research and advancement of methodologies in data science in heart, lung, blood, or sleep (HLBS) biomedical research, and ultimately translate new insights into decision-making to improve health.

108068	Notice of Special Interest (NOSI): Diagnostics and Disease Management Tools for Use in Underserved Populations	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-024	07-Sep-2024	Not Specified
--------	--	--	---------------	-------------	---------------

Contact Name	Bishow Adhikari, Ph.D.
Contact Telephone	301-594-2791
Contact Email	adhikarb@nhlbi.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025
Synopsis	The purpose of this NOSI is to stimulate research focused on the development of transformative diagnostics and disease management tools for heart, lung, blood, or sleep (HLBS) disorders that are designed to meet the needs of the underserved populations. Underserved populations, for the purpose of this NOSI, can include racial and ethnic minorities, immigrants, the homeless, low-income individuals, the uninsured and people who live in communities that are socioeconomically

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		disadvantaged, rural or have few health care resources. Please see NOT-OD-20-031 for NIH definitions. Special consideration will be given to technology solutions that are accessible and feasible in these communities. Working with community partners is required throughout the project to ensure successful development and implementation.			
108064	Notice of Special Interest (NOSI): Promoting Fundamental Research on Mitochondrial Involvement in Lung Diseases and Sleep Disorders	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-003	07-Sep-2024	Not Specified
	Contact Name	Jining Lu			
	Contact Telephone	301-827-2807			
	Contact Email	jining.lu@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025			
	Synopsis	The purpose of this NOSI is to stimulate research focused on cell-type-specific signatures of mitochondrial behavior in healthy and diseased lungs. Multidisciplinary collaboration among experts in recently developed technologies, such as iPS cell and lung progenitor/organoid culture systems, advanced single cell-and “-omic” technologies, and lung cell biology is encouraged. We encourage investigators to Utilization of lung cells from human donors and animal models with respiratory diseases and/or well-defined congenital mitochondrial diseases is also encouraged.			
122332	NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24-049	07-Sep-2024	450,000 USD
	Contact Name	Patrice Desvigne-Nickens, MD			
	Contact Telephone	301-435-0504			
	Contact Email	desvignp@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027			
	Synopsis	This Notice of Funding Opportunity (NOFO) supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106072	<p>Notice of Special Interest (NOSI): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases (Reissue)</p>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-024	07-Sep-2024	Not Specified

subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, or sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at Clinical Trial Development Continuum | NHLBI, NIH), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application. Plan for Enhancing Diverse Perspectives The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: -Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. - Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). - Individual applications and partnerships that enhance geographic and regional heterogeneity. - Investigators and teams composed of researchers at different career stages. - Participation of individuals from diverse backgrounds, including groups historically underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. - Opportunities to enhance the research environment to benefit early- and mid-career investigators. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Contact Name	Narasimhan Danthi, Ph.D.
Contact Telephone	301-435-5170
Contact Email	ndanthi@mail.nih.gov
Sponsor Website	

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis This Notice of Special Interest is a reissue of NOT-HL-20-796. The purpose of this NOSI is to advise potential applicants to the National Heart, Lung and Blood Institute (NHLBI) of an area of special interest to support early phases of innovative bioengineering projects which are expected to transition their research into future follow-on funding, technologies, or commercial products. Please note that this R21 program does not overlap with projects which are expected to transition their research into future follow-on funding, technologies, or commercial products. Please note that this R21 program does not overlap with the NHLBI Catalyze Program, and it does focus on new investigator-initiated ideas that will feed into the Catalyze pipeline.</p>				
109308	<p>RFA-HL-23-018 -- Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research (R21)</p>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-018	09-Aug-2024	150,000 USD
	<p>Contact Name Margaret Ochocinska, PhD</p> <p>Contact Telephone 301-827-8285</p> <p>Contact Email ochocinm@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Aug-2024 , 21-Oct-2024 , 10-Dec-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support meritorious exploratory research relevant to the NHLBI mission (http://www.nhlbi.nih.gov/about/org/mission) using the existing biospecimen collections that are stored in the NHLBI Biologic Specimen Repository (Biorepository), thereby maximizing the scientific value of the stored collections and providing researchers with an opportunity to generate preliminary data for subsequent research proposals.</p>				
112358	<p>Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)</p>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-193	11-Sep-2024	Not Specified
	<p>Contact Name Nancy DiFronzo, PhD</p> <p>Contact Telephone 301-435-0065</p> <p>Contact Email difronzon@nhlbi.nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Sep-2024 , 11-Oct-2024 , 10-Jan-2025 , 11-Feb-2025 , 12-May-2025 , 11-Jun-2025 , 11-Sep-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA PAR-22-192() that encourages applications for a collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborating CCC application. The application should also describe its approaches to collaborate with the CCC on implementation of the clinical trial community engagement and diversity plans. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.</p>				
112357	<p>Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)</p>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-192	11-Sep-2024	Not Specified
	<p>Contact Name Nancy DiFronzo, PhD</p> <p>Contact Telephone 301-435-0065</p> <p>Contact Email difronzon@nhlbi.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Sep-2024 , 11-Oct-2024 , 10-Jan-2025 , 11-Feb-2025 , 12-May-2025 , 11-Jun-2025 , 11-Sep-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-22-193). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The application should also describe its approaches to increasing community engagement and diversity as well as reducing health inequities and disparities. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.</p>				
111425	Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-189	11-Sep-2024	Not Specified
	Contact Name	Nahed El Kassar, MD			
	Contact Telephone	301-435-0065			
	Contact Email	nahed.elkassar@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Sep-2024 , 11-Oct-2024 , 11-Jan-2025 , 11-Feb-2025 , 11-May-2025 , 11-Jun-2025 , 11-Sep-2025			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. The application should also describe its approaches to increasing community engagement, reducing health inequities and disparities, and include a Plan for Increasing Diverse Perspectives (PDEP),.</p>			
112356	Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial	National Heart, Lung, and Blood	PAR-22-	11-Sep-2024	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Required	Institute/NIH/DHHS	189		Specified
	<p>Contact Name Nahed El Kassar, MD</p> <p>Contact Telephone 301-435-0065</p> <p>Contact Email nahed.elkassar@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Sep-2024 , 11-Oct-2024 , 11-Jan-2025 , 11-Feb-2025 , 11-May-2025 , 11-Jun-2025 , 11-Sep-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. The application should also describe its approaches to increasing community engagement, reducing health inequities and disparities, and include a Plan for Increasing Diverse Perspectives (PDEP).</p>				
113729	<p>RFA-HL-24-005 -- Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)</p>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-24-005	07-Sep-2024	150,000 USD
	<p>Contact Name Qing Lu, Ph.D.</p> <p>Contact Telephone 301-480-9158</p> <p>Contact Email Qing.Lu@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 17-Oct-2024 , 07-Jan-2025 , 13-Feb-2025 , 07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 13-Oct-2025 , 07-Jan-2026</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The purpose of this funding opportunity announcement (FOA) is to solicit current or recently completed NHLBI K01, K08, K23, and K25 recipients for small grant support to expand their current research objectives or to branch out to a new study that resulted from the research conducted under the K award. Active NHLBI K01, K08, K23, and K25 recipients may apply for R03 support after the notice of award (NoA) for their first type-5 K awards has been issued. Recently completed NHLBI K01, K08, K23, and K25 recipients are eligible to apply for the R03 if the earliest possible R03 start date falls within 2 years of their prior NHLBI K award Project Period end date. This FOA is intended to enhance the capability of NHLBI K01, K08, K23, and K25 recipients to conduct research as they complete their transition to fully independent investigator status. This R03 program is intended to support research projects that can be carried out and completed within a short period of time (no more than two years) with limited resources and that may generate preliminary data to support a subsequent R01-equivalent application. These studies include, but are not limited to, pilot or feasibility studies; proof of concept studies; secondary analysis of existing data; small, self-contained research projects; development of new research methodologies or technologies, or development of novel experimental models. A minimum of 40% protected overall research effort, not necessarily limited to the proposed R03 project, is required from applicants. For current and previous K23 recipients, research proposed in the R03 application may or may not include patient-oriented research.</p>				
127015	NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24-209	12-Oct-2024	Not Specified
	<p>Contact Name</p> <p>Kristen Z. Morgan, Ph.D.</p> <p>Contact Telephone</p> <p>301-827-5163</p> <p>Contact Email</p> <p>direducation@nhlbi.nih.gov</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Link to program URL</p> <p>Deadline Dates (ALL)</p> <p>12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027</p> <p>Synopsis</p> <p>The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers currently in training in the NHLBI Division of Intramural Research with the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA, PAR-24-211 "NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22- Clinical Trial Required)".

126957	RFA-HL-25-010--Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Clinical Coordinating Center (Collaborative UG3/UH3 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-25-010	09-Sep-2024	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name David Schopfer, M.D., M.A.S.
 Contact Telephone 301-402-3833
 Contact Email david.schopfer@nih.gov
 Sponsor Website
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 09-Sep-2024 , 28-Oct-2024

Synopsis The goal of this Notice of Funding Opportunity (NOFO) is to support a clinical trial which will test intervention(s) to reduce the progression of coronary atherosclerosis among young adults who are at low or borderline 10-year risk (<7.5%) for their first atherosclerotic cardiovascular disease (ASCVD) event, yet at high lifetime risk of developing cardiovascular disease (CVD). For the purpose of this NOFO, "young adults" is defined as less than or equal to 50 years for men, and given the lower rate of coronary atherosclerosis before menopause for women compared to men, it may be reasonable to use an expanded inclusion criteria to include women older than age 50. This opportunity will support a two component prevention clinical trial that will first efficiently screen the appropriate population eligible for the intervention, and second, to determine which intervention(s) are most efficacious at reducing the onset or slowing the progression of subclinical coronary atherosclerosis. Trial participants who are identified as meeting the subclinical coronary atherosclerosis criteria for enrollment in the screening component will be immediately enrolled in the intervention, even though component one recruitment continues until the trial is completely enrolled. It is expected that the trial will have three arms. One will be a control or comparison arm. The control arm is expected to be current guideline-based behavioral and pharmacological interventions. One of the two active arms is expected to involve an additional pharmacological intervention(s) with definite evidence of efficacy for primary prevention in older high-risk adults, such as LDL lowering therapy. The other active arm may involve intervention(s) with less definite evidence of primary prevention efficacy in older adults. The goal of this research strategy is to determine if earlier treatment of subclinical ASCVD will reduce adverse clinical events to a greater degree than current guideline-

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

recommend treatment. This NOFO will support applications to develop and implement a Clinical Coordinating Center (CCC) for a multi-site clinical trial among young adults without clinical ASCVD. It will utilize a milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion NOFO that encourages applications for a collaborating Data Coordinating Center (RFA-HL-25-007). The objective of this CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results for each stage (screening and trial) and each phase (UG3 and UH3). The application should also describe its approaches to increasing community engagement and reducing health inequities. Clinical trial designs using innovative designs such as platform trials, adaptive, and Bayesian designs are welcomed. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contacts prior to applying. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

126956	RFA-HL-25-007--Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Data Coordinating Center (Collaborative U24 Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-25-007	09-Sep-2024	Not Specified
--------	--	--	---------------	-------------	---------------

Contact Name | David Schopfer, M.D., M.A.S.
 Contact Telephone | 301-402-3833
 Contact Email | david.schopfer@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 09-Sep-2024 , 28-Oct-2024

Synopsis | The goal of this Notice of Funding Opportunity (NOFO) is to support a clinical trial which will test intervention(s) to reduce the progression of coronary atherosclerosis among young adults who are at low or borderline 10-year risk (<7.5%) for their first atherosclerotic cardiovascular disease (ASCVD) event, yet at high lifetime risk of developing cardiovascular disease (CVD). For the purpose of this NOFO, “young adults” is defined as less than or equal to 50 years for men, and given the lower rate of coronary atherosclerosis before menopause for women compared to men, it may be reasonable to use an expanded inclusion criteria to include women older than age 50. This opportunity will support a two component primary prevention clinical trial that will first, efficiently screen the appropriate population eligible for the intervention, and second, determine which intervention(s) are most efficacious at reducing the onset or slowing the progression of subclinical coronary atherosclerosis. Trial participants who are identified as meeting the subclinical coronary atherosclerosis criteria for enrollment in the

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

screening component will be immediately enrolled in the intervention, even though component one recruitment continues until the trial is completely enrolled. It is expected that the trial will have three arms. One will be a control or comparison arm. The control arm is expected to be current guideline-based behavioral and pharmacological interventions. One of the two active arms is expected to involve an additional pharmacological intervention(s) with definite evidence of efficacy for primary prevention in older high-risk adults, such as LDL-lowering therapy. The other active arm may involve intervention(s) with less definitive evidence of primary prevention efficacy in older adults. The goal of this research strategy is to determine if earlier treatment of subclinical ASCVD will reduce adverse clinical events to a greater degree than current guideline-recommend treatment. This NOFO will support applications to develop and implement a Data Coordinating Center (DCC) for a multi-site clinical trial among young adults without clinical ASCVD. It will utilize a milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion NOFO that encourages applications for a collaborating Clinical Coordinating Center (RFA-HL-25-010). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborating CCC application. The application should also describe its approaches to collaborate with the CCC (RFA-HL-25-010) on implementation of the clinical trial community engagement and diversity plans, as well as reducing health inequities. Clinical trials using innovative designs such as platform trials, adaptive, and Bayesian designs are welcomed. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contacts prior to applying. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

127019	NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24-211	12-Oct-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Kristen Z. Morgan, Ph.D.
Contact Telephone	301-827-5163
Contact Email	direducation@nhlbi.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027
Synopsis	The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers currently in training in the NHLBI Division of Intramural Research with the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Notice of Funding Opportunity Announcement (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not proposing to serve as lead investigator of an independent clinical trial must apply to the companion NOFO, PAR-24-209.</p>				
107786	Notice of Special Interest (NOSI): Methods Development for Genomic Studies of Genetic Variation, Function, and Disease	National Human Genome Research Institute/NIH/DHHS	NOT-HG-22-007	05-Sep-2024	Not Specified
	<p>Contact Name Lisa D. Brooks, Ph.D. Contact Telephone 301-547-1387 Contact Email lisa.brooks@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 Synopsis The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications that develop novel computational or experimental approaches for genomic studies of how genetic variants relate to genomic function, phenotype, and disease.</p>				
126963	RFA-HG-24-026 -- Limited Competition: Building Partnerships and Broadening Perspectives to Advance Ethical, Legal, and Social Implications (ELSI) Research (BBAER) Program (UM1), Clinical Trial Optional	National Human Genome Research Institute/NIH/DHHS	RFA-HG-24-026	16-Oct-2024 [Optional][LOI/Pre-App]	3,250,000 USD
	<p>Contact Name Rene Sterling, Ph.D., M.H.A. Contact Telephone 301-435-1275 Contact Email rene.sterling@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 16-Oct-2024 [Optional][LOI/Pre-App], 15-Nov-2024 , 01-Aug-2025 , 31-Jul-2026</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis The National Human Genome Research Institute (NHGRI) seeks to broaden the types of knowledge, skills, expertise, experience, and perspectives brought to bear in research addressing the ethical, legal, and social implications (ELSI) of advances in human genetics or genomics. The Building Partnerships and Broadening Perspectives to Advance Ethical, Legal, and Social Implications (ELSI) Research (BBAER) Program will support: 1) transdisciplinary ELSI research addressing timely, complex, and understudied topics associated with advances in human genetics and genomics, 2) the establishment of ELSI research teams that include partnerships with relevant communities affected by and with an interest in the proposed research, 3) research capacity building to develop, conduct, and sustain ELSI research, and 4) workforce development opportunities for early career scholars, research team members, and other BBAER project staff. This Notice of Funding Opportunity (NOFO) is for a limited competition that solicits UM1 applications from domestic organizations located in the United States and its territories that received less than \$30 million per year in total NIH funding for the past three fiscal years. These organizations are underrepresented among those receiving NHGRI funding for ELSI research.</p>				
119016	NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23-198	11-Oct-2024	1,500,000 USD
	<p>Contact Name Diane Lawrence, Ph.D. Contact Telephone 240-627-3202 Contact Email NIAIDDP2@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 11-Oct-2024 , 10-Oct-2025 Synopsis The NIAID New Innovator Award supports postdoctoral and other candidates in non-independent positions or newly independent Early Stage Investigators of exceptional creativity who propose novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms, or advance key concepts on broad, important problems in biomedical research of priority to NIAID. Applications proposing unexpected convergence of disciplines, new scientific directions, or the use of novel methodologies are encouraged. Applications from individuals with diverse backgrounds and in any topic relevant to the mission of NIAID are welcome.</p>				
120004	Notice of Special Interest (NOSI): Administrative Supplement for Collaborative Projects Supported by the NIAID/RNCP	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-23-044	02-Oct-2024	100,000 USD
	<p>Contact Name Andrea L. DiCarlo-Cohen, Ph.D. Contact Telephone 240-627-3492</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	cohen@niaid.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	02-Oct-2024 , 02-Oct-2025
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID’s interest in supporting research aimed at fostering collaborations between researchers throughout the NIAID/Radiation and Nuclear Countermeasures Program (RNCP)-funded grant and cooperative agreement portfolio (e.g., U01, U19, R21, R01, P01). The NIAID/RNCP has been tasked with developing safe and effective medical countermeasures (MCMs) and biodosimetry tools for civilians that can be used at least 24 hours post-exposure in a radiological or nuclear public health emergency. The multidisciplinary nature of radiation research lends itself to the establishment of formal partnerships across projects with similar goals, which enables collaborating research groups to achieve outcomes that would likely be impossible without the expertise, models, and facilities available at other institutions. The goal of NOSI is to foster collaborations that will allow awardees to develop data that can be leveraged for new funding that will enhance the state-of-the-science.

125560	RFA-AI-24-025 -- Engineering Durable HIV Vaccine Responses (ENDURE) (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-24-025	10-Sep-2024 [Optional][LOI/Pre-App]	750,000 USD
--------	--	--	---------------	-------------------------------------	-------------

Contact Name	Amy Palin, Ph.D.
Contact Telephone	240-627-3342
Contact Email	amy.palin@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	10-Sep-2024 [Optional][LOI/Pre-App], 09-Oct-2024
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to support basic and applied research to understand and improve durable immune responses to candidate HIV vaccines.

107638	Notice of Special Interest (NOSI): Accelerating Malaria Vaccine Discovery	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-014	07-Sep-2024	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name	Annie Mo, Ph.D.
Contact Telephone	240-627-3320

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email moa@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants about an area of special interest to NIAID on early phase translational research that will generate new malaria vaccine candidates with desirable features suitable for further downstream development and clinical evaluation. This NOSI encourages studies that will lead to discovery of new vaccine candidates that prevent infection, ameliorate disease, and/or interrupt transmission caused by human malaria parasites, especially Plasmodium falciparum and Plasmodium vivax.</p>				
123681	Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-24-112	05-Oct-2024	Not Specified
	<p>Contact Name Ari Joffe, Ph.D.</p> <p>Contact Telephone 240-669-5084</p> <p>Contact Email ari.joffe@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to support research that improves understanding of basic mechanisms and biomarkers of trained immunity (i.e., innate immune memory), plus the functional implications of trained immunity, related to 1) immune system development and function, 2) immunity to vaccines or natural infections, or 3) allergic diseases, autoimmunity, or rejection of organ/tissue/cell transplantation.</p>				
114374	Notice of Special Interest (NOSI): Complement in Fundamental Immunology	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-23-012	07-Sep-2024	Not Specified
	<p>Contact Name Ari Joffe, PhD</p> <p>Contact Telephone 240-669-5084</p> <p>Contact Email ari.joffe@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The main objective of this program is to support studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses involved in pathogenic infections, vaccination, post-infection sequelae, autoimmunity, allergy, or transplantation. The results of such studies will inform the development of vaccines or therapeutics that target complement components.</p>				
115066	NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23-071	07-Sep-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-594-5945</p> <p>Contact Email AITrainingHelpDesk@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-23-070).</p>				
115065	NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23-070	12-Oct-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-594-5945</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email AITrainingHelpDesk@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-23-071)</p>				
107851	Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Universal Influenza Vaccine	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-013	07-Sep-2024	Not Specified
	<p>Contact Name Jennifer L. Gordon, Ph.D.</p> <p>Contact Telephone 301-761-6805</p> <p>Contact Email Jennifer.gordon2@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to support research that contributes to the areas of interest outlined in “A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.”</p>				
108513	NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22-075	07-Sep-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email AITrainingHelpDesk@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of the NIAID Career Transition Award program is to assist postdoctoral fellows' transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by another investigator.</p>				
106991	Notice of Special Interest (NOSI): Leveraging Microbial Exposure for Improving Mouse Models of Human Immunity	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-21-072	07-Sep-2024	Not Specified
	<p>Contact Name Qian "Joy" Liu, M.D., M.Sc.</p> <p>Contact Telephone 301-761-6621</p> <p>Contact Email niaidmousemodelnosi@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis This Notice of Special Interest (NOSI) solicits research on immunologic characterization of mice with diverse microbial exposures (commonly referred to as "dirty mice") to determine their usefulness as research tools to advance understanding of human immune function in homeostasis and in response to infectious or immune-mediated diseases.</p>				
113565	Notice of Special Interest (NOSI): argeting the Pathogen within the Arthropod Vector	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-074	07-Sep-2024	Not Specified
	<p>Contact Name Adriana Costero-Saint Denis, Ph.D.</p> <p>Contact Telephone 240-292-4184</p> <p>Contact Email acostero@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 This Notice of Special Interest (NOSI) invites applications to stimulate multidisciplinary research to better understand pathogen/vector interactions to identify approaches to prevent pathogen transmission to the vertebrate host.			
116360	Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Coccidioidomycosis (Valley fever) Vaccine	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-23-031	05-Sep-2024	Not Specified
	Contact Name	Dona C. Love, Ph.D.			
	Contact Telephone	301-761-7788			
	Contact Email	Dona.Love@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID's interest in supporting research in the areas outlined in the NIAID Strategic Plan For Research To Develop A Valley Fever Vaccine. The proposed research should have clear relevance to the strategic priorities defined in the strategic plan, which encompasses three major research areas: 1) address gaps in Coccidioides basic research to support the development of a vaccine; 2) develop tools and resources to support vaccine development; 3) develop and advance vaccines to prevent coccidioidomycosis.			
123682	Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-24-111	16-Oct-2024	275,000 USD
	Contact Name	Ari Joffe, Ph.D.			
	Contact Telephone	240-669-5084			
	Contact Email	ari.joffe@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026			
	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to support research that improves understanding of basic mechanisms and biomarkers of trained immunity (i.e., innate immune memory), plus the functional implications of trained			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	immunity, related to 1) immune system development and function, 2) immunity to vaccines or natural infections, or 3) allergic diseases, autoimmunity, or rejection of organ/tissue/cell transplantation.																		
109336	Notice of Special Interest (NOSI): Optimizing Vascularized Composite Allograft Survival	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-023	07-Sep-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 15%; vertical-align: top;">Contact Name</td> <td>Patricia Kehn, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-627-3547</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>pkehn@NIAID.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting preclinical studies utilizing animal models or human tissue specimens that focus on 1) optimizing treatment and graft monitoring to reduce incidence of acute rejection and maximize graft survival after vascularized composite allotransplantation (VCA) and 2) minimizing immunosuppression required for long-term VCA acceptance.</td> </tr> </table>					Contact Name	Patricia Kehn, Ph.D.	Contact Telephone	240-627-3547	Contact Email	pkehn@NIAID.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026	Synopsis	The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting preclinical studies utilizing animal models or human tissue specimens that focus on 1) optimizing treatment and graft monitoring to reduce incidence of acute rejection and maximize graft survival after vascularized composite allotransplantation (VCA) and 2) minimizing immunosuppression required for long-term VCA acceptance.
Contact Name	Patricia Kehn, Ph.D.																		
Contact Telephone	240-627-3547																		
Contact Email	pkehn@NIAID.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026																		
Synopsis	The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting preclinical studies utilizing animal models or human tissue specimens that focus on 1) optimizing treatment and graft monitoring to reduce incidence of acute rejection and maximize graft survival after vascularized composite allotransplantation (VCA) and 2) minimizing immunosuppression required for long-term VCA acceptance.																		
126594	RFA-AI-24-029 -- Mechanisms of Inducing HIV Immunity in Early Life (MIEL) (U01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-24-029	10-Sep-2024 [Optional][LOI/Pre-App]	3,750,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 15%; vertical-align: top;">Contact Name</td> <td>Anjali Singh, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-507-4924</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>anjalisingh@niaid.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>10-Sep-2024 [Optional][LOI/Pre-App], 09-Oct-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this notice of funding opportunity (NOFO) is to support basic and applied research to define the mechanisms for establishing, developing and maintaining immunity to HIV in early life (from birth to less than 12 years of age), including the impact of prophylactic vaccination and broadly neutralizing HIV antibodies (bNAbs) to protect against acquisition of HIV infection.</td> </tr> </table>					Contact Name	Anjali Singh, Ph.D.	Contact Telephone	240-507-4924	Contact Email	anjalisingh@niaid.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	10-Sep-2024 [Optional][LOI/Pre-App], 09-Oct-2024	Synopsis	The purpose of this notice of funding opportunity (NOFO) is to support basic and applied research to define the mechanisms for establishing, developing and maintaining immunity to HIV in early life (from birth to less than 12 years of age), including the impact of prophylactic vaccination and broadly neutralizing HIV antibodies (bNAbs) to protect against acquisition of HIV infection.
Contact Name	Anjali Singh, Ph.D.																		
Contact Telephone	240-507-4924																		
Contact Email	anjalisingh@niaid.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	10-Sep-2024 [Optional][LOI/Pre-App], 09-Oct-2024																		
Synopsis	The purpose of this notice of funding opportunity (NOFO) is to support basic and applied research to define the mechanisms for establishing, developing and maintaining immunity to HIV in early life (from birth to less than 12 years of age), including the impact of prophylactic vaccination and broadly neutralizing HIV antibodies (bNAbs) to protect against acquisition of HIV infection.																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																																										
127123	Notice of Special Interest (NOSI): Understanding the Immune Functions of DEAD/H-box Helicases	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-24-058	05-Oct-2024	Not Specified																																										
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td colspan="5">Qian "Joy" Liu, M.D., M.Sc.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td colspan="5">301-761-6621</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td colspan="5">liujoy@niaid.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td colspan="5"></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td colspan="5">Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td colspan="5">05-Oct-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td colspan="5">This Notice of Special Interest (NOSI) supports research aimed at gaining a comprehensive understanding of the expression, function, and regulation of DEAD/H-box helicases in immune homeostasis, activation, and/or function. Knowledge obtained from such studies may be applied to the design of improved vaccines and immunotherapies to combat pathogenic infections or treat/prevent immune-mediated diseases.</td> </tr> </table>					Contact Name	Qian "Joy" Liu, M.D., M.Sc.					Contact Telephone	301-761-6621					Contact Email	liujoy@niaid.nih.gov					Sponsor Website						Program URL	Link to program URL					Deadline Dates (ALL)	05-Oct-2024					Synopsis	This Notice of Special Interest (NOSI) supports research aimed at gaining a comprehensive understanding of the expression, function, and regulation of DEAD/H-box helicases in immune homeostasis, activation, and/or function. Knowledge obtained from such studies may be applied to the design of improved vaccines and immunotherapies to combat pathogenic infections or treat/prevent immune-mediated diseases.				
Contact Name	Qian "Joy" Liu, M.D., M.Sc.																																														
Contact Telephone	301-761-6621																																														
Contact Email	liujoy@niaid.nih.gov																																														
Sponsor Website																																															
Program URL	Link to program URL																																														
Deadline Dates (ALL)	05-Oct-2024																																														
Synopsis	This Notice of Special Interest (NOSI) supports research aimed at gaining a comprehensive understanding of the expression, function, and regulation of DEAD/H-box helicases in immune homeostasis, activation, and/or function. Knowledge obtained from such studies may be applied to the design of improved vaccines and immunotherapies to combat pathogenic infections or treat/prevent immune-mediated diseases.																																														
113395	NIAID Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22-241	07-Sep-2024	Not Specified																																										
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td colspan="5">Diane Adger-Johnson, MPH</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td colspan="5"></td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td colspan="5">AITrainingHelpDesk@niaid.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td colspan="5"></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td colspan="5">Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td colspan="5">07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td colspan="5">The purpose of this funding opportunity announcement is to encourage applications for research projects within the NIAID mission. This FOA seeks to support either (a) a New Investigator (NI), an individual who has not previously competed successfully for substantial, independent funding from NIH, or (b) are an 'At-Risk' investigator, an individual who had prior support as a PD/PI on a substantial independent research award and unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year, from diverse backgrounds, including those from groups underrepresented in the health-related sciences.</td> </tr> </table>					Contact Name	Diane Adger-Johnson, MPH					Contact Telephone						Contact Email	AITrainingHelpDesk@niaid.nih.gov					Sponsor Website						Program URL	Link to program URL					Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025					Synopsis	The purpose of this funding opportunity announcement is to encourage applications for research projects within the NIAID mission. This FOA seeks to support either (a) a New Investigator (NI), an individual who has not previously competed successfully for substantial, independent funding from NIH, or (b) are an 'At-Risk' investigator, an individual who had prior support as a PD/PI on a substantial independent research award and unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year, from diverse backgrounds, including those from groups underrepresented in the health-related sciences.				
Contact Name	Diane Adger-Johnson, MPH																																														
Contact Telephone																																															
Contact Email	AITrainingHelpDesk@niaid.nih.gov																																														
Sponsor Website																																															
Program URL	Link to program URL																																														
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025																																														
Synopsis	The purpose of this funding opportunity announcement is to encourage applications for research projects within the NIAID mission. This FOA seeks to support either (a) a New Investigator (NI), an individual who has not previously competed successfully for substantial, independent funding from NIH, or (b) are an 'At-Risk' investigator, an individual who had prior support as a PD/PI on a substantial independent research award and unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year, from diverse backgrounds, including those from groups underrepresented in the health-related sciences.																																														
109790	NIAID Research Education Program (R25 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22-134	09-Oct-2024	1,755,000 USD																																										

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email AITrainingHelpDesk@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Oct-2024</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development Research Experiences Mentoring Activities</p>				
127233	RFA-AI-24-041 -- Novel Approaches for Radiation Biodosimetry and Medical Countermeasure Development (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-24-041	02-Oct-2024 [Optional][LOI/Pre-App]	200,000 USD
	<p>Contact Name Lanyn P. Taliaferro, Ph.D.</p> <p>Contact Telephone 240-669-5479</p> <p>Contact Email lanyn.taliaferro@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Oct-2024 [Optional][LOI/Pre-App], 01-Nov-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to support exploratory and conceptual research projects in radiation research focused on medical countermeasures, biodosimetry, and animal model development to diagnose/mitigate/treat injuries arising from radiation exposure sustained during a radiation mass casualty incident. This NOFO is intended to support development of preliminary data to help advance high-risk, high-reward projects needed for a robust early product development pipeline that can lead to the advancement of much-needed radiation-exposure related tools and products.</p>				
127288	RFA-AI-24-071 -- Promoting Innovative Research in Treponema pallidum Pathogenesis (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-24-071	05-Oct-2024 [Optional][LOI/Pre-App]	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Leah R. Vincent, PhD</p> <p>Contact Telephone 301-761-7365</p> <p>Contact Email leah.vincent@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 [Optional][LOI/Pre-App], 04-Nov-2024</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support basic and exploratory research projects to advance our understanding of Treponema pallidum bacterial pathogenesis.</p>				
120360	<p>Notice of Special Interest (NOSI): Administrative Supplement for Accelerating Research in Understudied Skin Types</p>	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-24-008	02-Oct-2024	300,000 USD
	<p>Contact Name Alexey Belkin, Ph.D.</p> <p>Contact Telephone 240-755-3031</p> <p>Contact Email alexey.belkin@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Oct-2024</p> <p>Synopsis The purpose of this announcement is to notify the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is interested in receiving administrative supplements to grants focused on skin research uncovering the basis for inferior diagnosis, increased prevalence, elevated clinical severity, and altered treatment response in Black Americans and African Americans, Hispanics and Latinos, American Indians and Alaskan Natives, Asians and Asian Americans, and Native Hawaiians and Pacific Islanders with skin diseases.</p>				
109528	<p>Limited Competition: Small Grant Program for NIAMS K01, K08, K23, and K25 Recipients (R03) (Clinical Trials Not Allowed)</p>	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-22-119	21-Oct-2024	100,000 USD
	<p>Contact Name Su-Yau Mao, Ph.D.</p> <p>Contact Telephone 301-594-5032</p> <p>Contact Email maos2@mail.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Oct-2024 , 19-Feb-2025</p> <p>Synopsis The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) announces a program that provides NIAMS-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support at an appropriate point during the second to fourth year of their K award. Through the use of this mechanism, which allows up to \$100,000 direct costs for the entire project period of up to two years, the NIAMS is seeking to enhance the capability of its scientists to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that provide support, in addition to the career development award, for a subsequent R01, or equivalent, application. Clinical trials of any phase will not be supported by this FOA.</p>				
114290	Notice of Special Interest (NOSI): Promoting Research Opportunities on HIV/AIDS in NIAMS	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-23-004	06-Aug-2024	Not Specified
	<p>Contact Name Heiyong Park, Ph.D.</p> <p>Contact Telephone 301-594-5032</p> <p>Contact Email parkh1@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 06-Dec-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 09-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 06-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Dec-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 16-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 16-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of this announcement is to inform potential applicants to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of an area of special interest in HIV/AIDS-associated comorbidities that are within the NIAMS mission.</p>				
117716	Notice of Special Interest (NOSI): Supporting Exploratory/Developmental	National Institute of Arthritis and	NOT-AR-	06-Aug-2024	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Research Focused on NIAMS Core Mission Areas	Musculoskeletal and Skin Diseases/NIH/DHHS	23-006		Specified
	<p>Contact Name Jana Eisenstein</p> <p>Contact Telephone 301-594-5032</p> <p>Contact Email jana.eisenstein@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 06-Dec-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 09-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 06-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Dec-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Jan-2027</p> <p>Synopsis The purpose of this announcement is to notify the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is interested in receiving Exploratory/Developmental grant applications focused on NIAMS core mission areas. Awards will provide support for innovative projects that introduce novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential for significant impact, and to substantially advance research within the NIAMS mission. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs of high value to the NIAMS research community.</p>				
127122	RFA-AR-25-005--HEAL Initiative: INTERACT INTEgRative Back Pain Longitudinal Cohort Teams (UC2 Clinical Trial Optional)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	RFA-AR-25-005	11-Sep-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Rebecca Lenzi, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email rebecca.lenzi@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Sep-2024 [Optional][LOI/Pre-App], 11-Oct-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to solicit cooperative agreement applications from interdisciplinary teams to enhance longitudinal data collection and analysis with existing large scale chronic low back pain (cLBP) cohort studies. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>Research teams will build upon the infrastructure and accomplishments of the initial efforts of the Back Pain Consortium (BACPAC) Research Program to continue to advance the diagnosis and treatment of low back pain to accelerate comprehensive understanding of chronic pain across musculoskeletal diseases. New applicant teams are encouraged, beyond the originally funded BACPAC awardees. Teams are encouraged, but not limited to, collaborative arrangements across existing HEAL projects. Funded teams, through this NOFO, will inform the structure and key elements of future HEAL efforts that will facilitate interactions, synergies, and integration of methodologies, data elements, and collaborative projects to accelerate the knowledge transfer across musculoskeletal disease groups.</p>			
127031	RFA-AR-24-007--HEAL KIDS (Knowledge, Innovation and Discovery Studies): Chronic Pain Program (UC2 Clinical Trial Optional)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	RFA-AR-24-007	21-Oct-2024 [Optional][LOI/Pre-App]	6,500,000 USD
	Contact Name	Robert Walker, Jr Ph.D.			
	Contact Telephone				
	Contact Email	robert.walker2@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	21-Oct-2024 [Optional][LOI/Pre-App], 08-Nov-2024			
	Synopsis	<p>As part of the NIH's Helping to End Addiction Long-term (HEAL) Initiative, the National Institute of Arthritis and Musculoskeletal and Skin Diseases and other participating NIH Institutes and Centers invite applications for the HEAL KIDS Chronic Pain Collaborating Research Teams (HEAL KIDS CPT) Program to conduct interdisciplinary team-based research projects that combine clinical research, novel/cutting-edge technologies, and measurement science, which will improve our understanding of primary and secondary chronic pain conditions in children and adolescents. The results are expected to enhance and expand our capacity to pursue challenging biological problems, therapeutics development, and effective management of pediatric pain conditions. The HEAL KIDS CPT projects are expected to address a significant scientific challenge in the biopsychosocial model of pain that requires collaboration, synergy, knowledge integration and team interactions. Teams are encouraged to consider transformative objectives and design projects that would lead to new, innovative, and improved strategies to enhance understanding of chronic pain mechanisms at the individual level. Research may include testing of powerful tools, models, and approaches to accelerate the development and translation of pain condition-specific, age-appropriate therapeutics, and next-generation clinical management of pain. This Notice of Funding Opportunity (NOFO) complements the previously issued NOFO (RFA-HD-24-011) and NOFO (RFA-HD-24-012) focused on clinical trials of acute pain in infants, children, and adolescents and the establishment of a HEAL KIDS Resource Center, respectively. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
117677	Notice of Special Interest (NOSI): Synthetic Biology for Biomedical Applications	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	NOT-EB-23-002	06-Sep-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Hye-Sook Kim, Ph.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-827-6910</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">hye-sook.kim@nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">06-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 08-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 16-Oct-2025</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">The purpose of this Notice is to announce that the National Center for Complementary and Integrative Health (NCCIH), the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), the National Institute on Aging (NIA), the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institute of General Medical Sciences (NIGMS) are encouraging new applications to advance research activities relevant to synthetic biology.</td> </tr> </table>					Contact Name	Hye-Sook Kim, Ph.D.	Contact Telephone	301-827-6910	Contact Email	hye-sook.kim@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	06-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 08-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 16-Oct-2025	Synopsis	The purpose of this Notice is to announce that the National Center for Complementary and Integrative Health (NCCIH), the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), the National Institute on Aging (NIA), the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institute of General Medical Sciences (NIGMS) are encouraging new applications to advance research activities relevant to synthetic biology.
Contact Name	Hye-Sook Kim, Ph.D.																		
Contact Telephone	301-827-6910																		
Contact Email	hye-sook.kim@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	06-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 08-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 16-Oct-2025																		
Synopsis	The purpose of this Notice is to announce that the National Center for Complementary and Integrative Health (NCCIH), the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), the National Institute on Aging (NIA), the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institute of General Medical Sciences (NIGMS) are encouraging new applications to advance research activities relevant to synthetic biology.																		
113425	Advancing Methods for Safe, Noninvasive, Real Time Assessment of Placenta Development and Function Across Pregnancy (R01 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-22-237	05-Oct-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">David Weinberg, PhD</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-435-6973</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">weinbergd@mail.nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">05-Oct-2024 , 05-Nov-2024</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">This Funding Opportunity Announcement (FOA) invites grant applications that seek to advance or clinically validate emerging novel approaches for the development of safe, real-time, non-invasive (or minimally invasive) methods to assess the development and function of the human placenta across pregnancy.</td> </tr> </table>					Contact Name	David Weinberg, PhD	Contact Telephone	301-435-6973	Contact Email	weinbergd@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Oct-2024 , 05-Nov-2024	Synopsis	This Funding Opportunity Announcement (FOA) invites grant applications that seek to advance or clinically validate emerging novel approaches for the development of safe, real-time, non-invasive (or minimally invasive) methods to assess the development and function of the human placenta across pregnancy.
Contact Name	David Weinberg, PhD																		
Contact Telephone	301-435-6973																		
Contact Email	weinbergd@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Oct-2024 , 05-Nov-2024																		
Synopsis	This Funding Opportunity Announcement (FOA) invites grant applications that seek to advance or clinically validate emerging novel approaches for the development of safe, real-time, non-invasive (or minimally invasive) methods to assess the development and function of the human placenta across pregnancy.																		
113423	Advancing Methods for Safe, Noninvasive, Real Time Assessment of	National Institute of Child Health and	PAR-22-	16-Oct-2024	275,000														

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Placenta Development and Function Across Pregnancy (R21 Clinical Trial Not Allowed)	Human Development/NIH/DHHS	236		USD
	<p>Contact Name David Weinberg, PhD</p> <p>Contact Telephone 301-435-6973</p> <p>Contact Email weinbergd@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024 , 16-Nov-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites grant applications that seek to advance or clinically validate emerging novel approaches for the development of safe, real-time, non-invasive (or minimally invasive) methods to assess the development and function of the human placenta across pregnancy.</p>				
118674	Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-23-193	03-Oct-2024	Not Specified
	<p>Contact Name Christopher C. Lindsey, PhD</p> <p>Contact Telephone 301-538-9761</p> <p>Contact Email chris.lindsey@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Oct-2024 , 03-Apr-2025 , 03-Oct-2025 , 03-Apr-2026</p> <p>Synopsis The NICHD has a state-of-the-art Chemical Synthesis and Optimization Facility for advancing both non-hormonal contraceptive and reproductive health related product development. This facility has the capabilities and capacity for preclinical services including Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies (e.g., protein generation, X-ray crystallography, high throughput screening, structure activity relationships, hit-to-lead generation, drug metabolism). The long-term objective is to enable a preclinical candidate for IND/IDE study(ies) that offers a safe therapeutic option in the field of contraception, and/or reproductive health related indications (pending contractor availability and available funding).</p>				
112833	Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-22-215	05-Oct-2024	2,499,995 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Reiko Toyama, Ph.D.</p> <p>Contact Telephone 301-435-2723</p> <p>Contact Email toyamar@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to support innovative research that will inform our understanding of the mechanisms underlying the formation of structural birth defects using animal models in conjunction with human translational/clinical approaches. Applicants are encouraged to take advantage of advances in genetics, 'omics methods (genomics, proteomics, metabolomics, etc.), and synthetic biology, biochemical and other approaches to developmental biology research to identify specific genetic, epigenetic, environmental, or gene/environment interactions associated with the formation of, susceptibility to, and variability of structural birth defects in human populations.</p>				
107317	Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21-353	05-Oct-2024	Not Specified
	<p>Contact Name Mollie Minear, Ph.D.</p> <p>Contact Telephone 301-827-9442</p> <p>Contact Email mollie.minear@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024</p> <p>Synopsis This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.</p>				
103657	NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required)	National Institute of Child Health and Human Development/NIH/DHHS	PA-21-231	07-Sep-2024	50,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email NICHDReferral@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The NICHD Small Research Grant Program (Clinical Trial Required) supports clinical trials that fall within the NICHD mission. This funding opportunity announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ FOA.</p>				
103656	NICHD Small Research Grant Program (R03 Clinical Trial Required)	National Institute of Child Health and Human Development/NIH/DHHS	PA-21-221	07-Sep-2024	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email NICHDReferral@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The NICHD Small Research Grant Program (R03 Clinical Trial Required) supports clinical trials that fall within the NICHD mission. The R03 activity code supports small research projects that can be carried out in a short period of time with limited resources. The R03 program may be used for different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.</p>				
126762	Advancement and Innovation in Measurement of Language Development and Predictors (R01 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-24-243	05-Oct-2024	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Virginia Salo</p> <p>Contact Telephone 301-402-3682</p> <p>Contact Email virginia.salo@nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Nov-2024 , 05-Feb-2025 , 05-Mar-2025 , 05-Jun-2025 , 05-Jul-2025 , 05-Oct-2025 , 05-Nov-2025 , 05-Feb-2026 , 05-Mar-2026 , 05-Jun-2026 , 05-Jul-2026 , 05-Oct-2026 , 05-Nov-2026 , 05-Feb-2027 , 05-Mar-2027 , 05-Jun-2027 , 05-Jul-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to encourage community-engaged research that broadens the conceptualization of qualities of the environment that can support language development in children and that focuses on the development of novel measures of children’s language development. The overall goal is to build the number of strengths-focused, culturally and linguistically responsive, and generalizable tools to further our understanding of children’s language development and/or impairment, and predictors thereof. This NOFO requires a Community Engagement (CE) Plan, which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a CE Plan will be considered incomplete and will be withdrawn. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
126760	<p>Advancement and Innovation in Measurement of Language Development and Predictors (R21 Clinical Trial Not Allowed)</p>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-24-244	16-Oct-2024	275,000 USD
	<p>Contact Name Virginia Salo</p> <p>Contact Telephone 301-402-3682</p> <p>Contact Email virginia.salo@nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024 , 16-Nov-2024 , 16-Feb-2025 , 16-Mar-2025 , 16-Jun-2025 , 16-Jul-2025 , 16-Oct-2025 , 16-Nov-2025 , 16-Feb-2026 , 16-Mar-2026 , 16-Jun-2026 , 16-Jul-2026 , 16-Oct-2026 , 16-Nov-2026 , 16-Feb-2027 , 16-Mar-2027 , 16-Jun-2027 , 16-Jul-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to encourage community-engaged research that broadens the conceptualization of qualities of the environment that can support language development in children and that focuses on the development of novel measures of children’s language development. The overall goal is to build the number of strengths-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

focused, culturally and linguistically responsive, and generalizable tools to further our understanding of children’s language development and/or impairment, and predictors thereof. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

107319	Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21-355	16-Oct-2024	275,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Mollie Minear, Ph.D.
Contact Telephone	301-827-9442
Contact Email	mollie.minear@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Oct-2024
Synopsis	This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

107320	Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R03 - Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21-354	16-Oct-2024	100,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Mollie Minear, Ph.D.
Contact Telephone	301-827-9442
Contact Email	mollie.minear@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Oct-2024
Synopsis	This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

113756	NCMRR Early Career Research Award (R03 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-23-029	16-Oct-2024	200,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Maria Nurminkaya, PhD
Contact Telephone	240-591-9986
Contact Email	Maria.nurminkaya@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026
Synopsis	The National Center for Medical Rehabilitation Research (NCMRR) Early Career Research (ECR) Award (R03) is intended to support both basic and clinical research from rehabilitation scientists who are establishing independent research careers. The research must be focused on one or more of the areas within the mission of NCMRR: Applicants are encouraged to refer to the NIH Research Plan on Rehabilitation for strategic priorities (https://www.nichd.nih.gov/newsroom/news/110121-NIH-rehab-plan). The NCMRR ECR Award R03 grant mechanism supports various types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new technology. Irrespective of the type of project, the intent of the NCMRR ECR Award R03 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.

113468	Notice of Special Interest (NOSI): High Priority Areas in Placental Research for Healthy Pregnancies (Reissue)	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-22-049	07-Sep-2024	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	John V. Ilekis, PhD
Contact Telephone	301-435-6895
Contact Email	ilekij@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Synopsis	Although the placenta is a short-lived organ limited to pregnancy, its importance is often underappreciated in being a crucial organ for the propagation of our species and future health of our progeny. Perturbations in any one of its many functions may result in many common adverse pregnancy outcomes. These include early pregnancy loss, preeclampsia, fetal growth restriction, stillbirth, and preterm birth. In addition, a poorly functioning placenta can lead to aberrant programming of the fetus that can impact the health of the individual later in adult life. This includes an increased incidence of adult diseases such as obesity, cardiovascular disease, and diabetes. Thus, a more comprehensive understanding of the placenta is necessary to help address a number of major gaps in knowledge.				
127099	RFA-HD-25-011 -- The Road to Prevention of Stillbirth – Data Coordinating Center (UM2 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-25-011	01-Oct-2024 [LOI/Pre-App]	Not Specified	
	Contact Name	Monica Longo, MD, PhD				
	Contact Telephone					
	Contact Email	Monica.Longo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Oct-2024 [LOI/Pre-App], 01-Nov-2024				
	Synopsis	This Notice of Funding Opportunity (NOFO) invites applications to participate as the Data Coordinating Center (DCC) for the Stillbirth Research Consortium. The DCC will assist the work of the research projects funded in the companion announcement (see RFA-HD-25-010) and will provide management and support for the Consortium. DCC staff must possess strong scientific qualifications, including but not limited to, expertise in clinical/health informatics, bioinformatics, -omics, biostatistics, epidemiology, and data science. DCC personnel must have experience in the supervision of clinical studies, as well as experience in the statistical analysis of high-volume demographic, clinical, laboratory, and imaging data, and experience working with large national datasets. The DCC and Research Centers together will establish an integrated and collaborative Stillbirth Research Consortium to support cutting-edge basic, translational, clinical and/or data sciences research to generate knowledge for advancement in stillbirth-relevant research across the United States, with a particular emphasis on approaches that utilize an equity lens to identify ways to decrease the incidence of stillbirth in vulnerable populations.				
126985	Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-24-256	16-Oct-2024	100,000 USD	
	Contact Name	Susan M. Jekielek, PhD				
	Contact Telephone					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email susan.jekielek@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to support the archiving and documentation of existing data sets within the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding.</p>				
127098	<p>RFA-HD-25-010 -- The Road to Prevention of Stillbirth – Clinical Research Centers (UG1 Clinical Trial Optional)</p>	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-25-010	01-Oct-2024 [LOI/Pre-App]	860,000 USD
	<p>Contact Name Monica Longo, MD, PhD</p> <p>Contact Telephone</p> <p>Contact Email Monica.Longo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024 [LOI/Pre-App], 01-Nov-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications from entities/institutions to participate as a Research Center in the Stillbirth Research Consortium. This NOFO runs in parallel with the Stillbirth Research Center Data Coordinating Center (see RFA-HD-25-011). The Research Centers and the DCC together will establish an integrated and collaborative Stillbirth Research Consortium to support cutting-edge basic, translational, clinical, and/or data sciences research to generate knowledge for advancement in stillbirth-relevant research across the United States, with a particular emphasis on approaches that utilize an equity lens to identify ways to decrease the incidence of stillbirth in vulnerable populations. International collaboration is encouraged and allowable. Awarded Research Centers, with complementary expertise, will have specific goals and objectives in their efforts to understand and prevent stillbirth including (1) supporting the development of tools, devices, instrumentation, models, and other technologies that could have a direct clinical or health impact on the incidence of stillbirth; (2) enhancing understanding of the mechanisms underlying vulnerability to stillbirth; (3) elucidating conditions such as structural defects, genetic factors, infections, and/or complications that may contribute to stillbirth and investigation of the fetus, placenta, and maternal tissues; (4) leveraging secondary data analysis and integration of existing datasets (including national datasets) and database resources, with the ultimate aim to elucidate stillbirth risk or prediction and related outcomes; and (5) improving communication between health professionals and families in pregnancy</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>care. Research Center applications must propose one to two research projects that may vary in scale and scope. Research Centers may actively collaborate on studies and projects with other NICHD Networks and initiatives to strengthen research efforts. This will likely include partnerships with the Maternal Fetal Medicine Units (MFMU) Network and the NICHD Maternal and Pediatric Precision in Therapeutics (MPRINT) initiative; NIH Institutes or Offices such as All of Us; and maternal health activities with partner Federal health agencies, including the Centers for Disease Control and Prevention, the Health and Research Services Administration, and the Office of the Assistant Secretary on Women's Health. These collaborations will foster interdisciplinary approaches, facilitate data sharing, and enhance the impact of their research on maternal and fetal health. To stimulate novel approaches, it is anticipated that key personnel in complementary disciplines (e.g., medicine, biology, nursing, environmental science, public health, biology, behavioral and social science, biostatistics/statistics, mathematics, computer science, nutrition, and engineering) will collaborate to address stillbirth-relevant research. In addition, Research Centers must include a plan for inclusion of People with Lived Experience (PWLE).</p>				
127100	RFA-HD-25-005--Women's Reproductive Health Research (WRHR) Career Development Program (K12 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-25-005	15-Oct-2024 [LOI/Pre-App]	Not Specified
	Contact Name	Donna Mazloomdoost, MD			
	Contact Telephone				
	Contact Email	donna.mazloomdoost@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Oct-2024 [LOI/Pre-App], 15-Nov-2024			
	Synopsis	<p>The purpose of this Notice of Funding Opportunity announcement (NOFO-) issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is to announce the re-competition of the Women's Reproductive Health Research (WRHR) Career Development Program. This nationwide group of mentored institutional career development programs trains junior faculty who have recently completed postgraduate clinical training in obstetrics and gynecology and are committed to an independent research career in women's reproductive health. The goal of this program is to continue to build the national capacity of outstanding junior clinician-investigators who will strengthen the field of obstetrics and gynecology and contribute to the improvement of women's health. This Notice of Funding Opportunity (NOFO) allows appointment of [Scholars (K12)] proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.</p>			
117230	NIDCR Research Grants for Analyses of Existing Genomics Data (R01)	National Institute of Dental and	PAR-23-	07-Sep-2024	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	(Clinical Trial Not Allowed)	Craniofacial Research/NIH/DHHS	133		Specified
	<p>Contact Name Noffisat Oki</p> <p>Contact Telephone 301-402-6778</p> <p>Contact Email noffisat.oki@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis The purpose of this NOFO is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) biology, and diseases and conditions, through analysis of existing and publicly available genomic data, with or without other types of complementary data, using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the proposed project(s), including methods for data and metadata mining, data integration, and Artificial Intelligence (AI)/Machine Learning (ML)/Deep Learning (DL) methods. In addition to analysis of existing data, experimental or in silico work is required to validate the results of the proposed analysis, or to validate a newly developed analytic method. Projects aimed at understanding oral health disparities to inform strategies for improving health for all individuals are a priority. Projects focused on investigating and/or characterizing human biological pathways to inform identification of intervention targets or defining the pathogenicity of known genetic variants are encouraged.</p>				
117461	NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-23-162	07-Sep-2024	Not Specified
	<p>Contact Name Lorena Baccaglini, DDS, MS, PhD</p> <p>Contact Telephone 301-435-7908</p> <p>Contact Email lorena.baccaglini@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis This NOFO will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| data/biospecimens.

102596	NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-160	06-Sep-2024	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Dena Fischer, DDS, MSD, MS
Contact Telephone	301-594-4876
Contact Email	dena.fischer@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	06-Sep-2024 , 03-Oct-2024 , 08-Jan-2025

Synopsis This Funding Opportunity Announcement (FOA) will support UG3/UH3 phased, cooperative agreement research applications to plan and implement clinical trials within the mission of the National Institute of Dental and Craniofacial Research (NIDCR). Studies appropriate for this FOA are those testing diagnostic, prevention or treatment approaches to test a drug, biologic, device, or procedure for dental, oral, or craniofacial diseases or conditions, including trials for any phase of testing for a Food and Drug Administration (FDA)-regulated product. Awards made under this FOA will initially support a one-year milestone-driven UG3 planning phase, with possible transition to a UH3 clinical trial implementation phase of up to five years. The UH3 phase of the award will support the conduct of one investigator-initiated clinical trial. The UG3 planning phase permits both operational and scientific planning activities. Operational planning activities include, at minimum, finalizing the protocol and preparing other documents to implement the clinical trial (e.g., data collection instruments, Manual of Procedures, data management plan). Allowable scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned intervention and associated study procedures (e.g., acceptability of mode of intervention delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures) and assessment of the subject population to determine recruitment potential for the future trial. The UG3 phase cannot be used to test for intervention safety or efficacy. If the application proposes a clinical trial with an investigational drug, biologic or device, the investigators must have submitted the appropriate investigational application to the FDA prior to the UH3 phase.

110754	Notice of Special Interest (NOSI): Achieving Tissue Robustness Through Harnessing Immune System Plasticity	National Institute of Dental and Craniofacial Research/NIH/DHHS	NOT-DE-22-005	07-Sep-2024	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	Preethi Chander, PhD
Contact Telephone	301-827-4620

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email preethi.chander@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis NIDCR announces its interest in encouraging state-of-the-art, systematic research approaches to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations, and to examine immune mechanisms of protection against recurrence of chronic inflammation in response to infectious and autoimmune diseases of dental, oral, and craniofacial (DOC) tissues. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward protection against episodic recurrence and preventative disease management in a patient-specific manner across the lifespan.</p>				
108353	<p>NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed)</p>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-041	07-Sep-2024	Not Specified
	<p>Contact Name Leslie A. Frieden, PhD</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email leslie.frieden@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and craniofacial health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. An option for five years of independent (R00) support is available to accommodate clinical training in a dental specialty program at no more than 3 person-months (25% full-time professional effort) in any year of the R00 phase. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

trial as lead investigator, should apply to the companion FOA (PAR-22-042). Applicants proposing basic experimental studies in humans referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants” should apply to the companion Basic Experimental Studies with Humans FOA (PAR-22-043).

110993	Short-term Mentored Career Enhancement Award in Dental, Oral and Craniofacial Research for Mid-Career and Senior Investigators (K18 Independent Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-121	07-Sep-2024	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Leslie A. Frieden, PhD
Contact Telephone	301-496-4263
Contact Email	leslie.frieden@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025
Synopsis	The goal of the NIDCR Career Enhancement Award (K18) is to support mentored research experiences for established investigators who either wish to expand or augment their dental, oral, or craniofacial (DOC) research program, or to redirect their research by incorporating DOC research into their research program to advance fundamental knowledge about dental, oral, and craniofacial health and disease. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

117231	NIDCR Small Research Grants for Analyses of Existing Genomics Data (R03 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-23-132	07-Sep-2024	200,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Noffisat Oki
Contact Telephone	301-402-6778
Contact Email	noffisat.oki@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis: The purpose of this NOFO is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) biology, and diseases and conditions, through analysis of existing and publicly available genomic data, with or without other types of complementary data, using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the proposed project(s), including methods for data and metadata mining, data integration, and Artificial Intelligence (AI)/Machine Learning (ML)/Deep Learning (DL) methods. Projects focused on investigating and/or characterizing human biological pathways to inform identification of intervention targets or defining the pathogenicity of known genetic variants are encouraged.</p>				
116699	Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19)	National Institute of Dental and Craniofacial Research/NIH/DHHS	NOT-DE-23-004	07-Sep-2024	Not Specified
	<p>Contact Name: Amanda Melillo, Ph.D. Contact Telephone: 301-529-7217 Contact Email: amanda.melillo@nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 Synopsis: The National Institute of Dental and Craniofacial Research (NIDCR) is reissuing this Notice of Special Interest (NOSI) to encourage research studies focused on the physiological involvement of oral cavity and oral manifestations related to SARS-CoV-2 and/or Coronavirus Disease 2019 (COVID-19).</p>				
106245	NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-317	06-Sep-2024	Not Specified
	<p>Contact Name: Melissa W. Riddle, PhD Contact Telephone: 301-451-3888 Contact Email: riddleme@mail.nih.gov Sponsor Website: Program URL: Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 06-Sep-2024 , 03-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this FOA include clinical trials to develop and test behavior change interventions related to dental, oral, or craniofacial conditions. Applications for NIDCR support of clinical trials research are expected to identify research proposals using the NIH Stage Model framework, described in detail here and incorporate an experimental medicine approach. Awards made under this FOA will initially support a milestone-driven UG3 planning phase for up to 2 years, with possible transition to a UH3 clinical trial implementation phase (UH3) of up to five years. The UG3 phase for behavioral and social intervention clinical trials will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned behavioral or social intervention and associated study procedures (e.g., acceptability of study content or mode of delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures). Operational planning activities include, at a minimum, development of: the final clinical protocol; the intervention manual or equivalent; the data management system and other tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents. The UH3 phase will support the conduct of investigator-initiated intervention research at all stages, from early mechanistic research and intervention development (e.g., Stages 0/ I) through implementation and health services research (Stages IV/V). This FOA may also support basic behavioral experimental studies with humans that are considered clinical trials based on the NIH's revised clinical trial definition (please see Clinical Trial Requirements for Grants and Contracts for guidance).</p>				
108402	<p>NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Not Allowed)</p>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-044	12-Oct-2024	Not Specified
	<p>Contact Name Leslie A. Frieden, PhD</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email leslie.frieden@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to facilitate transition of highly qualified dentists from NIH Intramural postdoctoral research positions to extramural academic tenure-track or equivalent faculty positions at eligible institutions. The award will provide support for two years of mentored postdoctoral research training in the NIH Intramural Research Program, and three years of independent research funding at</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-22-045).

123308	NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-24-094	09-Oct-2024	450,000 USD
--------	--	---	------------	-------------	-------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Tracy Rankin, Ph.D., M.P.H.</p> <p>301-594-4748</p> <p>rankint@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>09-Oct-2024 , 10-Jun-2025 , 11-Feb-2026 , 08-Oct-2026 , 10-Jun-2027</p> <p>NIDDK supports investigator-initiated, high-risk multi-center (more than one center) clinical studies through a two-part process that may include an implementation planning cooperative agreement (U34). The U34 is designed to: 1) Permit early peer review of the rationale for the proposed clinical study; 2) Permit assessment of the design and protocol of the proposed study; 3) Provide support for the development of documents needed for the conduct of the study, including a manual of operations; and 4) Support the development of other essential elements required for the conduct of the clinical study. The proposed clinical study should be hypothesis-driven and focus on a disease in the mission of NIDDK. Consultation with NIDDK scientific staff is strongly encouraged prior to the submission of the U34 application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the FOA instructions carefully and view the available PEDP guidance material.</p>
---	---

125668	RFA-DK-25-005--Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-25-005	16-Sep-2024 [Optional][LOI/Pre-App]	3,750,000 USD
--------	---	---	---------------	-------------------------------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p>	<p>Ellen Leschek, M.D.</p> <p>301-402-8291</p>
--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email LeschekE@extra.niddk.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Sep-2024 [Optional][LOI/Pre-App], 17-Oct-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to continue support for the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), a screening and clinical activities coordination unit for clinical trials focusing on the prevention of and early intervention in type 1 diabetes (T1D). The main objective of the HUB is to increase the efficiency and productivity of the TrialNet network by providing coordination of communications and outreach and developing new tools and approaches to increase screening, recruitment and retention. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
125588	RFA-DK-25-004 -- Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-25-004	16-Sep-2024 [Optional][LOI/Pre-App]	29,500,000 USD
	<p>Contact Name Ellen Leschek, MD</p> <p>Contact Telephone 301-402-8291</p> <p>Contact Email LeschekE@extra.niddk.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Sep-2024 [Optional][LOI/Pre-App], 17-Oct-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to continue support for the TrialNet Coordinating Center (TNCC). The TrialNet network identifies people with type 1 diabetes (T1D) at stages before and after onset of clinical symptoms and enrolls them in trials and studies aimed at prevention of progression to clinical disease and preservation of insulin production. The TNCC participates in ongoing studies and intervention trials as well as the design and conduct of new studies and intervention trials. The TNCC will: (1) support a wide range of research projects in varying stages of development, implementation and completion, and (2) provide data and sample management, including standardized acquisition, quality control, dissemination and public accessibility. The TNCC will be responsible for network administration and operations, including the evaluation, selection, and funding (through subcontracts) of Clinical Centers and central support units (such as laboratories) necessary for the conduct of TrialNet's clinical studies. The TNCC PD/PI will be a voting member of the TrialNet</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Executive and Steering Committees, contributing to network leadership. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
125933	RFA-DK-25-007 -- Nutrition Obesity Research Centers (P30 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-25-007	09-Sep-2024 [Optional][LOI/Pre-App]	3,750,000 USD
	<p>Contact Name Mary E. Evans, Ph.D. Contact Telephone 301-594-4578 Contact Email evansmary@niddk.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 09-Sep-2024 [Optional][LOI/Pre-App], 09-Oct-2024 , 10-Jun-2025 Synopsis This Funding Opportunity Announcement (FOA) invites applications from institutions/organizations that propose to establish core centers that are part of an integrated and existing program of nutrition and/or obesity research. The Nutrition Obesity Research Centers (NORC) program is designed to support and enhance the national research effort in nutrition and obesity. NORCs support three primary research-related activities: Research Core services, a Pilot and Feasibility (P and F) program, and an Enrichment program. All activities pursued by Nutrition Obesity Research Centers are designed to enhance the efficiency, productivity, effectiveness and multidisciplinary nature of research in nutrition and obesity.</p>				
125935	RFA-DK-25-011 -- Nutrition Obesity Research Centers Research Resource Center (RRC) (P2C- Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-25-011	09-Sep-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Mary E. Evans, Ph.D. Contact Telephone 301-594-4578 Contact Email evansmary@niddk.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 09-Sep-2024 [Optional][LOI/Pre-App], 09-Oct-2024</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p style="text-align: center;">Synopsis</p> <p>This Notice of Funding Opportunity (NOFO) invites applications from institutions/organizations that propose to establish a Research Resource Center (RRC) for the NIDDK Nutrition Obesity Research Centers (NORC) Program. The NORC Program consists of eleven Centers across the nation that support and enhance the national research effort in nutrition and obesity through cutting-edge basic, clinical, translational, and health disparities research in nutrition science and obesity. In collaboration with the existing NORC program, the RRC will (1) provide administrative support for the entire NORC Program, (2) establish and curate a NORC Program website and centralized repository of research resources, (3) implement a multi-pronged approach to support and grow a diverse early-to-midcareer research workforce with a goal of maximizing national outreach and impact, (4) administer and manage a NORC Opportunity Program to address gaps and promote collaboration, and (5) manage a Pilot and Feasibility Program. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
122000	RFA-DK-25-003 -- Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-25-003	23-Sep-2024 [Optional][LOI/Pre-App]	3,750,000 USD

Contact Name | Peter J. Perrin, Ph.D.
 Contact Telephone | 301-451-3759
 Contact Email | Peter.Perrin@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 23-Sep-2024 [Optional][LOI/Pre-App], 23-Oct-2024

Synopsis

This Notice of Funding Opportunity (NOFO) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK. The purpose of this Centers program is to bring together basic and clinical investigators as a means to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases within the NIDDK's mission. DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner. Each proposed DDRCC must be organized around a central theme that reflects the focus of the digestive or liver diseases research of the Center members. The central theme must be within the primary mission of the NIDDK, and not thematic areas for which other NIH Institutes or Centers are considered the primary source of NIH funding. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

107685	Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) (R01 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-22-074	05-Oct-2024	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Julie Barthold, MD
Contact Telephone	301-594-9655
Contact Email	julia.barthold@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025
Synopsis	The Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) program is intended to promote innovative, high quality, interdisciplinary research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK invites investigator-initiated research project grant applications (R01s) in specific areas of basic, translational, or clinical research in specific benign urologic conditions and diseases where needs and opportunities for progress are particularly timely. As such, research topics of interest will change over time to take advantage of emerging opportunities. The research topic area previously supported by the SUITOR program, urinary incontinence, will now transition to neurourology, as described below.

108051	Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-22-096	05-Oct-2024	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Shilpa Hattangadi, M.D.
Contact Telephone	301-594-7726
Contact Email	shilpam.hattangadi@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Oct-2024
Synopsis	The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the leading edge of the field will change over time and will be updated regularly through the NIH Guide to Grants and Contracts and hyperlinked to this FOA.

116589	Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-23-086	07-Sep-2024	600,000 USD
--------	---	---	------------	-------------	-------------

	Contact Name	Aynur Unalp-Arida, M.D., M.Sc., Ph.D.
	Contact Telephone	301-594-8879
	Contact Email	aynur.unalp-arida@nih.gov
	Sponsor Website	
	Program URL	Link to program URL
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026
	Synopsis	This Funding Opportunity Announcement encourages the submission of pilot and feasibility clinical trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term proof-of-concept clinical trials in humans to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this FOA should have clearly described aims and objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trials to improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. Preliminary data regarding intervention efficacy are not required.

123312	NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-24-103	05-Oct-2024	Not Specified
--------	---	---	------------	-------------	---------------

	Contact Name	Tracy Rankin, Ph.D., M.P.H.
	Contact Telephone	301-594-4748

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email rankint@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis This NOFO invites applications for investigator-initiated, high-risk multi-center clinical trials involving more than one clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this NOFO. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-24-094). Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the FOA instructions carefully and view the available PEDP guidance material located at: https://braininitiative.nih.gov/about/plan-enhancing-diverse-perspectives-pedp attached to "PEDP guidance material".</p>				
123309	NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-24-102	05-Oct-2024	Not Specified
	<p>Contact Name Tracy Rankin, Ph.D., M.P.H.</p> <p>Contact Telephone 301-594-4748</p> <p>Contact Email rankint@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis This NOFO invites applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this NOFO. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-24-094). Consultation with NIDDK Scientific/Research Staff strongly encouraged prior to the submission of either a U34 or U01 application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p style="text-align: center;">Applicants are strongly encouraged to read the FOA instructions carefully and view the available PEDP guidance material. (with link to https://braininitiative.nih.gov/about/plan-enhancing-diverse-perspectives-pedp for "PEDP guidance material").</p>					
112160	NIDDK Central Repository Non-renewable Sample Access (X01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-22-171	29-Oct-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Rebecca M. Rodriguez, Ph.D</p> <p>301-451-0323</p> <p>rebecca.rodriguez2@nih.gov</p> <p></p> <p>Link to program URL</p> <p>29-Oct-2024 , 04-Mar-2025 , 25-Jun-2025</p> <p>The NIDDK Central Repository houses valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at the Repository's website. Applicants must include a volume and impact assessment report from the NIDDK Central Repository with the X01 Application to document sample availability.</p>			
107664	High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-22-069	30-Oct-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Norann Zaghoul, Ph.D.</p> <p>301-435-6677</p> <p>norann.zaghoul@nih.gov</p> <p></p> <p>Link to program URL</p> <p>30-Oct-2024</p> <p>The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK. The interdisciplinary approach encouraged by this FOA is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This FOA seeks novel approaches in areas that address specific</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment, and prevention of diseases within the mission of the NIDDK.

127247	RFA-DK-25-019--The Chronic Pancreatitis Clinical Research Consortium (CPCRC)- Clinical Centers (CPCRC-CCs) (U01 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-25-019	18-Sep-2024 [Optional][LOI/Pre-App]	2,000,000 USD
--------	--	---	---------------	--	---------------

Contact Name	Aynur Unalp-Arida, M.D., Ph.D.
Contact Telephone	301-594-8879
Contact Email	aynur.unalp-arida@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	18-Sep-2024 [Optional][LOI/Pre-App], 18-Oct-2024

Synopsis This Notice of Funding Opportunity (NOFO) invites U01 applications from clinical centers (CCs) for the Chronic Pancreatitis Clinical Research Consortium (CPCRC) to contribute to ongoing and new studies on chronic pancreatitis, both in children and adults. The consortium will continue the work of the current Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC). The consortium has been renamed to reflect the revised research focus as described below. The CPDPC since its establishment in Fall 2015 has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, diabetes, and pancreatic cancer association. The CPDPC is composed of multiple Clinical Centers (CC) and one Data Coordinating Center (DCC). The continuation of the CPDPC, the CPCRC, will focus on chronic pancreatitis, both adults and children, to pursue and expand the objectives of the former consortium in these areas. Applications for the data coordinating center are being invited via RFA-DK-25-020 "Single Source for the NIDDK Chronic Pancreatitis Clinical Research Consortium (CPCRC) Data Coordinating Center (CPCRC- DCC) (U01 Clinical Trial Optional)." The DCC along with CCs share results freely within Consortium and will continue with collaborative projects that make use of the combined expertise and technological capabilities present in all the Consortium member institutions. In addition, a major collaborative effort within the Consortium is the establishment of an annotated repository of bio-specimens (blood, pancreatic and duodenal juice, stools and when feasible pancreatic tissue), administered by the DCC, to allow for the identification and validation of biomarkers for risk stratification and disease progression. To effectively contribute to the ongoing CPDPC clinical studies, each CC application should include researchers and clinicians with multi-disciplinary expertise to match the objectives of the ongoing consortium CPDPC (see <https://cpdpc.mdanderson.org/clinicalstudies.html>) and the new CPCRC. All CCs share results freely within Consortium

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and to develop Consortium-wide collaborative projects that make use of the combined expertise and technological capabilities present in all the CCs. Applications focused on basic and animal studies of pancreatitis or focused on pancreatic cancer will not be considered responsive to this NOFO.

113279	Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-22-129	07-Sep-2024	150,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Lisa M. Spain, Ph.D.
Contact Telephone	301-451-9871
Contact Email	SpainL@niddk.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 16-Nov-2024 , 07-Jan-2025 , 25-Feb-2025 , 16-Mar-2025 , 07-May-2025 , 16-Jun-2025 , 16-Jul-2025 , 07-Sep-2025
Synopsis	The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces a program that provides NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support during the latter years of the award period of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.

113566	Notice of Special Interest (NOSI): Understanding Exposure and Health Effects of Micro and/or Nanoplastics	National Institute of Environmental Health Sciences/NIH/DHHS	NOT-ES-23-002	07-Sep-2024	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name	Lingamanaidu V. Ravichandran, Ph.D
Contact Telephone	984-287-3309
Contact Email	lingamanaidu.ravichandran@nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 16-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 16-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 16-Oct-2027</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants that the National Institute of Environmental Health Sciences (NIEHS), has special interest in applications that investigate exposure to, and health effects of, microplastics (MPs) and nanoplastics (NPs).</p>				
127197	RFA-ES-24-004 -- Revolutionizing Innovative, Visionary Environmental Health Research (RIVER) (R35 Clinical Trial Optional)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-24-004	02-Oct-2024 [Optional][LOI/Pre-App]	6,000,000 USD
	<p>Contact Name Jennifer B. Collins</p> <p>Contact Telephone 984-287-3247</p> <p>Contact Email collins6@niehs.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Oct-2024 [Optional][LOI/Pre-App], 01-Nov-2024</p> <p>Synopsis The NIEHS Revolutionizing Innovative, Visionary Environmental health Research (RIVER) program is intended to provide support for outstanding investigators in the Environmental Health Sciences, giving them intellectual and administrative freedom, as well as sustained support to pursue their research in novel directions in order to achieve greater impacts. The program seeks to identify individuals with a potential for continued innovative and impactful research and combine their existing investigator-initiated research into a single award to support the majority of their independent environmental health sciences research program.</p>				
119809	RFA-ES-23-011 -- Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-23-011	01-Oct-2024	275,000 USD
	<p>Contact Name Toccara Chamberlain, M.A.</p> <p>Contact Telephone 984-287-4482</p> <p>Contact Email toccara.chamberlain@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 01-Oct-2024 , 02-Dec-2024 , 03-Mar-2025 , 02-Jun-2025 , 01-Aug-2025 , 01-Oct-2025 , 01-Dec-2025</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the NOFO is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 4-6 months.</p>				
110572	<p>Limited Competition: NIGMS Mature Synchrotron Resources for Structural Biology (P30 - Clinical Trial Not Allowed)</p>	National Institute of General Medical Sciences/NIH/DHHS	PAR-22-166	10-Oct-2024	Not Specified
	<p>Contact Name Mary Ann Wu, Ph. D.</p> <p>Contact Telephone </p> <p>Contact Email maryann.wu@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Oct-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications for support of “mature” resources at synchrotron facilities to provide user access to X-ray beamlines for structural biology research. “Mature” refers to the techniques made available at the resource beamlines; they must be well-established, requiring no significant novel technology development in order to provide utility to the communities they serve or to maintain them at the state of the art. This funding opportunity is limited to resources whose operations recently have been or currently are being supported by NIGMS funding. It is expected that the facility will be maintained or upgraded to current best practices, make its capability and availability known to the biomedical research community through outreach activities, and provide user training and support.</p>				
121233	<p>IDeA Clinical & Translational Research Development (CTR-D) Award (P20-Clinical Trial Optional)</p>	National Institute of General Medical Sciences/NIH/DHHS	PAR-23-257	09-Oct-2024	7,500,000 USD
	<p>Contact Name Michele McGuirl, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email michele.mcguirl@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Oct-2024 , 09-Oct-2025</p> <p>Synopsis The purpose of the Institutional Development Award (IDeA) Clinical & Translational Research Development (CTR-D) program is to support clinical and translational research, workforce development, and infrastructure enhancement at health research organizations in IDeA-eligible states that have limited clinical and translational research capacity. CTR-D awards are intended to build a foundation of clinical and translational research expertise and infrastructure that will enable recipients to conduct research on diseases and health challenges faced by the populations they serve.</p>				
121232	IDeA Clinical & Translational Research Network (CTR-N) Award (P50 - Clinical Trial Optional)	National Institute of General Medical Sciences/NIH/DHHS	PAR-23-241	09-Oct-2024	16,500,000 USD
	<p>Contact Name Michele McGuirl, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email michele.mcguirl@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Oct-2024 , 09-Oct-2025</p> <p>Synopsis The purpose of the Institutional Development Award (IDeA) Clinical and Translational Research Network (CTR-N) program is to support biomedical research capacity in IDeA states that have been conducting significant levels of clinical and translational research to further enhance their capacity to enable and strengthen research on health challenges faced by the populations served by the CTR-N. The program supports statewide or multi-state regional networks to: expand existing infrastructure for clinical and translational research; develop the research workforce and enhance the network organizations' abilities to design and implement clinical and translational research programs; and coordinate clinical research activities across one or more IDeA states.</p>				
112730	Institutional Research and Academic Career Development Awards (IRACDA) (K12 - Independent Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-22-212	03-Oct-2024	Not Specified
	<p>Contact Name Shakira Nelson, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email shakira.nelson@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Oct-2024</p> <p>Synopsis The Institutional Research and Academic Career Development Award (IRACDA) Program provides support for a mentored postdoctoral research experience at a research-intensive institution combined with an opportunity to develop critical teaching and mentoring skills at a teaching-intensive partner institution with a diverse student population. Accordingly, the IRACDA program requires effective partnerships between a research-intensive institution and a teaching-intensive partner institution that has a historical mission or a demonstrated commitment to educating students from groups underrepresented in the biomedical research workforce. One goal of the IRACDA program is to develop a diverse pool of well-trained biomedical scientists who have the necessary knowledge and skills to pursue independent academic teaching and research careers. An additional goal of the IRACDA program is to benefit the teaching-intensive partner institutions, e.g., by providing research-oriented, early career teachers, mentors, and role models for the students; enhancing science educational offerings; providing research opportunities for the faculty and students; and/or bringing expertise with state-of-the-art research methods and technologies. This Funding Opportunity Announcement (FOA) does not allow appointed scholars to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p>				
117879	Maximizing Investigators' Research Award (MIRA) for Early Stage Investigators (R35 - Clinical Trial Optional)	National Institute of General Medical Sciences/NIH/DHHS	PAR-23-145	03-Oct-2024	1,250,000 USD
	<p>Contact Name Sailaja Koduri, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email sailaja.koduri@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Oct-2024 , 03-Feb-2025 , 03-Oct-2025 , 03-Feb-2026</p> <p>Synopsis The Maximizing Investigators' Research Award (MIRA) under this FOA is a grant to provide support for a program of research in an early stage investigator's laboratory that falls within the mission of NIGMS. For the purpose of this FOA, a program of research is a collection of projects in the investigator's lab that are relevant to the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this FOA will: Enable investigators to apply earlier in their independent research careers, allowing them to secure grant funding that will launch and sustain successful research careers. Enhance investigators' ability to move into research areas that are distinct from those of their postdoctoral mentors, which could lead to new scientific discoveries. Increase the stability of funding for NIGMS-supported investigators, which</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>could enhance their ability to take on ambitious scientific projects and approach problems more creatively. Increase flexibility for investigators to follow important new research directions as opportunities arise, rather than being bound to specific aims proposed in advance of the studies. More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs. Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research. Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment.</p>				
126765	B-INSPIRE: Research on Behavioral Interventions that Promote Careers in the Biomedical Research Enterprise (R01 - Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-24-230	17-Oct-2024	Not Specified
	<p>Contact Name Mercedes Rubio</p> <p>Contact Telephone </p> <p>Contact Email mercedes.rubio@nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Oct-2024 , 15-Oct-2025 , 14-Oct-2026</p> <p>Synopsis The B-INSPIRE: Research on Behavioral INTERventionS that Promote Careers In the Biomedical Research Enterprise Notice of Funding Opportunity (NOFO) encourages applications that propose research designed to conduct studies of behavioral interventions to enhance research-oriented individuals' interest, motivation, persistence and preparedness for careers in the biomedical research workforce. Applications that propose conducting secondary data analysis of rigorous interventions, leveraging existing intervention cohorts, using new or advanced methods of analysis of rigorous intervention datasets, or general novel combinations and integration of rigorous intervention datasets for analysis, are also encouraged. Funded projects are expected to produce research findings that will guide the implementation of behavioral interventions in a variety of academic settings and career levels to enhance the diversity of the biomedical research workforce. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
108741	Notice of Special Interest (NOSI): Inclusion of Economic Factors and Outcomes in Infectious Disease Modeling Studies	National Institute of General Medical Sciences/NIH/DHHS	NOT-GM-22-021	08-Aug-2024	Not Specified
	<p>Contact Name Veerasamy (Ravi) Ravichandran, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email Veerasamy.ravichandra@nih.gov</p> <p>Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 08-Dec-2024 , 07-Jan-2025</p> <p>Synopsis The National Institute of General Medical Sciences (NIGMS) is issuing this Notice to highlight interest in receiving grant applications focused on infectious disease modeling research that incorporates economic factors. The Institute is particularly interested in mathematical and computational modeling studies of infectious disease spread and evolution, and of the effects of possible intervention strategies, that include consideration of economic influences and feedback.</p>				
125765	Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-24-152	07-Sep-2024	375,000 USD
	<p>Contact Name Charles Ansong, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email charles.ansong@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025 , 25-Feb-2025 , 07-May-2025 , 25-Jun-2025 , 07-Sep-2025 , 25-Oct-2025 , 07-Jan-2026 , 25-Feb-2026 , 07-May-2026 , 25-Jun-2026 , 07-Sep-2026 , 25-Oct-2026 , 07-Jan-2027 , 25-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole. See Part II. Section 3.1 Eligible Organizations for more information.</p>				
125769	Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)	National Institute of General Medical Sciences/NIH/DHHS	PAR-24-214	07-Sep-2024	375,000 USD
	<p>Contact Name Mahua Mukhopadhyay, PhD</p> <p>Contact Telephone</p> <p>Contact Email mukhopam@mail.nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025 , 25-Feb-2025 , 07-May-2025 , 25-Jun-2025 , 07-Sep-2025 , 25-Oct-2025 , 07-Jan-2026 , 25-Feb-2026 , 07-May-2026 , 25-Jun-2026 , 07-Sep-2026 , 25-Oct-2026 , 07-Jan-2027 , 25-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole. See Part II. Section 3.1 Eligible Organizations for more information. This Notice of Funding Opportunity (NOFO) supports investigator-initiated mechanistic and/or minimal risk clinical trials such as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm, and which address the mission and research interests of the participating NIH institutes.</p>				
127138	<p>Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)</p>	National Institute of General Medical Sciences/NIH/DHHS	PAR-24-225	07-Sep-2024	Not Specified
	<p>Contact Name Kenneth D. Gibbs, Jr., Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email kenneth.gibbs@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027</p> <p>Synopsis The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) program is to support a cohort of early career, independent investigators from diverse backgrounds (for example, individuals from underrepresented groups) conducting research in NIH mission areas. The program has two components: an individual career transition award for postdoctoral scholars (K99/R00) and a research education cooperative agreement (UE5) awarded to organizations to provide these scholars with additional mentoring, networking and professional development activities to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

support their transition to and success in independent, tenure-track or equivalent research-intensive faculty careers. The MOSAIC program supports NIH's efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The goal of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds from their mentored postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The program is designed to support postdoctoral researchers who have demonstrated meaningful contributions and proposed compelling future plans to promote broad participation in the biomedical research workforce, such as activities that promote inclusive, supportive, and accessible biomedical research environments that support the success of trainees and scientists from all backgrounds, including individuals from underrepresented groups. This Notice of Funding Opportunity (NOFO) is designed specifically to support candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Candidates seeking support through this NOFO are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Candidates proposing a clinical trial or an ancillary clinical trial as lead investigator, should work with their institutions to apply to the companion NOFO PAR-24-226.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
127080	Innovative Programs to Enhance Research Training (IPERT) (R25 Independent Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-24-252	17-Oct-2024	500,000 USD

Contact Name	Sydella Blatch Alexander, Ph.D.
Contact Telephone	
Contact Email	sydella.blatch@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-Oct-2024 , 15-Oct-2025 , 14-Oct-2026
Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this Notice of Funding Opportunity (NOFO) will support educational activities with a primary focus on: Courses for Skills Development Mentoring Activities Curriculum or Methods Development NIGMS will support innovative educational activities

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>designed to equip participants with technical, operational, or professional skills required for careers in the biomedical research workforce. Activities must be open to the broader biomedical research community and may focus on participants at one or more career stages from undergraduates to professionals (for example faculty, staff scientists). Funded programs will have a robust program leadership structure, participant recruitment plan, and evaluation and dissemination plans. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>			
108588	RFA-MH-22-155 -- NIMH Instrumentation Program (\$10 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-MH-22-155	09-Sep-2024 [Optional][LOI/Pre-App]	600,000 USD
	<p>Contact Name Yvonne Bennett, Ph.D.</p> <p>Contact Telephone 301-222-7094</p> <p>Contact Email yvonne.bennett@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Sep-2024 [Optional][LOI/Pre-App], 09-Oct-2024</p> <p>Synopsis The NIMH Instrumentation Program encourages applications from NIH funded investigators to purchase or upgrade a single commercially available instrument or to purchase a group of components to create an instrument that is not commercially available. The goal of the NIMH Instrumentation Program is to make such instruments available to either individual laboratories or core facilities that conduct mental health-related research. Examples of instruments that might be submitted under this Funding Opportunity Announcement (FOA) include light microscopes, electron microscopes, spectrophotometers, and biomedical imagers.</p>				
119014	RFA-MH-25-190 -- Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-25-190	18-Sep-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Michele Ferrante, PhD</p> <p>Contact Telephone 301-793-2634</p> <p>Contact Email michele.ferrante@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Sep-2024 [Optional][LOI/Pre-App], 18-Oct-2024</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The purpose of this phased Notice of Funding Opportunity (NOFO) is to create a pipeline to accelerate the development and early validation of predictive tools and/or biomarkers to inform individual-level treatment selection among two or more existing therapeutics for depression. This phased inter-agency program will be milestone-based and provide support from multi-disciplinary teams to address scientific, technical, clinical, regulatory, and commercialization requirements. In the first phase (UG3), investigators are expected to identify potential tools and/or biomarker(s) that can predict whether a patient will differentially respond to one well-established depression treatment versus another. This could be accomplished using secondary analysis of data from completed clinical trials or using real-world clinical data, or by conducting small, efficient pilot feasibility studies to assess promising new tools or biomarkers to predict individual treatment response to a specific therapeutic for depression. In the second phase (UH3), investigators will conduct independent, prospective clinical trials to initially validate the utility of the tool/biomarker for predicting differential response to established treatments for depression. The overall goal of this NOFO is to support the testing of various tools/biomarkers as predictors of response to well-established depression treatments and halt the development of those tools that do not meet sufficient performance characteristics to justify further testing. Ultimately, tools that are successful in early-stage studies could be further evaluated for future use in decision-making in clinical practice settings.</p>				
125379	<p>RFA-MH-25-130--Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical Trial Required)</p>	National Institute of Mental Health/NIH/DHHS	RFA-MH-25-130	30-Sep-2024 [Optional][LOI/Pre-App]	450,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Mary Rooney, Ph.D.</p> <p>301-827-1325</p> <p>mary.rooney@nih.gov</p> <p></p> <p>Link to program URL</p> <p>30-Sep-2024 [Optional][LOI/Pre-App], 30-Oct-2024 , 14-May-2025 [Optional][LOI/Pre-App], 13-Jun-2025</p> <p>NIMH seeks applications for pilot research to adapt, optimize, and test empirically supported behavioral interventions that address common sleep problems in adolescents and young adults with or at risk for a mental health disorder. Pilot trials should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach in real world settings, and to conduct a preliminary test of the intervention’s impact on target mechanisms and sleep and mental health outcomes, and to obtain preliminary data needed as a prerequisite a larger-scale effectiveness trial. An emphasis is placed on studies that address the needs of youth from understudied and underserved populations.</p>			
124037	<p>RFA-MH-25-170 -- BRAIN Initiative: Research on the Ethical Implications of</p>	National Institute of Mental	RFA-MH-	12-Sep-2024	1,200,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Advancements in Neurotechnology and Brain Science (R01 Clinical Trial Optional)	Health/NIH/DHHS	25-170	[Optional][LOI/Pre-App]	USD
	<p>Contact Name James Churchill, Ph.D.</p> <p>Contact Telephone 301-326-8800</p> <p>Contact Email James.Churchill@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Sep-2024 [Optional][LOI/Pre-App], 11-Oct-2024 , 11-Sep-2025 [Optional][LOI/Pre-App], 10-Oct-2025 , 10-Sep-2026 [Optional][LOI/Pre-App], 09-Oct-2026</p> <p>Synopsis Guided by the goals established in BRAIN 2025: A Scientific Vision and reinforced by the Advisory Council to the Director Working Group on BRAIN 2.0 Neuroethics Subgroup, this Funding Opportunity Announcement (FOA) from the NIH Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is intended to support efforts addressing core ethical issues associated with research focused on the human brain and resulting from emerging technologies and advancements supported by the BRAIN Initiative. This FOA encourages research project grant applications from multi-disciplinary teams focused on key ethical issues associated with BRAIN Initiative supported research areas. Efforts supported under this FOA are intended to be both complementary and integrative with the transformative, breakthrough neuroscience discoveries supported through the BRAIN Initiative.</p>				
124039	RFA-MH-25-171 -- BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-25-171	12-Sep-2024 [Optional][LOI/Pre-App]	400,000 USD
	<p>Contact Name James Churchill, Ph.D.</p> <p>Contact Telephone 301-326-8800</p> <p>Contact Email James.Churchill@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Sep-2024 [Optional][LOI/Pre-App], 11-Oct-2024 , 11-Sep-2025 [Optional][LOI/Pre-App], 10-Oct-2025 , 10-Sep-2026 [Optional][LOI/Pre-App], 09-Oct-2026</p> <p>Synopsis Guided by the goals established in BRAIN 2025: A Scientific Vision and reinforced by the Advisory Council to the Director Working Group on BRAIN 2.0 Neuroethics Subgroup, this Notice of Funding Opportunity (NOFO) from the NIH Brain Research</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

through Advancing Innovative Neurotechnologies® (BRAIN) Initiative invites Exploratory/Developmental Research Grant (R21) applications that propose to study core ethical issues associated with research focused on the human brain and resulting from emerging technologies and advancements supported by the BRAIN Initiative. This NOFO encourages research project grant applications from multi-disciplinary teams focused on key ethical issues associated with BRAIN Initiative supported research areas. Efforts supported under this NOFO are intended to be both complementary and integrative with the transformative, breakthrough neuroscience discoveries supported through the BRAIN Initiative. This NOFO seeks shorter, higher-risk R21 grant applications, whereas its companion funding opportunity RFA-MH-25-170 seeks R01 grant applications proposing longer term projects with supporting preliminary data. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

113136	RFA-MH-21-175 -- BRAIN Initiative: Engineering and Optimization of Molecular Technologies for Functional Dissection of Neural Circuits (UM1 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-MH-22-245	18-Sep-2024 [Optional][LOI/Pre-App]	Not Specified
--------	---	--	---------------	-------------------------------------	---------------

Contact Name	Douglas S. Kim, Ph.D.
Contact Telephone	301-827-6463
Contact Email	douglas.kim@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	18-Sep-2024 [Optional][LOI/Pre-App], 17-Oct-2024

Synopsis This funding opportunity announcement (FOA) is intended to support the creation of Centers for accelerated engineering and optimization of high-impact, molecular technologies to monitor and/or manipulate brain cell activity in experimental animals. The Centers will produce high-impact molecular probes such as, but not limited to, fluorescent protein indicators of neuronal state variables (e.g., intracellular calcium, membrane voltage, released neurotransmitters/neuromodulators, etc.), molecular integrators of neural activity, optogenetic, chemogenetic, sonogenetic, magnetogenetic actuators, and activity-dependent molecular switches. This FOA is part of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN Initiative Armamentarium project, whose goal is to generate tools to specifically access, manipulate, and monitor brain cell types across multiple species. In this FOA, technology optimization is sought for existing tools for brain cell monitoring or manipulation that are beyond the proof-of-concept stage and that can be delivered selectively as payloads to cell types using newly developed brain cell access reagents. Each Molecular Payloads Center is expected to integrate: (1) sufficiently scaled molecular engineering, (2) in vivo validation of improvements seen in engineering assays in intact brains of experimental

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	animals, (3) benchmarking throughout the technology development against existing best-in-class tools, and (4) adaptation of tools into easily produced and applied formats for neuroscience users. Molecular Payloads Centers may also include optional demonstration experiments that establish groundbreaking capabilities of improved molecular tools in vivo. This FOA will foster close interaction between technologists and neurobiologists in a research consortium including tool developers funded by other Armamentarium FOAs for brain cell access reagents. The Armamentarium consortium will promote rigorous technology design, benchmarking, validation, and distribution of monitoring and/or manipulation tools and associated brain cell access reagents.				

102908	Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-21-175	05-Oct-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Andrew Rossi, Ph.D.
Contact Telephone	301-443-1576
Contact Email	andrew.rossi@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Oct-2024
Synopsis	<p>A growing body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity. These findings indicate that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for the treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This Funding Opportunity Announcement (FOA) supports projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA uses the R01 grant mechanism, whereas its companion FOA, PAR-21-176, seeks shorter, higher-risk R21 grant applications.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106895	Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-22-039	05-Oct-2024	Not Specified

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>David McMullen, M.D.</p> <p>301-451-0180</p> <p>david.mcmullen@nih.gov</p> <p></p> <p>Link to program URL</p> <p>05-Oct-2024</p> <p>The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitting in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animal and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches.</p>
---	--

106926	Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-22-039	05-Oct-2024	Not Specified
--------	---	--	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p>	<p>David McMullen, M.D.</p> <p>301-451-0180</p> <p>david.mcmullen@nih.gov</p> <p></p> <p>Link to program URL</p>
---	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Oct-2024</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitting in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animal and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches.</p>				
115061	Mood and Psychosis Symptoms During the Menopause Transition (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-23-097	05-Oct-2024	Not Specified
	<p>Contact Name Laura M. Rowland, Ph.D.</p> <p>Contact Telephone 301-480-8335</p> <p>Contact Email laura.rowland@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts This FOA uses the R01 grant mechanism, while the companion FOA (PAR-22-036) uses the R21 mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with preliminary data who seek longer-term funding may wish to apply using the R01 mechanism.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
115060	Laboratories to Optimize Digital Health (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-23-096	05-Oct-2024	Not Specified
	<p>Contact Name Adam Haim, Ph.D.</p> <p>Contact Telephone 301-435-3593</p> <p>Contact Email Haima@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025</p> <p>Synopsis NIMH seeks applications for innovative research projects to test strategies to increase the reach, efficiency, effectiveness, and quality of digital mental health interventions which may impact mental health outcomes, including suicide behaviors and serious mental illness. This Funding Opportunity Announcement (FOA) is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations.</p>				
119702	Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-24-024	05-Oct-2024	Not Specified
	<p>Contact Name David Panchision</p> <p>Contact Telephone 301-402-3969</p> <p>Contact Email panchisiond@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) encourages research on the biology of high-confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular, and circuit substrates of neural function. For the purposes of this NOFO , the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>incorporated into the research design to facilitate the characterization of intracellular, transcellular, and circuit mechanisms, these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components, and processes. The resulting paradigms, component pathways, and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present NOFO (R01 activity code) can be used for applications to further develop lines of inquiry where feasibility or proof-of-concept has been established. Applicants proposing exploratory research at the early and conceptual stages of project development should apply to the companion R21 NOFO PAR-24-025</p>				
117750	Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-23-168	07-Sep-2024	Not Specified
	<p>Contact Name Enrique Michelotti, PhD Contact Telephone 301-443-5415 Contact Email michelottiel@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 Synopsis The overarching goal of this Notice of Funding Opportunity (NOFO) is to support the development and validation of screening assays for the discovery of validated hits that can be used in future drug discovery/development efforts for identifying potential drug candidates for the treatment of mental illness. For purposes of this initiative, a “hit” is defined as a compound that has the desired activity in a compound screen and whose activity is confirmed upon retesting in orthogonal assays. Stages of discovery research covered by this NOFO include 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); and 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.</p>				
119663	Schizophrenia and Related Disorders During mid- to Late-Life (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-24-023	05-Oct-2024	Not Specified
	<p>Contact Name Laura M. Rowland, Ph.D. Contact Telephone 301-480-8335</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email laura.rowland@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions. This NOFO uses the R01 grant mechanism, while the companion NOFO (PAR-24-026), uses the R21 mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism.</p>				
118003	Notice of Special Interest (NOSI): NIMH Planning Grants for Natural History Studies of Rare Genetic Neurodevelopmental Disorders	National Institute of Mental Health/NIH/DHHS	NOT-MH-23-235	07-Sep-2024	Not Specified
	<p>Contact Name Margaret Grabb, Ph.D.</p> <p>Contact Telephone 301-443-3563</p> <p>Contact Email mgrabb@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026</p> <p>Synopsis The National Institute of Mental Health (NIMH) is issuing this Notice to highlight its interest in supporting planning grants to conduct retrospective natural history studies that explore the prevalence of disabling psychiatric symptoms and disruptions in function in patients (birth to 25 years of age) with rare genetic neurodevelopmental disorders (NDD). The principal goal of these studies is to assess the time of onset and severity of these symptoms, identify appropriate outcome measures, and establish potential timepoints for intervention. Additionally, the planning grants should focus on identifying potential quantitative clinical functional measures or biomarkers that could be used as prognostics and/or measures of change in future clinical trials. These retrospective natural history studies are expected to enable future prospective longitudinal studies (see Food and Drug Administration's (FDA's) guidance on natural history studies for rare disorders).</p>				
118004	Notice of Special Interest (NOSI): Pre-Clinical Research on Gene Therapies for Rare Genetic Neurodevelopmental Disorders	National Institute of Mental Health/NIH/DHHS	NOT-MH-23-236	07-Sep-2024	Not Specified
	Contact Name				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-443-3563</p> <p>Contact Email NIMHgenetherapies@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026</p> <p>Synopsis The National Institute of Mental Health (NIMH) is issuing this Notice of Special Interest (NOSI) to highlight interest in pre-clinical research aimed at developing novel approaches for somatic cell gene therapies to treat neurodevelopmental disorders with prominent cognitive, social and/or affective impairment.</p>				
112309	<p>Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)</p>	National Institute of Mental Health/NIH/DHHS	PAR-22-170	07-Sep-2024	Not Specified
	<p>Contact Name Jamie Driscoll</p> <p>Contact Telephone 301-443-5288</p> <p>Contact Email jdrisco1@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. This FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as pharmacokinetic/pharmacodynamic (PK/PD) markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline in which treatment candidates and therapeutic targets can be evaluated for their ability to impact neurobiological mechanisms of potential clinical relevance to mental illnesses. The objectives of this FOA will be accomplished by supporting basic neuroscience aimed at improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. The FOA may be considered a prequel</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.																		
114657	Clinical Studies of Mental Illness (Collaborative R01) (Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-23-050	07-Sep-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Jonathan Pevsner, Ph.D</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-728-5618</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>jonathan.pevsner@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, that primarily focus on mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology). Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase the inclusion of women and minorities (NOT-OD-18-014) and NIH-defined health disparity populations. (see https://www.nimhd.nih.gov/about/strategic-plan/nih-strategic-plan-definitions-and-parameters.html). It is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration. For a linked set of collaborative R01s, each application has its own Program Director/Principal Investigator (PD/PI). The collaborative R01 program provides a mechanism for cross-R01 coordination, quality control, database management, statistical analysis, and reporting.</td> </tr> </table>					Contact Name	Jonathan Pevsner, Ph.D	Contact Telephone	301-728-5618	Contact Email	jonathan.pevsner@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026	Synopsis	This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, that primarily focus on mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology). Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase the inclusion of women and minorities (NOT-OD-18-014) and NIH-defined health disparity populations. (see https://www.nimhd.nih.gov/about/strategic-plan/nih-strategic-plan-definitions-and-parameters.html). It is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration. For a linked set of collaborative R01s, each application has its own Program Director/Principal Investigator (PD/PI). The collaborative R01 program provides a mechanism for cross-R01 coordination, quality control, database management, statistical analysis, and reporting.
Contact Name	Jonathan Pevsner, Ph.D																		
Contact Telephone	301-728-5618																		
Contact Email	jonathan.pevsner@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026																		
Synopsis	This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, that primarily focus on mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology). Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase the inclusion of women and minorities (NOT-OD-18-014) and NIH-defined health disparity populations. (see https://www.nimhd.nih.gov/about/strategic-plan/nih-strategic-plan-definitions-and-parameters.html). It is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration. For a linked set of collaborative R01s, each application has its own Program Director/Principal Investigator (PD/PI). The collaborative R01 program provides a mechanism for cross-R01 coordination, quality control, database management, statistical analysis, and reporting.																		
126283	RFA-MH-25-160 -- Suicide Prevention Across the Life Span in Low- and Middle-Income Countries (R34 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-25-160	24-Sep-2024 [Optional][LOI/Pre-App]	450,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Vidya Vedham, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>vidya.vedham@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> </table>					Contact Name	Vidya Vedham, Ph.D.	Contact Telephone		Contact Email	vidya.vedham@nih.gov	Sponsor Website							
Contact Name	Vidya Vedham, Ph.D.																		
Contact Telephone																			
Contact Email	vidya.vedham@nih.gov																		
Sponsor Website																			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 24-Sep-2024 [Optional][LOI/Pre-App], 24-Oct-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to support formative research and pilot testing of culturally sensitive, innovative interventions to identify and mitigate the risk of suicidal ideation and behavior (SIB), and/or non-suicidal self-injury (NSSI) in Low- and Middle-Income Countries (LMICs). The proposed research initiatives must incorporate a plan to strengthen research capacity within the LMIC community where the study will be conducted.</p>				
103213	Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-210	05-Oct-2024	Not Specified
	<p>Contact Name Adam Haim, Ph.D.</p> <p>Contact Telephone 301-435-3593</p> <p>Contact Email haima@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024</p> <p>Synopsis NIMH seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This Funding Opportunity Announcement (FOA) encourages clinical trials to establish the effectiveness and test hypotheses regarding moderators, mediators, and mechanisms of action of post-acute phase therapeutic and services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden for promoting optimal longer-term outcomes. This FOA is intended to support trials that are statistically powered to provide a definitive answer regarding the effectiveness of the post-acute phase intervention. Support for pilot effectiveness trials designed to evaluate the initial feasibility, tolerability, acceptability, safety and preliminary indications of post-acute phase intervention approaches is provided via the R34, PAR-21-211.</p>				
115030	Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-23-091	07-Sep-2024	Not Specified
	<p>Contact Name Jamie Driscoll</p> <p>Contact Telephone 301-443-5288</p> <p>Contact Email jdrisco1@mail.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. This FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as pharmacokinetic/pharmacodynamic (PK/PD) markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline in which treatment candidates and therapeutic targets can be evaluated for their ability to impact neurobiological mechanisms of potential clinical relevance to mental illnesses. The objectives of this FOA will be accomplished by supporting basic neuroscience aimed at improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. The FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.</p>				
114549	Notice of Special Interest (NOSI): The Neural Mechanisms of Multi-Dimensional Emotional and Social Representation	National Institute of Mental Health/NIH/DHHS	NOT-MH-23-120	07-Sep-2024	Not Specified
	<p>Contact Name Andrew Breeden, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email andrew.breeden@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis NIMH is issuing this Notice of Special Interest (NOSI) to outline priorities for research that incorporates a multi-dimensional perspective into studies of the neural mechanisms underlying emotional and/or social representations. The ability to integrate a broad array of emotional and social information is impaired in many mental disorders, yet the neural mechanisms</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

underlying these processes are not well understood. This NOSI encourages studies in humans and animals investigating how diverse multi-dimensional emotional and/or social cues are represented across brain circuits that are important for mental health relevant cognitive, social, and affective behavioral functions. The term “multi-dimensional” refers to the consideration of multiple modalities (e.g., social, emotional, visual, and auditory), the effects of complex contexts and development, and/or dynamic processes that unfold over a variety of temporal scales.

115209	Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-23-105	16-Oct-2024	450,000 USD
--------	---	--	------------	-------------	-------------

Contact Name | Susan T. Azrin, Ph.D.
 Contact Telephone | 301-443-3267
 Contact Email | azrinst@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 16-Oct-2024 , 16-Feb-2025

Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial pilot projects that address NIMH strategic priorities to strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan. Proposed research should seek to: Identify mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of mental health services, which may serve as targets in future service delivery intervention development; Develop and test new research tools, technologies, measures, or methods and statistical approaches to study these issues; Test the feasibility of integrating and analyzing large data sets to understand factors affecting mental health services outcomes using advanced computational and predictive analytic approaches; Wherever possible, leverage existing infrastructure and partnerships to accomplish these goals.

119705	Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-24-025	16-Oct-2024	275,000 USD
--------	--	--	------------	-------------	-------------

Contact Name | David Panchision
 Contact Telephone | 301-402-3969
 Contact Email | panchisiond@mail.nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this NOFO , the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present NOFO (R21 activity code) can be used for applications to develop early stage, high-risk, exploratory approaches or establish proof-of-concept where there is little or no preliminary data. Applicants proposing to develop lines of inquiry where feasibility or proof of concept has been established should apply to the companion R01 NOFO (PAR-24-024).</p>				
102513	Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-135	15-Oct-2024	Not Specified
	<p>Contact Name Alexander Talkovsky, Ph.D.</p> <p>Contact Telephone 301-827-7614</p> <p>Contact Email alexander.talkovsky@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Oct-2024</p> <p>Synopsis NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-inhuman, early testing of new interventions, confirmatory efficacy trials,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>through to effectiveness trials. The purpose of this FOA is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH's experimental therapeutics approach, this FOA is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial interventions may be standalone interventions or augmentations to efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of a novel intervention's impact on a target process or mechanism associated mental disorder risk, causation, or maintenance (target engagement). Up to 3 years of additional support (R33 phase) will be provided for studies with findings that meet the "go/no-go" milestones embedded in the R61 phase. The R33 phase is intended to support the replication of target engagement and to test whether engaging the intervention target/mechanism mediates changes in clinical outcomes. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development and/or testing of the intervention. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.</p>				

102530	Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-137	15-Oct-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Margaret Grabb, Ph.D.
Contact Telephone	301-443-3563
Contact Email	mgrabb@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	15-Oct-2024
Synopsis	<p>NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase) prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. The R61/R33 FOAs are intended to support biphasic high-risk applications. Support for a single phased award that does not need the developmental (R61) phase is available in the companion R33, PAR-21-136 . Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.

102528	Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-136	15-Oct-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name | Margaret Grabb, Ph.D.
 Contact Telephone | 301-443-3563
 Contact Email | mgrabb@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 15-Oct-2024

Synopsis | NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult and geriatric focused interventions are appropriate for this FOA. This R33 FOA supports single-phased clinical trial awards. Applicants proposing high risk projects are encouraged to apply to the companion FOA, PAR-21-137or PAR-21-133.

102910	Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-21-176	16-Oct-2024	275,000 USD
--------	--	--	------------	-------------	-------------

Contact Name | Andrew Rossi, Ph.D.
 Contact Telephone | 301-443-1576

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email andrew.rossi@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024</p> <p>Synopsis A growing body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity. These findings indicate that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This Funding Opportunity Announcement (FOA) supports projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA uses the R21 exploratory grant mechanism, whereas its companion FOA, PAR-21-175, seeks R01 grant applications for larger research applications that have an established premise.</p>				
103214	<p>Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34 Clinical Trial Required)</p>	National Institute of Mental Health/NIH/DHHS	PAR-21-211	16-Oct-2024	450,000 USD
	<p>Contact Name Adam Haim, Ph.D.</p> <p>Contact Telephone 301-435-3593</p> <p>Contact Email haima@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024</p> <p>Synopsis NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes. This FOA supports pilot research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on post-acute phase interventions is provided via the R01, PAR-21-210.

108843	Notice of Special Interest (NOSI): NIMH Priorities on Research on Aggression and Violence Against Others	National Institute of Mental Health/NIH/DHHS	NOT-MH-22-095	08-Aug-2024	Not Specified
--------	--	--	---------------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	NIMHResearchOnAggres@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 08-Dec-2024 , 07-Jan-2025
Synopsis	NIMH is issuing this Notice of Special Interest (NOSI) to outline priorities for research on the etiology, risks for, and prevention of interpersonal aggression and violence against others.

108834	Notice of Special Interest (NOSI): Neuro-Glia Mechanisms Governing Complex Behaviors (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	NOT-MH-22-090	07-Sep-2024	Not Specified
--------	--	--	---------------	-------------	---------------

Contact Name	Michele Ferrante, Ph.D.
Contact Telephone	301-435-6782
Contact Email	michele.ferrante@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis This Notice of Special Interest (NOSI) encourages projects to experimentally test mechanistic hypotheses on the role of neuro-glia activity coupling in modulating complex behaviors.</p>				
115199	Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-23-087	21-Oct-2024	Not Specified
	<p>Contact Name Jamie Driscoll Contact Telephone 301-443-5288 Contact Email jdrisco1@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 21-Oct-2024 , 21-Feb-2025 , 20-Jun-2025</p> <p>Synopsis The goal of this initiative is to identify neurophysiological measures as potential assays for treatment development research. The Funding Opportunity Announcement (FOA) will support efforts to optimize and evaluate pharmacodynamic (PD) measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data may also reveal assay measures where performance is dissimilar between preclinical animal species and humans, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate goal of this FOA is to improve the efficiency of the therapeutic development process by identifying congruent measures as well as inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates. The objectives of the FOA will be accomplished by supporting partnerships among basic and translational neuroscientists who are committed to advancing the discovery of in vivo physiological measures as tools for target validation and therapeutic development. Groups will be tasked with developing and optimizing in vivo assays of brain processes in both animals and in healthy humans. Groups will evaluate assay performance across both species in response to pharmacologic manipulations. In this way, projects will reveal the potential of specific assays to translate from animals to humans, suggesting assays for further development as tools in the treatment development pipeline.</p>				
126545	RFA-MH-25-180 -- Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-MH-25-180	08-Oct-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Jeymohan Joseph, Ph.D. Contact Telephone 240-627-3869</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email jjeymoha@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Oct-2024 [Optional][LOI/Pre-App]</p> <p>Synopsis The goal of this Notice of Funding Opportunity (NOFO) is to examine mechanisms of reciprocal interactions between HIV-associated neuroinflammation and central nervous system (CNS) HIV persistence. In particular this NOFO encourages research focused on defining the role and mechanisms of defective proviruses, HIV proteins and/or nucleic acids in inducing inflammation, immune activation and CNS co-morbidities. The impact of neuroinflammation in regulating CNS reservoir dynamics is also an area of interest. Novel therapeutic strategies targeting the reciprocal impact of persistent virus and associated neuroinflammation in the CNS compartment is also an area of high priority for this initiative. State-of-the-art CNS cell systems, organoid models, post-mortem tissue, animal models and single-cell technologies can be used as potential tools to address this research area. Basic and Translational research in domestic and international settings are also of interest. Multidisciplinary research teams and collaborations are encouraged but not required. High risk/high payoff projects that lack preliminary data may be most appropriate for the companion R21 NOFO, RFA-MH-25-181 while applicants with preliminary data may wish to apply using this R01 mechanism.</p>				
126735	RFA-MH-25-195--Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH) (U01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-25-195	18-Sep-2024 [Optional][LOI/Pre-App]	12,500,000 USD
	<p>Contact Name Jenni Pacheco, Ph.D.</p> <p>Contact Telephone 301-443-3645</p> <p>Contact Email jenni.pacheco@nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Sep-2024 [Optional][LOI/Pre-App], 18-Oct-2024</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) is intended to stimulate and support research that will use behavioral measures and computational methods to define novel clinical signatures that can be used for individual-level prediction and clinical decision making in mental disorders. A multi-component approach is proposed in which grantees will (1) identify and/or develop behavioral tasks (and other types of measures, as appropriate) that are optimized for measurement of individual differences in individuals with or at risk of developing mental disorders; (2) collect the data from novel clinical cohorts and/or identify existing datasets that include behavioral data and other data that are typically available in the clinical record; (3)</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

derive novel clinical signatures that incorporate behavioral measures and information derived from the clinical record, and are informative for clinical purposes; and (4) partner with the existing Data Coordinating Center (DCC) (funded under previous RFA-MH-23-106), which is responsible for coordinating the harmonization of methods, aggregation of data, analysis of combined data, and creation of a data infrastructure to support data sharing with the scientific community. Applicants may propose new cohorts from one or more populations targeted to specific clinical groupings (e.g., mood/anxiety disorders, disorders of behavior regulation, psychosis) and/or care delivery settings, may leverage data from existing clinical research cohorts that have appropriate data structures, or may use a combination of approaches with new and existing data. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

117822	Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Required)	National Institute of Mental Health/NIH/DHHS	PA-23-150	12-Oct-2024	Not Specified
--------	--	--	-----------	-------------	---------------

Contact Name	Ashlee Van't Veer
Contact Telephone	301-443-3107
Contact Email	dnbbstrainingbranch@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026
Synopsis	The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA, PAR-23-149.

117821	Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Not Allowed)	National Institute of Mental Health/NIH/DHHS	PA-23-149	12-Oct-2024	Not Specified
--------	---	--	-----------	-------------	---------------

Contact Name	Ashlee Van't Veer
Contact Telephone	301-443-3107

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email dnbbstrainingbranch@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026</p> <p>Synopsis The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator should apply to the companion FOA, PAR-23-150.</p>				
126538	RFA-MH-25-136 -- Pilot Research Opportunities in Crisis Response Services for Suicide Prevention (R34 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-25-136	02-Sep-2024 [Optional][LOI/Pre-App]	675,000 USD
	<p>Contact Name Jennifer Humensky, Ph.D.</p> <p>Contact Telephone 301-480-1265</p> <p>Contact Email jennifer.humensky@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Sep-2024 [Optional][LOI/Pre-App], 01-Oct-2024 , 03-May-2025 [Optional][LOI/Pre-App], 02-Jun-2025</p> <p>Synopsis This NOFO seeks to promote pilot exploratory/developmental research examining the effectiveness and implementation of crisis response services, approaches to improve the quality and outcomes of services, and the impact of state and local policy on implementation and outcomes. Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related characteristics (e.g., youth; adult; older adult), geographic context (rural/remote settings), racial/ethnic and cultural considerations, and health disparities influence the types of care that are provided. Studies are encouraged that address the continuum of crisis service systems. Support for larger-scale or fully-powered studies is provided through a companion NOFO that utilizes the R01 mechanism (RFA-MH-25-135; Research</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| Opportunities in Crisis Response Services for Suicide Prevention (R01 Clinical Trial Optional).

126537	RFA-MH-25-135 -- Research Opportunities in Crisis Response Services for Suicide Prevention (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-25-135	02-Sep-2024 [Optional][LOI/Pre-App]	Not Specified
--------	--	--	---------------	-------------------------------------	---------------

Contact Name	Jennifer Humensky, Ph.D.
Contact Telephone	301-480-1265
Contact Email	jennifer.humensky@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	02-Sep-2024 [Optional][LOI/Pre-App], 01-Oct-2024 , 03-May-2025 [Optional][LOI/Pre-App], 02-Jun-2025
Synopsis	This Notice of Funding Opportunity (NOFO) encourages research examining the effectiveness and implementation of crisis response services, approaches to improve the quality and outcomes of services, and the impact of state and local policy on implementation and outcomes. Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related characteristics (e.g., youth; adult; older adult), geographic context (rural/remote settings), racial/ethnic and cultural considerations, and health disparities influence the types of care that are provided. Studies are encouraged that address the continuum of crisis service systems. Support for pilot studies is provided through a companion NOFO that utilizes the R34 mechanism (RFA-MH-25-136); Pilot Research Opportunities in Crisis Response Services for Suicide Prevention (R34 Clinical Trial Optional)).

126543	RFA-MH-25-181 -- Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R21 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-MH-25-181	08-Oct-2024 [Optional][LOI/Pre-App]	275,000 USD
--------	--	--	---------------	-------------------------------------	-------------

Contact Name	Jeymohan Joseph, Ph.D.
Contact Telephone	240-627-3869
Contact Email	jjeymoha@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Oct-2024 [Optional][LOI/Pre-App]
Synopsis	The goal of this Notice of Funding Opportunity (NOFO) is to examine mechanisms of reciprocal interactions between HIV-

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

associated neuroinflammation and central nervous system (CNS) HIV persistence. In particular this NOFO encourages research focused on defining the role and mechanisms of defective pro viruses, HIV proteins and/or nucleic acids in inducing inflammation, immune activation and CNS co-morbidities. The impact of neuroinflammation in regulating CNS reservoir dynamics is also an area of interest. Novel therapeutic strategies targeting the reciprocal impact of persistent virus and associated neuroinflammation in the CNS compartment is also an area of high priority for this initiative. State of the art CNS cell systems, organoid models, post-mortem tissue, animal models and single-cell technologies can be used as potential tools to address this research area. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborations are encouraged but not required. High risk/high payoff projects that lack preliminary data are most appropriate for the RFA-MH-25-181 R21 mechanism, while applicants with preliminary data should apply to the R01 mechanism, RFA-MH-25-180.

102507	Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-131	15-Oct-2024	450,000 USD
--------	---	--	------------	-------------	-------------

Contact Name | Joel Sherrill, Ph.D.
 Contact Telephone | 301-443-2477
 Contact Email | jsherril@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 15-Oct-2024

Synopsis | NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-inhuman, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage pilot research consistent with NIMH's priorities for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. Consistent with the NIMH experimental therapeutics approach, this FOA is intended to support pilot studies of intervention effectiveness or service delivery approaches that explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects (i.e., the mechanism(s) that accounts for changes in clinical/functional outcomes, changes in provider behavior, improved access or continuity of services, etc.). In this pilot effectiveness phase of research, NIMH places highest priority on intervention and service delivery approaches that can be justified in terms of their potential to substantially impact practice and public health. This FOA supports pilot studies and provides resources for evaluating the feasibility, tolerability, acceptability and safety and preliminary effectiveness of approaches to improve mental health/functional outcomes, to modify risk factors, or to improve

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>service delivery, and for obtaining the preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, pragmatic trial). Support for fully-powered effectiveness studies is provided through separate FOAs that utilize the R01 mechanism for single-site effectiveness trials (PAR-21-130; "Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01).") and collaborative R01 mechanism for multi-site effectiveness trials (PAR-21-129;"Clinical Trials to Test the Effectiveness of Treatment, Prevention, and Services Interventions (Collaborative R01 Clinical Trial Required)"). Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.</p>				

102506	Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-130	15-Oct-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Joel Sherrill, Ph.D.
Contact Telephone	301-443-2477
Contact Email	jsherril@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	15-Oct-2024
Synopsis	<p>NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. This FOA seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (e.g., psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA uses the R01 grant mechanism to support trials that are adequately powered and of sufficient scope to test effectiveness and examine mediators and moderators of response. Support for multi-site trials that require participation of two or more collaborative sites for completion of the study (e.g., in order to increase sample size, accelerate recruitment, or increase sample diversity and representation) is provided through a separate FOA, PAR-21-129 "Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01)." This FOA is designed for applicants seeking funding for single-site clinical trials to establish the effectiveness of interventions.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.

102511	Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-134	15-Oct-2024	Not Specified
--------	---	--	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Alexander Talkovsky, Ph.D.</p> <p>301-827-7614</p> <p>alexander.talkovsky@nih.gov</p> <p></p> <p>Link to program URL</p> <p>15-Oct-2024</p> <p>NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH’s experimental therapeutics approach, this FOA is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. They may also be standalone interventions or augmentations of efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. Support will be provided for up to 3 years for studies to replicate previous target engagement findings, and to relate change in the intervention target/mechanism to clinical benefit. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support “go/no-go” decisions about further development and/or testing of the intervention. This FOA is designed for applicants seeking to fund pilot stages of research. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.</p>
---	--

102509	First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-133	15-Oct-2024	Not Specified
--------	--	--	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p>	<p>Margaret Grabb, Ph.D.</p> <p>301-443-3563</p>
--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email mgrabb@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Oct-2024</p> <p>Synopsis NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action investigational drugs or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drug's impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private or other public funding (when appropriate) for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development. This FOA is designed for applicants seeking funding for cooperative agreements supporting early stage clinical trials as outlined above. Applicants pursuing other stages of the clinical trial pipeline or funding for clinical research not involving cooperative agreements should consider one of the companion FOAs.</p>				
102508	<p>Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)</p>	National Institute of Mental Health/NIH/DHHS	PAR-21-132	15-Oct-2024	Not Specified
	<p>Contact Name Adam Haim, Ph.D.</p> <p>Contact Telephone 301-435-3593</p> <p>Contact Email haima@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Oct-2024</p> <p>Synopsis NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to support confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to behavioral, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as noninvasive/transcranial) approaches, or a combination thereof. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action, a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the intervention's efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the mechanism and change in functional or clinical effects. Ultimately, this FOA is intended to support a sufficiently-powered efficacy trial to determine the intervention's potential for significant clinical benefit. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs</p>			
106896	Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-22-038	16-Oct-2024	275,000 USD
	Contact Name	David McMullen, M.D.			
	Contact Telephone	301-451-0180			
	Contact Email	david.mcmullen@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Oct-2024			
	Synopsis	<p>The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience,</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

engineering, clinical, and regulatory affairs. Applications submitted in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animals and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA. This FOA uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity, PAR-22-039, seeks R01 grant applications.

106927	Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-22-038	16-Oct-2024	275,000 USD
--------	---	--	------------	-------------	-------------

Contact Name David McMullen, M.D.
 Contact Telephone 301-451-0180
 Contact Email david.mcmullen@nih.gov
 Sponsor Website
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 16-Oct-2024

Synopsis The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animals and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
This FOA uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity, PAR-22-039, seeks R01 grant applications.					
104058	NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PA-21-235	07-Sep-2024	275,000 USD
	Contact Name	Susan Koester, Ph.D.			
	Contact Telephone	301-443-3563			
	Contact Email	koesters@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	The NIMH Exploratory/Developmental Grant program supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care.			
115201	Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-23-102	16-Oct-2024	275,000 USD
	Contact Name	Laura M. Rowland, Ph.D.			
	Contact Telephone	301-480-8335			
	Contact Email	laura.rowland@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Oct-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts. This FOA uses the R21 mechanism, while the companion			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

FOA (PAR-23-097) uses the R01 grant mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with preliminary data who seek longer-term funding may wish to apply using the R01 mechanism.

119664	Schizophrenia and Related Disorders During mid- to Late-Life (R21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-24-026	16-Oct-2024	275,000 USD
--------	--	--	------------	-------------	-------------

Contact Name	Laura M. Rowland, Ph.D.
Contact Telephone	301-480-8335
Contact Email	laura.rowland@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions. This NOFO uses the R21 grant mechanism, while the companion NOFO (PAR-24-023) uses the R01 mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism, while applicants with preliminary data who seek longer-term funding should apply using the R01 mechanism.

123916	Advancing Learning Health Care Research in Outpatient Mental Health Treatment Settings (R34 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-24-118	17-Sep-2024 [Optional][LOI/Pre-App]	450,000 USD
--------	--	--	------------	-------------------------------------	-------------

Contact Name	Michael Freed, Ph.D.
Contact Telephone	301-443-3747
Contact Email	michael.freed@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-Sep-2024 [Optional][LOI/Pre-App], 16-Oct-2024 , 17-Jan-2025 [Optional][LOI/Pre-App], 16-Feb-2025 , 17-May-2025 [Optional][LOI/Pre-App], 16-Jun-2025 , 17-Sep-2025 [Optional][LOI/Pre-App], 16-Oct-2025
Synopsis	This Notice of Funding Announcement (NOFO) solicits exploratory/developmental research applications within the learning

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>health care framework to support adoption, implementation, sustainability, and continuous improvement of evidence-based practices in outpatient mental health and substance use treatment systems. These settings could include, but are not limited to, Certified Community Behavioral Health Clinics (CCBHCs) funded through the Substance Abuse and Mental Health Services Administration (SAMHSA) expansion grant program and CCBHCs participating in their states' Section 223 CCBHC Medicaid demonstration program, or as a part of independent state programs where the CCBHCs are meeting the federal CCBHC certification criteria. This NOFO requires active collaboration between behavioral health researchers and community behavioral health partners across all phases of the research process. Studies that are co-designed between community clinic staff/service users and health services researchers may focus on (1) identifying subgroups within the population of individuals served by CCBHCs with unique needs, including health disparities experienced by people from racial and ethnic minority groups or underserved communities; (2) workforce development strategies, including new approaches to train providers who vary in terms of prior experience, expertise and skills; (3) developing and testing tools to promote measurement-based treatment; (4) hybrid effectiveness-implementation trials aimed at implementing and improving evidence-based prevention, treatment, or services delivery approaches in real-world settings; and (5) research to establish and/or expand 988 crisis response services within CCBHC settings.</p>				
126959	Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations II (U01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-24-240	15-Sep-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Miri Gitik, Ph.D. Contact Telephone 301-827-3523 Contact Email miri.gitik@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 15-Sep-2024 [Optional][LOI/Pre-App], 11-Oct-2024 , 13-Jun-2025 , 13-Feb-2026 Synopsis The following Notice of Funding Opportunity (NOFO) seeks cooperative agreements proposing coordinated efforts to accelerate gene discovery for psychiatric disorders in cohorts of non-European ancestry to advance our understanding of the genetic architecture of mental illnesses across ancestrally diverse global populations. Applicants should carefully read the NOFO instructions and review the accompanying U24 NOFO, PAR-24-241.</p>				
126961	Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations II (U24 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-24-241	15-Sep-2024 [Optional][LOI/Pre-App]	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Miri Gitik, Ph.D.</p> <p>Contact Telephone 301-827-3523</p> <p>Contact Email miri.gitik@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Sep-2024 [Optional][LOI/Pre-App], 11-Oct-2024</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites applications for a Coordinating Center (CC) to support the network-wide, collaborative, work between PAR-24-240U01 research projects funded under the Ancestral Populations Network 2 (APN-2) initiative described in the companion announcement. The APN-2 initiative has an overall goal of enhancing diversity in psychiatric genetic studies by supporting large scale genomic studies in populations of non-European Ancestry around the globe, currently significantly underrepresented in the field. The APN Coordinating Center (APN-2 CC) will: (a) Coordinate data harmonization and joint analyses across network projects, (b) Plan, coordinate and facilitate research training activities across the network and develop best practices guidance for individual member projects and the wider scientific community, (c) Develop and disseminate ethical best practices for APN members and the scientific communities, with a specific focus on psychiatric genetic studies in different settings around the world, (d) Serve as a liaison between the different network working groups and the network steering committee, and (e) Provide administrative support for the network workgroups and steering committee as needed. Applicants should carefully read the NOFO instructions and review the accompanying U01 NOFO, PAR-24-240</p>				
111257	RFA-NS-22-036 -- NINDS Interdisciplinary Team Science Grant (RM1 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-22-036	08-Sep-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name David Owens, Ph.D.</p> <p>Contact Telephone 301-496-9248</p> <p>Contact Email NINDSteamscience@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Sep-2024 [Optional][LOI/Pre-App], 08-Oct-2024</p> <p>Synopsis This funding opportunity announcement (FOA) is designed to support integrated efforts of three or more (up to six) PDs/PIs to pursue bold, impactful, and challenging research in any area within the scope of the NINDS mission. The research approach</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>should be interdisciplinary in nature, and the research teams are expected to establish a common goal that requires collaboration, synergy, and managed team interactions. Proposed research should not represent a collection of individual efforts or parallel projects. This program is distinct from the NINDS P01 in that it will support a cohesive, single, well-integrated research plan with a singular focus, one set of aims, and a budget without subprojects. Teams are encouraged to consider transformative objectives with defined 5-year outcomes.</p>				
118525	RFA-NS-23-027 -- Collaborative Opportunities for Multidisciplinary, Bold, and Innovative Neuroscience (COMBINE) (RM1 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-23-027	08-Sep-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-496-9248</p> <p>Contact Email NINDSteamscience@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Sep-2024 [Optional][LOI/Pre-App], 08-Oct-2024</p> <p>Synopsis</p> <p>The Collaborative Opportunities for Multidisciplinary, Bold, and Innovative Neuroscience (COMBINE) program is designed to support integrated efforts of three to six PDs/PIs to pursue a bold, impactful, and challenging goal with defined 5-year outcomes within the scope of this program and the NINDS mission. This defined research goal must only be achievable by an interdisciplinary team approach involving innovative combination of distinct disciplines and/or intellectual viewpoints, synergy in expertise and approaches, and well-managed team interactions. Proposed research must not represent a collection of individual efforts or parallel projects, but rather an integrated effort from all PIs to achieve a single, transformative research goal. This program is distinct from the NINDS P01 and parent R01 in that it will support a single, focused goal instead of multiple aims.</p>				
118126	RFA-NS-24-020 -- NINDS Sustainable Transformation of Institutional Research Rigor (STIRR) Program (RC2 - Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-24-020	17-Sep-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Devon Crawford</p> <p>Contact Telephone 301-827-7758</p> <p>Contact Email devon.crawford@nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Sep-2024 [Optional][LOI/Pre-App], 17-Oct-2024 , 17-Sep-2025 [Optional][LOI/Pre-App], 17-Oct-2025</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) aims to support the establishment of programs to enhance research rigor and transparency practices within academic and research institutions to promote a culture of high-quality neuroscience research. Attention to principles of rigorous study design and transparent reporting are essential to enable the neuroscientific community, as well as the biomedical community at large, to design and perform valid experiments and to assess the value of scientific findings. Awards are intended to support the implementation of innovative programs, strategies, and approaches at the departmental, inter-departmental, or equivalent intra-institutional entity level.</p>				
125193	<p>Mechanistic and Hemodynamic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID)(R01 - Clinical Trial Not Allowed)</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-196	04-Oct-2024	500,000 USD
	<p>Contact Name Roderick A. Corriveau, Ph.D.</p> <p>Contact Telephone 301-496-5680</p> <p>Contact Email roderick.corriveau@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Oct-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to support hypothesis-testing research to elucidate molecular, cellular and hemodynamic mechanisms that underlie diffuse white matter disease and small vessel disease in the brain and how they may contribute to cognitive decline and dementia.</p>				
117726	<p>RFA-NS-23-026 -- BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed)</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-23-026	11-Oct-2024	Not Specified
	<p>Contact Name Natalie Trzcinski, Ph.D</p> <p>Contact Telephone 301-469-1779</p> <p>Contact Email natalie.trzcinski@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 11-Oct-2024</p> <p>Synopsis This funding opportunity announcement (FOA) supports efforts to disseminate resources for integration into neuroscience research practice. The resource(s) should be relevant to the goals of the BRAIN Initiative as outlined in the "BRAIN 2025: A Scientific Vision" and "The BRAIN Initiative 2.0: From Cells to Circuits, Toward Cures" and shared broadly to the neuroscience community. The resource(s) should address compelling needs of neuroscience researchers that are otherwise unavailable or impractical in their current form. Activities must include dissemination of an existing resource, and may include one or more of the following activities: distribution of tools and reagents; user training on the usage of new technologies or techniques; providing access to existing technology platforms and/or specialized facilities; minor improvements to increase the scale/efficiency of resource production and delivery; minor adaptations to meet the needs of a user community. Applications primarily focused on technology or software development and where broad dissemination is not planned to be initiated by year 2 are not responsive to this FOA.</p>				
121162	<p>HEAL INITIATIVE: Development and Validation of Remote or Patient Wearable Device Derived Objective Biosignatures or Functional Assessments to Monitor Pain for use as Endpoints in Clinical Trials (UG3/UH3 - Clinical Trial Optional)</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-24-023	04-Oct-2024	Not Specified
	<p>Contact Name Ram Arudchandran, PhD</p> <p>Contact Telephone 301-402-5257</p> <p>Contact Email ramachandran.arudchandran@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Oct-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to promote the discovery, development, and validation of real-world digital endpoints derived from data generated by existing remote or wearable devices. These endpoints will be used for monitoring the experience of pain, its progression, response to interventions, and impact on quality of life. In this NOFO, endpoints refer to biosignatures obtained from functional and physiological assessments captured by remote or wearable devices. Development of digital endpoints will involve clinical research using existing wearable or remote devices, with a specific focus on selecting and validating novel measurements as appropriate digital endpoints for pain assessment. The proposed digital endpoints may focus on a specific pain condition or encompass multiple pain conditions. Applications aiming to identify digital endpoints across various pain conditions should involve Multiple Principal Investigator (MPI)-led teams that represent each relevant pain condition and associated clinical networks. These teams should collaborate to discover, develop, and validate digital endpoints that accurately measure pain and related outcomes, such as quality of life or appropriate pain-related functional measures. In addition, the applicant should include experts in digital technology, data</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>analysis, and advanced statistical methods to handle real-world data. Applicants must establish centralized resource groups responsible for coordinating clinical trials, standardizing sample or data collection methods, technology development, statistical analysis, and algorithm development across all pain conditions under investigation. For applications focused on developing digital endpoints for a single pain condition, MPI-led teams with cross-functional expertise should be included, along with centralized resource groups responsible for coordinating clinical trials, standardizing sample or data collection methods, technology development, and statistical analysis. Furthermore, the inclusion of people with lived experience in the team is required to incorporate patient perspectives, concerns, and valuable input regarding the relevance and acceptability of digital measurements in the study. The final products of this effort would be algorithms and software designed to analyze data from existing remote or wearable technologies. The goal is to demonstrate that digital biosignatures or digital functional assessments, serving as digital endpoints, are sensitive and objective measures of clinical benefit.</p>			
123822	RFA-NS-24-030 -- NIH Blueprint and BRAIN Initiative Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award (F99/K00 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-24-030	08-Oct-2024	Not Specified
	<p>Contact Name Michelle Jones-London, PhD Contact Telephone 301-451-7966 Contact Email jonesmiche@ninds.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 08-Oct-2024 , 20-Mar-2025 , 07-Oct-2025 , 20-Mar-2026 , 06-Oct-2026 Synopsis The purpose of the NIH Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award is to support a defined pathway across career stages for outstanding graduate students from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences. This two-phase award will facilitate completion of the doctoral dissertation and transition of talented graduate students to strong neuroscience research postdoctoral positions, and will provide career development opportunities relevant to their long-term career goal of becoming independent neuroscience researchers. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor</p>				
111360	Notice of Special Interest (NOSI): Disease Mechanisms of Prenatal and Pediatric Hydrocephalus	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS-23-004	07-Sep-2024	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Jill Morris, Ph.D.</p> <p>Contact Telephone 301-496-5754</p> <p>Contact Email jill.morris@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025</p> <p>Synopsis The purpose of this Notice is to inform potential applicants about an area of special interest to NINDS in hypothesis-driven research projects that focus on deciphering the molecular, cellular and developmental mechanisms involved in the pathogenesis of prenatal and/or pediatric hydrocephalus and to examine new approaches for treatment.</p>				

126126	RFA-NS-24-041 -- NIH HEAL Initiative: Coordinated Approaches to Pain Care in Health Care Systems (UG3/UH3 - Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-24-041	08-Oct-2024	Not Specified
--------	--	--	---------------	-------------	---------------

	<p>Contact Name Linda Porter, PhD</p> <p>Contact Telephone 301-451-4460</p> <p>Contact Email porterl@ninds.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Oct-2024 , 07-Nov-2024</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) solicits research applications that propose implementation science methodology to embed existing evidence-based coordinated pain care models into a variety of public and private health care systems (HCS) where this type of care does not exist. This NOFO is intended to embed the coordinated care model under study into the health care delivery system of applicant institutions. Coordinated pain care approaches proposed for study are expected to include interventions from multiple disciplines as described below and should aim to improve pain management based on the biopsychosocial model of pain. Emphasis should be on reaching populations of patients with greatest need. Models of coordinated care proposed by the study team should be aligned with health care resources of the participating HCS and should be informed through engagement of stakeholders including patients, providers, healthcare system executives, policymakers, and payors. The study teams are expected to include health care providers from multiple disciplines and implementation scientists. Trials will be supported by the Coordinating Center (CC) of the HEAL Pragmatic and Implementation Studies to Improve the Management of Pain and Reduce Opioid Prescribing (PRISM) Program</p>				
--	---	--	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>(https://rethinkingclinicaltrials.org/.) The Coordinating Center will provide technical expertise in all aspects of research and coordination across studies awarded through this NOFO. Recipients will work with the CC to facilitate planning and refinement of proposed studies in partnership with health care delivery systems.</p>				
126258	RFA-NS-25-011 -- Functional Target Validation for Alzheimer's Disease-Related Dementias (R61/R33 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-25-011	09-Oct-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Pascal Laeng, PhD Contact Telephone 301-496-7416 Contact Email pascal.laeng@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 09-Oct-2024 [Optional][LOI/Pre-App], 08-Nov-2024</p> <p>Synopsis This NOFO invites applications that propose the comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer's Disease-Related Dementias (ADRD). This NOFO seeks to promote critical target validation approaches to help de-risk subsequent translational research and accelerate the advancement of novel therapies for ADRD. Target(s) or molecular pathway(s) to be considered for validation must have been already identified using tissue expression or genetic data generated in human samples. In its initial phase, this NOFO provides support for up to two years (R61 stage) for the development of customized technologies, models, and protocols to modulate the expression or activity of target candidate(s) in cells and/or tissues and monitor their functional biological consequences in vitro or in vivo disease models. Upon demonstration of technical feasibilities, a second phase (R33 stage) will carefully and reproducibly measure and cross-validate the impact of the target modulation in different modalities across collaborating laboratories using the NIH rigor and reproducibility guidelines. This NOFO will support applications that address objectives for both the R61 and R33 phases and are expected to have a substantial collaborative effort between independent laboratories. This NOFO is not specific for anyone or group within the ADRD spectrum of disorders. Disorders covered in these applications are frontotemporal degeneration (FTD), Lewy body dementias (LBD) (including dementia with Lewy bodies (DLB)), Parkinson disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), and mixed dementias including the multiple etiology dementias (MED).</p>				
107186	Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-053	05-Oct-2024	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Codrin Lungu, MD 301-496-9135 lunguci@ninds.nih.gov Link to program URL 05-Oct-2024 Synopsis Functional Neurological Disorders (FNDs) are characterized by symptoms of altered voluntary motor or sensory function with clinical findings providing evidence of incompatibility between the symptoms and recognized neurological or medical conditions. FNDs are highly prevalent and associated with significant morbidity, health care costs, and even mortality. In some respects, this group of conditions sits at the intersection of neurology and psychiatry, but the majority of cases first come to the attention of neurologists. Management is complex and requires interdisciplinary approaches. Given the disability caused by the symptoms, and the high cost in healthcare utilization and loss of productivity, FNDs amount to a significant missed opportunity for therapeutic intervention and therefore, a healthcare crisis. Diagnosis and management of FNDs remain very challenging. Diagnostic criteria have been proposed but they are not universally agreed upon. Diagnosis is based on positive clinical findings, and can be supported by laboratory or ancillary investigation findings. Certain FND subtypes are more difficult to correctly diagnose than others. More importantly, laboratory-supported diagnosis is possible, and biomarkers can be developed, but significantly more research is needed in these areas to advance clinical management of FNDs. Therapies exist and have been studied in select populations but gathering high-level evidence through clinical trials is hampered by limitations in available outcome measures. Differential responses to treatments have been recorded, and thus, prediction of aggregate treatment response has been difficult. This FOA invites researchers to submit prospective clinical projects that address critical needs for clinical trial readiness in FNDs. Projects appropriate for this FOA include the validation of biomarkers, endpoints and clinical outcome assessments (COA) that are fit-for-purpose and have a defined context of use for clinical trials. Projects involving biomarker discovery or early validation should apply to the relevant FOAs (PAR-19-315, PAR-21-056, PAR-21-057, PAR-21-058, PAR-21-059). The initiative will promote partnerships among academic investigators, industry, and patient groups, and will encourage interactions with the Food and Drug Administration (FDA).
--	--

104258	NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-237	10-Sep-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name Contact Telephone	Jeremy Brown, MD 301-496-9135
-----------------------------------	----------------------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	Jeremy.brown@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	10-Sep-2024 , 09-Oct-2024 , 08-Jan-2025
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (https://www.ninds.nih.gov/).

110549	NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-142	08-Oct-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Jeremy Brown MD
Contact Telephone	
Contact Email	jeremy.brown@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Oct-2024 , 10-Feb-2025
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory Phase 1 and Phase 2 clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS. They may include studies of drugs and biologics, feasibility or preliminary efficacy studies of devices, and early studies of surgical, behavioral or rehabilitation therapies. All Phase 1 exploratory trials must contribute to the justification for and provide some of the data required to inform a future Phase 2 trial that may also be performed as part of the current grant application, should the results of the Phase 1 studies be encouraging. This FOA uses the UG3/UH3 mechanism.

115920	NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-23-090	08-Oct-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Jeremy Brown, MD
--------------	------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-594-4481</p> <p>Contact Email jeremy.brown@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Oct-2024 , 07-Feb-2025 , 06-Jun-2025 , 07-Oct-2025 , 06-Feb-2026</p> <p>Synopsis This funding opportunity announcement (FOA) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols. Applicants do not need to be part of the existing SIREN infrastructure to apply under this FOA. The NIH SIREN Network will also be uniquely poised to collaborate with other U.S. and international consortia necessary to conduct larger, definitive trials of promising interventions for neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN.</p>				
126433	<p>RFA-NS-25-013--Clinical Trial Readiness to Understand and Develop Solutions to Social, Ethical, Behavioral Implications and Barriers to Health Equity in ADRD (R01 - Clinical Trial Not Allowed)</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-25-013	04-Sep-2024 [Optional][LOI/Pre-App]	2,000,000 USD
	<p>Contact Name Kristina Mclinden, Ph.D.</p> <p>Contact Telephone 301-827-2563</p> <p>Contact Email kristina.mclinden@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Sep-2024 [Optional][LOI/Pre-App], 04-Oct-2024</p> <p>Synopsis This Notice of Funding Opportunity invites applications for clinical research to uncover social, ethical, and behavioral implications (SEBI) and barriers for health equity research in Alzheimer's Disease Related Dementias. Applications to this NOFO will propose research to establish clinical trial readiness for community-driven interventions to understand and develop solutions addressing barriers to equity in ADRD outcomes among populations defined by the NIH to experience health disparities and communities that intersect with them. These research projects are expected to produce preliminary data to support or inform future clinical trials that address either the social ethical and/or behavioral implications (SEBI) related to assessing risk for, identification of, or treatment of ADRD populations designated by the NIH to experience</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>health disparities and how these factors may relate to existing or potential barriers to achieving equity. This NOFO requires a Community Engaged Research Inclusion (CERI) Plan and Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP or a CERI will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP and CERI guidance material.</p>			
100306	NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-032	07-Sep-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Stephen Korn, Ph.D.</p> <p>301-496-4188</p> <p>korns@ninds.nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-Sep-2024 , 10-Oct-2024 , 07-Jan-2026</p>			
	Synopsis	<p>The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 4 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early, thoughtful planning and timely completion of "mentored training" within a particular lab or environment. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>			
111323	Notice of Special Interest (NOSI): Tools to Enhance the Study of Prenatal and Pediatric Hydrocephalus	National Institute of Neurological Disorders and	NOT-NS-23-003	07-Sep-2024	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Stroke/NIH/DHHS					
	<p>Contact Name Jill Morris, Ph.D.</p> <p>Contact Telephone 301-496-5754</p> <p>Contact Email jill.morris@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025</p> <p>Synopsis The purpose of this Notice is to inform potential applicants about an area of special interest to NINDS in research to develop or substantially modify existing cutting-edge tools that will advance prenatal and/or pediatric hydrocephalus research. Applications should aim to transform the field of prenatal and/or pediatric hydrocephalus research by generating tools including animal and cell models, novel methods and innovative technologies that will be widely used throughout the neuroscience community to understand disease mechanisms and/or developing therapeutics.</p>				
107322	Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-030	10-Oct-2024	Not Specified
	<p>Contact Name Ann-Marie Broome, PhD, MBA</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email ann-marie.broome@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Oct-2024</p> <p>Synopsis The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this funding opportunity announcement (FOA) is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.</p>				
106359	Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical)	National Institute of	PAR-21-	12-Oct-2024	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Trial Required)	Neurological Disorders and Stroke/NIH/DHHS	327		Specified
	<p>Contact Name Stephen Korn, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email korns@ninds.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Oct-2024</p> <p>Synopsis This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA PAR-21-328.</p>				
106361	Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-328	12-Oct-2024	Not Specified
	<p>Contact Name Stephen Korn, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email korns@ninds.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Oct-2024</p> <p>Synopsis This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-327.

109940	Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-076	07-Sep-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Adam L. Hartman, MD
Contact Telephone	301-496-9135
Contact Email	adam.hartman@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 18-Oct-2024 , 07-Jan-2025 , 19-Feb-2025 , 07-May-2025
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS) (note: only prospective observational studies will be considered). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.

126697	RFA-NS-24-040 -- The NINDS Human Cell and Data Repository (U24 - Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-24-040	17-Sep-2024 [Optional][LOI/Pre-App]	4,575,000 USD
--------	--	--	---------------	-------------------------------------	---------------

Contact Name	Rebecca Price , PhD
Contact Telephone	301-827-3587
Contact Email	rebecca.price@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-Sep-2024 [Optional][LOI/Pre-App], 17-Oct-2024
Synopsis	This Funding Opportunity Announcement (FOA) invites applications to support the National Institute of Neurological

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	Disorders and Stroke (NINDS) Human Cell and Data Repository (NHCDR). The repository will maintain the current collection of fibroblast and induced pluripotent stem cell (iPSC) lines as well as develop, characterize, expand source cells and iPSCs, and where appropriate, genetically modify new high-quality iPSC lines in accordance with the NINDS mission. The NINDS Human Cell and Data Repository will distribute human cell resources broadly to qualified academic and industry researchers to advance basic and translational research in neurological disorders.																		
126698	NINDS Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-212	12-Oct-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Amelie Gubitz, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-451-7966</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>ADRDK99@ninds.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of the NINDS Alzheimer’s Disease-Related Dementias (ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of new and talented, independent investigators from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences (e.g. see NOT-OD-20-031, Notice of NIH’s Interest in Diversity), conducting ADRD research. The program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help recipients establish independent research programs in the ADRD field. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are permitted to propose research experiences in a clinical trial led by a mentor or co-mentor.</td> </tr> </table>					Contact Name	Amelie Gubitz, Ph.D.	Contact Telephone	301-451-7966	Contact Email	ADRDK99@ninds.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027	Synopsis	The purpose of the NINDS Alzheimer’s Disease-Related Dementias (ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of new and talented, independent investigators from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences (e.g. see NOT-OD-20-031, Notice of NIH’s Interest in Diversity), conducting ADRD research. The program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help recipients establish independent research programs in the ADRD field. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are permitted to propose research experiences in a clinical trial led by a mentor or co-mentor.
Contact Name	Amelie Gubitz, Ph.D.																		
Contact Telephone	301-451-7966																		
Contact Email	ADRDK99@ninds.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027																		
Synopsis	The purpose of the NINDS Alzheimer’s Disease-Related Dementias (ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of new and talented, independent investigators from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences (e.g. see NOT-OD-20-031, Notice of NIH’s Interest in Diversity), conducting ADRD research. The program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help recipients establish independent research programs in the ADRD field. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are permitted to propose research experiences in a clinical trial led by a mentor or co-mentor.																		
126699	NINDS Alzheimer’s Disease-Related Dementias (ADRD) Advanced Postdoctoral Career Transition Award (K99/R00 Independent Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-213	12-Oct-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Amber McCartney, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td></td> </tr> </table>					Contact Name	Amber McCartney, Ph.D.	Contact Telephone											
Contact Name	Amber McCartney, Ph.D.																		
Contact Telephone																			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email amber.mccartney@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027</p> <p>Synopsis The purpose of the NINDS Alzheimer’s Disease-Related Dementias (ADRD) Advanced Postdoctoral Career Transition Award (K99/R00) program is to support a cohort of new and talented, independent investigators conducting ADRD research. The program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help recipients establish independent research programs in the ADRD field. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Candidates to this NOFO are permitted to propose research experiences in a clinical trial led by a mentor or co-mentor.</p>				
126710	PAR-24-249 -- Interaction Between Environmental Factors and Lewy Body Dementia (R01 - Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-249	04-Sep-2024 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name David A. Jett</p> <p>Contact Telephone 301-496-6035</p> <p>Contact Email jettd@nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Sep-2024 [Optional][LOI/Pre-App], 04-Oct-2024</p> <p>Synopsis Many avenues of research are focused on improving our understanding of Lewy body dementia (LBD), including the disease's underlying biology and genetic risk factors. Environmental risk factors are also considered but are understudied. This Notice of Funding Opportunity (NOFO) is to support research that establishes causal links between a range of environmental factors and Lewy body formation. These factors include exposures to environmental toxicants, light and noise, climate, and other external exposures. This NOFO will support mechanistic, translational, and human subject studies to understand the relationship between environmental factors and LBD. It is expected that these studies will identify environmental risk factors related to the cause of LBD and its progression and their clinical relevance. Ultimately, these studies on LBD should accelerate mechanism-focused research to identify relevant pathways with potential to lead towards better and novel therapeutic</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| interventions and quality of life.

126781	NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Patient-Oriented Research Career Development award (K23 - Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-220	12-Oct-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Laura D. Wandner
Contact Telephone	
Contact Email	Laura.Wandner@nih.gov
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	12-Oct-2024 , 12-Nov-2024 , 12-Feb-2025 , 12-Mar-2025 , 12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2025 , 12-Feb-2026 , 12-Mar-2026 , 12-Jun-2026 , 12-Jul-2026 , 12-Oct-2026 , 12-Nov-2026 , 12-Feb-2027 , 12-Mar-2027 , 12-Jun-2027 , 12-Jul-2027
Synopsis	The purpose of the NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Patient-Oriented Research Career Development award (K23) (Clinical Trial Required) is to support the career development of individuals with clinical doctoral degrees to create a group of new and well-trained, independent investigators. This supervised career development program will provide independent NIH research support during the early-career phase to help recipients establish independent research programs in areas supported by the NIH HEAL Initiative’s Clinical Research in Pain Management program. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion NOFO.

126790	NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08 - Clinical Trials Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-219	12-Oct-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Laura D. Wandner
Contact Telephone	
Contact Email	Laura.Wandner@nih.gov
Sponsor Website	Link to sponsor website
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 12-Oct-2024 , 12-Nov-2024 , 12-Feb-2025 , 12-Mar-2025 , 12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2025 , 12-Feb-2026 , 12-Mar-2026 , 12-Jun-2026 , 12-Jul-2026 , 12-Oct-2026 , 12-Nov-2026 , 12-Feb-2027 , 12-Mar-2027 , 12-Jun-2027 , 12-Jul-2027</p> <p>Synopsis The purpose of this NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08 - Clinical Trials Not Allowed) is to support the career development of individuals with clinical doctoral degrees to create a group of new and well-trained, independent investigators. This supervised career development program will provide independent NIH research support during the early-career phase to help recipients establish independent research programs in areas supported by the NIH HEAL Initiative’s Clinical Research in Pain Management program. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator should apply to the companion NOFO. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>				
126806	NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08 - Clinical Trials Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-217	12-Oct-2024	Not Specified
	<p>Contact Name Laura D. Wandner</p> <p>Contact Telephone</p> <p>Contact Email Laura.Wandner@nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Oct-2024 , 12-Nov-2024 , 12-Feb-2025 , 12-Mar-2025 , 12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2025 , 12-Feb-2026 , 12-Mar-2026 , 12-Jun-2026 , 12-Jul-2026 , 12-Oct-2026 , 12-Nov-2026 , 12-Feb-2027 , 12-Mar-2027 , 12-Jun-2027 , 12-Jul-2027</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Jul-2027</p> <p>Synopsis The purpose of this NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08) (Clinical Trials Required) is to support the career development of individuals with clinical doctoral degrees to create a group of new and well-trained, independent investigators. This supervised career development program will provide independent NIH research support during the early-career phase to help recipients establish independent research programs in areas supported by the NIH HEAL Initiative’s Clinical Research in Pain Management program. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to a companion NOFO.</p>				
102747	<p>Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-122	21-Oct-2024	750,000 USD
	<p>Contact Name Becky Roof, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email rebecca.roof@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Oct-2024</p> <p>Synopsis This funding opportunity announcement (FOA) provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.</p>				
102739	<p>Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-123	21-Oct-2024	750,000 USD
	<p>Contact Name Becky Roof, PhD</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-1779</p> <p>Contact Email rebecca.roof@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Oct-2024</p> <p>Synopsis This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.</p>				
126641	<p>CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT)</p> <p>Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-030	18-Sep-2024 [Optional][LOI/Pre-App]	300,000 USD
	<p>Contact Name Shardell Spriggs, Ph.D.</p> <p>Contact Telephone 301-443-8189</p> <p>Contact Email shardell.spriggs@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Sep-2024 [Optional][LOI/Pre-App], 17-Oct-2024 , 18-Sep-2025 [Optional][LOI/Pre-App], 17-Oct-2025 , 17-Sep-2026 [Optional][LOI/Pre-App], 16-Oct-2026</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for basic research projects on chemical warfare agents, toxic industrial chemicals, and pesticides that have primary or secondary effects on the nervous system. These chemical threats are toxic compounds that have been identified by the United States Government (USG) as Chemicals of Concern (CoC) that could be deliberately or accidentally released into the civilian population. Research supported by this NOFO is expected to generate results that further elucidate mechanism(s) of toxicity of these agents and potential new targets for development of therapeutic/medial countermeasures that are effective in civilian mass exposure situations.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
123196	NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-101	18-Oct-2024	Not Specified														
	<table border="0" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Scott Janis, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-496-9135</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>moyc@ninds.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>18-Oct-2024 , 19-Feb-2025 , 20-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 19-Oct-2026</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td> <p>This NOFO encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet. Following peer review, NINDS will prioritize studies among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. The NIH StrokeNet network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for stroke treatment, prevention, and recovery. It is NINDS's intent that all NINDS-supported multi-center clinical trials in stroke treatment, recovery, or prevention will be conducted within the NIH StrokeNet. Only in exceptional circumstances will NINDS consider funding multi-site stroke clinical trials outside of this network. This NOFO uses the bi-phasic, milestone driven UG3/UH3 cooperative agreement activity code. Awards made under this NOFO will initially support a one-year milestone-driven planning and start-up phase, with possible transition to an implementation (UH3) phase of up to 6 additional years. Only UG3 projects that meet the scientific milestones and award requirements of the UG3 phase may transition to the UH3 phase. Applications submitted in response to this FOA must address both the UG3 and UH3 phases and are expected to include plans for project management and performance milestones for each phase. Applicants do not need to be part of the existing NIH StrokeNet infrastructure to apply under this NOFO.</p> </td> </tr> </table>					Contact Name	Scott Janis, Ph.D.	Contact Telephone	301-496-9135	Contact Email	moyc@ninds.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	18-Oct-2024 , 19-Feb-2025 , 20-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 19-Oct-2026	Synopsis	<p>This NOFO encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet. Following peer review, NINDS will prioritize studies among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. The NIH StrokeNet network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for stroke treatment, prevention, and recovery. It is NINDS's intent that all NINDS-supported multi-center clinical trials in stroke treatment, recovery, or prevention will be conducted within the NIH StrokeNet. Only in exceptional circumstances will NINDS consider funding multi-site stroke clinical trials outside of this network. This NOFO uses the bi-phasic, milestone driven UG3/UH3 cooperative agreement activity code. Awards made under this NOFO will initially support a one-year milestone-driven planning and start-up phase, with possible transition to an implementation (UH3) phase of up to 6 additional years. Only UG3 projects that meet the scientific milestones and award requirements of the UG3 phase may transition to the UH3 phase. Applications submitted in response to this FOA must address both the UG3 and UH3 phases and are expected to include plans for project management and performance milestones for each phase. Applicants do not need to be part of the existing NIH StrokeNet infrastructure to apply under this NOFO.</p>
Contact Name	Scott Janis, Ph.D.																		
Contact Telephone	301-496-9135																		
Contact Email	moyc@ninds.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	18-Oct-2024 , 19-Feb-2025 , 20-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 19-Oct-2026																		
Synopsis	<p>This NOFO encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet. Following peer review, NINDS will prioritize studies among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. The NIH StrokeNet network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for stroke treatment, prevention, and recovery. It is NINDS's intent that all NINDS-supported multi-center clinical trials in stroke treatment, recovery, or prevention will be conducted within the NIH StrokeNet. Only in exceptional circumstances will NINDS consider funding multi-site stroke clinical trials outside of this network. This NOFO uses the bi-phasic, milestone driven UG3/UH3 cooperative agreement activity code. Awards made under this NOFO will initially support a one-year milestone-driven planning and start-up phase, with possible transition to an implementation (UH3) phase of up to 6 additional years. Only UG3 projects that meet the scientific milestones and award requirements of the UG3 phase may transition to the UH3 phase. Applications submitted in response to this FOA must address both the UG3 and UH3 phases and are expected to include plans for project management and performance milestones for each phase. Applicants do not need to be part of the existing NIH StrokeNet infrastructure to apply under this NOFO.</p>																		
124093	RFA-NS-24-032 -- Development and Validation of Human Cellular Models for Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-24-032	20-Sep-2024 [Optional][LOI/Pre-App]	2,500,000 USD														

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Linda McGavern, PhD</p> <p></p> <p>mcgavernlm@ninds.nih.gov</p> <p></p> <p>Link to program URL</p> <p>20-Sep-2024 [Optional][LOI/Pre-App], 21-Oct-2024</p> <p>This Notice of Funding Opportunity (NOFO) supports the development and validation of novel, complex, and pathophysiologically relevant human cellular models of Alzheimer's Disease Related Dementias (ADRD). The cellular model system needs to reflect multiple aspects of the human condition as much as possible, such as capturing the multiple pathologies and brain cell types observed in ADRD. Validation is required, including face and construct validity. Human cellular models could be developed and validated with the goal of supporting therapeutic development or better understanding of human disease mechanisms and mechanisms that cause predisposition or resilience to developing ADRD.</p>
---	---

126685	NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-228	12-Oct-2024	Not Specified
--------	--	--	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Michelle Jones-London, Ph.D.</p> <p>301-451-7966</p> <p>NINDSDiversityTraining@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027</p> <p>The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to enhance participation in the independent neuroscience research workforce by providing junior faculty from diverse backgrounds, including those from groups underrepresented in biomedical research, with research cost support, protected research time, and career stage-appropriate mentorship and professional development in neuroscience research. Individuals are eligible for support under this award if they are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This notice of funding opportunity (NOFO) is designed specifically for candidates proposing research that does</p>
---	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion NOFO (PAR-24-229).

126690	NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-229	12-Oct-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Michelle Jones-London
Contact Telephone	301-451-7966
Contact Email	NINDSDiversityTraining@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027
Synopsis	The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to enhance participation in the independent neuroscience research workforce by providing junior faculty from diverse backgrounds, including those from groups underrepresented in biomedical research, with research cost support, protected research time, and career stage-appropriate mentorship and professional development in neuroscience research. Individuals are eligible for support under this award if they are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This notice of funding opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-24-228).

126342	Mechanistic Investigations into ADRD Associated Protein Structures in Biological Settings (R01 - Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-234	04-Oct-2024	500,000 USD
--------	--	--	------------	-------------	-------------

Contact Name	George Umanah, PhD
Contact Telephone	

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email umanahgk@ninds.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Oct-2024</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) supports studies proposing to utilize methodologies for in-cell structural biology to address the mechanistic insights and causal cellular and molecular relationships between molecular pathology and Alzheimer’s disease-related dementias (ADRD) clinical phenotypic outcomes. The applications are expected to focus on determining structures of ADRD-linked macromolecular in native (healthy and pathological) settings. The proposed methodology is expected to provide high-resolution information on the identity, dynamics and relative abundance of macromolecular species associated with ADRD and how pathological environments influence dynamics and structural conformations. Studies in response to this NOFO can also include the development of in situ research tools and resources to further characterize and validate the structural findings. The long-term goal of this funding opportunity is for these structural studies in the native cellular environment to inform efficient tools development and designs that better identify and monitor the accumulation of dysfunctional proteins in patients, as well as for other diagnostic, treatment response, therapeutic development and other related applications.</p>				
108301	<p>RFA-NS-22-034 -- HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-22-034	07-Aug-2024	Not Specified
	<p>Contact Name Michael L. Oshinsky, PhD</p> <p>Contact Telephone 301-496-9964</p> <p>Contact Email michael.oshinsky@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Aug-2024 , 02-Oct-2024 , 06-Dec-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices is not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery. This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, orofacial pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA.</p>				
127154	RFA-NS-25-002 -- Materials to Enhance Training in Experimental Rigor (METER) (UE5 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-25-002	10-Sep-2024 [Optional][LOI/Pre-App]	250,000 USD
	<p>Contact Name Devon Crawford Contact Telephone 301-496-1917 Contact Email devon.crawford@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 10-Sep-2024 [Optional][LOI/Pre-App], 10-Oct-2024 Synopsis The NIH Research Education Program (UE5) supports research education activities in the mission areas of the NIH. The overarching goal of this UE5 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Curriculum or Methods Development The NINDS Materials to Enhance Training in Experimental Rigor (METER) UE5 will support curriculum development in the form of innovative educational materials that will be incorporated into a new cutting-edge online resource that aims to promote awareness, understanding, and practice of fundamental principles of rigorous biomedical research for researchers and other scientists in various career stages and learning environments.</p>				
127141	Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Basic Experimental Studies with Humans Required (BESH))	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-227	07-Sep-2024	Not Specified
	<p>Contact Name Lanay M. Mudd, Ph.D., FACSM Contact Telephone 301-594-9346</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email lanay.mudd@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027</p> <p>Synopsis The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) program is to support a cohort of early career, independent investigators from diverse backgrounds (for example, individuals from underrepresented groups) conducting research in NIH mission areas. The program has two components: an individual career transition award for postdoctoral scholars (K99/R00) and a research education cooperative agreement (UE5) awarded to organizations to provide these scholars with additional mentoring, networking and professional development activities to support their transition to and success in independent, tenure-track or equivalent research-intensive faculty careers. The MOSAIC program supports NIH's efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The goal of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds from their mentored postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The program is designed to support postdoctoral researchers who have demonstrated meaningful contributions and proposed compelling future plans to promote broad participation in the biomedical research workforce, such as activities that promote inclusive, supportive, and accessible biomedical research environments that support the success of trainees and scientists from all backgrounds, including individuals from underrepresented groups. This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>				
113257	NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-22-230	07-Sep-2024	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name David L. Tilley, MPH, MS, CPH</p> <p>Contact Telephone 301-827-6014</p> <p>Contact Email david.tilley@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025</p> <p>Synopsis This funding announcement solicits R01 grant applications that propose independent research projects that are consistent with the scientific framework detailed in the 2022-2026 National Institute of Nursing Research (NINR) Strategic Plan. This research will be rooted in nursing's holistic, contextualized approach to understanding people and their health, address the nation's most pressing and persistent health challenges with a solutions orientation, and employ innovative and rigorous study designs to inform practice and policy.</p>				
113258	NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-22-231	07-Sep-2024	200,000 USD
	<p>Contact Name David L. Tilley, MPH, MS, CPH</p> <p>Contact Telephone 301-827-6014</p> <p>Contact Email david.tilley@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 16-Nov-2024 , 07-Jan-2025 , 16-Feb-2025 , 16-Mar-2025 , 07-May-2025</p> <p>Synopsis This funding announcement solicits R21 grant applications that propose exploratory/developmental research projects that are consistent with the research framework detailed in the 2022-2026 National Institute of Nursing Research (NINR) Strategic Plan. This research will be rooted in nursing's holistic, contextualized approach to understanding people and their health, address the nation's most pressing and persistent health challenges with a solutions orientation, and employ innovative and rigorous study designs to inform practice and policy.</p>				
113071	NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurship Enhancement Award (R25 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-22-226	17-Sep-2024 [Optional][LOI/Pre-App]	1,250,000 USD
	Contact Name Saroj Regmi, Ph.D.				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-402-7700</p> <p>Contact Email saroj.regmi@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Sep-2024 [Optional][LOI/Pre-App], 17-Oct-2024</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development This FOA invites applications to the Research and Entrepreneurial Development Immersion (REDI) Award program. The program promotes the development of entrepreneurial education programs that are designed to broaden the skillset of graduate students and postdoctoral researchers, as well as early-career master's, Ph.D., and Dr.P.H. scientists, in fields relevant to the mission of NIA, including aging and Alzheimer's disease (AD) research. The goal of the program is to prepare trainees for a wide-range of career paths, including those that are outside the traditional research environment.</p>				
113072	<p>NIA Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award (K01 Clinical Trial Not Allowed)</p>	National Institute on Aging/NIH/DHHS	PAR-22-227	17-Sep-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Saroj Regmi, Ph.D.</p> <p>Contact Telephone 301-480-8964</p> <p>Contact Email saroj.regmi@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Sep-2024 [Optional][LOI/Pre-App], 17-Oct-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications to the National Institute on Aging's (NIA) Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award program. The purpose of the program is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. The program is designed to support participants' transition to research independence in a multitude of career options, including research and teaching faculty, as well as entrepreneurial, industry, science policy, and research administration positions. Optimal candidates for this opportunity are experienced postdoctoral researchers (two years minimum) and/or recently appointed</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
116492	RFA-AG-24-015 -- Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	RFA-AG-24-015	18-Sep-2024 [Optional][LOI/Pre-App]	1,125,000 USD

junior faculty members (usually with Ph.D. degrees) in biomedical, social, or behavioral sciences who are interested in entrepreneurial training and are pursuing careers in research areas supported by NIA. This K01 FOA includes entrepreneurial training and career development opportunities for early-career academic scientists as part of its translational research and supervised career development activities. This FOA is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA, candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.

Contact Name
 Contact Telephone
 Contact Email
 Sponsor Website
 Program URL
 Deadline Dates (ALL)

NIATraining@nih.gov

[Link to program URL](#)

18-Sep-2024 [Optional][LOI/Pre-App], 18-Oct-2024

Synopsis

The overall goal of the NIH Research Career Development program is to help ensure that a diverse pool of highly trained scientists is available in appropriate scientific disciplines to address the Nation's biomedical, behavioral, and clinical research needs. NIH Institutes and Centers (ICs) support a variety of mentored and non-mentored career development award programs designed to foster the transition of new investigators to research independence and to support established investigators in achieving specific objectives. Candidates should review the different career development (K) award programs to determine the best program to support their goals. More information about Career programs may be found at the NIH Extramural Training Mechanisms website. The objective of the NIH Emerging Leaders Career Development Award (K76) is to help develop a cadre of scientists prepared to take an active leadership role in transformative change that will lead to improved research or healthcare outcomes. This program supports basic or clinically trained faculty members who seek additional research, professional career and leadership skills essential for assuming a leadership role in an increasingly global biomedical workforce. NIH Emerging Leaders are early-stage investigators conducting research who have shown early signs of leadership and who will use this award to further develop the tools, skills and resources to have a significant impact as leaders in their field of expertise. These skills will prepare them to assume academic leadership roles and independent careers in an emerging discipline within their professional specialty. Emerging leaders demonstrate a commitment to increasing the visibility and overall research support and academic capacity within their educational, medical/health, and/or research community. It is anticipated that their scientific expertise will be in demand as future reviewers, educators, and

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

policymakers. Within the field of aging research, the small numbers of individuals skilled in geriatrics, and the smaller numbers pursuing research on aging, are inadequate to address the burgeoning needs of the rapidly growing older population. A key goal of this initiative, therefore, is to foster the careers of emerging clinical investigators who possess the skills necessary for academic leadership in aging and geriatrics. Unlike other mentored K award programs, this initiative aims to recruit investigators who have had competitively awarded research support at the faculty level and who have shown early signs of leadership in their field of expertise. Although early-stage investigators, through their efforts, these individuals are well poised to change theory, practice, and outcomes related to the health of older individuals. Through this announcement and the companion FOA, emerging leaders will aim to capitalize on current opportunities in clinical, translational, or groundbreaking basic research in aging and geriatrics to advance an emerging discipline or effect changes in practice within their professional specialty. Through the NIH Emerging Leaders Career Development Award, investigators are provided salary and research support for a sustained period of "protected time" (3-5 years) for career development and to advance the leadership skills of physician-investigators and other investigators trained in health professions. These investigators conduct research in basic, translational or clinical, and Patient-Oriented Research (POR) in disciplines relevant to aging and geriatrics. The award is intended to prepare early-stage investigators for academic research leadership, as well as provide mentoring in their scientific research area of interest. The focus is on building a cadre of investigators and leaders to advance knowledge and skills in a new field, a new methodology, or a new approach, both through their own research and through their leadership, in the broader community of their specialty. The Beeson Program Through this FOA, NIA uses the NIH Emerging Leaders Career Development Award to administer the Paul B. Beeson Emerging Leaders Career Development Award in Aging program. The program is named after Dr. Paul B. Beeson, who profoundly influenced the career paths of many physicians, including several who now form the core leadership in geriatric medicine. Dr. Beeson was Chairman of Medicine at Emory and Yale Medical Schools, Nuffield Professor at Oxford University, and Professor and Distinguished VA Physician at the University of Washington. He chaired the first Institute of Medicine study on "Aging and Medical Education" in 1978. His leadership as an editor of the Cecil Textbook of Medicine greatly influenced medical education. From his research and patient care base, he grew increasingly interested in the process of aging, and this interest led to a commitment that included his editorship of the Journal of the American Geriatrics Society. The aims of the program are as follows: To provide support for career development and to advance the leadership skills of medical and surgical specialists conducting clinically relevant basic, translational or clinical, and POR in disciplines relevant to aging and geriatrics. To deepen the commitment of research institutions to promote transformative academic research and leadership in aging and geriatric medicine by linking mentors to emerging scientists with a commitment to future leadership in aging research and policy. Research Objectives This FOA provides an opportunity for candidates to expand their research area of interest and pursue activities consistent with the expectation of future leadership in the candidate's chosen field. NIA welcomes applications in all fields of aging research, including basic, translational, genetic, biological, neuroscientific, clinical, behavioral, and social sciences research on aging. A particular priority of NIA at the moment is research on Alzheimer's disease (AD) and Alzheimer's disease-related dementias

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

(ADRD). This initiative is targeted primarily towards individuals who have had prior training in research coursework, methods, and resources related to aging, and who have received initial funding for research, such as through small grant support from NIH, similar support from other federal agencies, or foundation funding. The award(s) should have been competitively awarded to the candidate at the faculty level. Individuals who have leveraged faculty-level research development support to advance and develop an independent line of research and who can provide evidence that they possess the attributes of committed and skilled leaders in their respective fields are also welcome to apply. Prior evidence of leadership can be in either clinical duties or research activities that illustrate keen engagement and commitment to moving the applicant's field forward. Examples include organizing seminar series, conferences or symposia at a national meeting; organizing workshops; or other activities where the candidates have played a leading role in enhancing their fields' academic medical/health and research accomplishments and visibility. The proposed career development and research should focus on aging or older adults. For this FOA, the candidate's project may be in any of a broad range of basic, translational, behavioral, clinical, or POR areas relevant to aging. The full range of research methods appropriate to completing the proposed investigation is encouraged, including basic and translational research and cell or computational models, provided that the application makes clear the eventual clinical relevance of the proposed work. We expect that scholars will contribute significantly to the research and scientific literature associated with the field of aging research.

Required Elements

Mentorship - Candidates must identify mentors who are senior researchers in aging and/or age-related diseases and conditions, and who agree to commit time to supervise and guide the candidate during the period of the award. A part of that commitment is the intent to advance the candidate both as a researcher and as an emerging leader in the field.

Annual meetings - A central part of this award is an annual meeting for Beeson scholars and their mentors. Accordingly, awardees must attend the annual meeting. Annual meetings are a valuable forum for scientific and professional networking opportunities for current Beeson awardees, Beeson alumni, and mentors. The meetings are intended to spark collaboration and expose scholars to a wide range of exciting science on aging.

Clinical Trials This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA, RFA-AG-24-014. NIH defines a clinical trial as "A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes." (NOT-OD-15-015). NIH not only supports trials of safety and efficacy, it also supports mechanistic exploratory studies that meet the definition of a clinical trial and are designed to explore or understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention. These studies may focus on basic and/or translational discovery research in healthy human subjects and in human subjects who are affected by the pathophysiology of diseases and disorders. By addressing basic questions and concepts in biology, behavior, and pathophysiology, these studies may provide insight into understanding human diseases and disorders along with potential treatments or preventive

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>strategies. NIH also supports biomarker studies that meet the definition of a clinical trial and that may provide information about physiological function, target engagement of novel therapeutics, and/or the impact of therapeutics on treatment response. NIH thus supports studies that meet the definition of clinical trials (as noted above) but do not seek to establish safety, clinical efficacy, effectiveness, clinical management, and/or implementation of preventive, therapeutic, and services interventions. Investigators proposing NIH-defined clinical trials may refer to the Research Methods Resources website for information about developing statistical methods and study designs. Clinical Research Operations Management System NIA supports a central resource to NIA staff and extramural investigators to facilitate/support the conduct and management of clinical research. This resource, the Clinical Research Operations Management System (CROMS), is a comprehensive data management system to support the business functions, management, and oversight responsibilities of NIA grants that support the conduct of clinical research with human subjects. It is the expectation by NIA that all successful applicants will interface, integrate, or adapt their information system(s) and processes to interact with existing and future components of the CROMS as necessary, including the use of CROMS data templates as specified.</p>				
116490	RFA-AG-24-014 -- Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Independent Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-24-014	18-Sep-2024 [Optional][LOI/Pre-App]	1,125,000 USD

Contact Name	
Contact Telephone	
Contact Email	NIAttraining@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	18-Sep-2024 [Optional][LOI/Pre-App], 18-Oct-2024
Synopsis	<p>This Funding Opportunity Announcement (FOA) invites early-stage physicians and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award with the goal of advancing their research and leadership skills in their specialty and in the broader field of aging and geriatrics research. The National Institute on Aging (NIA) is pursuing this initiative to recruit early-stage investigators who have successfully competed for a research grant and begun to establish research programs and who, through this award, will be ready to assume leadership roles in their field of expertise and be poised to change theory, practice, and health outcomes related to the health of older individuals. Unlike other mentored K awards, candidates for this award must have received competitively awarded research support as a Program Director/Primary Investigator (PD/PI) at the faculty level or have otherwise leveraged faculty-level research support to develop an independent line of research. They must show evidence of leadership in the clinical or research domain. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as a lead investigator should apply to the companion FOA, RFA-AG-24-015.																		
110477	RFA-AG-23-016 -- Transition to Aging Research for Predoctoral Students (F99/K00 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-23-016	18-Oct-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>NIATraining@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>18-Oct-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td> The National Institute on Aging (NIA) invites outstanding graduate students from a wide range of broad research areas who are interested in receiving aging-related postdoctoral training to apply to this Funding Opportunity Announcement (FOA). This FOA seeks to foster the development of research and clinician scientists in the following areas: genetic, biological, clinical, epidemiological, neuroscientific, behavioral, social, and economic research on aging, both basic and translational. Successful applicants will be awarded the Transition to Aging Research Award for Predoctoral Students, whose purpose is to recruit and retain emerging investigators in aging research. This two-phase award will allow awardees to complete doctoral dissertation projects and provide a variety of training supports to facilitate the smooth transition of doctoral graduates into competitive, aging-focused postdoctoral positions. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor. </td> </tr> </table>					Contact Name		Contact Telephone		Contact Email	NIATraining@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	18-Oct-2024	Synopsis	The National Institute on Aging (NIA) invites outstanding graduate students from a wide range of broad research areas who are interested in receiving aging-related postdoctoral training to apply to this Funding Opportunity Announcement (FOA). This FOA seeks to foster the development of research and clinician scientists in the following areas: genetic, biological, clinical, epidemiological, neuroscientific, behavioral, social, and economic research on aging, both basic and translational. Successful applicants will be awarded the Transition to Aging Research Award for Predoctoral Students, whose purpose is to recruit and retain emerging investigators in aging research. This two-phase award will allow awardees to complete doctoral dissertation projects and provide a variety of training supports to facilitate the smooth transition of doctoral graduates into competitive, aging-focused postdoctoral positions. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.
Contact Name																			
Contact Telephone																			
Contact Email	NIATraining@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	18-Oct-2024																		
Synopsis	The National Institute on Aging (NIA) invites outstanding graduate students from a wide range of broad research areas who are interested in receiving aging-related postdoctoral training to apply to this Funding Opportunity Announcement (FOA). This FOA seeks to foster the development of research and clinician scientists in the following areas: genetic, biological, clinical, epidemiological, neuroscientific, behavioral, social, and economic research on aging, both basic and translational. Successful applicants will be awarded the Transition to Aging Research Award for Predoctoral Students, whose purpose is to recruit and retain emerging investigators in aging research. This two-phase award will allow awardees to complete doctoral dissertation projects and provide a variety of training supports to facilitate the smooth transition of doctoral graduates into competitive, aging-focused postdoctoral positions. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.																		
125974	RFA-AG-25-024 -- Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/DRD (R61/R33 Clinical Trial Not allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-25-024	06-Sep-2024 [Optional][LOI/Pre-App]	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Erin E. Gray, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-451-3968</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>erin.gray@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> </table>					Contact Name	Erin E. Gray, Ph.D.	Contact Telephone	301-451-3968	Contact Email	erin.gray@nih.gov	Sponsor Website		Program URL	Link to program URL				
Contact Name	Erin E. Gray, Ph.D.																		
Contact Telephone	301-451-3968																		
Contact Email	erin.gray@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) 06-Sep-2024 [Optional][LOI/Pre-App], 07-Oct-2024

Synopsis This Notice of Funding Opportunity (NOFO) invites applications proposing innovative strategies to target and manipulate brain cell subtypes that are altered in aging, Alzheimer's Disease (AD), and AD-Related Dementias (ADRDs). ADRDs include frontotemporal disorders (FTD), Lewy body dementia (LBD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). Specifically, the goal of this NOFO is to encourage the development and utilization of sophisticated tools that pair breakthroughs in adeno-associated virus (AAV) capsid engineering with enhancer element identification to do the following: Optimize precise targeting of disease-relevant cell subtypes in aged and degenerating mammalian brains. Monitor and/or manipulate these cells in vivo to address mechanistic hypotheses related to brain aging and AD/ADRD in animal models. To achieve the goal, this NOFO utilizes the R61/R33 Exploratory/Developmental Phased Award activity code. The R61 phase provides up to 2 years of support for pilot activities to demonstrate proof-of-principle. The R33 phase provides up to 3 years of support for implementation activities, including hypothesis testing.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

125539	RFA-AG-25-004 -- Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Older Adults (UG3/UH3 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	RFA-AG-25-004	11-Sep-2024 [Optional][LOI/Pre-App]	Not Specified
--------	---	--------------------------------------	---------------	-------------------------------------	---------------

Contact Name Sekai Chideya-Chihota, MD, MPH

Contact Telephone 240-552-2994

Contact Email sekai.chideya@nih.gov

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 11-Sep-2024 [Optional][LOI/Pre-App], 10-Oct-2024

Synopsis This NOFO invites applications to support a clinical trials network involving multiple institutions to collect safety and early efficacy data of psychedelic-assisted therapy (PAT) in defined groups of older adults living with specific chronic pain conditions. This NOFO uses the UG3 / UH3 Exploratory/Developmental Phased Award Cooperative Agreement activity code. Applications must include a research plan describing both UG3 and UH3 phases. The first phase, the UG3 phase, may last up to two years, and should involve preliminary studies in healthy older adults across a broad age range to evaluate safety, pharmacokinetic, and pharmacodynamic properties of psychedelic agents and preliminary testing of PAT elements.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Activities in the UG3 phase will inform further development and testing in the second phase, the UH3 phase. The UH3 phase may last up to 3 years and should include expanded safety and preliminary efficacy studies in older adults with chronic pain conditions and must include participants living with non-contraindicated co-occurring conditions representative of real-world older adults. In both phases, participants across a broad range of ages must be included, with particular attention to strata at the upper age range (i.e., 75-80 years, and 80+ years old). For the purposes of this NOFO, the term psychedelic includes “classic” psychedelics, typically understood to be 5-HT2 agonists such as psilocybin, N,N-Dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and mescaline, as well as entactogens or empathogens such as methylenedioxymethamphetamine (MDMA). Synthetic analogs of these agents are also included. Cannabis, ketamine, and their related products are not considered psychedelic agents in this NOFO.</p>				
108299	NIA Renewal and Competing Revision Cooperative Agreements in Aging Research (U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-22-362	01-Oct-2024	Not Specified
	<p>Contact Name Ramesh Vemuri, Ph.D. Contact Telephone 301-402-7700 Contact Email ramesh.vemuri@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 01-Oct-2024 Synopsis This Funding Opportunity Announcement (FOA) allows for renewal and competing revision applications, and their resubmissions, for awarded U01 research project cooperative agreements focused on aging research.</p>				
120843	Analytical and Clinical Validation of Biomarkers for Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD)?(U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-23-258	05-Oct-2024	Not Specified
	<p>Contact Name Yuan Luo, Ph.D. Contact Telephone 301-496-9350 Contact Email Yuan.Luo@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Oct-2025 , 05-Feb-2026 Synopsis This notice of funding opportunity (NOFO) invites applications to accelerate the establishment of effective and reliable</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

biomarkers of Alzheimer’s disease (AD) and AD-related dementias (ADRD) for use in therapy/medical product discovery and development, clinical trials, and/or clinical practice. Specifically, this NOFO will support analytical and/or clinical validation of a biomarker, composite biomarker, or biomarker signature, with rigor comparable to the expectations described in the Food and Drug Administration (FDA's) Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways.

115099	Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-23-082	25-Oct-2024	Not Specified
--------	---	--------------------------------------	------------	-------------	---------------

Contact Name	Nandini Arunkumar, Ph.D.
Contact Telephone	301-451-2313
Contact Email	nandini.arunkumar@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	25-Oct-2024 , 21-Feb-2025
Synopsis	This Funding Opportunity Announcement (FOA) invites applications that apply a cross-disciplinary and team science approach to gain a comprehensive mechanistic understanding of the impact of sex differences on the molecular trajectories of brain aging on the phenotypes of risk and resilience to Alzheimer's disease (AD) and AD-related dementias (ADRD), and on the molecular determinants underlying responsiveness to pharmacologic and non-pharmacologic interventions.

112937	Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-22-228	25-Oct-2024	Not Specified
--------	---	--------------------------------------	------------	-------------	---------------

Contact Name	Nandini Arunkumar, Ph.D.
Contact Telephone	301-451-2313
Contact Email	nandini.arunkumar@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	25-Oct-2024 , 21-Feb-2025
Synopsis	This Funding Opportunity Announcement (FOA) invites applications that apply a cross-disciplinary and team science approach

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		to gain a comprehensive mechanistic understanding of the impact of sex differences on the molecular trajectories of brain aging on the phenotypes of risk and resilience to Alzheimer's disease (AD) and AD-related dementias (ADRD), and on the molecular determinants underlying responsiveness to pharmacologic and non-pharmacologic interventions.			
114469	NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	PAR-23-057	05-Oct-2024	Not Specified
	<p>Contact Name Sergei Romashkan, M.D., Ph.D.</p> <p>Contact Telephone 301-435-3047</p> <p>Contact Email romashks@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the NIA website.</p>				
108328	Early and Late Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-18-878	05-Oct-2024	Not Specified
	<p>Contact Name Laurie Ryan</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email ryanl@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite applications that propose to develop and implement early to late stage clinical trials of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
124752	New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-24-160	05-Oct-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Elizabeth Newman, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-480-7937</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>elizabeth.newman@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop new approaches or apply existing approaches in novel ways to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease. Research can include healthy human participants of any age; specific clinical groups such as those with cognitive, motor, or affective regulation challenges; and/or animal research on these domains of function. The studies can focus on longitudinal neuroanatomical or functional changes at any level, including genetics/genomics, single cells, connectomics, neural population activity patterns, and others. This funding opportunity is intended to encourage technological and conceptual innovation to improve repeated measures across longer epochs of the lifespan, to better predict outcomes at later ages. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</td> </tr> </table>					Contact Name	Elizabeth Newman, Ph.D.	Contact Telephone	301-480-7937	Contact Email	elizabeth.newman@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027	Synopsis	The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop new approaches or apply existing approaches in novel ways to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease. Research can include healthy human participants of any age; specific clinical groups such as those with cognitive, motor, or affective regulation challenges; and/or animal research on these domains of function. The studies can focus on longitudinal neuroanatomical or functional changes at any level, including genetics/genomics, single cells, connectomics, neural population activity patterns, and others. This funding opportunity is intended to encourage technological and conceptual innovation to improve repeated measures across longer epochs of the lifespan, to better predict outcomes at later ages. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.
Contact Name	Elizabeth Newman, Ph.D.																		
Contact Telephone	301-480-7937																		
Contact Email	elizabeth.newman@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027																		
Synopsis	The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop new approaches or apply existing approaches in novel ways to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease. Research can include healthy human participants of any age; specific clinical groups such as those with cognitive, motor, or affective regulation challenges; and/or animal research on these domains of function. The studies can focus on longitudinal neuroanatomical or functional changes at any level, including genetics/genomics, single cells, connectomics, neural population activity patterns, and others. This funding opportunity is intended to encourage technological and conceptual innovation to improve repeated measures across longer epochs of the lifespan, to better predict outcomes at later ages. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.																		
114865	Pilot Studies for the Spectrum of Alzheimer’s Disease/Alzheimer’s Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-23-083	18-Oct-2024	650,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Laurie Ryan</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-496-9350</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>ryanl@mail.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>18-Oct-2024</td> </tr> </table>					Contact Name	Laurie Ryan	Contact Telephone	301-496-9350	Contact Email	ryanl@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	18-Oct-2024		
Contact Name	Laurie Ryan																		
Contact Telephone	301-496-9350																		
Contact Email	ryanl@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	18-Oct-2024																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite research grant applications that enable the collection of pilot data to support early stage testing of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.			
108329	Pilot Studies for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-21-360	18-Oct-2024	650,000 USD
	Contact Name	Laurie Ryan			
	Contact Telephone	301-496-9350			
	Contact Email	ryanl@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	18-Oct-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite research grant applications that enable the collection of pilot data to support early stage testing of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.			
108054	Notice of Special Interest (NOSI): Research on Pain, Pain Management, and Opioids in Aging	National Institute on Aging/NIH/DHHS	NOT-AG-22-004	08-Aug-2024	Not Specified
	Contact Name	Devon Oskvig, Ph.D.			
	Contact Telephone	301-827-5899			
	Contact Email	devon.oskvig@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Aug-2024 , 05-Sep-2024 , 07-Sep-2024 , 25-Sep-2024 , 12-Oct-2024 , 25-Oct-2024 , 05-Jan-2025 , 08-Dec-2025			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to highlight that the National Institute on Aging (NIA) is interested in			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	receiving grant applications focused on pain, pain management, and opioids related to aging or older adults and within NIA's mission areas. This NOSI invites research applications that focus on improving the understanding of mechanisms underlying pain experience with aging; enhancing assessment, prevention, and management strategies for pain in older adults; and improving health equity of aging populations suffering with pain. New applications, resubmissions, competing renewals, and competing revisions to existing awards are all encouraged through this NOSI. For administrative supplements focused on pain, pain management, and opioids related to aging or older adults and within NIA's mission areas, please see NOT-AG-22-005.				
120970	Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	PAR-23-274	21-Oct-2024	Not Specified
	<p>Contact Name Akanni Clarke</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email akanni.clarke@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Oct-2024 , 21-Feb-2025 , 23-Jun-2025 , 20-Oct-2025 , 20-Feb-2026 , 22-Jun-2026 , 19-Oct-2026</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and AD-related dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum, from pre-symptomatic to more severe stages of disease. This NOFO uses a phased award activity code. Applications must include prespecified, go/no-go safety and tolerability milestones that must be met to advance from phase 1 to latter stages of clinical development.</p>				
126483	RFA-AG-25-003 -- Research Collaboration Network in Structural Racism Measurement and Modeling (U24 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	RFA-AG-25-003	17-Sep-2024 [Optional][LOI/Pre-App]	5,000,000 USD
	<p>Contact Name Frank Bandiera, PhD</p> <p>Contact Telephone 301-402-7629</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email frank.bandiera@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Sep-2024 [Optional][LOI/Pre-App], 17-Oct-2024</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites applications to form an interdisciplinary network of scholars from a variety of disciplines to collaborate with each other in the measurement and modeling of structural racism to facilitate research on life course health and aging. Applicants should propose activities that include the following: Expansion of structural racism measures and methods through input from the broader research community and development of a publicly available data repository for use by researchers, community members, and policy makers through a data portal to facilitate research on life course health and aging. Support of activities that bring together scholars in the behavioral/sciences, humanities, education, political science, and the public health sciences to improve measurement and methods for the study of structural racism in life course health and aging research. Engagement with national and international scientific organizations to promote further advances in measurement and methods of structural racism in research on life course health and aging. Pilot projects on measurement and methods of structural racism in life course health and aging research, incorporating interdisciplinary approaches from the behavioral/social sciences, humanities, education, and political science with the public health sciences. Collaboration with NIA Centers and other NIA research networks on measurement and methods for the study of structural racism. Serving as a central resource for the organization of meetings and other educational activities (e.g., intensive summer institutes, series of workshops, advanced seminars on methodology, or short-term residential opportunities) on measures and methods of structural racism for aging research.</p>				
117878	<p>Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)</p>	National Institute on Aging/NIH/DHHS	PAR-23-179	16-Oct-2024	200,000 USD
	<p>Contact Name Luci Roberts, Ph.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email roberlu@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026</p> <p>Synopsis This Small Research Grant Program (R03) will support meritorious projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this NOFO will support projects covering a wide range of topics related to AD/ADRD. The</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>overall goal of this NOFO is (i) to encourage the next generation of researchers to pursue research and academic careers in AD/ADRD research; and (ii) to stimulate established researchers who have not had a major award in AD/ADRD research to perform pilot studies to develop new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from diverse backgrounds, including those from underrepresented groups are always encouraged to apply for NIH support. Investigators who have not successfully competed for an award under this or prior versions of this announcement are specifically encouraged to apply.</p>			
124754	New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-24-161	16-Oct-2024	400,000 USD
	Contact Name	Elizabeth Newman, Ph.D.			
	Contact Telephone	301-480-7937			
	Contact Email	elizabeth.newman@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027			
	Synopsis	<p>The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop exploratory, highly novel new approaches, or innovative applications of existing approaches, to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease, by improving repeated measures across longer epochs of the lifespan to better predict outcomes at later ages. Research can include healthy human participants of any age; specific clinical groups such those with cognitive, motor, or affective regulation challenges; and/or animal research on these domains of function. The studies can focus on longitudinal neuroanatomical or functional changes at any level, including genetics/genomics, single cells, connectomics, neural population activity patterns, and others. This funding opportunity is intended to encourage technological and conceptual innovation through this high risk, high reward funding mechanism to develop highly innovative ideas that either lack preliminary data or need additional preliminary data. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>			
126831	RFA-AG-25-011--Early and Late Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Related Dementias and Age-Related	National Institute on Aging/NIH/DHHS	RFA-AG-25-011	17-Oct-2024	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[Cognitive Decline \(R01 Clinical Trial Optional\)](#)

Contact Name	Laurie Ryan
Contact Telephone	301-496-9350
Contact Email	ryanl@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-Oct-2024
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to 1) invite applications that propose to develop and implement early- to late-stage clinical trials of promising pharmacological and non-pharmacological interventions to prevent and/or treat the cognitive, behavioral, and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD), and 2) stimulate studies to enhance trial design and methods.

126832	RFA-AG-25-010--Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	RFA-AG-25-010	17-Oct-2024	Not Specified
--------	--	--------------------------------------	---------------	-------------	---------------

Contact Name	Laurie Ryan, Ph.D.
Contact Telephone	301-496-9350
Contact Email	ryanl@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-Oct-2024
Synopsis	This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.

113465	Notice of Special Interest (NOSI): Development of Radiotracers for Diagnosis and Clinical Studies in Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)	National Institute on Aging/NIH/DHHS	NOT-AG-22-032	05-Sep-2024	Not Specified
--------	---	--------------------------------------	---------------	-------------	---------------

Contact Name	Lorenzo M. Refolo, Ph.D.
Contact Telephone	301-594-7576

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email refolol@nia.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 05-Sep-2025</p> <p>Synopsis This Notice of Special Interest (NOSI) invites applications for research grants that propose to develop radiotracers for Positron Emission Tomography (PET) for use in Alzheimer's disease (AD) and AD-related dementias (ADRD) research targeting new and/or emerging biological process or molecular pathways that have been shown to be relevant in the etiology and pathophysiology of neurodegeneration.</p>				
126974	RFA-AG-25-020 -- Claude D. Pepper Older Americans Independence Centers (P30 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	RFA-AG-25-020	11-Sep-2024 [Optional][LOI/Pre-App]	4,625,000 USD
	<p>Contact Name Basil Eldadah, MD, PhD</p> <p>Contact Telephone 301-496-6761</p> <p>Contact Email eldadahb@nia.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Sep-2024 [Optional][LOI/Pre-App], 11-Oct-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for the Claude D. Pepper Older Americans Independence Centers (OAICs) award. The goal of the OAIC program is to establish centers of excellence in geriatrics research and research education to increase scientific knowledge leading to better ways to maintain or restore independence in older persons. OAIC awards are designed to develop or strengthen programs that focus on, and sustain progress in, a key area of aging research related to the mission of the OAIC program.</p>				
108048	NIA Renewal and Revision Cooperative Agreements in AD/ADRD Research (U54 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-22-077	17-Oct-2024	Not Specified
	<p>Contact Name Suzana Petanceska, Ph.D.</p> <p>Contact Telephone 301-594-7754</p> <p>Contact Email petanceskas@nia.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Oct-2024 , 14-Feb-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) allows for renewal and competing revision applications, and their resubmissions, for funded U54 Specialized Center cooperative agreements that support large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD). It is anticipated that such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions, and will address one or more AD/ADRD implementation research milestones supporting the research goals of the National Plan to Address Alzheimer’s and Related Dementias.</p>				
127244	<p>RFA-AG-25-023 -- Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R21 Clinical Trial Not Allowed)</p>	National Institute on Aging/NIH/DHHS	RFA-AG-25-023	01-Oct-2024 [Optional][LOI/Pre-App]	400,000 USD
	<p>Contact Name Alison Yao, Ph.D.</p> <p>Contact Telephone 301-827-7264</p> <p>Contact Email yaoal@nia.nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024 [Optional][LOI/Pre-App], 01-Nov-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to catalyze innovative research to elucidate the molecular landscape and functional implications of RNA modifications in brain aging and Alzheimer's disease (AD) and AD-related dementias (ADRD). AD-related dementias include Lewy body dementia (LBD), frontotemporal dementia (FTD), vascular cognitive impairment/dementia (VCI/D), and mixed dementias. This NOFO supports exploratory and developmental grant (R21) applications focused on uncovering novel mechanisms underlying RNA modification-mediated processes and their impact on brain aging and the pathogenesis of AD/ADRD. Proposed studies should focus on functional characterization and mechanistic investigation of previously identified RNA modifications.</p>				
127243	<p>RFA-AG-25-021 -- Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) (R03 Clinical Trial Optional)</p>	National Institute on Aging/NIH/DHHS	RFA-AG-25-021	01-Oct-2024 [Optional][LOI/Pre-App]	250,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email niagemsstar@mail.nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024 [Optional][LOI/Pre-App], 01-Nov-2024</p> <p>Synopsis The goal of the Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) program is to provide support for early-career physician-scientists trained in medical or surgical specialties and early-career dentist-scientists to launch careers as future leaders in aging- or geriatric-focused research. In support of the program's goal, this GEMSSTAR notice of funding opportunity (NOFO) invites applications that propose to conduct transdisciplinary aging research that will yield pilot data and experience for subsequent aging research projects. The GEMSSTAR program encourages candidates to seek out a supportive research environment to achieve the program's goal of fostering the development of early-career physician- and dentist-scientists in aging- or geriatric-focused research, particularly as it applies to their clinical specialty/discipline. Toward this end, GEMSSTAR candidates should include a Professional Development Plan that reflects this supportive research environment. In selecting GEMSSTAR awardees, the National Institute on Aging (NIA) will consider the extent to which a candidate's environment is supportive of aging- or geriatric-focused research.</p>				
122532	Aging Research Dissertation Awards to Promote Diversity (R36 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-24-052	16-Oct-2024	Not Specified
	<p>Contact Name Jamie Lahvic, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email NIATraining@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024 , 16-Nov-2024 , 16-Feb-2025 , 16-Mar-2025 , 16-Jun-2025 , 16-Jul-2025 , 16-Oct-2025 , 16-Nov-2025 , 16-Feb-2026 , 16-Mar-2026 , 16-Jun-2026 , 16-Jul-2026 , 16-Oct-2026 , 16-Nov-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites R36 applications to promote diversity in the scientific research workforce engaged in research on aging and aging-related health conditions by providing dissertation awards in all areas of research within NIA's strategic priorities.</p>				
123977	NIA Career Transition Award (K22 Independent Clinical Trial Not Allowed)	National Institute on	PAR-24-	12-Oct-2024	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Aging/NIH/DHHS	120		Specified
	<p>Contact Name Jamie Lahvic, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email NIATraining@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Oct-2024 , 12-Nov-2024 , 12-Feb-2025 , 12-Mar-2025 , 12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2025</p> <p>Synopsis The purpose of the NIA Career Transition Award (CTA) is to facilitate the transition of mentored, postdoctoral researchers to tenure-track or equivalent faculty positions conducting research that advances the mission of NIA. This award does not provide postdoctoral phase funding; therefore, candidates should be prepared to transition to tenure-track or equivalent faculty positions within 12 months after confirmation of a positive funding decision. After transition to an approved faculty position at an extramural institution/organization, the award will provide three years of protected research time through salary and research support. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial.</p>				
127251	<p>RFA-AG-25-022 -- Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)</p>	National Institute on Aging/NIH/DHHS	RFA-AG-25-022	01-Oct-2024 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name Alison Yao, Ph.D.</p> <p>Contact Telephone 301-827-7264</p> <p>Contact Email yaoal@nia.nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024 [Optional][LOI/Pre-App], 01-Nov-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to catalyze innovative research to elucidate the molecular landscape and functional implications of RNA modifications in brain aging and Alzheimer's disease (AD) and AD-related dementias (ADRD). AD-related dementias include Lewy body dementia (LBD), frontotemporal dementia (FTD), vascular cognitive impairment/dementia (VCI/D), and mixed dementias. This NOFO supports applications focused on uncovering novel mechanisms underlying RNA modification-mediated processes and their impact on brain aging and the pathogenesis and progression of AD/ADRD. The ultimate goal is to identify targets for biomarker discovery and drug development for</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
				AD/ADRD.	
127271	RFA-AG-25-029 -- Short Courses on Utilizing the NIH Stage Model to Develop Behavioral Interventions to Promote Healthy Aging (R25 - Independent Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-25-029	06-Sep-2024 [Optional][LOI/Pre-App]	1,750,000 USD
	<p>Contact Name Lisa Onken, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email NIATraining@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Sep-2024 [Optional][LOI/Pre-App], 08-Oct-2024</p> <p>Synopsis</p>	<p>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications. To accomplish the stated over-arching goal, this Notice of Funding Opportunity (NOFO) will support educational activities with a primary focus on: Courses for Skills Development The purpose of this NOFO is to invite applications that propose the creation of short courses on utilizing the NIH Stage Model to develop behavioral interventions to promote healthy aging and prevent illness, improve care, foster disease management, assist with end of life decision-making and care, and support the needs of the growing older adult population. The term behavioral intervention is used broadly here, to include a variety of non-pharmacological interventions for individuals, dyads, families, groups, communities, organizations, and systems. The NIH Stage Model is a conceptual framework of behavioral intervention development composed of the following six stages: Stage 0 - Basic science Stage I - Intervention generation, refinement, modification, and adaptation and pilot testing Stage II - Traditional efficacy testing (Stage II) Stage III - Efficacy testing with real-world providers (Stage III); Stage IV - Effectiveness research Stage V - Dissemination and implementation research The goal of the NIH Stage Model is to produce potent, scalable, and culturally competent behavioral interventions that are defined by their mechanism(s) of behavior change (MoBC(s); therefore, examination of MoBC is encouraged in every stage of intervention development. The Model can be used for the development of single or multi-component interventions and for interventions meant for individuals, dyads, groups, communities, organizations, or systems. This NOFO supports the development, delivery, and evaluation of a short-course curriculum to equip investigators to apply the NIH Stage Model to intervention development research.</p>			
125752	RFA-AA-24-008 -- Comprehensive Alcohol Research Centers (P60 Clinical trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-24-008	15-Oct-2024 [Optional][LOI/Pre-	6,250,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

App]

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Gregory Bloss, M.A. 301-443-3865 Gregory.Bloss@nih.gov Link to program URL 15-Oct-2024 [Optional][LOI/Pre-App], 15-Nov-2024 Synopsis This Notice of Funding Opportunity (NOFO) invites applications for Comprehensive Alcohol Research Centers using the P60 mechanism which requires a dissemination core to initiate and expand community education related to the activities of the center. The overall purpose of the NIAAA Alcohol Research Center program is to provide leadership in conducting and fostering interdisciplinary, collaborative research on a wide variety of topics relevant to the Institute’s mission. These topics include, but are not limited to: the nature, etiology, genetics, epigenetics, diagnosis, epidemiology, treatment, and prevention of alcohol misuse, alcohol use disorder, alcohol-related end organ diseases and their biomedical, neurochemical, behavioral, psychosocial, and economic consequences across the lifespan and impacting racial and ethnic minority groups and other NIH-designated populations that experience health disparities. Centers also are regional or national resources that contribute to the development of new research methods, technologies and approaches that sustain innovative goal-directed research.
--	--

125740	RFA-AA-24-007 -- Specialized Alcohol Research Centers (P50 Clinical trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-24-007	15-Oct-2024 [Optional][LOI/Pre-App]	5,750,000 USD
--------	---	---	---------------	-------------------------------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Gregory Bloss, M.A. 301-443-3865 Gregory.Bloss@nih.gov Link to program URL 15-Oct-2024 [Optional][LOI/Pre-App], 15-Nov-2024 Synopsis The National Institute on Alcohol Abuse and Alcoholism (NIAAA) supports a broad-based Alcohol Research Centers program to foster and conduct interdisciplinary, collaborative research on Alcohol Use Disorder (AUD), alcohol misuse and alcohol related problems, and other health related consequences across the lifespan. The NIAAA Centers Program provides
--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>leadership in research, and research methodology development on a wide variety of topics relevant to the Institute’s mission. Topics include, but are not limited to, the nature, etiology, genetics, diagnosis, treatment, and prevention of AUD, alcohol-related end organ diseases and their biomedical, psychosocial, and economic consequences across the lifespan and minority health and NIH-designated populations that experience health disparities. Centers are also major contributors to the development of research methods, technologies, and approaches that sustain innovative goal-directed research.</p>				
120716	Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23-250	05-Oct-2024	2,500,000 USD
	<p>Contact Name Brett T. Hagman, Ph.D. Contact Telephone 301-443-0638 Contact Email brett.hagman@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 Synopsis The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.</p>				
120720	Alcohol Health Services Research (R01 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23-251	05-Oct-2024	Not Specified
	<p>Contact Name Laura E. Kwako, Ph.D. Contact Telephone 301-451-8507 Contact Email laura.kwako@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 Synopsis The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.			
120718	Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23-249	16-Oct-2024	450,000 USD
	Contact Name	Brett T. Hagman, Ph.D.			
	Contact Telephone	301-443-0638			
	Contact Email	brett.hagman@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026			
	Synopsis	The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.			
120721	Alcohol Health Services Research (R01 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23-252	16-Oct-2024	450,000 USD
	Contact Name	Laura E. Kwako, Ph.D.			
	Contact Telephone	301-451-8507			
	Contact Email	laura.kwako@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026			
	Synopsis	The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2)			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.			
122636	Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-24-068	16-Oct-2024	Not Specified
	<p>Contact Name William Dunty, PhD</p> <p>Contact Telephone 301-443-7351</p> <p>Contact Email duntyw@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024 , 17-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider NOFO (PAR-24-067, the R34 option).</p>				
124492	RFA-AA-24-006--Model Continuums of Care Initiative (MCCI) to Advance Health Equity and End Health Disparities Among Women and Girls in Racial/Ethnic Minority and Other Underserved Communities (U34 Clinical Trials Required)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-24-006	19-Sep-2024 [Optional][LOI/Pre-App]	600,000 USD
	<p>Contact Name Deidra Roach, M.D.</p> <p>Contact Telephone 301-443-5820</p> <p>Contact Email droach@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 19-Sep-2024 [Optional][LOI/Pre-App], 18-Oct-2024 , 20-Jan-2025 [Optional][LOI/Pre-App], 19-Feb-2025</p> <p>Synopsis The purpose of this NOFO is to support the planning phase of the Model Continuums of Care Initiative (MCCI) to Advance Health Equity and End Health Disparities Among Women and Girls in Racial/Ethnic Minority Communities. MCCI is a multi-ICO dissemination and implementation science initiative to advance racial equity and end health disparities in racial/ethnic minority women and girls of reproductive age. Specifically, the Model Continuums of Care Initiative will apply the latest dissemination and implementation science approaches to significantly reduce the prevalence and impact of multi-morbidity among racial/ethnic minority women and girls of reproductive age at risk and living with mental health disorders, substance use disorders, chronic stress, cardiopulmonary diseases, common metabolic disorders (e.g., diabetes), cancer, and HIV/AIDS. This concept proposes a continuum of care approach that integrates preventive health services, primary care, behavioral health, integrative care, and cardiopulmonary and endocrine specialties to fully address health care needs in each of these domains, and to have maximum impact on the overall health and well-being of racial and ethnic minority and other underserved women and girls. While MCCI is not a maternal health initiative, women and girls ages 15-44 yrs. are centered because it is during the early reproductive period, i.e., adolescence, that multimorbidity typically begins and rapidly progresses, setting the stage for multiple chronic debilitating conditions in later life. Special emphasis will be placed on using stakeholder partnerships, provider training, and infrastructure changes to improve access for subgroups of racial/ethnic minority women and girls who currently have the least access to high quality health care (e.g., racial/ethnic minority women and girls living in low resource settings). Applications that include a partnership between Research Centers in Minority Institutions and other institutions with extensive programs in women's health research are strongly encouraged. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
107782	<p>Notice of Special Interest (NOSI): Epidemiology and Prevention of Alcohol Misuse in Understudied Young Adult Populations; Military, Workforce, and Community College</p>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-22-001	05-Sep-2024	Not Specified
	<p>Contact Name Bradley Kerridge, Ph.D.</p> <p>Contact Telephone 301-827-7493</p> <p>Contact Email bradley.kerridge@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this future grant application solicitation is to balance the NIAAA research portfolio by supporting research on alcohol misuse among persons aged 18 to 29 who are not enrolled in four-year colleges or universities. These persons are commonly in the military, workforce, or community college populations, which are understudied relative to their age peers in four-year colleges. Research on epidemiology, prevention, and screening centered on these understudied populations are all encouraged.			
116584	Notice of Special Interest (NOSI): Advancing mHealth Interventions for Understanding and Preventing Alcohol-Related Domestic Violence	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-23-003	07-Sep-2024	Not Specified
	Contact Name	Robert Freeman, Ph.D.			
	Contact Telephone	301-443-8820			
	Contact Email	rfreeman@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 12-Jun-2026 , 16-Jun-2026 , 07-Sep-2026			
	Synopsis	In light of the documented increases in both alcohol misuse (among some individuals) and domestic violence (DV) as a result of the global COVID-19 pandemic and array of mandated restrictions enacted to mitigate COVID spread, the purpose of this grant application solicitation is to announce NIAAA’s interest in addressing the critical need for research related to developing, testing, and intervening proximal to drinking occasions, when risk of DV is elevated, to decrease the likelihood of alcohol consumption at levels sufficient to trigger DV and to provide skills shown to reduce risk of DV perpetration and victimization. In particular, this solicitation seeks to advance the development, feasibility, acceptability, pilot testing, potential efficacy, and implementation of scalable, low resource, and remotely delivered interventions via mobile devices (mHealth) that rely on communication technologies for reducing and preventing alcohol consumption and DV. For this FOA, the term “domestic violence” will extend to child maltreatment (abuse and neglect) and elder abuse, in addition to intimate partner violence (IPV).			
122632	Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-24-067	16-Oct-2024	450,000 USD
	Contact Name	William Dunty, PhD			
	Contact Telephone	301-443-7351			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email duntyw@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. Applicants interested in exploratory phased projects may consider NOFO (PAR-24-068, the R61/R33 option).</p>				
126230	<p>RFA-DC-24-008 -- Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)</p>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC-24-008	11-Sep-2024 [Optional][LOI/Pre-App]	400,000 USD
	<p>Contact Name Holly L. Storkel, Ph.D.</p> <p>Contact Telephone 301-496-5061</p> <p>Contact Email holly.storkel@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Sep-2024 [Optional][LOI/Pre-App], 11-Oct-2024</p> <p>Synopsis NIDCD invites applications for early-stage dissemination and implementation (D&I) research projects in the NIDCD mission areas of hearing, balance, taste, smell, voice, speech, and language.</p>				
122439	<p>RFA-DC-24-004 -- In Vivo High-Resolution Imaging for Inner Ear Visualization (R01 Clinical Trial optional)</p>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC-24-004	01-Oct-2024	2,499,995 USD
	<p>Contact Name Amy Poremba, Ph.D.</p> <p>Contact Telephone 301-997-3152</p> <p>Contact Email amy.poremba@nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024 , 03-Feb-2025</p> <p>Synopsis This funding opportunity aims to support the development of in vivo high-resolution structural and functional imaging technologies for the living human inner ear. Proposed projects should focus on improving the resolution of current imaging techniques or developing new imaging techniques that can visualize inner ear structures in vivo with significantly greater detail and accuracy than currently possible. Both structural and functional aspects, including visualizing dynamic elements are important to the development of new and improved techniques. Projects may also focus on developing new imaging probes or contrast agents that can enhance visualization of the inner ear structures. Research supported in response to this funding opportunity is expected to significantly advance the ability to visualize auditory and vestibular components, such as hair cells, otoliths, membranes, ions, and vasculature, in detail in awake patients in a clinical setting using non-invasive techniques. To achieve this goal, a multidisciplinary team approach that takes advantage of the expertise of each team member is highly encouraged. Studies in humans and intermediate studies in mammalian animal models may be proposed to develop or advance the needed technology. Any intermediate studies must articulate a clear path of the proposed methodology to application in awake humans or define the limitations and the usefulness in anesthetized humans. This notice of funding opportunity announcement (NOFO) also supports investigator initiated low-risk clinical trials addressing the development or improvement of human in vivo structural and functional imaging technologies. Clinical trials must meet ALL the following criteria: meet the budget limits of this NOFO, not require FDA oversight, not be an NIH-defined Phase III Clinical Trial, have low risks to subjects, and intend to gather scientific data/evidence to inform subsequent studies. This NOFO also supports low-risk trials determined to be Basic Experimental Studies with Humans (BESH). These studies fall within the NIH definition of a clinical trial and meet the definition of basic research. It is advisable that only one clinical trial be proposed in each application. High-risk clinical trials not meeting all the criteria above are referred to the companion U01 Cooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (Clinical Trial required) NOFO RFA-DC-24-005.</p>				
122441	RFA-DC-24-005 -- Cooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (U01 Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC-24-005	01-Oct-2024	2,499,995 USD
	<p>Contact Name Amy Poremba, Ph.D.</p> <p>Contact Telephone 301-997-3152</p> <p>Contact Email amy.poremba@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024 , 03-Feb-2025</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p style="margin-left: 20px;">Synopsis</p> <p>This funding opportunity aims to support high risk clinical trials for the development of in vivo high-resolution structural and functional imaging technologies for the living human inner ear. Proposed projects should focus on improving the resolution of current imaging techniques or developing new imaging techniques that can visualize inner ear structures in vivo with significantly greater detail and accuracy than currently possible. Structural and functional aspects, including visualizing dynamic elements, are important to developing new and improved techniques. Projects may also focus on developing new imaging probes or contrast agents that can enhance visualization of the inner ear structures. Research supported in response to this funding opportunity is expected to significantly advance the ability to visualize auditory and vestibular components, such as hair cells, otoliths, membranes, ions, and vasculature, in detail in awake patients in a clinical setting using non-invasive techniques. To achieve this goal, a multidisciplinary team approach that takes advantage of the expertise of each team member is highly encouraged. Studies in humans must be proposed to develop, advance, or test the needed technology. Any intermediate studies must articulate a clear path of the proposed methodology to application in awake humans or define the limitations and the usefulness in anesthetized humans. This funding opportunity supports a cooperative agreement between an NIDCD Project Scientist and an Investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has potentially higher risks to participants. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed per application submitted to this funding opportunity. Low risk clinical trials not meeting any of the criteria above are referred to the companion In Vivo High-Resolution Imaging for Inner Ear Visualization (R01 - Clinical Trial Optional) RFA-DC-24-004. Investigators are strongly encouraged to contact the scientific/research contact, prior to submission, to ensure this is the correct NOFO for their proposed research.</p>				

123925	NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-142	07-Sep-2024	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	riverara@nidcd.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 08-Oct-2024 , 07-Jan-2025 , 10-Feb-2025 , 07-May-2025 , 09-Jun-2025 , 07-Sep-2025 , 08-Oct-2025 , 07-Jan-2026 , 09-Feb-2026 , 07-May-2026 , 08-Jun-2026 , 07-Sep-2026 , 08-Oct-2026 , 07-Jan-2027 , 08-Feb-2027 , 07-May-2027
Synopsis	The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFOs PAR-24-140 and PAR-24-143

123928	NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Clinical Trial Not Allowed)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-143	07-Sep-2024	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	riverara@nidcd.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 08-Oct-2024 , 07-Jan-2025 , 10-Feb-2025 , 07-May-2025 , 09-Jun-2025 , 07-Sep-2025 , 08-Oct-2025 , 07-Jan-2026 , 09-Feb-2026 , 07-May-2026 , 08-Jun-2026 , 07-Sep-2026 , 08-Oct-2026 , 07-Jan-2027 , 08-Feb-2027 , 07-May-2027
Synopsis	The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (NOFO# PAR-24-140 and PAR-24-142).

123922	NIDCD Research Career Enhancement Award for Established Investigators (K18 Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-140	07-Sep-2024	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	riverara@nidcd.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 08-Oct-2024 , 07-Jan-2025 , 10-Feb-2025 , 07-May-2025 , 09-Jun-2025 , 07-Sep-2025 , 08-Oct-2025 , 07-Jan-2026 , 09-Feb-2026 , 07-May-2026 , 08-Jun-2026 , 07-Sep-2026 , 08-Oct-2026 , 07-Jan-2027 , 08-Feb-2027 , 07-May-2027
Synopsis	The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFOs PAR-24-142 and PAR-24-143.

122021	NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-051	07-Sep-2024	2,499,995 USD
--------	---	---	------------	-------------	---------------

Contact Name	Trinh T. Ly, M.D.
Contact Telephone	301-435-4085
Contact Email	trinh.ly@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis: The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This notice of funding opportunity announcement (NOFO) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this NOFO, not require FDA oversight, not an NIH defined Phase III Clinical Trial, have low risks to subjects, and intends to gather scientific data/evidence to inform subsequent studies. This NOFO also supports low risk trials determined to be Basic Science Experimental Studies involving Humans (BESH). These studies fall within the NIH definition of a clinical trial and meet the definition of basic research. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred to companion U01 NOFO, PAR-24-050, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.</p>				
117406	Notice of Special Interest (NOSI): Promoting Language and Communication in Minimally Verbal/Non-Speaking Individuals with Autism	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-23-009	05-Sep-2024	Not Specified
	<p>Contact Name: Holly L. Storkel, Ph.D. Contact Telephone: 301-496-5061 Contact Email: holly.storkel@nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 05-Apr-2026 , 07-May-2026 , 05-Jun-2026 Synopsis: The purpose of this Notice of Special Interest (NOSI) is to encourage applications for research to promote language and communication in autistic individuals who are minimally verbal/non-speaking. Further research is needed to evaluate and tailor existing interventions, develop novel interventions, develop and apply new research designs and methods to intervention efforts, and identify meaningful outcome measures.</p>				
114999	Notice of Special Interest (NOSI): Fundamental Science Research on the Neural Circuits Underlying Sensory Processing	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-23-001	07-Sep-2024	Not Specified
	<p>Contact Name: Merav Sabri, Ph.D. Contact Telephone: 301-827-0908</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email merav.sabri@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The National Institute on Deafness and Other Communication Disorders (NIDCD) is issuing this Notice to highlight priorities from its new strategic plan, in basic and mechanistic research on neural circuits underlying sensory processing in hearing, balance, taste and smell. NIDCD encourages multidisciplinary and innovative projects, from diverse teams, to advance a mechanistic understanding of the behavior of neural circuits at cellular and sub-second temporal resolution by integrating cutting-edge technologies and approaches for recording and modulation of cells and circuits (e.g., electrophysiology, optical imaging, optogenetics, chemogenetics, sonogenetics, magnetogenetics, pharmacologic modulation). Applications are expected to integrate appropriate domains of expertise, including but not limited to biological, chemical and physical sciences, engineering, computational modeling, statistical analysis, and bioethics, as appropriate. Mechanistic human studies and comparative, cross-species projects are highly encouraged.</p>				
117259	Notice of Special Interest (NOSI): Encouraging Women’s Health Research within the NIDCD Mission Areas	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-23-006	07-Sep-2024	Not Specified
	<p>Contact Name Christopher Myers</p> <p>Contact Telephone 301-435-0713</p> <p>Contact Email myersc@nidcd.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 25-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 25-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 25-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 25-Feb-2026 , 07-May-2026</p> <p>Synopsis The National Institute on Deafness and Other Communication Disorders (NIDCD) is issuing this Notice of Special Interest (NOSI) to stimulate research in areas regarding the health of women within the scope of NIDCD’s mission. NIDCD's mission is to conduct and support research and research training in the normal and disordered processes of hearing, balance, taste, smell, voice, speech, and language. As noted in the recently issued 2023–2027 NIDCD Strategic Plan (2023-2027 NIDCD Strategic Plan NIDCD), research projects to improve the health of women covering the lifespan are encouraged across all</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		the NIDCD mission areas. These projects may include biological studies which may incorporate anatomical, structural, hormonal, or genetic aspects, behavioral traits, societal aspects, or healthcare related activities that may benefit a women's quality of life.			
122020	NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-050	28-Oct-2024	Not Specified
	<p>Contact Name Trinh T. Ly, M.D.</p> <p>Contact Telephone 301-435-4085</p> <p>Contact Email trinh.ly@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Oct-2024 , 27-Feb-2025 , 27-Jun-2025 , 28-Oct-2025 , 27-Feb-2026 , 29-Jun-2026 , 27-Oct-2026</p> <p>Synopsis The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting well-designed and well-executed clinical trials. This funding opportunity supports a cooperative agreement between an NIDCD Project Scientist and an Investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has potentially higher risks to participants. Clinical trial applications exceeding the annual direct costs of \$700,000 or more, in certain cases, may also be a criterion for this funding opportunity. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed per application submitted to this funding opportunity. Low risk clinical trials not meeting any of the criteria above are referred to the companion NIDCD Low Risk Clinical Trials in Communication Disorders (R01-Clinical Trial Required) PAR-24-051. Investigators are strongly encouraged to contact Dr. Trinh Ly, prior to submission, to ensure this is the correct NOFO for their proposed research.</p>				
123134	RFA-DC-24-007 -- NIDCD Research Opportunities for New Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC-24-007	28-Oct-2024	2,495,000 USD
	<p>Contact Name Kelly King, Au.D., Ph.D.</p> <p>Contact Telephone 301-402-3458</p> <p>Contact Email kingke@nidcd.nih.gov</p> <p>Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Oct-2024 , 06-Feb-2025</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Institute on Deafness and Other Communication Disorders (NIDCD). This program is intended to support Early Stage and New Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences. Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIH's Interest in Diversity), are encouraged to work with their institutions to apply. Preliminary data are not required for this NOFO.</p>				
124315	NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-119	17-Oct-2024	375,000 USD
	<p>Contact Name Bracie Watson, Jr.</p> <p>Contact Telephone 301-402-3458</p> <p>Contact Email watsonb@nidcd.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Oct-2024 , 19-Feb-2025 , 17-Jun-2025 , 17-Oct-2025 , 18-Feb-2026 , 17-Jun-2026 , 19-Oct-2026 , 17-Feb-2027</p> <p>Synopsis The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.</p>				
124298	NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-150	07-Sep-2024	315,000 USD
	Contact Name Alberto L. Rivera-Rentas, Ph.D.				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-1804</p> <p>Contact Email riverara@nidcd.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 17-Oct-2024 , 07-Jan-2025 , 13-Feb-2025 , 07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 15-Oct-2025 , 07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 15-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-Jan-2027 , 17-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-24-159).</p>				
124297	<p>NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Clinical Trial Required)</p>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-149	07-Sep-2024	315,000 USD
	<p>Contact Name Alberto L. Rivera-Rentas, Ph.D.</p> <p>Contact Telephone 301-496-1804</p> <p>Contact Email riverara@nidcd.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 17-Oct-2024 , 07-Jan-2025 , 13-Feb-2025 , 07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 15-Oct-2025 , 07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 15-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-Jan-2027 , 17-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-085 for Clinical Trial Required or for PAR-21-087 for Independent Basic Experimental Studies with Humans Required..

124299	NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Clinical Trial Not Allowed)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-159	07-Sep-2024	315,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	riverara@nidcd.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 17-Oct-2024 , 07-Jan-2025 , 13-Feb-2025 , 07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 15-Oct-2025 , 07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 15-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-Jan-2027 , 17-Feb-2027 , 07-May-2027
Synopsis	The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFOs (PAR-24-149 and PAR-24-150).

127101	Dissemination and Implementation Research in Communication Disorders Conference (U13 Clinical Trial Not Allowed)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC-24-009	25-Oct-2024 [LOI/Pre-App]	100,000 USD
--------	--	---	---------------	---------------------------	-------------

Contact Name	Holly L. Storkel, Ph.D.
Contact Telephone	301-496-5061
Contact Email	holly.storkel@nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 25-Oct-2024 [LOI/Pre-App], 25-Nov-2024</p> <p>Synopsis NIDCD invites applications to organize and execute an annual conference on dissemination and implementation (D&I) research skills applicable to all NIDCD mission areas, specifically hearing, balance, taste, smell, voice, speech, and language. A conference or scientific meeting is defined as a gathering, symposium, seminar, workshop or any other organized and formal meeting where persons assemble in person or meet virtually to coordinate, exchange, and disseminate information or to explore or clarify a defined subject, problem, or area of knowledge. This is a U13 cooperative agreement conference grant mechanism to support recipient sponsored and directed meetings, conferences, and workshops. Cooperative agreements are an assistance mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, before and after award, scientific or program staff will assist, guide, coordinate, or participate in project activities.</p>				
106846	NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-22-025	09-Oct-2024	7,500,000 USD
	<p>Contact Name Lana Shekim, Ph.D.</p> <p>Contact Telephone 301-496-5061</p> <p>Contact Email shekiml@nidcd.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Oct-2024 , 06-Feb-2025</p> <p>Synopsis The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human communication disorders. For this announcement, Clinical Research is defined as research involving individuals with communication disorders or data/tissues from individuals with a communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of a disease or disorder of hearing, balance, smell, taste, voice, speech, or language. Applications may propose a low risk clinical trial but are not required to (optional).</p>				
122290	RFA-DA-25-022 -- Advancing Technologies to Improve Delivery of Pharmacological, Gene Editing, and other Cargoes for HIV and SUD Mechanistic or Therapeutic Research (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-022	15-Oct-2024 [Optional][LOI/Pre-App]	Not Specified
	Contact Name Kathleen Borgmann, Ph.D.				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 301-594-6561 Contact Email Kahtleen.Borgmann@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 15-Oct-2024 [Optional][LOI/Pre-App], 15-Nov-2024 Synopsis The purpose of this funding opportunity is to develop technologies to improve the delivery of pharmacological, gene editing, or other cargoes for HIV and SUD mechanistic research.				
122217	RFA-DA-25-021 -- Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-021	15-Oct-2024 [Optional][LOI/Pre-App]	Not Specified
	Contact Name Sunila Nair, PhD Contact Telephone 301-827-6832 Contact Email sunila.nair@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 15-Oct-2024 [Optional][LOI/Pre-App], 15-Nov-2024 Synopsis The purpose of this notice of funding opportunity (NOFO) is to solicit applications for research targeted at elucidating the effect of HIV and/or anti-retroviral therapy on the growth, development and functioning of the placenta in pregnant individuals with substance use/misuse, the impact of placental abnormalities on maternal outcomes, and the underlying mechanisms.				
111212	RFA-DA-23-008 -- Stimulants and HIV: Addressing Contemporary and Recurring Epidemics (R61/R33 - Clinical Trial Required)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-008	13-Oct-2024 [Optional][LOI/Pre-App]	Not Specified
	Contact Name Richard A. Jenkins PhD Contact Telephone 301-443-1923 Contact Email jenkinsri@mail.nih.gov Sponsor Website Program URL Link to program URL				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 13-Oct-2024 [Optional][LOI/Pre-App], 12-Nov-2024</p> <p>Synopsis The primary goal of this Funding Opportunity Announcement (FOA) is to support research to improve HIV prevention and care outcomes among people who use stimulants, encompassing a range of stimulant use (from episodic to persistent, methamphetamine and cocaine derivatives), including stimulant use co-occurring with the use of opioids and/or other drugs. Applications responding to this FOA should: (1) implement evidence-based approaches that address the intersection of stimulant use and HIV or (2) develop and test new intervention approaches that can reduce stimulant use, particularly among episodic users, while also reducing HIV risk and/or improving HIV care outcomes. Intervention approaches should be tailored to meet the unique needs of target populations such as patterns of stimulant use, age, race/ethnicity, gender identity, sexual orientation, and co-occurring conditions.</p>				
112875	<p>RFA-DA-23-032 -- NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional)</p>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-032	15-Oct-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Kathy Etz, PhD</p> <p>Contact Telephone 301-402-1749</p> <p>Contact Email ketz@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Oct-2024 [Optional][LOI/Pre-App], 14-Nov-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI). This FOA invites R01 applications to conduct research that will have a major impact in identifying, developing, implementing, or testing strategies to improve outcomes related to substance misuse, with a goal of preventing, reducing, or eliminating disparities in racial and ethnic minority populations in substance use, addiction, and related health consequences, including HIV. Community engaged research can facilitate rapid advances in this scientific area by ensuring relevant research questions with immediate applicability. As such, applications must be submitted by collaborative community partnered investigative teams who will conduct research projects that address issues prioritized by the relevant communities. No preliminary data are required. However, projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce desired outcomes. This FOA solicits applications from minority serving institutions (see Section III. Eligibility).</p>				
112854	<p>RFA-DA-23-013 -- NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research (R01 Clinical Trial Optional)</p>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-013	14-Oct-2024 [Optional][LOI/Pre-App]	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Kathy Etz, PhD</p> <p>Contact Telephone 301-402-1749</p> <p>Contact Email ketz@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Oct-2024 [Optional][LOI/Pre-App], 14-Nov-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI). This FOA invites R01 applications to conduct research that will have a major impact in identifying, developing, implementing, or testing strategies to improve outcomes related to substance misuse, with a goal of preventing, reducing, or eliminating disparities in racial and/or ethnic communities insubstance use, addiction, and related health consequences, including HIV. Community engaged research can facilitate rapid advances in this scientific area by ensuring relevant research questions with immediate applicability. As such, applications must be submitted by collaborative community partnered investigative teams who will conduct research projects that address issues prioritized by the relevant communities. No preliminary data are required. However, projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce desired outcomes. .</p>				
112855	<p>RFA-DA-23-061 -- NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R01 Clinical Trial Optional)</p>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-061	15-Oct-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Sheba K. Dunston, EdD</p> <p>Contact Telephone 301-402-1526</p> <p>Contact Email Sheba.Dunston@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Oct-2024 [Optional][LOI/Pre-App], 14-Nov-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI), with goals that include promoting racial equity in NIDA’s research portfolio. The purpose of this FOA is to stimulate new observational and intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	minority populations affected by persistent HIV disparities. Research that addresses the multiple dimensions of individuals' identity (e.g., race, ethnicity, gender, sexual orientation, gender identity) and social systems as they intersect with one another is encouraged.																		
113590	RFA-DA-23-062 --NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R34 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-062	15-Oct-2024 [Optional][LOI/Pre-App]	450,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Sheba K. Dunston, EdD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-402-1526</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>Sheba.Dunston@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>15-Oct-2024 [Optional][LOI/Pre-App], 14-Nov-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA) is a part of NIDA's Racial Equity Initiative (REI), with goals that include promoting racial equity in NIDA's research portfolio. The purpose of this FOA is to support pilot or feasibility research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities. Research that addresses the multiple dimensions of individuals' identity (e.g., race, ethnicity, gender, sexual orientation, gender identity) and social systems as they intersect with one another is encouraged.</td> </tr> </table>					Contact Name	Sheba K. Dunston, EdD	Contact Telephone	301-402-1526	Contact Email	Sheba.Dunston@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	15-Oct-2024 [Optional][LOI/Pre-App], 14-Nov-2024	Synopsis	This Funding Opportunity Announcement (FOA) is a part of NIDA's Racial Equity Initiative (REI), with goals that include promoting racial equity in NIDA's research portfolio. The purpose of this FOA is to support pilot or feasibility research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities. Research that addresses the multiple dimensions of individuals' identity (e.g., race, ethnicity, gender, sexual orientation, gender identity) and social systems as they intersect with one another is encouraged.
Contact Name	Sheba K. Dunston, EdD																		
Contact Telephone	301-402-1526																		
Contact Email	Sheba.Dunston@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	15-Oct-2024 [Optional][LOI/Pre-App], 14-Nov-2024																		
Synopsis	This Funding Opportunity Announcement (FOA) is a part of NIDA's Racial Equity Initiative (REI), with goals that include promoting racial equity in NIDA's research portfolio. The purpose of this FOA is to support pilot or feasibility research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities. Research that addresses the multiple dimensions of individuals' identity (e.g., race, ethnicity, gender, sexual orientation, gender identity) and social systems as they intersect with one another is encouraged.																		
112861	RFA-DA-23-029 -- NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-029	15-Oct-2024 [Optional][LOI/Pre-App]	2,000,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Vani Pariyadath, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-443-3209</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>vani.pariyadath@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>15-Oct-2024 [Optional][LOI/Pre-App], 14-Nov-2024</td> </tr> </table>					Contact Name	Vani Pariyadath, Ph.D.	Contact Telephone	301-443-3209	Contact Email	vani.pariyadath@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	15-Oct-2024 [Optional][LOI/Pre-App], 14-Nov-2024		
Contact Name	Vani Pariyadath, Ph.D.																		
Contact Telephone	301-443-3209																		
Contact Email	vani.pariyadath@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	15-Oct-2024 [Optional][LOI/Pre-App], 14-Nov-2024																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI) and invites clinical research applications that are exploratory/developmental in nature and seek to parse the complex effects of structural racism and investigate their impact on neurocognition, with an emphasis on reducing SUD risk and informing preventative interventions. This FOA solicits applications from minority serving institutions (see Section III. Eligibility).			
112859	RFA-DA-23-028 -- NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-028	15-Oct-2024 [Optional][LOI/Pre-App]	2,000,000 USD
	Contact Name	Vani Pariyadath, Ph.D.			
	Contact Telephone	301-443-3209			
	Contact Email	vani.pariyadath@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Oct-2024 [Optional][LOI/Pre-App], 14-Nov-2024			
	Synopsis	This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI) and invites clinical research applications that are exploratory/developmental in nature and seek to parse the complex effects of structural racism and investigate their impact on neurocognition, with an emphasis on reducing SUD risk and informing preventative interventions.			
112862	RFA-DA-23-031 -- NIDA REI: Racial Equity Visionary Award Program for Research at Minority Serving Institutions on Substance Use and Racial Equity (DP1 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-031	15-Oct-2024 [Optional][LOI/Pre-App]	3,500,000 USD
	Contact Name	Vani Pariyadath, Ph.D.			
	Contact Telephone	301-443-3209			
	Contact Email	vani.pariyadath@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Oct-2024 [Optional][LOI/Pre-App], 14-Nov-2024			
	Synopsis	This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI), with goals that include promoting racial equity in NIDA’s research portfolio. This announcement invites applications supporting independent, early career or established scholars who self-identify as health equity, health disparities, or social determinants of health			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>experts with the skills to make exceptionally creative contributions to the study of equity for underserved U.S. racial and/or ethnic minority groups that experience poorer outcomes related to substance use and substance use disorders. This award supports transformative, boundary-pushing applications that may be risky or at a stage too early to fare well in the traditional peer review process. This FOA is a limited-competition announcement, open to institutions meeting the eligibility criteria in Section III (below). All institutions are eligible to submit applications for the companion FOA, RFA-DA-23-026.</p>				
112858	RFA-DA-23-026 -- NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-026	15-Oct-2024 [Optional][LOI/Pre-App]	3,500,000 USD
	<p>Contact Name Aria Davis Crump, Sc.D. Contact Telephone 301-435-0881 Contact Email aria.crump@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 15-Oct-2024 [Optional][LOI/Pre-App], 14-Nov-2024 Synopsis This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI), with goals that include promoting racial equity in NIDA’s research portfolio.. This announcement invites applications supporting independent, early career or established scholars who self-identify as health equity, health disparities, or social determinants of health experts with the skills to make exceptionally creative contributions to the study of equity for underserved U.S. racial and/or ethnic minority groups that experience poorer outcomes related to substance use and substance use disorders. This award supports transformative, boundary-pushing applications that may be risky or at a stage too early to fare well in the traditional peer review process.</p>				
122881	RFA-DA-25-010 -- Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R21 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-010	14-Oct-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Shang-Yi Anne Tsai, PhD Contact Telephone 301-827-5842 Contact Email stsai@nih.gov Sponsor Website Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 14-Oct-2024 [Optional][LOI/Pre-App], 14-Nov-2024</p> <p>Synopsis The notice of funding opportunity (NOFO) aims to support studies to expand our knowledge of mechanisms driving autophagy and to identify autophagy pathways that can be exploited to control HIV infection and pathogenesis of comorbidities in the context of addictive substance use. The NOFO invites mechanistic studies and preclinical studies testing effects of compounds known to interfere with autophagy pathways on HIV infection and immune system. All studies must clearly address the intersection between HIV and substance use.</p>				
122876	<p>RFA-DA-25-009 -- Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R01 Clinical Trial Not Allowed)</p>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-009	14-Oct-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Shang-Yi Anne Tsai, PhD</p> <p>Contact Telephone 301-827-5842</p> <p>Contact Email stsai@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Oct-2024 [Optional][LOI/Pre-App], 14-Nov-2024</p> <p>Synopsis The notice of funding opportunity (NOFO) aims to support studies to expand our knowledge of mechanisms driving autophagy and to identify autophagy pathways that can be exploited to control HIV infection and pathogenesis of comorbidities in the context of addictive substance use. The NOFO invites mechanistic studies and preclinical studies testing effects of compounds known to interfere with autophagy pathways on HIV infection and immune system. All studies must clearly address the intersection between HIV and substance use.</p>				
121015	<p>Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)</p>	National Institute on Drug Abuse/NIH/DHHS	PAR-24-027	31-Oct-2024	Not Specified
	<p>Contact Name Heather L. Kimmel, Ph.D.</p> <p>Contact Telephone 301-443-6504</p> <p>Contact Email heather.kimmel@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Oct-2024 , 30-Apr-2025 , 31-Oct-2025 , 30-Apr-2026 , 30-Oct-2026</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The Population Assessment of Tobacco and Health (PATH) Study provides the scientific community with biospecimens (urine, plasma, serum, and genomic DNA) and related research data on behaviors, attitudes, biomarkers and health outcomes associated with tobacco use in the U.S. This notice of funding opportunity (NOFO) allows investigators to apply for access to the biospecimens from the PATH Study. Information about the PATH Study and this resource may be found on the at the University of Michigan’s National Addiction & HIV Data Archive Program (NAHDAP) website, part of the Inter-University Consortium for Political and Social Research’s (ICPSR) website (https://nida.nih.gov/research/nida-research-programs-activities/population-assessment-tobacco-health-path-study/data-access).</p>			
124661	RFA-DA-25-005 --Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R21 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-005	13-Oct-2024 [Optional][LOI/Pre-App]	400,000 USD
	Contact Name	Kiran Vemuri, Ph.D.			
	Contact Telephone	301-435-4446			
	Contact Email	kiran.vemuri@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	13-Oct-2024 [Optional][LOI/Pre-App], 13-Nov-2024			
	Synopsis	<p>The purpose of this notice of funding opportunity (NOFO) is to support research towards identifying and characterizing neuroimmune networks, communication pathways, and targets that reside within neuroimmune axes, in the context of HIV and substance use. This NOFO will also support research on the discovery of novel modulatory probes/tools that can advance our knowledge of the regulatory mechanisms by which neuroimmune interactions contribute to HIV and substance use disorder comorbidity. Exploratory projects are appropriate for this NOFO. Applicants with projects testing a fully conceptualized premise founded with adequate preliminary data should consider applying to the companion R01 announcement RFA-DA-25-004.</p>			
124658	RFA-DA-25-004 --Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-004	13-Oct-2024 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Kiran Vemuri, Ph.D.			
	Contact Telephone	301-435-4446			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email kiran.vemuri@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Oct-2024 [Optional][LOI/Pre-App], 13-Nov-2024</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support research towards identifying and characterizing neuroimmune networks, communication pathways, and targets that reside within neuroimmune axes, in the context of HIV and substance use. This NOFO will also support research on the discovery of novel modulatory probes/tools that can advance our knowledge of the regulatory mechanisms by which neuroimmune interactions contribute to HIV and substance use disorder comorbidity. Applications testing a fully conceptualized premise founded with adequate preliminary data are appropriate for this NOFO. Exploratory research projects should consider applying to the companion R21 announcement RFA-DA-25-005.</p>				
126229	<p>RFA-DA-25-056 -- Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics (U54 Clinical Trials Not Allowed)</p>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-056	13-Oct-2024 [Optional][LOI/Pre-App]	9,500,000 USD
	<p>Contact Name Tam Nguyen, Ph.D.</p> <p>Contact Telephone 301-451-1203</p> <p>Contact Email tam.nguyen@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Oct-2024 [Optional][LOI/Pre-App], 13-Nov-2024</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to establish a Center that educates and mentors researchers in formal product development for new substance use disorder (SUD) pharmacotherapeutics and to advance the best concepts through initial experiments via technical and financial support.</p>				
126209	<p>RFA-DA-24-040 -- BRAIN Initiative: Brain-Behavior Quantification and Synchronization – Transformative and Integrative Models of Behavior at the Organismal Level (U01 Clinical Trial Optional)</p>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-24-040	10-Sep-2024 [Optional][LOI/Pre-App]	8,000,000 USD
	<p>Contact Name Holly Moore, PhD</p> <p>Contact Telephone 301-827-7376</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email holly.moore@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Sep-2024 [Optional][LOI/Pre-App], 09-Oct-2024 , 10-Sep-2025 [Optional][LOI/Pre-App], 09-Oct-2025 , 10-Sep-2026 [Optional][LOI/Pre-App], 09-Oct-2026</p> <p>Synopsis This Brain-Behavior Quantification and Synchronization notice of funding opportunity (NOFO) seeks applications that bring together transdisciplinary teams and aim to 1) develop, validate, and apply cutting-edge tools and methods for minimally invasive, multi-dimensional, high-resolution objective measurement of behavior at the organismal level, with synchronous capture of dynamic environmental data; 2) develop advanced analytic approaches to integrate multidimensional behavioral, neural and environmental data; and 3) develop and test new theoretical and computational models aiming to advance understanding of behavior as a complex dynamic system. Proposed projects are expected to be designed with the capacity to integrate synchronously recorded neural data and/or inform existing models of neurobehavioral function, such as those developed with the support of the NIH BRAIN Initiative. This BRAIN Initiative NOFO is specifically soliciting applications proposing basic research involving human subjects, including observational studies and secondary data analysis, that aims to reveal and understand fundamental principles underlying behavioral function. This NOFO is not intended to stimulate research focused on specific diseases or disorders, nor research limited to the use of non-human animal models. Applications proposing research exclusively in non-human animal models should apply under the companion NOFO, RFA-DA-24-041. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
126211	<p>RFA-DA-24-041 -- BRAIN Initiative: Brain-Behavior Quantification and Synchronization – Transformative and Integrative Models of Behavior at the Organismal Level (U01 Clinical Trials Not Allowed)</p>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-24-041	10-Sep-2024 [Optional][LOI/Pre-App]	8,000,000 USD
	<p>Contact Name Holly Moore, PhD</p> <p>Contact Telephone 301-827-7376</p> <p>Contact Email holly.moore@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Sep-2024 [Optional][LOI/Pre-App], 09-Oct-2024 , 10-Sep-2025 [Optional][LOI/Pre-App], 09-Oct-2025 , 10-Sep-2026 [Optional][LOI/Pre-App], 09-Oct-2026</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	<p>Synopsis This Brain-Behavior Quantification and Synchronization notice of funding opportunity (NOFO) seeks applications using non-human animal models that bring together transdisciplinary teams and aim to 1) develop, validate, and apply cutting-edge tools and methods for minimally invasive, multi-dimensional, high-resolution measurement of behavior at the organismal level, with synchronous capture of data from the dynamic environment of the organism; 2) develop advanced analytic approaches to integrate multidimensional behavioral, neural and environmental data; and 3) develop and test new theoretical and computational models aiming to advance understanding of behavior as a complex dynamic system. Proposed projects are expected to be designed with the capacity to integrate synchronously recorded neural data and/or inform existing models of neurobehavioral function, such as those developed with the support of the NIH BRAIN Initiative. This NOFO is intended for applications using non-human animal models. Applicants proposing research involving humans or use of human subjects data as a significant component should submit under the companion NOFO RFA-DA-24-040. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>					
111673	Notice of Special Interest (NOSI): High Priority Areas in Integrative Neuroscience Branch in the Division of Neuroscience and Behavior		National Institute on Drug Abuse/NIH/DHHS	NOT-DA-22-058	07-Sep-2024	Not Specified
	<p>Contact Name Olivier Berton, Ph.D.</p> <p>Contact Telephone 301-827-7771</p> <p>Contact Email Olivier.berton@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The mission of the Division of Neuroscience and Behavior (DNB) is to facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of substance use and substance use disorders (SUD) across the lifespan and to guide treatment strategies. The Integrative Neuroscience (IN) Branch within DNB supports research on the cellular mechanisms and circuitry that underlie substance use and SUD. Research supported by the Branch covers: 1) the regulation and plasticity of neurotransmitter and neuromodulatory systems induced by chronic or intermittent exposure to, and/or withdrawal from, addictive substances, 2) the study of substance-induced neurotoxicity, 3) neuron-glia interactions and their modification by substance use and SUD 4) neuroendocrine modulation of neural systems in relation to substance use and SUD , and 5) neuroimmune modulation of the brain including the influences of neuroAIDS and substance-</p>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	induced neuroinflammation.				
115450	Notice of Special Interest (NOSI): Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A Jump Into Precision Medicine.	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-001	07-Sep-2024	Not Specified
	Contact Name	Guifang Lao, Ph.D.			
	Contact Telephone	301-827-5931			
	Contact Email	laog@nih.gov			
	Sponsor Website				
	Program URL				
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026			
	Synopsis	NIDA is interested in receiving research proposals focusing on studying pharmacogenomics in PLWH with SUD as a crucial step in the science of Precision Medicine, in the path of personalized care for HIV and drug abuse..			
104862	Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-030	07-Sep-2024	Not Specified
	Contact Name	Yu (Woody) Lin			
	Contact Telephone	301-435-1318			
	Contact Email	ylin1@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Sep-2024 , 25-Sep-2024 , 12-Oct-2024 , 25-Oct-2024 , 07-Jan-2025			
	Synopsis	This Notice of Special Interest [NOSI] is to support computational HIV/AIDS research as it relates to NIDA’s mission through collaborative research between investigators with experimental expertise related to HIV/AIDS and those with computational proficiency, including scientists from statistics, physics, mathematics, engineering, and computer science. The NOSI will support meritorious and innovative research built on well-established computational strategies (theory, models, and methods) to investigate HIV-related neurocognitive deficits and neuropathogenesis in the context of substance use or substance use disorder (SUD). Investigators are expected to have complementary and integrated expertise in their field(s), but an ongoing collaboration or record of co-authorship is not required.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
126763	Combined Neuromodulation and Behavioral Treatment Algorithm Development for Stimulant Use Disorder (StUD) Enriched for Vulnerable Phenotype (U01 Clinical Trial Required)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-057	27-Oct-2024 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name Tanya Ramey</p> <p>Contact Telephone 301-827-5944</p> <p>Contact Email tanya.ramey@nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 27-Oct-2024 [Optional][LOI/Pre-App], 27-Nov-2024</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support the development of neuromodulatory devices with behavioral treatment as a component for Stimulant Use Disorder (StUD). Given the high rates of relapse and poor treatment outcomes in StUD, the objective is to target patients with vulnerable phenotype including those with reported qualitatively high levels of impulsivity, compulsivity, and cognitive dysfunction. Moreover, this NOFO concentrates on advancing treatment modalities combinations: pairing non-invasive neuromodulation (including, but not limited to transcranial magnetic stimulation, transcranial direct current stimulation, vagal stimulation, alternating current stimulation, low-intensity focused ultrasound, and others) with either known efficacious behavioral interventions (e.g., contingency management, cognitive behavioral therapy) or novel treatments. Applications should plan to move devices to their next step in the Food and Drug Administration (FDA) approval process, with the ultimate goal of generating new, FDA-approved device-based treatments and/or combination products for StUD.</p>				
126634	RFA-DA-25-044 -- Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Basic Experimental Studies with Humans Required)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-044	29-Sep-2024 [Optional][LOI/Pre-App]	1,500,000 USD
	<p>Contact Name Sunila Nair, PhD</p> <p>Contact Telephone 301-827-6832</p> <p>Contact Email sunila.nair@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 29-Sep-2024 [Optional][LOI/Pre-App], 29-Oct-2024</p> <p>Synopsis The purpose of this FOA is to support basic science experimental studies involving humans to expand our knowledge of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

the interrelationships between sleep/circadian rhythms and substance use disorders (SUDs). These mechanistic studies will offer insights into the fundamental processes that link SUDs to sleep/circadian rhythms and vice-versa, and may also have implications for managing risks associated with developing SUDs and/or identifying new targets for prevention and therapeutics. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP). Check if this is a PEDP opportunity to include the mandatory PEDP language through out the content. This NOFO is for basic science experimental studies involving humans, referred to in the NIH Grants Policy Statement Section 4.1.3.1 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ NOFO.

126635	RFA-DA-25-045 -- Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Clinical Trials Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-045	29-Sep-2024 [Optional][LOI/Pre-App]	1,500,000 USD
--------	--	---	---------------	-------------------------------------	---------------

Contact Name | Sunila Nair, PhD
 Contact Telephone | 301-827-6832
 Contact Email | sunila.nair@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 29-Sep-2024 [Optional][LOI/Pre-App], 29-Oct-2024

Synopsis | The purpose of this FOA is to support research project applications to expand our knowledge on the basic neurobiology of the interrelationship between sleep/circadian rhythms and substance use disorders (SUDs). These mechanistic studies will offer insights into the fundamental processes that link SUDs to disorders of sleep/circadian rhythms and vice-versa, and may also have implications for managing risks associated with developing SUDs and/or identifying new targets for prevention and therapeutics. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

117589	Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)	National Institute on Drug Abuse/NIH/DHHS	PAR-23-158	09-Oct-2024	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name | Vani Pariyadath, Ph.D.
 Contact Telephone | 301-443-3209

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	vani.pariyadath@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	09-Oct-2024 , 13-Mar-2025 , 20-Jun-2025 , 09-Oct-2025 , 13-Mar-2026
Synopsis	<p>This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. This NOFO is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and studies that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion NOFO - Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) PAR-23-157. For projects not requiring a phased research approach, applicants are encouraged to apply under a different activity code (e.g., PA-20-184 “Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)”).</p>

117587	Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-23-157	09-Oct-2024	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Vani Pariyadath, Ph.D.
Contact Telephone	301-443-3209
Contact Email	vani.pariyadath@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	09-Oct-2024 , 13-Mar-2025 , 20-Jun-2025 , 09-Oct-2025 , 13-Mar-2026
Synopsis	<p>This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. Note: For basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants” please use the companion NOFO - Exploratory Clinical Neuroscience Research</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH)) PAR-23-282 For projects not requiring a phased research approach, applicants are encouraged to apply under a different funding activity code (e.g., PA-20-183 "Research Project Grant (Parent R01 Clinical Trial Required)").</p>				
104182	Notice of Special Interest (NOSI): Advanced Computational Approaches to Elucidate Disease Pathology and Identify Novel Therapeutics for Addiction	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-004	07-Sep-2024	Not Specified
	<p>Contact Name: Susan Wright, Ph.D. Contact Telephone: 301-402-6683 Contact Email: susan.wright@nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 Synopsis: The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse (NIDA) of NIDA's interest in grant applications that will develop or utilize advanced computational approaches to describe complex drug-disease relationships in ways that will rapidly advance the development of new treatments, allow for targeted funding of substance use disorder (SUD) drug discovery and improve health care. NIDA has a particular interest in applications that include approaches in one or more of the following categories: 1) artificial intelligence, including machine learning and deep learning, 2) supercomputing/parallel computing, and/or 3) quantum computing.</p>				
114003	Notice of Special Interest (NOSI): Targeting Epigenetic Regulators for Treating Addiction and Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-004	08-Aug-2024	Not Specified
	<p>Contact Name: Sam Ananthan, Ph.D. Contact Telephone: 301-435-2199 Contact Email: sam.ananthan@nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 08-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 08-Dec-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 08-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 08-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 08-Dec-2025 , 07-Jan-2026</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to inform applicants about NIDA's special interest in innovative research that uses chemical and pharmacological approaches to identify and target epigenetic regulators and mechanisms for the treatment of addiction and substance use disorders.			
114150	Notice of Special Interest (NOSI): Chemsex and HIV: Prevalence, Medical/Psychosocial Consequences, and Treatment	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-002	07-Sep-2024	Not Specified
	Contact Name	Raul Mandler, MD			
	Contact Telephone	240-281-0569			
	Contact Email	mandlerr@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026			
	Synopsis	The purpose of this notice is to support research on the epidemiology, medical/psychosocial impact, and preventive and therapeutic measures for chemsex in people with HIV and HIV-vulnerable populations including sexual minorities (SM) e.g. lesbian, gay, bisexual.			
113995	Notice of Special Interest (NOSI): Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R01, R21, R03)	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-23-012	07-Sep-2024	Not Specified
	Contact Name	Tisha Wiley, Ph.D.			
	Contact Telephone	301-594-4381			
	Contact Email	tisha.wiley@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026			
	Synopsis	The purpose of this Notice is to inform potential applications to the National Institute on Drug Abuse (NIDA) of special interest in grant applications to conduct rigorous health services and economic research to maximize the availability and delivery of efficient, effective drug, alcohol, and tobacco treatment and recovery support services. Examples of such research			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation science; (4) availability, demand, access, and financing; (5) effectiveness; and (6) development or improvement of research methodology, analytic approaches, and measurement instrumentation.

114048	Notice of Special Interest (NOSI): Chemoproteomic Approaches for Discovery of Targets and Therapeutics to Treat Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-005	08-Aug-2024	Not Specified
--------	---	---	---------------	-------------	---------------

	Contact Name	Sam Ananthan, Ph.D.
	Contact Telephone	301-435-2199
	Contact Email	sam.ananthan@nih.gov
	Sponsor Website	
	Program URL	Link to program URL
	Deadline Dates (ALL)	08-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 08-Dec-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 08-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 08-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 08-Dec-2025 , 07-Jan-2026
	Synopsis	The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in supporting basic research on the application of chemoproteomic approaches for the discovery of targets and for development of drugs to treat addiction and substance use disorders.

114151	Notice of Special Interest (NOSI): Chemsex and HIV: Prevalence, Medical/Psychosocial Consequences, and Treatment	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-002	07-Sep-2024	Not Specified
--------	--	---	---------------	-------------	---------------

	Contact Name	Raul Mandler, MD
	Contact Telephone	240-281-0569
	Contact Email	mandlerr@nih.gov
	Sponsor Website	
	Program URL	Link to program URL
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026
	Synopsis	The purpose of this notice is to support research on the epidemiology, medical/psychosocial impact, and preventive and therapeutic measures for chemsex in people with HIV and HIV-vulnerable populations including sexual minorities (SM) e.g.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	lesbian, gay, bisexual.				
117405	Notice of Special Interest (NOSI): Leveraging Glial Cells to Treat Addiction	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-006	07-Sep-2024	Not Specified
	<p>Contact Name Shang-Yi Anne Tsai, Ph.D.</p> <p>Contact Telephone 301-827-5842</p> <p>Contact Email stsai@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 [LOI/Pre-App], 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 12-Jun-2026 , 16-Jun-2026 , 07-Sep-2026</p> <p>Synopsis This Notice of Special Interest (NOSI) encourages studies to exploit the unique properties and functions of glial cells and develop strategies to mitigate Central Nervous System (CNS) damage due to acute or chronic exposure to addictive substances or therapeutic avenues for addiction treatments.</p>				
119295	Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-23-194	07-Sep-2024	100,000 USD
	<p>Contact Name Marsha F. Lopez, Ph.D., M.H.S.</p> <p>Contact Telephone 301-443-6504</p> <p>Contact Email marsha.lopez@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026</p> <p>Synopsis The goal of this Notice of Funding Opportunity (NOFO) is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with the NIDA Strategic Plan (2022-2026 NIDA Strategic Plan Director's Message National Institute on Drug Abuse (NIDA) (nih.gov). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources.
109484	Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance use Prevention and Treatment	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-23-006	07-Sep-2024	Not Specified
	Contact Name	Janet Kuramoto-Crawford, PhD			
	Contact Telephone	301-443-8856			
	Contact Email	janet.kuramoto-crawford@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025			
	Synopsis	This Notice encourages research projects that 1) leverage data science to provide actionable insights for substance use prevention and treatment 2) shorten the time between data capture and data availability so that data are available real-time or near real-time, and 3) explore methods and tools that may allow for faster or better localized responses for substance use treatment and prevention. Priority will be given to projects that emphasize the use of existing data streams (e.g., electronic health records, syndromic surveillance, claims data, registry data, pharmacy dispensing, social media, and mortality records).			
109268	Notice of Special Interest (NOSI): Epidemiology of Drug Abuse	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-22-004	07-Sep-2024	Not Specified
	Contact Name	Marsha Lopez, PhD, MHS			
	Contact Telephone	301-443-6504			
	Contact Email	Marsha.Lopez@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025			
	Synopsis	The purpose of this Notice is to encourage the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across individuals, families, communities, and diverse population groups. Of interest are applications that address multiple levels of			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

risk, resilience, and causation across scientific disciplines, and that apply novel methods to advance knowledge of the interplay among genetic, environmental, neurobiological, and developmental factors and associated health and disease outcomes. Priority will be given to research with a well described path towards translation and/or public health impact. In addition to novel data collection, approaches are encouraged that build on the research investments of NIH and sister HHS agencies to harness existing data on the epidemiology and etiology of drug misuse to improve public health prevention and treatment programs. The research areas noted below should be considered in the context of topics such as health disparities or inequities, familial/genetic liability, and physical, psychiatric, and polysubstance comorbidities and interactions.

127083	RFA-DA-25-037 -- Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA) (U01 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-037	07-Oct-2024 [Optional][LOI/Pre-App]	Not Specified
--------	--	---	---------------	-------------------------------------	---------------

Contact Name	Holly Moore, PhD
Contact Telephone	301-827-7376
Contact Email	holly.moore@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Oct-2024 [Optional][LOI/Pre-App], 07-Nov-2024
Synopsis	The goal of this Notice of Funding Opportunity (NOFO) is to seek applications proposing team-science research projects aimed at longitudinal research designs in animal models and advanced neuroscience and theoretical tools to elucidate mechanisms mediating the impact of the early-life social environment on neurobehavioral development and the risk for substance use disorders (SUD) and their comorbidities in adolescence and adulthood. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

126437	RFA-DA-25-085 -- Translational Resource Centers to Build Bridges Between Substance Use Epidemiology/Etiology and Prevention Intervention Research (U24 Clinical Trials Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-085	13-Oct-2024 [Optional][LOI/Pre-App]	1,400,000 USD
--------	---	---	---------------	-------------------------------------	---------------

Contact Name	Alexa Romberg, PhD
Contact Telephone	301-435-0264
Contact Email	alexa.romberg@nih.gov
Sponsor Website	

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Oct-2024 [Optional][LOI/Pre-App], 13-Nov-2024</p> <p>Synopsis Effective translation and cross-fertilization between research disciplines are long-standing and challenging problems. The purpose of this notice of funding opportunity (NOFO) is to seek innovative applications for Translational Resource Centers that will establish and support multidisciplinary research teams to conduct translational research between the fields of 1) substance use epidemiology and etiology and 2) substance use prevention intervention. Resource centers are expected to conduct activities that bring investigators in these fields together for active collaboration to develop research questions, design study approaches (with either collection of new data or analysis of existing data), and to develop strategies for application of findings from one field into research in the other field. Collaborative activities supported by the Center should have specific goals that lead to concrete products (e.g., publications, grant applications, intervention development or adaptation) and must include a plan for evaluating center success.</p>				
125421	Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-24-110	05-Oct-2024	Not Specified
	<p>Contact Name Arielle S. Gillman, PhD, MPH</p> <p>Contact Telephone 301-435-0060</p> <p>Contact Email arielle.gillman@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027</p> <p>Synopsis The purpose of this initiative is to support non-pharmacological interventions to promote sleep health, reduce sleep health disparities, and examine sleep as a modifiable factor to reduce disparities for other health outcomes among populations that experience health disparities.</p>				
126432	Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 - Clinical Trial Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-24-231	06-Sep-2024 [Optional][LOI/Pre-App]	1,000,000 USD
	Contact Name Crystal L. Barksdale, PhD, MPH				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-827-4288</p> <p>Contact Email crystal.barksdale@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Sep-2024 [Optional][LOI/Pre-App], 05-Oct-2024 , 07-Jan-2025 , 06-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 07-Jan-2026 , 06-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 07-Jan-2027</p> <p>Synopsis The purpose of this initiative is to support research to develop and test community-level interventions to improve minority health and reduce health disparities.</p>				
115679	NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-23-111	07-Sep-2024	275,000 USD
	<p>Contact Name </p> <p>Contact Telephone 301-402-1366</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026</p> <p>Synopsis NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S.</p>				
110301	Notice of Special Interest (NOSI): Administrative Supplements for Research on Women’s Health in the IDeA States	National Institutes of Health/DHHS	NOT-GM-22-005	17-Oct-2024	200,000 USD
	<p>Contact Name Crina Frincu, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email crina.frincu@nih.gov</p> <p>Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL	Link to program URL
Deadline Dates (ALL)	17-Oct-2024
Synopsis	The Office of Research on Women's Health (ORWH) and the National Institute of General Medical Sciences (NIGMS), along with the other participating NIH Institutes, Centers, and Offices (ICOs) announce the availability of administrative supplements to IDeA awards to expand research and research capacity in the IDeA states to address important issues of women's health across the lifespan. The proposed research must be within the scope of the parent grant and must address at least one of the strategic goals of the 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women."

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

112311	CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-209	17-Oct-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Shardell Spriggs, PhD
Contact Telephone	301-443-8189
Contact Email	shardell.spriggs@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-Oct-2024
Synopsis	This Funding Opportunity Announcement (FOA) solicits applications for the early-stage development of therapeutics to mitigate the adverse health effects resulting from toxic chemical exposure. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include specific chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The overall scope of this solicitation includes validation of therapeutic targets and preclinical characterization of lead compounds. The UG3 phase of this FOA supports target validation and characterization of initial lead compound(s); UH3 phase activities include candidate optimization and in vivo demonstration of activity and efficacy in relevant post-exposure models. At the conclusion of the overall UG3/UH3 funding period, projects are expected to deliver at least one well-characterized therapeutic candidate.

118192	RFA-OD-23-017 -- Tobacco Regulatory Science (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-OD-23-017	04-Oct-2024	2,500,000 USD
--------	---	------------------------------------	---------------	-------------	---------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Rachel Grana Mayne, PhD</p> <p>Contact Telephone 240-276-5899</p> <p>Contact Email Rachel.Mayne@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Oct-2024 , 02-May-2025</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this NOFO will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this NOFO are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.</p>				
112989	<p>RFA-DA-23-056 -- Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	RFA-DA-23-056	20-Oct-2024 [Optional][LOI/Pre-App]	900,000 USD
	<p>Contact Name Kiran Vemuri, Ph.D.</p> <p>Contact Telephone 301-435-4446</p> <p>Contact Email kiran.vemuri@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 20-Oct-2024 [Optional][LOI/Pre-App], 19-Nov-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support transformative research to identify and validate mechanisms, signaling pathways, and therapeutic targets, for understanding and reversing the effects of an overdose and the observed toxicities caused by acute Ultra-Potent Synthetic (UPS) opioid exposure. This FOA will also support mechanistic studies of persistent or delayed pathophysiological effects after acute exposure to UPS opioids.</p>				
109762	<p>RFA-HL-23-007 -- Limited Competition: Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38 Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	RFA-HL-23-007	11-Oct-2024	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name David Schopfer, M.D.</p> <p>Contact Telephone 301-402-3833</p> <p>Contact Email david.schopfer@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Oct-2024 , 10-Jan-2025</p> <p>Synopsis The purpose of the Stimulating Access to Research in Residency Transition Scholar (StARRTS) K38 Career Development program is to retain and support clinician investigators who have successfully completed the Stimulating Access to Research in Residency (StARR) R38 Program (RFA-HL-18-023 or RFA-HL-23-006) as resident-investigators. Individuals who are awarded K38 grants described in this FOA will be referred to as Transition Scholars. The intent of this FOA is to provide Transition Scholars with opportunities for additional research and career development during subsequent clinical fellowship or early career faculty appointments (as defined in Section III. 3. Additional Information on Eligibility). It is anticipated that the StARRTS K38 program will provide a pathway to retain the newly-created pool of clinician-investigators generated through the StARR R38 program. Transition Scholar grantees will receive support for continued research and career development opportunities in basic, clinical and/or translational research thereby providing enhanced potential to accelerate the transition to independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p>				
121524	<p>RFA-DA-24-067 -- HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R01 Clinical Trial Optional)</p>	National Institutes of Health/DHHS	RFA-DA-24-067	17-Sep-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Amy B. Goldstein, PhD</p> <p>Contact Telephone 301-827-4124</p> <p>Contact Email amy.goldstein@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Sep-2024 [Optional][LOI/Pre-App], 17-Oct-2024 , 18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025 , 17-Dec-2025 [Optional][LOI/Pre-App], 16-Jan-2026</p> <p>Synopsis Despite an evidence base of effective programs to prevent the initiation of substance use, misuse and disorder, a substantial</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>research to practice gap exists. The goal of this initiative is to support projects that fill this research to practice gap, improving public health and responding to the opioid crisis by increasing knowledge pertaining to the delivery of prevention services. This notice of funding opportunity (NOFO) solicits applications to address understudied areas of opportunity that, if researched, could create the foundation needed to inform a prevention infrastructure for ongoing delivery and sustainment of interventions to prevent opioid and other substance misuse and use disorders. This NOFO invites projects for which preliminary or feasibility data is available. This NOFO is a companion to RFA-DA-24-066 which solicits applications for which pilot data is unavailable.</p>				
121525	RFA-DA-24-066 -- HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R61/R33 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-DA-24-066	17-Sep-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Amy B. Goldstein, PhD Contact Telephone 301-827-4124 Contact Email amy.goldstein@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 17-Sep-2024 [Optional][LOI/Pre-App], 17-Oct-2024 , 18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025 , 17-Dec-2025 [Optional][LOI/Pre-App], 16-Jan-2026 Synopsis Despite an evidence base of effective programs to prevent the initiation of substance use, misuse and disorder, a substantial research to practice gap exists. The goal of this initiative is to support projects that fill this research to practice gap, improving public health and responding to the opioid crisis by increasing knowledge pertaining to the delivery of prevention services. This notice of funding opportunity (NOFO) solicits applications to address understudied areas of opportunity that, if researched, could create the foundation needed to inform a prevention infrastructure for ongoing delivery and sustainment of interventions to prevent opioid and other substance misuse and use disorders. This NOFO invites projects for which preliminary or feasibility data is not available. This NOFO is a companion to RFA-DA-24-067 which solicits applications for which pilot data is available.</p>				
115551	Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 - Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-112	09-Oct-2024	2,500,000 USD
	<p>Contact Name Jennifer Alvidrez, PhD Contact Telephone 301-594-9567 Contact Email jennifer.alvidrez@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 09-Oct-2024 , 07-Jan-2025 , 09-Oct-2025 , 07-Jan-2026 Synopsis This initiative will support intervention research that addresses structural racism and discrimination (SRD) in order to improve minority health or reduce health disparities.				
125252	Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01 - Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-24-198	04-Oct-2024	2,500,000 USD
	Contact Name Francesca Bosetti, PhD Contact Telephone 301-496-1431 Contact Email Francesca.Bosetti@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 04-Oct-2024 Synopsis This notice of funding opportunity (NOFO) will support mechanistic investigations to better understand the cellular and molecular mechanisms that underlie brain blood vessels responses to passive anti-beta-amyloid immunotherapy that result in amyloid-related imaging abnormalities (ARIA). The goal is to establish an understanding of molecular mechanisms that can be targeted to protect the BBB, and thus the brain blood vessels, during therapeutic interventions that target beta-amyloid.				
120775	NIH Brain Development Cohorts (NBDC) Biospecimen Access (X01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-23-229	06-Oct-2024	Not Specified
	Contact Name Kimberly LeBlanc, Ph.D Contact Telephone 301-827-4102 Contact Email kimberly.leblanc@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 06-Oct-2024 , 06-Feb-2025 , 05-May-2025 , 07-Oct-2025 , 06-Feb-2026 , 05-May-2026 Synopsis The Adolescent Brain Cognitive DevelopmentSM (ABCD) Study is the largest longitudinal study of brain development and child health in the U.S., collecting data from more than 11,000 children across the country beginning when they were 9-10 years old and continuing for a decade. In addition to behavioral assessments, youth undergo neuroimaging and provide				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>biospecimens, including oral fluids for hormone analysis, urine and hair for substance use and exposure, deciduous teeth for environmental exposures, and blood for genetic analysis and metabolic and hematologic assays. This initiative allows investigators to apply for access to biological samples from the ABCD Study®. More information about the ABCD Study can be found on the NIDA ABCD Study web page. Additional information about this resource is available on the NIDA funding opportunities page, under Supplemental Information for NOFOs. ABCD Study biospecimens are managed through the NIH Brain Development Cohorts (NBDC) Biorepository and Analysis Center, which offers a web portal with services related to biospecimen access. Visit the NBDC portal to query available samples using the Biospecimen Explorer, submit a Biospecimen Availability Inquiry to determine the resource availability and impact on existing samples, and learn more about this resource.</p>				
117936	RFA-NS-23-023 -- BRAIN Initiative: Targeted BRAIN Circuits Planning Projects – TargetedBCPP (R34 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	RFA-NS-23-023	02-Sep-2024 [Optional][LOI/Pre-App]	450,000 USD
	<p>Contact Name Karen K David, PhD Contact Telephone 301-496-9964 Contact Email BRAINcircuits@NIH.GOV Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 02-Sep-2024 [Optional][LOI/Pre-App], 02-Oct-2024 Synopsis This R34 FOA solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects - TargetedBCP R01, as described in the companion FOA (RFA-NS-23-024). Applications should be adventurous, exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior.</p>				
122567	Notice of Special Interest (NOSI): Administrative Supplements to Support Addiction Science and Related Neuroscience Pilot Research Projects at NIMHD-Funded Research Centers in Minority Institutions	National Institutes of Health/DHHS	NOT-MD-23-019	17-Oct-2024	Not Specified
	<p>Contact Name Arundhati Gogineni, PhD Contact Telephone 301-427-9545 Contact Email arundhati.gogineni@nih.gov Sponsor Website Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 17-Oct-2024 , 17-Jan-2025 , 17-Apr-2025 , 17-Oct-2025 , 17-Jan-2026 , 17-Apr-2026</p> <p>Synopsis This Notice of Special Interest (NOSI) invites applications for administrative supplements to NIMHD Research Centers in Minority Institutions (RCMI) U54 awards to support pilot research projects led by early-stage investigators (ESIs) and new investigators (NIs) focused on research on substance use, addiction, and/or neuroscience, as a bridge to independently funded careers. It is expected that pilot project PIs will work with their institutions to prepare and submit follow-up research grant or career development applications to NIH based on the research supported by these supplemental funds.</p>				
125296	Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-24-203	04-Sep-2024 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name William Daley, Ph.D.</p> <p>Contact Telephone 301-496-1431</p> <p>Contact Email william.daley@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Sep-2024 [Optional][LOI/Pre-App], 04-Oct-2024</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) is to solicit applications that propose studies in animal, cell culture, and/or human tissue models to elucidate the mechanisms by which COVID-19 interacts with and/or modulates ADRD-relevant phenotypes. The NOFO intends to support studies that are disease mechanistic in nature and must incorporate ADRD outcomes, risk factors, pathologies, or relevant comorbidities.</p>				
117665	Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-23-159	17-Oct-2024	275,000 USD
	<p>Contact Name Alice Chen Grady, M.D.</p> <p>Contact Telephone 301-827-2015</p> <p>Contact Email alice.chen2@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Oct-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.
117667	Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-23-160	17-Oct-2024	100,000 USD
	Contact Name	Alice Chen Grady, M.D.			
	Contact Telephone	301-827-2015			
	Contact Email	alice.chen2@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	17-Oct-2024			
	Synopsis	This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.			
112756	RFA-DA-23-054 -- HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-DA-23-054	16-Sep-2024 [Optional][LOI/Pre-App]	3,750,000 USD
	Contact Name	Carrie Mulford, Ph.D.			
	Contact Telephone	301827-6473			
	Contact Email	carrie.mulford@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Sep-2024 [Optional][LOI/Pre-App], 17-Oct-2024 , 19-Feb-2025 [Optional][LOI/Pre-App], 20-Mar-2025			
	Synopsis	The goal of this initiative is to support action-oriented research that accelerates the translation of research to practice to address the overdose crisis. There remains an urgent need for research that advances the design of stigma-free patient-			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>centered systems of care such that people who experience addiction can recover and sustain their recovery over the long-term. This Funding Opportunity Announcement (FOA) solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels. Projects should be in alignment with the overall goals of the HEAL Initiative, and should focus on replicable, scalable, equitable approaches for accelerating the movement of moving evidence-based and promising treatments into routine use. This FOA invites projects for which preliminary or feasibility data is available. This FOA is a companion to RFA-DA-23-053, which solicits applications for which pilot data is unavailable.</p>				
112755	RFA-DA-23-053 -- HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-DA-23-053	16-Sep-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Carrie Mulford, Ph.D. Contact Telephone 301827-6473 Contact Email carrie.mulford@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 16-Sep-2024 [Optional][LOI/Pre-App], 17-Oct-2024 , 19-Feb-2025 [Optional][LOI/Pre-App], 20-Mar-2025 Synopsis The goal of this initiative is to support action-oriented research that accelerates the translation of research to practice to address the overdose crisis. There remains an urgent need for research that advances the design of stigma-free patient-centered systems of care such that people who experience addiction can recover and sustain their recovery over the long-term. This FOA solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels. Projects should be in alignment with the overall goals of the HEAL Initiative, and should focus on replicable, scalable, equitable approaches for accelerating the movement of evidence-based and promising treatments into routine use. This FOA invites phased applications to support projects for which preliminary or feasibility data is not available at the time of submission. This FOA is a companion to RFA-DA-23-054 , which solicits applications for which pilot data is available.</p>				
113055	RFA-EB-22-002 -- HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-EB-22-002	15-Sep-2024 [Optional][LOI/Pre-App]	2,250,000 USD
	<p>Contact Name Moria F. Bittmann Contact Telephone 301-496-7699 Contact Email moria.bittmann@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Sep-2024 [Optional][LOI/Pre-App], 15-Oct-2024 , 18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to develop clinical-grade prototype devices intended for use as safe, effective, and non-addictive diagnostics and treatments for pain or opioid use disorder (OUD). The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain or OUD, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain or OUD. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use.</p>				
123143	Limited Competition: Revision Applications of Existing NIH Centers for AIDS Research (CFAR) and Developmental Centers for AIDS Research (D-CFAR) Grants (P30 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-24-080	09-Oct-2024	Not Specified
	<p>Contact Name Eric Refsland, Ph.D.</p> <p>Contact Telephone 301-761-7193</p> <p>Contact Email eric.refsland@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Oct-2024 , 09-Oct-2025</p> <p>Synopsis This notice of funding opportunity (NOFO) encourages revision applications from currently funded NIH Centers for AIDS Research (CFAR) and Developmental CFARs (D-CFAR) to expand the role of the CFARs and D-CFARs to include additional support and infrastructure for training, mentoring, and research related to HIV and HIV-related health disparities in the United States and globally. Additionally this NOFO supports expanding experimental approaches while engaging and encouraging collaborations and incorporation of diverse perspectives into the CFAR and D-CFAR goals. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation.</p>				
123794	NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)	National Institutes of Health/DHHS	PAR-24-124	21-Oct-2024	1,750,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Sekai Chideya, M.D., MPH 301-827-1916 sekai.chideya@nih.gov Link to program URL 21-Oct-2024 , 13-Nov-2024 , 23-Jun-2025 , 15-Jul-2025 , 23-Feb-2026 , 17-Mar-2026 , 20-Oct-2026 , 13-Nov-2026 <p>This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to three years (R61 phase) of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural product’s effect (i.e., measure of mechanism of action) when used by humans on a biological signature(s). If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the biological signature by optimizing the delivery of the natural product by examining different doses or formulation. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same biological signature; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R61/R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer. A maximum of 5 years will be supported by the two phases of the R61/R33 award. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.</p>
--	---

123784	NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)	National Institutes of Health/DHHS	PAR-24-116	21-Oct-2024	1,050,000 USD
--------	--	------------------------------------	------------	-------------	---------------

Contact Name Contact Telephone	Sekai Chideya, M.D., MPH 301-827-1916
-----------------------------------	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email sekai.chideya@nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL</p> <p>Deadline Dates (ALL) 21-Oct-2024 , 13-Nov-2024 , 23-Jun-2025 , 17-Jul-2025 , 23-Feb-2026 , 17-Mar-2026 , 20-Oct-2026 , 13-Nov-2026</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to 3 years support for studies to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications are encouraged to design studies to determine how to optimize the impact of the natural product on the biological signature by optimizing the delivery of the natural product by examining different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same biological signature; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer.</p>				
121295	Intervention Research to Improve Native American Health (R34 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-285	21-Oct-2024	450,000 USD

	<p>Contact Name Alexa Romberg Ph.D.</p> <p>Contact Telephone 301-435-0264</p> <p>Contact Email alexa.romberg@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Oct-2024 , 07-Jan-2025 , 21-Oct-2025 , 07-Jan-2026 , 25-Oct-2026 , 07-Jan-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support planning and development, including pilot or feasibility research, to improve health in Native American populations. Proposed research may address health promotion, disease prevention, treatment, recovery, or services research to inform intervention implementation and dissemination.</p>				
--	--	--	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Research with Native American populations requires engagement with tribal partners and communities to develop and/or adapt interventions and clinical trial protocols, understand intervention feasibility and acceptability, and identify and/or develop scientifically rigorous and culturally appropriate study designs and methods. Preparatory studies may fill information gaps, address unknowns, allow for strengthening of partnerships with Native American community leaders and organizations, and pilot test the feasibility of the intervention and clinical trial design, thereby improving scientific rigor and cultural appropriateness of a future efficacy, effectiveness, or implementation trial. This NOFO is part of the Intervention Research to Improve Native American Health (IRINAH) initiative, which also includes PAR-23-298, which uses the R01 Research Project Grant mechanism and PAR-23-299, which uses the R21 Exploratory/Developmental Research Grant mechanism. For the purposes of this NOFO, Native Americans include the following populations: Alaska Natives, American Indians (whose ancestral lands fall at least partially within the U.S. mainland border), and Native Hawaiians. The term 'Native Hawaiian' means any individual any of whose ancestors were natives, prior to 1778, of the area which now comprises the State of Hawaii.

102069	Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-21-115	05-Oct-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name | Melissa Parisi, MD, PhD
 Contact Telephone | 301-435-6880
 Contact Email | parisima@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 05-Oct-2024

Synopsis | This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disorder, a valuable resource will be developed for the field. In addition, for some disorders, specific genotype-phenotype correlations may allow prediction of the clinical course, and for other disorders, identification of modifying genetic, epigenetic, or environmental factors will enhance an understanding of the clinical outcomes for an individual with such a condition. Comprehensive data on natural history will facilitate the field's ability to: 1) accurately diagnose the disorder; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the disorder; 3) identify underlying mechanisms related to basic defects; 4) potentially prevent, manage, and treat symptoms and complications of the disorder; and 5) provide children and their families with needed support and

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| predictive information about the disorder.

105617	Effectiveness of School-Based Health Centers to Advance Health Equity (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-21-287	07-Sep-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025</p>	<p>Synopsis</p> <p>The purpose of this Funding Opportunity Announcement is to support research that investigates the effectiveness of school-based health centers (SBHCs) as a health services care delivery model to address the needs of school-aged children from populations with health disparities (hence, underserved youth). The goals of this FOA are to support multidisciplinary research that investigates the effectiveness of SBHCs as a health services care delivery model to detect, manage, and prevent chronic illnesses that disproportionately burden underserved youth. The mechanisms of impact by which SBHCs improve the health of at-risk populations such as sexual and gender minority youth, immigrant youth, and youth who reside in rural areas are also a relevant focus for understanding effective models of SBHCs. Applications are expected to provide a conceptual model that describes hypothesized causal pathways by which SBHCs engage underserved youth to improve health outcomes and how SBHCs may complement (or reduce) the use of other services. Lessons learned through this initiative can help determine whether SBHCs can be adopted as a best practice care model to address the health services needs of underserved youth and if so, whether SBHCs given their accessibility to students can be an effective site of intervention to address disparities in chronic conditions, and behavioral, oral, and reproductive health of youth from underserved communities who lack access to health care.</p>
--	--

105618	Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-294	05-Oct-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone 301-945-7573</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>	
---	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Oct-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite research grant applications (R01) for the development and use of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo. The motivation for this initiative is that much of current imaging research into the role of inflammation in cancer is largely based on in vitro and ex vivo methods with limited utilization of imaging approaches that could lead to significant new insights relevant to dynamic cancer and inflammation interactions. Utilization of molecular imaging probes in pre-clinical and clinical investigations for precise temporal resolution at the molecular and cellular level are valuable approaches for identification and characterization of in vivo inflammatory cellular physiology in cancers and of molecular changes in response to treatment. This FOA encourages applications that focus on developing integrated imaging approaches to interrogate the role of inflammation in cancer through strong cross-field collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance science and understanding of cancer inflammation interactions.</p>				
106925	<p>Notice of Special Interest (NOSI): Promoting Research To Understand Vascular Contributions to Cognitive Impairment and Dementia (VCID)</p> <p>Contact Name Jue Chen, Ph.D. Contact Telephone 301-435-0550 Contact Email jue.chen@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 Synopsis The purpose of this Notice is to inform potential applicants about an area of special interest to NHLBI, NINDS and NIA in research to understand mechanisms of vascular contributions to cognitive impairment and dementia (VCID) and to develop new approaches for the treatment of VCID.</p>	National Institutes of Health/DHHS	NOT-HL-23-002	07-Sep-2024	Not Specified
107608	<p>Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)</p> <p>Contact Name Enrique Michelotti, PhD Contact Telephone 301-443-5415 Contact Email michelottiel@mail.nih.gov Sponsor Website</p>	National Institutes of Health/DHHS	PAR-22-031	05-Oct-2024	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA, NIMH, NIAAA, NIDA and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.</p>				
108571	Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy	National Institutes of Health/DHHS	NOT-HL-23-003	07-Sep-2024	Not Specified
	<p>Contact Name Anthony Agresti</p> <p>Contact Telephone 301-827-8014</p> <p>Contact Email agrestia@nhlbi.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis This Notice of Special Interest (NOSI) aims to accelerate a comprehensive understanding of the mechanisms of COVID-19-Associated Coagulopathy (CAC) which are provoked by vascular endothelial cell injury, hyperimmune responses, and hypercoagulability at genomic, molecular, and cellular levels. Knowledge obtained from such studies may be applied to the future design of early diagnostics and effective treatment for high-risk patients as well as enable CAC research findings to be applied to on-going COVID-19 clinical trials.</p>				
111036	Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-22-105	07-Sep-2024	Not Specified
	<p>Contact Name Gila Neta, Ph.D.</p> <p>Contact Telephone 240-276-6785</p> <p>Contact Email gila.neta@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.</p>				
111616	<p>Notice of Special Interest (NOSI): NIH Research Project Grants on Down Syndrome (R01) for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome) Project</p>	National Institutes of Health/DHHS	NOT-OD-22-123	07-Sep-2024	Not Specified
	<p>Contact Name Charlene Schramm, PhD</p> <p>Contact Telephone 301-402-3739</p> <p>Contact Email schrammc@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to support research project grant (R01) applications that are focused on Down syndrome and that meet programmatic objectives for the INCLUDE Project. Sharing of resources and effective communication of outputs of appropriate interest to broader communities are a high priority of the INCLUDE Project. Applicants responding to this NOSI are strongly encouraged to describe plans for rapid sharing of data and results as well as innovative data analytics approaches (see Goal 3, NIH Strategic Plan For Data Science).</p>				
114120	<p>Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)</p>	National Institutes of Health/DHHS	PAR-23-046	07-Sep-2024	Not Specified
	<p>Contact Name David M. Panchision, Ph.D.</p> <p>Contact Telephone 301-443-5288</p> <p>Contact Email panchisiond@mail.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function, and aging in healthy and disease states. This FOA is intended to encourage the further development of projects with feasibility support for the line of investigation. Applicants proposing exploratory research at the early and conceptual stages of project development may instead wish to apply to the companion R21 FOA (PAR-23-047).</p>				
115197	<p>In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	PAR-23-074	05-Oct-2024	2,499,995 USD
	<p>Contact Name Mahua Mukhopadhyay, PhD</p> <p>Contact Telephone 301-435-6886</p> <p>Contact Email mukhopam@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Jun-2025 , 05-Oct-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. The current (July 19, 2022) IMPC data release includes phenotypic data for 8260 knockout genes. Overall, the IMPC hopes to generate a null mutant and undertake broad-based phenotyping for every gene in the mouse genome. About 30% of these strains are expected to be either embryonic or perinatal lethal, or subviable. However, a large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in-depth phenotyping and research.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
119254	Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-207	05-Oct-2024	Not Specified
	<p>Contact Name Laura M. Rowland, Ph.D.</p> <p>Contact Telephone 301-480-8335</p> <p>Contact Email laura.rowland@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis The goal of this Notice of Funding Opportunity (NOFO) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This NOFO uses the R01 mechanism, while the companion announcement PAR-23-208 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.</p>				
117793	Interventions to Expand Cancer Screening and Preventive Services to ADVANCE Health in Populations that Experience Health Disparities (R01, Clinical Trial Required)	National Institutes of Health/DHHS	PAR-23-170	05-Oct-2024	Not Specified
	<p>Contact Name JoyAnn Courtney, Ph.D.</p> <p>Contact Telephone 301-402-3911</p> <p>Contact Email joyann.courtney@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this R01 to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. Interventions should include screening, preventive services, or other healthcare processes, including timely follow-up of abnormal findings, and referral to accessible care. Projects are encouraged to leverage collaborations with community partners and service providers. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

neighborhood/community. Specific research interests of participating NIH ICs are detailed within. Projects are encouraged to leverage collaborations with community partners and service providers to promote or enhance existing interventions and/or adapt new combinations of evidence-based strategies. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community.

093897	Research Project Grant (Parent R01 Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-183	07-Sep-2024	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	grantsinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025
Synopsis	The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. NOTE: The following Institutes/Centers only accept mechanistic studies that meet NIH's definition of a clinical trial. National Heart, Lung, and Blood Institute (NHLBI) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institute of Neurological Disorders and Stroke (NINDS) National Center for Complementary and Integrative Health (NCCIH) National Institute of Mental Health (NIMH)

093907	Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-184	07-Sep-2024	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	301-496-4000
Contact Email	grantsinfo@od.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R01 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>				
105755	Investigator Initiated Research in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-254	05-Oct-2024	2,500,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>				
	<p>Daniel Gilchrist, Ph.D.</p> <p>daniel.gilchrist@nih.gov</p> <p>Link to program URL</p> <p>05-Oct-2024</p> <p>The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research that develops innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems.</p>				
108001	Notice of Special Interest (NOSI): Epidemiologic studies in Asian Americans, Native Hawaiians, and Pacific Islanders (Parent R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	NOT-HL-23-001	07-Sep-2024	Not Specified
	<p>Contact Name</p>				
	<p>Robb Rowley, MD</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-827-9126</p> <p>Contact Email Robb.Rowley@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to stimulate novel epidemiological research to address key knowledge gaps within and between subpopulations of Asian Americans, Native Hawaiians, and Pacific Islanders. These populations are frequently aggregated in research, potentially masking important social and health differences. Given clear heterogeneity in ancestry, culture, immigration patterns among Asian Americans, socioeconomic position, and acculturation into American life, a critical need exists for epidemiological research to enhance our understanding of the interplay of environmental exposures, lifestyle, behavioral, genomics, social, neighborhood, and biological factors that impact the health of Asian American, Native Hawaiian, and Pacific Islander subpopulations.</p>				
107841	Risk and Protective Factors of Family Health and Family Level Interventions (R01 - Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-21-358	07-Sep-2024	Not Specified
	<p>Contact Name Deborah E. Linares, PhD, MA</p> <p>Contact Telephone 301-402-2516</p> <p>Contact Email Deborah.Linares@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis The purpose of this initiative is to advance the science of minority health and health disparities by supporting research on family health and well-being and resilience. The NIMHD Research Framework recognizes family health, family well-being, and family resilience as critically important areas of research to decrease disparities and promote equity.</p>				
109791	Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-137	07-Sep-2024	1,250,000 USD
	<p>Contact Name Julia Zehr, Ph.D.</p> <p>Contact Telephone 301-443-1617</p> <p>Contact Email Zehrj@mail.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org). This FOA uses the R01 grant mechanism, whereas its companion FOA, PAR-22-138, seeks shorter, higher-risk R21 grant applications.</p>				
109172	Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-085	05-Oct-2024	Not Specified
	<p>Contact Name Avi Rasooly, PhD</p> <p>Contact Telephone 240-276-6196</p> <p>Contact Email rasoolya@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. This funding opportunity is part of a broader NCI-sponsored research on microbial based cancer therapy.</p>				
109941	Focused Technology Research and Development (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-127	07-Sep-2024	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Fei Wang, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email wangf@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports projects relevant to the NIGMS mission or those of other NIH institutes or Centers (ICs) participating in the FOA that focus solely on the development of technologies with the potential to enable acquisition of biomedical knowledge. Projects should be justified in terms of technical innovation and utility of such technical innovation for impacting future biomedical research. Outcomes or products of the proposed project should significantly advance the current state of the art and be sufficiently characterized for application in addressing a broad range of biomedical research questions. These outcomes may include, but are not limited to: laboratory instruments and other devices, algorithms and software, chemical reagents and processes, biological molecules or systems that have been modified by human intervention to become research tools. The goal of this FOA is to support the development of technologies with demonstrated proof-of-concept that have remaining significant technical challenges to full implementation and broad utility. As such, applications should not propose to test specific biological questions. Applications proposing to test specific biological questions are not responsive to this FOA and will be administratively withdrawn without review. Applications with a focus on optimization, hardening, or obvious extrapolations of established technology will be a lower priority for funding.</p>				

114402	Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (U01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-037	07-Sep-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

	<p>Contact Name Robert Tamburro, MD, MSc</p> <p>Contact Telephone 301-480-2619</p> <p>Contact Email NICHD-Network-ClinicalResearch@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to invite applications for multisite clinical trials and</p>				
--	---	--	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

observational studies developed in conjunction with NICHD Networks that will be conducted using NICHD-supported Network infrastructure. The goal of this FOA is to operationalize the previously reported NICHD guiding principles for multisite clinical trials delineated in Notice NOT-HD-19-034: To enhance the rigor and reproducibility of clinical trial protocols To promote greater availability of multisite clinical trial infrastructure to support trials from a wider range of investigators To facilitate data sharing and access to biospecimens to efficiently expand research capacity for all investigators To facilitate greater involvement of diverse populations in multisite clinical trials. Consequently, multisite clinical trials and observational studies conducted by and within the participating NICHD-supported Clinical Research Networks will be submitted as investigator-initiated, multi-Principal Investigator (PI) grant applications by any qualified investigator in the extramural community (including NICHD Network investigators) in conjunction with the respective NICHD Network Data Coordinating Center (DCC). It is the intent of this initiative to utilize the NICHD Clinical Research Network infrastructure in a manner that will promote the funding and support of the best science in a timely, transparent, equitable and cost-effective manner.

116476	Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-130	05-Oct-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Katie M. Vance, Ph.D.
Contact Telephone	301-435-6640
Contact Email	Katie.Vance@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026
Synopsis	The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.

115307	Notice of Special Interest (NOSI): Understanding Sudden Death in the Young Through Research	National Institutes of Health/DHHS	NOT-HL-22-040	07-Sep-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Kristin M. Burns, MD
--------------	----------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-594-6859</p> <p>Contact Email kristin.burns@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>Synopsis This Notice of Special Interest (NOSI) highlights interest in receiving grant applications focused on mechanistic, genetic, and other studies to evaluate causes and consequences of, and risk factors for sudden death in the young (SDY). Studies are required to use phenotypic data and/or DNA samples and/or associated sequence data from the NIH/CDC Sudden Death in the Young (SDY) Case Registry as foundations for their research. Studies may use SDY Case Registry phenotypic data and/or samples and/or sequence data alone or in combination with other cohorts. Results of such studies are required to adhere to the NIH Data Sharing Policy so that the data is disseminated widely and provides an evidence base to advance discussions about screening and prevention of SDY.</p>				
116310	Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy	National Institutes of Health/DHHS	NOT-HL-23-003	07-Sep-2024	Not Specified
	<p>Contact Name Anthony Agresti</p> <p>Contact Telephone 301-827-8014</p> <p>Contact Email agrestia@nhlbi.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis This Notice of Special Interest (NOSI) aims to accelerate a comprehensive understanding of the mechanisms of COVID-19-Associated Coagulopathy (CAC) which are provoked by vascular endothelial cell injury, hyperimmune responses, and hypercoagulability at genomic, molecular, and cellular levels. Knowledge obtained from such studies may be applied to the future design of early diagnostics and effective treatment for high-risk patients as well as enable CAC research findings to be applied to on-going COVID-19 clinical trials.</p>				
116911	Research With Activities Related to Diversity (ReWARD) (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-122	07-Sep-2024	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Alison Gammie</p> <p>Contact Telephone </p> <p>Contact Email alison.gammie@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis The NIH Research With Activities Related to Diversity (ReWARD) Program's overarching goal is to enhance the breadth and geographical location of research and research-related activities supported by NIH. The ReWARD program provides support for the health-related research of scientists who are making a significant contribution to Diversity, Equity, Inclusion, and Accessibility (DEIA) and who have no current NIH research project grant funding. The ReWARD program provides funding for both the scientific research and the DEIA activities of investigators. The grant will support scientific research in areas related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) and ongoing DEIA activities focused on enhancing diversity in the biomedical research enterprise within the United States and territories.</p>				
116616	Notice of Special Interest (NOSI): Research Project Grants in Valvular Heart Disease (CAROL Act)	National Institutes of Health/DHHS	NOT-HL-23-079	07-Sep-2024	Not Specified
	<p>Contact Name Frank Evans, PhD</p> <p>Contact Telephone 301-435-0510</p> <p>Contact Email evansf@nhlbi.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis As part of the National Heart, Lung, and Blood Institute's implementation of the Cardiovascular Advances in Research and Opportunities Legacy (CAROL) Act, this Notice of Special Interest is seeking R01 applications that propose research in valvular heart disease.</p>				
114327	Research Infrastructure Development for Interdisciplinary Aging Studies (R61/R33 - Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-053	04-Oct-2024	2,499,995 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Dr. Sanoj Suneja</p> <p>Contact Telephone 301-402-7710</p> <p>Contact Email sunejas@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Oct-2024 , 02-Jun-2025 , 03-Oct-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA utilizes NIH's R61/R33 Exploratory/Developmental Phased Award activity code. The R61 phase provides up to 2 years of support for initial developmental activities. The R33 phase provides up to 3 years of support for expanded activities. Through this award, investigators will endeavor to develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.</p>				
114328	Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-054	04-Oct-2024	2,499,995 USD
	<p>Contact Name Dr. Sanoj Suneja</p> <p>Contact Telephone 301-402-7710</p> <p>Contact Email sunejas@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Oct-2024 , 02-Jun-2025 , 03-Oct-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA utilizes NIH's R33 Exploratory/Developmental Grants Phase II activity code to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed with other NIH or non-NIH support. Through this award, investigators will endeavor to develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.</p>				
093908	NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-185	07-Sep-2024	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantsinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R01 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>				
103168	Research on Autism Spectrum Disorders (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PA-21-201	05-Oct-2024	Not Specified
	<p>Contact Name Lisa Gilotty, Ph.D.</p> <p>Contact Telephone 301-443-3825</p> <p>Contact Email gilottyl@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). The Research Project Grant (R01) mechanism supports discrete, specified projects based in scientific areas that represent the investigators' specific interests and competencies, and that fall within the mission of the participating NIH Institutes and Centers (ICs). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions, and preliminary data are generally expected. Applicants pursuing exploratory/developmental research to support early and conceptual stages of project development should consider the companion R21 FOA, PA-21-200. Applicants pursuing secondary analysis of existing</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
110794	Notice of Special Interest (NOSI): Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP)	National Institutes of Health/DHHS	NOT-AI-22-042	07-Sep-2024	Not Specified
	<p>Contact Name Marina Protopopova, Ph.D.</p> <p>Contact Telephone 301-761-7653</p> <p>Contact Email marina.protopopova@niaid.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis The purpose of this Notice is to encourage new applications to support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of three (3) months from either a single dosing (injection, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.) to reflect current state of SR/LA drug market for HIV treatment or prevention.</p>				
110513	Notice of Special Interest (NOSI): High Priority Areas in Genetics, Epigenetics, and Developmental Neuroscience Branch in the Division of Neuroscience and Behavior	National Institutes of Health/DHHS	NOT-DA-23-004	07-Sep-2024	Not Specified
	<p>Contact Name Jonathan D. Pollock, Ph.D.</p> <p>Contact Telephone 301-435-1309</p> <p>Contact Email jpollock@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The mission of the Division of Neuroscience and Behavior (DNB) is to discover, facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of drug addiction across the lifespan and to guide treatment strategies. The Genetics, Epigenetics, and Development (GED) Branch within DNB supports research on the genetics, epigenetics, and developmental mechanisms that underlie addiction and substance use disorders (SUD).</p>				
112441	Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-22-210	05-Oct-2024	2,500,000 USD
	<p>Contact Name Liam O'Fallon</p> <p>Contact Telephone 984-287-3298</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email ofallon@niehs.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages multidisciplinary projects to investigate the potential health risks of environmental exposures of concern to a community and to develop and implement an environmental public health action plan based on research findings. Projects supported under this program will employ community-engaged research methods to conduct research and to translate research findings into public health action. This announcement reflects NIEHS' and NIMHD's commitment to environmental health disparities and environmental justice research. This FOA also advances efforts to nurture and sustain trust and bi-directional communication between academic researchers and affected communities. The Research to Action program is part of the National Institute of Environmental Health Sciences (NIEHS) "Partnerships for Environmental Public Health" (PEPH) network (https://www.niehs.nih.gov/research/supported/translational/peph/index.cfm).</p>				
112472	Notice of Special Interest (NOSI): Respiratory Complications of the Muscular Dystrophies (R01)	National Institutes of Health/DHHS	NOT-HL-22-025	07-Sep-2024	Not Specified
	<p>Contact Name Aruna Natarajan, MD, PhD</p> <p>Contact Telephone 301-827-0180</p> <p>Contact Email aruna.natarajan@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of this NOSI is to encourage research grant applications focused on respiratory complications of the muscular dystrophies. This includes further elucidation of respiratory phenotypes in humans; research to optimize pulmonary function testing and existing respiratory therapies in humans; and mechanistic and translational research, including in vitro and in animal models, that examines respiratory muscle response to gene therapies and other therapeutic strategies in the muscular dystrophies.</p>				
117550	Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-164	07-Sep-2024	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Enrique Michelotti, Ph.D.</p> <p>Contact Telephone 301-443-5415</p> <p>Contact Email michelottiel@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis This Funding Opportunity Announcement (NOFO) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain and the incorporation of pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research. Projects proposing only preclinical animal studies should consider the companion NOFO (PAR-23-164).</p>				
117551	Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-23-165	07-Sep-2024	Not Specified
	<p>Contact Name Enrique Michelotti, Ph.D.</p> <p>Contact Telephone 301-443-5415</p> <p>Contact Email michelottiel@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Projects proposing clinical assessments of novel radioligands should respond to NOFO (PAR-23-164).</p>				
120387	Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and	National Institutes	PAR-23-	05-Oct-2024	1,750,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Related Outcomes (R01 Clinical Trial Not Allowed)	of Health/DHHS	254		USD
	<p>Contact Name Melissa Rotunno, Ph.D.</p> <p>Contact Telephone 240-276-7245</p> <p>Contact Email rotunnom@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.</p>				
120821	RFA-HD-24-007 -- Understanding and Mitigating Health Disparities Experienced by People with Disabilities Caused by Ableism (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-HD-24-007	07-Sep-2024	2,499,995 USD
	<p>Contact Name Toyin Ajisafe, PhD</p> <p>Contact Telephone 301-827-9242</p> <p>Contact Email toyin.ajisafe@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis The goal of this NOFO is to encourage research to understand the impact of ableism on health outcomes. Research on the underlying mechanisms by which ableism adversely influences the health of persons with disabilities (PWD), as well as developing and/or testing interventions at a community or health systems level to mitigate adverse health effects of ableism are high priority.</p>				
120101	Social Disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional)	National Institutes	PAR-23-	05-Oct-2024	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		of Health/DHHS	238		Specified
	<p>Contact Name Jovier Evans, Ph.D.</p> <p>Contact Telephone 301-443-6328</p> <p>Contact Email jevans1@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 02-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. This NOFO solicits R01 applications, while the companion announcement PAR-23-239 solicits R21 applications. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism.</p>				
120715	Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-245	05-Oct-2024	1,000,000 USD
	<p>Contact Name Allison Dennis, PhD</p> <p>Contact Telephone 301-827-9721</p> <p>Contact Email allison.dennis@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to advance the development of novel informatics and data science approaches that can help individuals understand and improve their health through actionable insights. The NLM and participating institutes listed in this NOFO seek applications that further the science of personal health informatics by providing meaningful and actionable insights to individuals through innovative personal health data collection, integration, analysis, and personalized risk assessments and interpretation. Applications seeking to advance the understanding of how informatics tools, systems, and platforms can best present the results, interpretation, and limitations of personalized assessments for the benefit of individuals are encouraged. Applications should include end user engaged approaches and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	real-world evaluation to inform the design of generalizable, reusable, and scalable personal health informatics tools, systems, and platforms for the benefit of individuals in understanding and improving their health.																		
120817	Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-244	05-Oct-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>David Berrigan</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-276-6752</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>berrigad@mail.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control. Proposals addressing understudied areas are encouraged, as is attention to underrepresented minority (URM) populations experiencing cancer and alcohol-related disparities such as American Indian, Alaskan Native, and sexual and gender minority populations.</td> </tr> </table>					Contact Name	David Berrigan	Contact Telephone	240-276-6752	Contact Email	berrigad@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026	Synopsis	This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control. Proposals addressing understudied areas are encouraged, as is attention to underrepresented minority (URM) populations experiencing cancer and alcohol-related disparities such as American Indian, Alaskan Native, and sexual and gender minority populations.
Contact Name	David Berrigan																		
Contact Telephone	240-276-6752																		
Contact Email	berrigad@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026																		
Synopsis	This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control. Proposals addressing understudied areas are encouraged, as is attention to underrepresented minority (URM) populations experiencing cancer and alcohol-related disparities such as American Indian, Alaskan Native, and sexual and gender minority populations.																		
111805	Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-22-181	06-Sep-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Albert Avila, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-496-8804</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>aavila@nida.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>06-Sep-2024 , 07-Sep-2024 , 08-Oct-2024 , 07-Jan-2025 , 08-Jan-2025 , 06-Feb-2025 , 05-May-2025 , 07-May-2025 , 06-Jun-2025 , 07-Sep-2025</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects</td> </tr> </table>					Contact Name	Albert Avila, Ph.D.	Contact Telephone	301-496-8804	Contact Email	aavila@nida.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	06-Sep-2024 , 07-Sep-2024 , 08-Oct-2024 , 07-Jan-2025 , 08-Jan-2025 , 06-Feb-2025 , 05-May-2025 , 07-May-2025 , 06-Jun-2025 , 07-Sep-2025	Synopsis	This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects
Contact Name	Albert Avila, Ph.D.																		
Contact Telephone	301-496-8804																		
Contact Email	aavila@nida.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	06-Sep-2024 , 07-Sep-2024 , 08-Oct-2024 , 07-Jan-2025 , 08-Jan-2025 , 06-Feb-2025 , 05-May-2025 , 07-May-2025 , 06-Jun-2025 , 07-Sep-2025																		
Synopsis	This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

that are within the scientific mission areas of the participating NIH Institutes or Centers. This program is intended to support New Investigators and At-Risk Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences. Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIH’s Interest in Diversity), are encouraged to work with their institutions to apply for support under this program. Investigators from categories A and B are particularly encouraged to work with their institutions to apply.

105957	Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-305	09-Aug-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Mary Evans, Ph.D.</p> <p>301-594-4578</p> <p>evansmary@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>09-Aug-2024 , 10-Sep-2024 , 09-Oct-2024 , 07-Nov-2024 , 10-Dec-2024 , 09-Jan-2025</p> <p>This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, sedentary behavior, and/or sleep) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity-related policy or program offers an uncommon and scientifically-compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date; however, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.</p>
---	--

121565	Health and Health Care Disparities Among Persons Living with Disabilities (R01 - Clinical Trials Optional)	National Institutes of Health/DHHS	PAR-23-309	05-Oct-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p>	<p>Sundania J. W. Wonnum, PhD, LCSW</p> <p></p> <p>sundania.wonnum@nih.gov</p>
---	---

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to support novel and innovative research that examines and/or intervenes on the underlying and multilevel causes, pathways, and factors adversely impacting the health and well-being of persons with disabilities at the intersections of race and ethnicity, and socioeconomic status.</p>				
121868	<p>Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed)</p>	National Institutes of Health/DHHS	PAR-23-303	07-Sep-2024	Not Specified
	<p>Contact Name Larissa Avilés-Santa, MD, MPH, Director</p> <p>Contact Telephone 301-827-6924</p> <p>Contact Email avilessantal@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) will support innovative, collaborative, and interdisciplinary research focused on clinical epidemiology, evaluation of public and/or health care policies, and validation of measurements that address health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos.</p>				
121337	<p>NIAID and NIDDK Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)</p>	National Institutes of Health/DHHS	PAR-23-275	07-Sep-2024	Not Specified
	<p>Contact Name Diane Adger-Johnson, MPH</p> <p>Contact Telephone 240-669-2924</p> <p>Contact Email Altraininghelpdesk@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The purpose of this notice of funding opportunity (NOFO) is to encourage researchers from diverse backgrounds to work with their institutions to submit applications for research projects within the mission of either NIAID or NIDDK. This NOFO seeks to support either (a) a New Investigator (NI), who has not previously competed successfully for substantial, independent funding from NIH, or (b) an 'At-Risk' investigator, who had prior support as a PD/PI on a substantial independent research award and unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year.</p>				
120869	<p>Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for Alcohol, Tobacco, and Other Drugs (ATOD) Use and Misuse in Adult Populations That Experience Health Disparities (R01, Clinical Trial Required)</p>	National Institutes of Health/DHHS	PAR-23-270	05-Oct-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Denise Stredrick, Ph.D.</p> <p>301-402-9749</p> <p>denise.stredrick@nih.gov</p> <p></p> <p>Link to program URL</p> <p>05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027</p> <p>The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICOs) are issuing this NOFO seeking applications to test innovative approaches to implementing SBIRT/P for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities. SBIRT/P, (a term used for purposes of this funding announcement), involves screening individuals for risk of ATOD use and misuse, briefly intervening with a conversation about harmful substance use, and referring individuals for treatment or preventive services, as needed. Proposed research should include prospective tests of SBIRT/P and should leverage collaborations with healthcare and community partners Specific research interests of participating NIH ICOs are detailed within.</p>			
121246	<p>Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional)</p>	National Institutes of Health/DHHS	PAR-23-292	05-Oct-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p>	<p>David Dean Jr., Ph.D., M.S.</p> <p>240-276-8703</p> <p>bconnole@mail.nih.gov</p> <p></p> <p>Link to program URL</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) intends to support the rigorous assessment of barriers to quality cancer treatment and follow-up care for sexual and gender minority (SGM) cancer survivors. This funding opportunity is intended to address a critical need for improved care delivery and outcomes for SGM cancer survivors. The goal is to address the disease burden in an underserved and understudied population that is at higher risk of poorer health outcomes. The NCI solicits proposals for observational and/or interventional studies of SGM survivors designed to understand barriers and/or improve care and outcomes for SGM people with cancer, using interoperable sexual orientation and gender identity (SOGI) data collection in cancer care settings, where appropriate.</p>				
121563	<p>Developing Novel Theory and Methods for Understanding the Genetic Architecture of Complex Human Traits (R01 Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	PAR-23-302	05-Oct-2024	Not Specified
	<p>Contact Name Alexander Arguello, Ph.D.</p> <p>Contact Telephone 240-731-3753</p> <p>Contact Email alexander.arguello@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should be interdisciplinary drawing from the natural and social sciences, account for interdependencies across scales of biological, social, and ecological organization, and make extensive use of theory, modeling, and validation with available large-scale datasets.</p>				
124219	<p>Long-Term Effects of Disasters on Healthcare Systems in Populations with Health Disparities (R01- Clinical Trial Optional)</p>	National Institutes of Health/DHHS	PAR-24-109	06-Sep-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Carolina Solis-Sanabria, MD, MPH, FACS</p> <p>Contact Telephone 301-827-3460</p> <p>Contact Email carolina.solissanabria@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 06-Sep-2024 [Optional][LOI/Pre-App], 07-Sep-2024 , 05-Oct-2024 , 06-Jan-2025 [Optional][LOI/Pre-App], 07-Jan-2025 , 05-Feb-2025 , 06-May-2025 [Optional][LOI/Pre-App], 07-May-2025 , 05-Jun-2025 , 06-Sep-2025 [Optional][LOI/Pre-App], 07-Sep-2025 , 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 07-Jan-2026 , 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 07-May-2026 , 05-Jun-2026 , 06-Sep-2026 [Optional][LOI/Pre-App], 07-Sep-2026 , 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 07-Jan-2027 , 05-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to support collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on healthcare systems serving populations that experience health disparities living in the U.S. and its territories.</p>				
120789	<p>RFA-NS-24-021 -- HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional)</p>	National Institutes of Health/DHHS	RFA-NS-24-021	08-Oct-2024	3,250,000 USD
	<p>Contact Name D.P. Mohapatra, Ph.D.</p> <p>Contact Telephone 301-496-9964</p> <p>Contact Email dp.mohapatra@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Oct-2024 , 06-Feb-2025</p> <p>Synopsis This notice of funding opportunity (NOFO) seeks to support research aimed at holistic understanding of inter-individual or between-person differences in human pain conditions, focusing on ‘Whole Person Health’ and enhancing pain treatment and management strategies towards personalized pain medicine. The goal of this NOFO is to support studies that focus on the collection of clinical and/or preclinical data to enable evidence-based modeling and understanding of inter-individual differences and/or heterogeneity of pain occurring with use of pain therapy/management, or with conditions such as a second pain condition, a comorbid health condition, a comorbid mental health condition, or conditions of use / misuse of opioids, alcohol or other substances. Applicants are encouraged to develop and implement novel, multidisciplinary research approaches, and include investigators with complementary expertise to fulfill the project and program goals. Input from patients and caregivers on the goals of the project is highly encouraged. Rigorous data-driven and evidence-based research approaches supported under this NOFO are expected to provide better understanding of biological and/or biopsychosocial underpinnings of inter-individual differences, heterogeneity, and stratification of persons with lived pain experience, which would accelerate the development of evidence-based solutions toward precision pain medicine.</p>				
123847	<p>Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD & other ADRDs (R01 - Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	PAR-24-148	04-Oct-2024	2,500,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Contact Name	Linda McGavern, PhD			
	Contact Telephone				
	Contact Email	mcgavernlm@ninds.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	04-Oct-2024			
	Synopsis	<p>This Notice of Funding Opportunity (NOFO) supports studies establishing deeper mechanistic insights and causal cellular and molecular relationships between TDP-43 pathology and clinical phenotypic outcomes. Additionally, it requires comparisons between at least two TDP-43 proteinopathies, one of which must be an Alzheimer’s Disease-Related Dementia (ADRD), such as, but not limited to, Limbic-predominant Age-related TDP-43 Encephalopathy (LATE), with or without Alzheimer’s disease neuropathological change (AD-NC), or Frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP), to further understand distinct and overlapping mechanisms in these syndromes.</p>			

123846	Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-24-147	04-Oct-2024	2,500,000 USD
--------	---	------------------------------------	------------	-------------	---------------

	Contact Name	Linda McGavern, PhD			
	Contact Telephone				
	Contact Email	mcgavernlm@ninds.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	04-Oct-2024			
	Synopsis	<p>This Notice of Funding Opportunity (NOFO) supports investigations with a minimum of two Alzheimer’s Disease-Related Dementias (ADRD) co-pathologies (e.g., tau, alpha-synuclein, TDP-43, TMEM106B, vascular), with or without risk factors and co-morbidities, in the same model system to identify interactions and cellular and molecular mechanisms to determine how, whether, and when these interactive multi-pathology mechanisms drive worsening pathophysiology and clinical phenotypic outcomes, such as cognitive, behavioral, or functional impairment.</p>			

122945	Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-24-091	07-Sep-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

	Contact Name	Ann Namkung, MPH
--	--------------	------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-6838</p> <p>Contact Email ann.namkung@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</p> <p>Synopsis This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches. Proposed research must be consistent with the HIV/AIDS Research Priorities outlined by NIH's Office of AIDS Research (OAR), as described in NOT-OD-20-018.</p>				
122756	<p>Addressing Health and Health Care Disparities among Sexual and Gender Minority Populations (R01 - Clinical Trials Optional)</p>	National Institutes of Health/DHHS	PAR-24-077	07-Sep-2024	2,500,000 USD
	<p>Contact Name Rada K. Dagher, Ph.D., M.P.H.</p> <p>Contact Telephone 301-451-2187</p> <p>Contact Email ada.dagher@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to support innovative observational and intervention-based research to identify and characterize the pathways and mechanisms through which health and health care disparities occur among sexual and gender minority populations of minoritized racial/ethnic and socio-economic statuses. Per Notice Number: NOT-MH-24-170: Research Priorities The National Institute of Mental Health (NIMH) will only accept nonclinical trials applications that reflect the mission and scientific priorities as identified in the strategic plan NIMH » The National Institute of Mental Health Strategic Plan (nih.gov) and also NIMH's Approach to Mental Health Disparities Research. Clinical trial applications will not be accepted under this notice. Per NOT-MH-20-067, NIMH expects that grant applications involving human research participants will collect a minimum set of Common Data Elements.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
121869	Interventions on Health and Healthcare Disparities on Non-Communicable and Chronic Diseases in Latin America: Improving Health Outcomes Across the Hemisphere (R01 - Clinical Trial Required)	National Institutes of Health/DHHS	PAR-23-304	07-Sep-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Larissa Avilés-Santa, MD, MPH, Director</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-827-6924</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>avilessantal@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this Notice of Funding Opportunity (NOFO) is to support innovative and interdisciplinary team research focused on clinical, health services, and/or community-based interventions that address health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos.</td> </tr> </table>					Contact Name	Larissa Avilés-Santa, MD, MPH, Director	Contact Telephone	301-827-6924	Contact Email	avilessantal@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to support innovative and interdisciplinary team research focused on clinical, health services, and/or community-based interventions that address health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos.
Contact Name	Larissa Avilés-Santa, MD, MPH, Director																		
Contact Telephone	301-827-6924																		
Contact Email	avilessantal@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027																		
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to support innovative and interdisciplinary team research focused on clinical, health services, and/or community-based interventions that address health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos.																		
123009	Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-24-088	05-Oct-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Enrique L. Michelotti, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-443 5415</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>michelottiel@mail.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this Notice of Funding Opportunities (NOFOs) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (validated hits) for chemical optimization and bioassays for testing new analog compounds. Through this NOFO, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Eye Institute (NEI), and/or National Institute on Aging (NIA) and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be</td> </tr> </table>					Contact Name	Enrique L. Michelotti, Ph.D.	Contact Telephone	301-443 5415	Contact Email	michelottiel@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026	Synopsis	The purpose of this Notice of Funding Opportunities (NOFOs) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (validated hits) for chemical optimization and bioassays for testing new analog compounds. Through this NOFO, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Eye Institute (NEI), and/or National Institute on Aging (NIA) and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be
Contact Name	Enrique L. Michelotti, Ph.D.																		
Contact Telephone	301-443 5415																		
Contact Email	michelottiel@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026																		
Synopsis	The purpose of this Notice of Funding Opportunities (NOFOs) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (validated hits) for chemical optimization and bioassays for testing new analog compounds. Through this NOFO, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Eye Institute (NEI), and/or National Institute on Aging (NIA) and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	placed on projects that provide new insight into important disease-related biological targets and biological processes.				
122108	RFA-AI-23-061 -- Long-Acting Drug Delivery Systems for ART Optimization in Children Living with HIV-1 II (LADDS II) (R61/R33 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-AI-23-061	07-Sep-2024	5,450,000 USD
	<p>Contact Name Tania B. Lombo Rodriguez, Ph.D.</p> <p>Contact Telephone 301-761-7612</p> <p>Contact Email tania.lombo@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to accelerate the development of safe and effective long-acting drug delivery systems for improved, simplified treatment of HIV-1 in children. This NOFO invites applicants engaged in the development of existing long-acting platforms at early stages of development stages to perform specific preclinical activities that enable product optimization and accelerated translation to HIV-infected children. Collaborative research partnerships with industry are required.</p>				
122024	Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality (R01 - Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-24-059	05-Oct-2024	Not Specified
	<p>Contact Name Rada K. Dagher, PhD, MPH</p> <p>Contact Telephone 301-451-2187</p> <p>Contact Email rada.dagher@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis </p>				
112420	Notice of Special Interest (NOSI): Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan	National Institutes of Health/DHHS	NOT-OD-22-178	07-Sep-2024	Not Specified
	<p>Contact Name Melissa C. Green Parker, PhD</p> <p>Contact Telephone 301-480-1161</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email melissa.greenparker@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this Notice of Special Interest (NOSI) to encourage applications proposing to test multilevel strategies and interventions to improve the uptake of evidence-based screening services across the lifespan and in populations including, but not limited to, those experiencing health disparities and those that are underserved. Studies addressing efficacy, effectiveness, dissemination and implementation research, as well as studies seeking to understand and address barriers to screening are encouraged.</p>				
112421	Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening	National Institutes of Health/DHHS	NOT-OD-22-179	07-Sep-2024	Not Specified
	<p>Contact Name Melissa C. Green Parker, PhD</p> <p>Contact Telephone 301-480-1161</p> <p>Contact Email melissa.greenparker@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this Notice of Special Interest (NOSI) to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and harms cannot be determined. This NOSI encourages the development and use of innovative and rigorous methods and approaches to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation.</p>				
112791	Notice of Special Interest (NOSI): Community-Based Participatory Research (CBPR) Initiative in Reducing and Eliminating Health Disparities With a Focus on Addressing Diverse Representation in Research On Down Syndrome (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	NOT-OD-22-142	07-Sep-2024	Not Specified
	<p>Contact Name Sujata Bardhan, Ph.D.</p> <p>Contact Telephone 301-435-0471</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email sujata.bardhan@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025</p> <p>Synopsis The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH support for exploratory/developmental grant (R21) applications that are focused on community-based participatory research (CBPR) in DS to address health disparities and that meet programmatic objectives for the INCLUDE Project.</p>				
112471	Notice of Special Interest (NOSI): Single-Cell Level Spatiotemporal Mapping of Dental and Craniofacial Embryogenesis	National Institutes of Health/DHHS	NOT-DE-22-003	07-Sep-2024	Not Specified
	<p>Contact Name Kathryn Stein, PhD</p> <p>Contact Telephone 301-827-4653</p> <p>Contact Email kathryn.stein@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025</p> <p>Synopsis The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research that applies cutting edge imaging and high-throughput ‘omics approaches at the single-cell level to understand the complex spatiotemporal context of the developing dental and craniofacial tissues in the embryo.</p>				
112267	Notice of Special Interest (NOSI): Advancing Research on Early Pregnancy Loss	National Institutes of Health/DHHS	NOT-HD-22-026	07-Sep-2024	Not Specified
	<p>Contact Name Clara Cheng, PhD</p> <p>Contact Telephone 301-435-6992</p> <p>Contact Email clara.cheng@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis Early Pregnancy loss (EPL), defined as a pregnancy loss occurring up to 20 weeks gestation, is a very common pregnancy complication, occurring in 12-15% of clinically recognized pregnancies, with increased prevalence associated with increasing maternal age. The use of highly sensitive hCG assays allows the detection of pregnancy earlier in gestation than the time of clinical recognition, and gives an even higher estimated loss of 50-70% of conceptions prior to the second trimester. To achieve a successful pregnancy, a series of strict embryonic and maternal conditions must be met, that include high quality embryos, favorable conditions for embryo implantation, receptive maternal endometrium and optimal uterine environment to sustain the conceptus to term. In addition, maternal immune tolerance and hormonal factors play a critical role. While approximately half of all cases of EPL appear to be due to embryonic aneuploidy, very little is known about the physiologic and pathophysiologic processes that underlie non-aneuploid EPL. As a result, there is also a lack of understanding for the underlying causes of recurrent pregnancy loss (RPL). This NOSI seeks to address these critical knowledge gaps by encouraging basic, translational and clinical studies on biological processes that may uncover potential etiologies of EPL and RPL. This includes research to understand implantation mechanistically and identify a range of key factors, involved in implantation and placentation that are important for early pregnancy establishment, including abnormalities that contribute to sporadic EPL and recurrent pregnancy loss.</p>				
114596	<p>Development of Animal Models and Related Biological Materials for Down Syndrome Research (R21 Clinical Trials Not Allowed)</p>	National Institutes of Health/DHHS	PAR-23-067	16-Oct-2024	275,000 USD
	<p>Contact Name Sige Zou, PhD</p> <p>Contact Telephone 301-435-0749</p> <p>Contact Email zous@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025</p> <p>Synopsis The INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (INCLUDE) Project encourages exploratory and innovative research to develop, characterize, or improve animal models and related biological materials for Down syndrome (DS) related research and to improve access to information about or from the use of animal models for DS research. The animal models and related biological materials developed must have utility in targeted or basic science studies in areas highly relevant to DS. With this funding opportunity announcement, the INCLUDE Project encourages, but is not limited to, projects focusing on development of various animal models, genetic resources, atlases at a single cell or subcellular level, advanced informatics technologies including artificial intelligence (AI) or machine learning</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	(ML), and integration of multiple animal models and technology platforms for enhancing rigor and reproducibility of preclinical DS research.				
114589	Notice of Special Interest (NOSI): Research to Address 'Ending the HIV Epidemic' Initiative Goals Relevant to Substance Using Populations At-Risk for or Living with HIV	National Institutes of Health/DHHS	NOT-DA-23-013	09-Aug-2024	Not Specified
	<p>Contact Name Vasundhara Varthakavi, PhD</p> <p>Contact Telephone 301-443-2146</p> <p>Contact Email vasundhara.varthakavi@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 14-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 21-Mar-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Oct-2027</p> <p>Synopsis The purpose of this NOSI is to support a broad spectrum of multi-disciplinary, substance use research to address the goals of the four pillars, including Diagnose, Treat, Prevent, and Respond of the 'Ending the HIV Epidemic in the U.S. (EHE)' initiative. Projects proposed in response to this NOSI are required to meet the needs of the substance using populations who are at high risk for contracting HIV or living with HIV in the geographically defined EHE priority areas within the U.S.</p>				
114367	Notice of Special Interest (NOSI): Advancing Development of Rapid Point-of-Care Hepatitis C Virus Diagnostics	National Institutes of Health/DHHS	NOT-AI-23-001	05-Sep-2024	Not Specified
	<p>Contact Name Julie Dyall, PhD</p> <p>Contact Telephone 301-631-7296</p> <p>Contact Email dyallj@niaid.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026</p> <p>Synopsis The purpose of this Notice of Special Interest is to announce that the National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the National Cancer Institute (NCI) are</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	encouraging applications in the area of translational research and development of rapid Point-of-Care diagnostics that will diagnose active viremic HCV infections.				
115289	Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services	National Institutes of Health/DHHS	NOT-MH-23-140	07-Sep-2024	Not Specified
	<p>Contact Name: Stephen O'Connor, Ph.D.</p> <p>Contact Telephone: 301-480-8366</p> <p>Contact Email: stephen.o'connor2@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis: The National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), and Office of Research on Women's Health (ORWH) are issuing this Notice of Special Interest (NOSI) to outline priorities for research in crisis response services. Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remote settings), cultural considerations, and health disparities influence the types of care that are provided. Studies are encouraged that address the continuum of crisis service systems, as well as applications that address crisis services for children and under-resourced populations.</p>				
120393	Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-23-255	16-Oct-2024	275,000 USD
	<p>Contact Name: Melissa Rotunno, Ph.D.</p> <p>Contact Telephone: 240-276-7245</p> <p>Contact Email: rotunnom@mail.nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026</p> <p>Synopsis: Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.</p>				
120102	Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-239	16-Oct-2024	275,000 USD
	<p>Contact Name Jovier Evans, Ph.D. Contact Telephone 301-443-6328 Contact Email jevans1@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. This NOFO solicits R21 applications, while the companion announcement PAR-23-238 solicits R01 applications. High risk/high payoff projects that lack preliminary data may be most appropriate for this R21 mechanism, while applications with preliminary data should apply to the R01 mechanism, PAR-23-238.</p>				
121564	Developing Novel Theory and Methods for Understanding the Genetic Architecture of Complex Human Traits (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-23-301	16-Oct-2024	275,000 USD
	<p>Contact Name Alexander Arguello, Ph.D. Contact Telephone 240-731-3753 Contact Email alexander.arguello@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should account for interdependencies across scales of biological, social, and ecological organization, make extensive use of theory, modeling, and validation with available large-scale datasets, and may be interdisciplinary drawing from the natural and social sciences.</p>				
103180	Research on Autism Spectrum Disorders (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PA-21-200	16-Oct-2024	275,000 USD
	<p>Contact Name Lisa Gilotty, Ph.D. Contact Telephone 301-443-3825 Contact Email gilottyl@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 16-Oct-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. Exploratory, novel studies that break new ground or extend previous discoveries toward new directions are appropriate for this mechanism. No preliminary data are required but may be included if available. Applicants pursuing secondary analysis of existing data, and pilot or feasibility studies that can be completed with limited budgets should consider the companion R03 FOA, PA-21-199 . Applicants pursuing larger studies in established scientific areas where preliminary data are expected should consider the companion R01 FOA, PA-21-201.</p>				
107609	Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-22-032	16-Oct-2024	275,000 USD
	<p>Contact Name Enrique Michelotti, PhD Contact Telephone 301-443-5415 Contact Email michelottiel@mail.nih.gov Sponsor Website Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 16-Oct-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH, NIA, NIAAA and NIDA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents. This FOA will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).</p>				
107483	<p>Notice of Special Interest (NOSI): Mechanistic Studies on the Impact of Substance Use in Sex and Gender Differences in HIV-Associated Neurocognitive Disorders</p> <p>Contact Name </p> <p>Contact Telephone </p> <p>Contact Email </p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis Compared to men, women are often more likely to develop HIV-associated neurocognitive impairments. The purpose of this notice is to inform potential applicants of NIDA's special interest in understanding the neurobiological bases for sex or gender-specific differences in HIV-associated neurocognitive disorders. This information can be used for targeted therapeutics and optimization of treatment options in HIV positive individuals with substance use disorders.</p>	National Institutes of Health/DHHS	NOT-DA-22-047	07-Sep-2024	Not Specified
107484	<p>Notice of Special Interest (NOSI): The Functional Oral Microbiome</p> <p>Contact Name Tamara McNealy, PhD.</p> <p>Contact Telephone 202-430-1474</p> <p>Contact Email tamara.mcnealy@nih.gov</p> <p>Sponsor Website </p>	National Institutes of Health/DHHS	NOT-DE-21-015	07-Sep-2024	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research studies that focus beyond the bacteria to the multispecies communities making up the oral microbiome.</p>				
103183	Research on Autism Spectrum Disorders (R03 Clinical Trial Optional)	National Institutes of Health/DHHS	PA-21-199	16-Oct-2024	100,000 USD
	<p>Contact Name Lisa Gilotty, Ph.D.</p> <p>Contact Telephone 301-443-3825</p> <p>Contact Email gilottyl@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). An R03 grant supports small, discrete, well-defined projects that can be completed in two years and that require limited resources. R03 applications may include development of new research methodologies or technology, secondary analysis of existing data, and pilot or feasibility studies. Preliminary data are not required, particularly in applications proposing pilot or feasibility studies. Applicants pursuing exploratory/developmental research to support early and conceptual stages of project development should consider the companion R21 FOA, PA-21-200. Applicants pursuing larger studies in established scientific areas where preliminary data are expected should consider the companion R01 FOA, PA-21-201.</p>				
104057	Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PA-21-219	07-Sep-2024	275,000 USD
	<p>Contact Name Karrah Benson</p> <p>Contact Telephone 301-496-0838</p> <p>Contact Email Karrah.benson@nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025
Synopsis	<p>The Joint NINDS/NIMH Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community. While this funding opportunity also accepts clinical trials, only applications proposing “mechanistic clinical trials or studies” (studying pathophysiology or mechanism of action of an intervention, but not safety or efficacy) or basic experimental studies with humans (BESH) will be supported. For information on NIH clinical trial definitions and the types of clinical trials that are within scope of this funding opportunity announcement refer to the NIH Definition of a Clinical Trial page and the Funding Opportunity Description, below, respectively.</p>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

108898	Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services	National Institutes of Health/DHHS	NOT-MH-22-110	07-Sep-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Stephen O'Connor, Ph.D.
Contact Telephone	301-480-8366
Contact Email	stephen.o'connor2@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025
Synopsis	<p>The National Institutes of Health seeks research conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remote settings), cultural considerations, and health disparities influence the types of care that are provided. Examples of NIMH and NIDA studies that are encouraged through this Notice address the continuum of crisis service systems. Applications that include crisis services for children and under-resourced populations are encouraged. Topics of research interest span the crisis care continuum, including the effectiveness of these components: call center capabilities to address distress and coordinate care, deployed mobile crisis outreach and support, and crisis services that can diagnose and provide short term stabilization.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
109173	Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-086	16-Oct-2024	275,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Avi Rasooly, PhD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-276-6196</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>rasoolya@mail.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>16-Oct-2024 , 16-Feb-2025</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis This funding opportunity is part of a broader NCI-sponsored research on microbial based cancer therapy.</td> </tr> </table>					Contact Name	Avi Rasooly, PhD	Contact Telephone	240-276-6196	Contact Email	rasoolya@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025	Synopsis	This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis This funding opportunity is part of a broader NCI-sponsored research on microbial based cancer therapy.
Contact Name	Avi Rasooly, PhD																		
Contact Telephone	240-276-6196																		
Contact Email	rasoolya@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	16-Oct-2024 , 16-Feb-2025																		
Synopsis	This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis This funding opportunity is part of a broader NCI-sponsored research on microbial based cancer therapy.																		
108483	Notice of Special Interest (NOSI): COVID-19 Pandemic Mental Health Research	National Institutes of Health/DHHS	NOT-MH-22-100	07-Sep-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Pim Brouwers, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-627-3863</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>ebrouwer@mail.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in basic, translational, intervention and services research relevant to the COVID-19 pandemic. NIMH is especially interested in research to provide an evidence base to understand how mental illness contributes to COVID-19 risk and mortality, how incident mental illness develops with COVID-19, and the development of scalable interventions to meet the public mental health needs during and resulting from</td> </tr> </table>					Contact Name	Pim Brouwers, Ph.D.	Contact Telephone	240-627-3863	Contact Email	ebrouwer@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025	Synopsis	NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in basic, translational, intervention and services research relevant to the COVID-19 pandemic. NIMH is especially interested in research to provide an evidence base to understand how mental illness contributes to COVID-19 risk and mortality, how incident mental illness develops with COVID-19, and the development of scalable interventions to meet the public mental health needs during and resulting from
Contact Name	Pim Brouwers, Ph.D.																		
Contact Telephone	240-627-3863																		
Contact Email	ebrouwer@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025																		
Synopsis	NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in basic, translational, intervention and services research relevant to the COVID-19 pandemic. NIMH is especially interested in research to provide an evidence base to understand how mental illness contributes to COVID-19 risk and mortality, how incident mental illness develops with COVID-19, and the development of scalable interventions to meet the public mental health needs during and resulting from																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					the pandemic both specifically related to the virus but also at a broader population level that is impacted by stress, disruptions, and loss of lives in the pandemic. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH. Research is anticipated to focus on particularly vulnerable populations based on existing evidence of increased mental health symptoms and illness and preexisting and worsening health disparities.
108358	Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-090	16-Oct-2024	275,000 USD
	Contact Name	Miguel R. Ossandon, Ph.D.			
	Contact Telephone	240-276-5714			
	Contact Email	ossandom@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Oct-2024			
	Synopsis	The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility			
110997	Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-22-167	17-Oct-2024	3,250,000 USD
	Contact Name	Soju Chang, M.D., M.P.H.			
	Contact Telephone	301-827-9206			
	Contact Email	soju.chang@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	17-Oct-2024			
	Synopsis	The Clinical and Translational Science Award (CTSA) Program Collaborative and Innovative Acceleration Award (CCIA) supports synergistic activities that accelerate the translational research process through collaboration and innovation. This			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

funding opportunity announcement (FOA) invites applications to develop, demonstrate and disseminate innovative solutions to transform the field of translational science by addressing the inefficiencies that are common across diseases and bringing more interventions to all people more quickly through collaborative science among the CTSA Program hubs, NIH Institutes, Centers, Offices (ICOs), and/or external stakeholders.

112346	Notice of Special Interest (NOSI): Research on the Health of Sexual and Gender Minority (SGM)	National Institutes of Health/DHHS	NOT-MD-22-012	07-Sep-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Crystal L. Barksdale, PhD MPH
Contact Telephone	301-827-4228
Contact Email	crystal.barksdale@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 09-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025
Synopsis	This Notice calls for research on the health of sexual and gender minority populations. SGM populations include, but are not limited to, individuals who identify as lesbian, gay, bisexual, asexual, transgender, Two-Spirit, queer, and/or intersex. Individuals with same-sex or -gender attractions or behaviors and those with a difference in sex development are also included. These populations also encompass those who do not self-identify with one of these terms but whose sexual orientation, gender identity or expression, or reproductive development is characterized by non-binary constructs of sexual orientation, gender, and/or sex.

122410	Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)	National Institutes of Health/DHHS	PAR-24-062	14-Aug-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Amy B. Goldstein, PhD
Contact Telephone	301-827-4124
Contact Email	amy.goldstein@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	14-Aug-2024 , 11-Oct-2024 , 13-Dec-2024 , 14-Feb-2025 , 17-Mar-2025 , 13-Jun-2025 , 14-Aug-2025 , 10-Oct-2025 , 15-Dec-2025 , 13-Feb-2026 , 16-Mar-2026 , 15-Jun-2026 , 14-Aug-2026 , 14-Oct-2026 , 14-Dec-2026

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of this notice of this funding opportunity (NOFO) is to support translational research across epidemiology, addiction services, and prevention to, ultimately, reduce the burden of substance use on public health. This NOFO encourages research that facilitates rapid translation from one discipline to another (e.g., epidemiology to prevention); supports community/stakeholder engagement in substance use treatment and prevention clinical trials; or reduces the research to practice gap through the rapid transition from pilot study to clinical trial, or effectiveness to implementation study. The goal is to support translational research improving our ability to 1) identify and characterize malleable individual, familial, behavioral, developmental, and socio-cultural/environmental factors (within the population or precise subgroups) with the potential for multi-directional transfer of knowledge; 2) prevent initiation of substance use or progression to misuse or use disorder; and 3) maximize the efficient delivery of high-quality, personalized addiction treatment and related services to ultimately inform and facilitate real world responses designed to reduce the burden of substance use, misuse and/or addiction on the health of the population. This NOFO invites projects for which preliminary feasibility or pilot data are not available. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>			
106848	Notice of Special Interest (NOSI): Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities	National Institutes of Health/DHHS	NOT-DE-21-013	07-Sep-2024	Not Specified
	Contact Name	Hiroko Iida, DDS, MPH			
	Contact Telephone	301-594-7404			
	Contact Email	hiroko.iida@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	<p>The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research studies designed to identify and understand the mechanisms by which biologic factors (microbial, immune, genetic) contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence.</p>			
110996	Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-160	07-Sep-2024	100,000 USD
	Contact Name	Gila Neta, PhD			
	Contact Telephone	240-276-6785			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email Gila.Neta@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.</p>				
109942	Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-126	07-Sep-2024	275,000 USD
	<p>Contact Name Fei Wang, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email wangf@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports exploratory research leading to the development of innovative technologies for biomedical research that is relevant to the NIGMS mission or that of other NIH Institutes or Centers (ICs) participating in this FOA. Projects should entail a high degree of risk and/or novelty, which will be offset by a high future potential impact in biomedical research. Outcomes or products of the proposed project, which should significantly advance the current state of the art, may include, but are not limited to: laboratory instruments and other devices, algorithms and software, chemical reagents and processes, biological molecules or systems that have been modified by human intervention to become research tools. The goal of this FOA is to support proof of concept, high-risk and potentially high-reward studies for feasibility and exploratory technology development. Due to the constraints that would be imposed on broad utility, this FOA does not support technology development that is narrowly focused on addressing specific biological questions. Rather,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

applications should propose development of innovative tools that can potentially benefit a broad spectrum of biomedical research. Moreover, feasibility of the proposed technology must not have already been established in the literature or with preliminary data. Applications that are focused on technology development to address specific biological questions and/or include unpublished or published data that provide proof of concept are not responsive to this FOA and will be administratively withdrawn without review.

110034	Notice of Special Interest (NOSI): Research Using Implementation Science To Support the Delivery of Evidence-Based Practices in Community-Based Mental or General Medical Healthcare Settings	National Institutes of Health/DHHS	NOT-MH-22-170	07-Sep-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025
Synopsis	This Notice of Special Interest (NOSI) highlights interest in mental health services and implementation science research to support the adoption and sustainability of evidence-based practices (EBPs) in community-based settings that deliver care to people with mental illness. These settings could include, but are not limited to, Certified Community Behavioral Health Clinics (CCBHCs) funded through the Substance Abuse and Mental Health Services Administration (SAMHSA) Certified Community Behavioral Health Clinic-Expansion (CCBHC-E) grant program.

110813	Notice of Special Interest (NOSI): Towards Developing a Cure for HBV in HIV/HBV Co-Infection	National Institutes of Health/DHHS	NOT-AI-22-043	05-Sep-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Chris Lambros, PhD
Contact Telephone	240-627-3093
Contact Email	clambros@niaid.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this NOSI is to encourage applications for support of innovative basic, translational, and clinical research to identify and address the unique challenges to achieving HBV cure in the presence of HIV. Research on HIV/HBV co-infection relating to the following areas will be encouraged: (1) immunology; (2) virology; and (3) therapeutics.			
107545	Notice of Special Interest (NOSI): Expanding the Otitis Media Research Workforce: Focus on Early Stage Investigators	National Institutes of Health/DHHS	NOT-DC-22-001	07-Sep-2024	Not Specified
	Contact Name	Bracie Watson, Jr., Ph.D.			
	Contact Telephone	301-402-3458			
	Contact Email	watsonb@nidcd.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025			
	Synopsis	The National Institute on Deafness and Other Communication Disorderse (NIDCD) is interested in expanding the cadre of basic and clinical scientists who conduct research on otitis media (OM). The purpose of this Notice of Special Interest (NOSI) is to invite Early Stage Investigators (ESIs), as defined by the NIH https://grants.nih.gov/grants/new_investigators/index.htm#earlystage , to submit research applications that focus on OM—commonly known as ear infections. There is a critical need for focused, novel, creative and innovative research approaches that accelerate the development of effective ways to prevent and treat OM.			
114700	RFA-NS-22-022 -- HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research (K99/R00 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-NS-22-022	11-Oct-2024	Not Specified
	Contact Name	DP Mohapatra, Ph.D.			
	Contact Telephone	301-496-9964			
	Contact Email	dp.mohapatra@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Oct-2024 , 11-Feb-2025			
	Synopsis	The purpose of the NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and well-trained independent investigators conducting Pain and/or SUD research, in order to increase the independent investigator workforce in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, an ancillary study to a clinical trial, or an independent Basic Experimental Studies with Humans (BESH). Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing an independent BESH as lead investigator, should apply to the companion FOA (RFA-NS-22-023).

125534	NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-193	07-Sep-2024	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis</p>	<p>The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Candidates not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-194).</p>
--	---

125537	NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-194	07-Sep-2024	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-193).</p>				
125516	<p>Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)</p>	National Institutes of Health/DHHS	PA-24-183	07-Sep-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-496-8580</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
125527	Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-177	07-Sep-2024	Not Specified

Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Contact Name	
Contact Telephone	
Contact Email	grantsinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027
Synopsis	<p>The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.				
125530	Independent Scientist Award (Parent K02 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-178	07-Sep-2024	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	grantinfo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027			
	Synopsis	<p>The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-179).</p>			
125513	Mentored Clinical Scientist Research Career Development Award (Parent K08 – Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-182	07-Sep-2024	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 301-496-8580</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-181).</p>				
125524	Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-175	07-Sep-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantsinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and "protected time" (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-176).</p>			
125532	Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-179	07-Sep-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis</p>	<p>The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by another investigator. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-178). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-179).</p>			
125526	Mentored Research Scientist Development Award (Parent K01 - Independent	National Institutes of	PA-24-176	07-Sep-2024	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Clinical Trial Not Allowed	Health/DHHS			Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantsinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs use the K01 to support career development in specific fields. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-175).</p>				
108327	Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)	National Institutes of Health/DHHS	PAR-21-357	07-Sep-2024	375,000 USD
	<p>Contact Name Mahua Mukhopadhyay, Ph.D.</p> <p>Contact Telephone 301-435-6886</p> <p>Contact Email mukhopam@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate or advanced science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the schools and colleges within the institution as a whole. Help determining the Organization Funding Level can be found here or <https://grants.nih.gov/grants/funding/r15.htm>. This REAP funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. For purposes of this FOA, minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.

110968	National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-22-143	25-Oct-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name | Linda Brady, Ph.D.
 Contact Telephone | 301-443-3563
 Contact Email | lbrady@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 25-Oct-2024 , 24-Feb-2025

Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies appropriate for this FOA will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders or alcohol use disorder (AUD); develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative candidates for mental disorders or AUD; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders or AUD. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or AUD, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach should consider the companion FOA (PAR-22-144) This FOA will also support

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral vector-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). This FOA supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.

126793	NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08 - Basic Experimental Studies with Humans (BESH) Required)	National Institutes of Health/DHHS	PAR-24-218	12-Oct-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Laura D. Wandner
Contact Telephone	
Contact Email	Laura.Wandner@nih.gov
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	12-Oct-2024 , 12-Nov-2024 , 12-Feb-2025 , 12-Mar-2025 , 12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2025 , 12-Feb-2026 , 12-Mar-2026 , 12-Jun-2026 , 12-Jul-2026 , 12-Oct-2026 , 12-Nov-2026 , 12-Feb-2027 , 12-Mar-2027 , 12-Jun-2027 , 12-Jul-2027
Synopsis	<p>The purpose of this NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08) (BESH) is to support the career development of individuals with clinical doctoral degrees to create a group of new and well-trained, independent investigators. This supervised career development program will provide independent NIH research support during the early-career phase to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative’s Clinical Research in Pain Management program. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial basic experimental study with humans led by another investigator, must apply to the Independent Clinical Trial Not Allowed companion NOFO.			
113466	Notice of Special Interest (NOSI): BRAIN Initiative: Notice of Support for Research on Interoception Circuits	National Institutes of Health/DHHS	NOT-AT-23-003	13-Sep-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 13-Sep-2024 , 21-Sep-2024 , 02-Oct-2024 Synopsis The purpose of this announcement is to notify the research community that NIH welcomes BRAIN Initiative applications targeting interoceptive processes and circuits, as appropriate to the goals and requirements of specific BRAIN Initiative FOAs.				
115095	Mentored Career Development Program for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-23-073	07-Sep-2024	Not Specified
	Contact Name Contact Telephone Contact Email AITraininghelpdesk@niaid.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to provide early-stage investigators with support and “protected time” (up to five years) for intensive, research-focused career development program activities under the guidance of an experienced mentorship team with expertise in both the preclinical application of nonhuman primate (NHP) models and in translation of the results from such studies to clinical application. The focus of this program is to increase the number of				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>highly skilled scientists using NHP models to address complex translational biomedical research designed to foster translation of outcomes into the clinic. The expectation is that through this sustained period of research career development and training, awardees will launch independent research careers and become competitive for new research project grant (e.g., R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p>			
125230	Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-186	07-Sep-2024	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	grantinfo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027			
	Synopsis	<p>The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>			
125228	Mentored Patient-Oriented Research Career Development Award (Parent K23 – Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-185	07-Sep-2024	Not Specified
	Contact Name				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Contact Telephone Contact Email grantinfo@nih.gov Sponsor Website Program URL Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-184).				
Synopsis					

125227	Mentored Patient-Oriented Research Career Development Award (Parent K23 – Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-184	07-Sep-2024	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

	Contact Name Contact Telephone Contact Email grantinfo@nih.gov Sponsor Website Program URL Link to program URL				
Deadline Dates (ALL)	07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-185).				
Synopsis					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
125538	NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-195	07-Sep-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>				
125559	Midcareer Investigator Award in Patient-Oriented Research (Parent K24 - Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-189	07-Sep-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and junior clinical faculty. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>				
125557	Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-187	07-Sep-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-188).</p>				
125583	Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-180	07-Sep-2024	Not Specified

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>GrantsInfo@nih.gov</p> <p>Link to program URL</p> <p>07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans,</p>
---	---

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

125558	Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-188	07-Sep-2024	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis</p>	<p>The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and/or junior clinical faculty. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-187).</p>
--	---

112444	HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23 - Clinical Trial Required)	National Institutes of Health/DHHS	PAS-22-207	12-Oct-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email Lori.Ducharme@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025</p>	<p>Lori Ducharme, Ph.D.</p> <p>301-827-6331</p>
--	---

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Synopsis	<p>The purpose of this Mentored Patient-Oriented Research Career Development Award in Implementation Science for Substance Use Prevention and Treatment (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research from an implementation science perspective. These awards provide salary and research support for a sustained period of “protected time” (3-5 years) for an intensive, supervised career development experience leading to research independence in this area of specialization. Realizing the return on public investment in the development of evidence-based treatments and preventive interventions to address the ongoing overdose crisis depends on a cadre of skilled clinician researchers with expertise in implementation science, who can help move these interventions into routine clinical practice. Implementation science focuses on identifying modifiable barriers to the uptake and sustained use of evidence-based practices in real world clinical settings, and developing replicable and scalable strategies to overcome those barriers. While this field has grown rapidly over the past 15 years, there remain a limited number of independent clinician researchers with dual expertise in substance use and implementation science, limiting the field’s capacity to address persistent gaps in this area. There is a pressing need for a deeper bench of clinician researchers who can be called upon to meet ongoing and emerging implementation challenges in the substance use field. This Funding Opportunity Announcement (FOA) will support early career investigators who have foundational clinical training in substance use prevention or treatment and/or co-occurring mental illness, and will provide support and protected time to acquire training and research experience in implementation science. Development and execution of an independent NIH-defined clinical trial applying implementation science methods to patient-oriented research in one or more of the four domains of the HHS Overdose Prevention Strategy (prevention; evidence-based addiction treatment; harm reduction; or recovery research) is required. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, should consult the NIH Research Career Development Awards website for alternative funding opportunities.</p>			
--	----------	--	--	--	--

112443	HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required)	National Institutes of Health/DHHS	PAS-22-206	12-Oct-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Lori Ducharme, Ph.D.
Contact Telephone	301-827-6331
Contact Email	Lori.Ducharme@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p style="text-align: center;">Synopsis</p>	<p>The purpose of this Mentored Research Scientist Development Award in Implementation Science for Substance Use Prevention and Treatment (K01) is to provide support and “protected time” (3-5 years) for an intensive, supervised career development experience leading to research independence in this area of specialization. Realizing the return on public investment in the development of evidence-based treatments and preventive interventions to address the ongoing overdose crisis depends on a cadre of skilled researchers with expertise in implementation science, who can help move these interventions into routine practice. Implementation science focuses on identifying modifiable barriers to the uptake and sustained use of evidence-based practices in real world settings and developing replicable and scalable strategies to overcome those barriers. While this field has grown rapidly over the past 15 years, there remain a limited number of independent researchers with dual expertise in addiction research and implementation science, constraining the field’s capacity to respond to continued calls for research in this area. There is a pressing need for a deeper bench of researchers who can be called upon to meet ongoing and emerging implementation challenges in the addiction field. This Funding Opportunity Announcement (FOA) will support early career investigators who have foundational training in substance use prevention or treatment research and will provide support and protected time to acquire training and research experience in implementation science. Development and execution of an independent NIH-defined clinical trial applying implementation science methods to one of the four domains of the HHS Overdose Prevention Strategy (prevention; evidence-based addiction treatment; harm reduction; or recovery research) is required. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, should consult the NIH Research Career Development Awards website for alternative funding opportunities.</p>			
--	---	--	--	--	--

112749	Notice of Special Interest (NOSI): HEAL Initiative: Opioid Use Disorder Care Pathways for Individuals with Histories of Exposure to Violence	National Institutes of Health/DHHS	NOT-DA-23-007	12-Oct-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Carrie Mulford
Contact Telephone	301-827-6473
Contact Email	Carrie.Mulford@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025
Synopsis	The proposed initiative seeks to test innovative models of service delivery to improve substance use and mental health outcomes for individuals who have actionable needs following exposure to violence.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
121738	Advancing Research Careers (ARC) Predoctoral to Postdoctoral Transition Award to Promote Diversity (F99/K00 - Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-23-222	07-Sep-2024	Not Specified
	<p>Contact Name Laurie Stepanek, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email laurie.stepanek@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 11-Oct-2024 , 07-Jan-2025 , 13-Feb-2025 , 07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 10-Oct-2025 , 07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 15-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-Jan-2027 , 11-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the Advancing Research Careers (ARC) Predoctoral to Postdoctoral Transition Award to Promote Diversity (F99/K00) program is to support promising, late-stage graduate students from diverse backgrounds, for example those from underrepresented groups (see Notice of NIH's Interest in Diversity), to transition into and succeed in mentored postdoctoral research positions. It is anticipated that successful completion of this phased award program will position ARC scholars to advance in impactful careers in the biomedical research workforce that typically require postdoctoral training (e.g., academic research and teaching at a range of institution types, industry or government research). This two-phase award will provide support for late-stage graduate students pursuing research related to the mission areas of participating NIH Institutes, Centers, and Offices (ICOs) to facilitate the completion of doctoral dissertation projects and research training (F99 phase), and to transition into and succeed in postdoctoral biomedical research and career development opportunities (K00 phase). ARC F99 fellows/K00 scholars will be part of organized cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by ARC Institutionally-Focused Research Education Award to Promote Diversity (UE5) recipients. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Candidates to this NOFO are permitted to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
122207	Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-293	21-Oct-2024	Not Specified
	<p>Contact Name Dave Kaufman</p> <p>Contact Telephone 301-402-4997</p> <p>Contact Email dave.kaufman@nih.gov</p> <p>Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Oct-2024 , 20-Feb-2025 , 17-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 20-Oct-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genetic or genomic research. Applications may propose studies using either single or mixed methods. Approaches may include but are not limited to empirical qualitative and quantitative methods, and conceptual, legal, and normative analyses. Applied research designed to address ELSI issues in genetics and genomics will also be considered responsive. Direct engagement with communities and other interested groups is encouraged, but not required. Plan for Enhancing Diverse Perspectives The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: Transdisciplinary research projects and collaborations among researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-career investigators. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
122256	Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-294	21-Oct-2024	275,000 USD
	<p>Contact Name Dave Kaufman</p> <p>Contact Telephone 301-402-4997</p> <p>Contact Email dave.kaufman@nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Oct-2024 , 20-Feb-2025 , 17-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 20-Oct-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genetic or genomic research. Applications may propose studies using either single or mixed methods, that break new ground, extend previous discoveries in new directions, or develop preliminary data in preparation for larger studies. Approaches may include but are not limited to empirical qualitative and quantitative methods, and conceptual, legal, and normative analyses. Applied research designed to address ELSI issues in genetics and genomics will also be considered responsive. Direct engagement with communities and other stakeholders is encouraged, but not required.</p>				
122258	Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-295	21-Oct-2024	100,000 USD
	<p>Contact Name Dave Kaufman</p> <p>Contact Telephone 301-402-4997</p> <p>Contact Email dave.kaufman@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Oct-2024 , 20-Feb-2025 , 17-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 20-Oct-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites Small Research Grant (R03) applications that propose to study the ethical, legal and social implications (ELSI) of human genetic or genomic research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data. Applications may propose studies using either single or mixed methods. Applied research designed to address ELSI issues in genetics and genomics will also be considered responsive. Direct engagement with communities and other stakeholders is encouraged, but not required.</p>				
102740	Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-124	21-Oct-2024	750,000 USD
	Contact Name Becky Roof, PhD				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-1779</p> <p>Contact Email rebecca.roof@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Oct-2024</p> <p>Synopsis This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.</p>				
114710	<p>RFA-NS-22-024 -- HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research to Promote Diversity (K99/R00 Independent Basic Experimental Studies with Humans Required)</p>	National Institutes of Health/DHHS	RFA-NS-22-024	11-Oct-2024	Not Specified
	<p>Contact Name DP Mohapatra, Ph.D.</p> <p>Contact Telephone 301-496-9964</p> <p>Contact Email dp.mohapatra@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Oct-2024 , 11-Feb-2025</p> <p>Synopsis The purpose of this NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new and well-trained, independent investigators from diverse backgrounds (e.g. see NOT-OD-20-031, Notice of NIH’s Interest in Diversity) conducting Pain and/or SUD research, in order to promote a diverse pool of available independent investigators working in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

114711	RFA-NS-22-025 -- HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-NS-22-025	11-Oct-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name | DP Mohapatra, Ph.D.
 Contact Telephone | 301-496-9964
 Contact Email | dp.mohapatra@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 11-Oct-2024 , 11-Feb-2025

Synopsis | The purpose of this NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new and well-trained, independent investigators from diverse backgrounds (e.g. see NOT-OD-20-031, Notice of NIH's Interest in Diversity) conducting Pain and/or SUD research, in order to promote a diverse pool of available independent investigators working in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, an ancillary study to a clinical trial, or an independent Basic Experimental Studies with Humans (BESH). Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing an independent BESH as lead investigator, should apply to the companion FOA (RFA-NS-22-024).

114707	RFA-NS-22-023 -- HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research (Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	RFA-NS-22-023	11-Oct-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name | DP Mohapatra, Ph.D.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-9964</p> <p>Contact Email dp.mohapatra@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Oct-2024 , 11-Feb-2025</p> <p>Synopsis The purpose of the NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new and well-trained independent investigators conducting Pain and/or SUD research, in order to increase the independent investigator workforce in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>				
108065	Notice of Special Interest (NOSI): Pediatric COVID-19 and Respiratory Viral Co-infection	National Institutes of Health/DHHS	NOT-HL-22-004	07-Sep-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis This NOSI is intended to support projects that will employ existing and new clinical trial cohorts/observational cohorts to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	screen for co-infection, phenotype and collect biospecimens to answer some of these questions and to encourage investigator-initiated applications for basic, translational and human subject research (not clinical trials) in this space.				
108347	Notice of Special Interest (NOSI): Advancing NEI AGI Research on newly Identified Factors Into Models of Visual System Regeneration	National Institutes of Health/DHHS	NOT-EY-22-002	05-Sep-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024</p> <p>Synopsis The National Eye Institute (NEI) is issuing this Notice of Special Interest (NOSI) to encourage novel research that incorporates newly identified factors into new or existing models of visual system regeneration. These factors were identified by a consortium of research teams as part of the Audacious Goal Initiative (AGI) and are being shared broadly with the research community. Applicants beyond the original consortium are strongly encouraged to apply.</p>				
125485	Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-192	07-Sep-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>research. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>			
125482	Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-190	07-Sep-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis</p>	<p>The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Candidates not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-191).</p>			
125483	Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-191	07-Sep-2024	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-192).</p>				
125512	Mentored Clinical Scientist Research Career Development Award (Parent K08 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-181	07-Sep-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-496-8580</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>biomedical and behavioral research, including translational research. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-182).</p>				
111464	Notice of Special Interest (NOSI): Mentored Career Development Awards to Foster the Careers of Investigators Pursuing Research Related to Down syndrome as Part of the INCLUDE Project	National Institutes of Health/DHHS	NOT-OD-22-124	07-Sep-2024	Not Specified
	<p>Contact Name Charlene Schramm, PhD Contact Telephone 301-402-3793 Contact Email schrammc@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-Sep-2024 , 12-Oct-2024</p> <p>Synopsis The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH support for the professional development of early career scientists aiming to establish a career in DS-related research. By providing these scientists with training, resources, and mentorship, the NIH intends to support the career development of junior investigators in DS who will lead future research to improve the understanding of the biology of DS and support development of new treatments for health conditions experienced by those with DS.</p>				
094033	NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical	National Institutes of	PA-20-195	07-Sep-2024	275,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Trial Not Allowed	Health/DHHS			USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantsinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R21 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>				
094032	NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-194	07-Sep-2024	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantsinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (see Related Notices) only accept applications proposing mechanistic studies that meet NIH's</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>definition of a clinical trial through this funding opportunity announcement. The following Institutes/Centers only accept mechanistic studies that meet NIH's definition of a clinical trial. See Related Notices section below. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institute of Mental Health (NIMH) Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R21 Basic Experimental Studies with Humans Required IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>				
094034	NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-196	07-Sep-2024	275,000 USD
	Contact Name				
	Contact Telephone	301-496-4000			
	Contact Email	grantsinfo@od.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	<p>The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R21 Basic Experimental Studies with Humans Required IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
107449	Notice of Special Interest (NOSI): Reducing Stigma Related to Drug Use in Human Service Settings	National Institutes of Health/DHHS	NOT-DA-21-060	07-Sep-2024	Not Specified
	<p>Contact Name Richard A. Jenkins PhD</p> <p>Contact Telephone 301-443-1923</p> <p>Contact Email jenkinsri@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The National Institute on Drug Abuse (NIDA) recognizes that stigma is pervasive in clinic, social service and other settings related to HIV prevention and care. Stigma contributes to a lack of attention to drug use screening, inadequate outreach to people who use drugs (PWUD) and insufficient uptake of services to prevent, treat, or mitigate HIV infection (and related consequences of drug use) among PWUD. Stigmas of interest include: internalized stigma among drug users, stigma associated with providing services to PWUD, and stigma toward PWUD by providers or service settings. Policies and practices that create or augment stigma also are of interest here, as well as stigma experienced by providers who might otherwise broaden their services to PWUD. Stigma reduction interventions for HIV service settings have been developed and, in some cases, implemented on a wide scale, but generally target sexual transmission as the primary behavioral risk; however, knowledge from this work can inform stigma among PWUD. Large literatures on stigma also exist in a variety of other conditions (e.g., cancer, mental illness) which also can provide conceptual and programmatic bases to speed the development of new interventions addressing PWUD.</p>				
106966	Notice of Special Interest (NOSI): Somatic Cell Gene Editing Therapies To Improve Transplantation Outcomes	National Institutes of Health/DHHS	NOT-AI-21-080	07-Sep-2024	Not Specified
	<p>Contact Name Nasrin Nabavi, Ph.D.</p> <p>Contact Telephone 240-627-3538</p> <p>Contact Email nnabavi@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting research that applies somatic cell gene editing (SCGE) approaches to improve graft survival and outcomes for recipients of allogenic solid organ, pancreatic</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	islet, or vascularized composite allograft (VCA) transplants in animal models or human tissues or organs excluded from clinical use.				
107248	Notice of Special Interest (NOSI): Improving Outcomes in Cancer Treatment-Related Cardiotoxicity	National Institutes of Health/DHHS	NOT-CA-22-001	07-Sep-2024	Not Specified
	<p>Contact Name Crystal Wolfrey</p> <p>Contact Telephone 240-276-6277</p> <p>Contact Email wolfreyc@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 08-Oct-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to encourage collaborative and innovative approaches to mitigate cardiovascular dysfunction while optimizing cancer outcomes by understanding the mechanisms of cancer treatment-related cardiotoxicity and translating the findings to improve risk stratification, early detection, prevention, and management.</p>				
117692	RFA-MH-23-331 -- BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-MH-23-331	11-Oct-2024	Not Specified
	<p>Contact Name James Churchill, Ph.D.</p> <p>Contact Telephone 301-326-8800</p> <p>Contact Email BRAINDIVERSITYK99R00@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Oct-2024 , 13-Feb-2025 , 13-Jun-2025 , 15-Oct-2025 , 13-Feb-2026</p> <p>Synopsis The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds, including those from underrepresented groups in the biomedical and behavioral sciences, in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to assist awardees in launching independent research careers. This</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this Notice of Funding Opportunity (NOFO) are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (RFA-MH-22-330).

117690	RFA-MH-23-330 -- BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Required)	National Institutes of Health/DHHS	RFA-MH-23-330	11-Oct-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	James Churchill, Ph.D.
Contact Telephone	301-326-8800
Contact Email	BRAINDIVERSITYK99R00@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	11-Oct-2024 , 13-Feb-2025 , 13-Jun-2025 , 15-Oct-2025 , 13-Feb-2026

Synopsis The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds, including those from underrepresented groups in the biomedical and behavioral sciences, in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to assist awardees in launching independent research careers. This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (RFA-MH-22-331).</p>			
104076	Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional)	National Institutes of Health/DHHS	PA-21-180	07-Sep-2024	450,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Carrie Mulford</p> <p>Carrie.Mulford@nih.gov</p> <p>Link to program URL</p> <p>07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>This Funding Opportunity Announcement (FOA) encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches, in addition to usual trial preparation activities.</p>			
111986	Notice of Special Interest (NOSI): Stimulating Research to Understand and Address Hunger, Food and Nutrition Insecurity	National Institutes of Health/DHHS	NOT-OD-22-135	07-Sep-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Marya Levintova, PhD</p> <p>301-496-9535</p> <p>marya.levintova@nih.gov</p> <p>Link to program URL</p> <p>07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024</p> <p>The purpose of this NOSI is to encourage research on the efficacy of interventions that address nutrition security and the mechanisms of food insecurity on a variety of health outcomes. It also calls for the development of new measures for</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	nutrition security and assessment of food insecurity that are broadly applicable. . It was developed by the Office of Nutrition Research (ONR) Implementation Working Group on Nutrition and Health Disparities in collaboration with NIH Institutes and Centers (ICs) and Offices in support of the goals and objectives of the Strategic Plan for NIH Nutrition Research.																		
111858	Notice of Special Interest (NOSI): Preventive Interventions to Address Cardiometabolic Risk Factors in Populations that Experience Health Disparities	National Institutes of Health/DHHS	NOT-OD-22-154	07-Sep-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Jennifer Alvidrez, PhD</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-827-0071</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>Jennifer.alvidrez@nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The purpose of this NOSI is to solicit projects on preventive interventions that address cardiometabolic risk factors in populations that experience health disparities.</td> </tr> </table>					Contact Name	Jennifer Alvidrez, PhD	Contact Telephone	301-827-0071	Contact Email	Jennifer.alvidrez@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025	Synopsis	The purpose of this NOSI is to solicit projects on preventive interventions that address cardiometabolic risk factors in populations that experience health disparities.
Contact Name	Jennifer Alvidrez, PhD																		
Contact Telephone	301-827-0071																		
Contact Email	Jennifer.alvidrez@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025																		
Synopsis	The purpose of this NOSI is to solicit projects on preventive interventions that address cardiometabolic risk factors in populations that experience health disparities.																		
111039	Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-22-109	07-Sep-2024	275,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Gila Neta, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>240-276-6785</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>gila.neta@nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health</td> </tr> </table>					Contact Name	Gila Neta, Ph.D.	Contact Telephone	240-276-6785	Contact Email	gila.neta@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health
Contact Name	Gila Neta, Ph.D.																		
Contact Telephone	240-276-6785																		
Contact Email	gila.neta@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025																		
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.

111040	Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-106	07-Sep-2024	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Gila Neta, Ph.D.</p> <p>240-276-6785</p> <p>gila.neta@nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.</p>
---	--

114123	Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-23-047	07-Sep-2024	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>David M. Panchision, Ph.D.</p> <p>301-443-5288</p> <p>panchisiond@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026</p>
---	---

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high reward projects that lack preliminary data may be most appropriate for this FOA. Applicants with preliminary data may instead wish to apply to the companion R01 mechanism (PAR-23-046).</p>			
114061	Notice of Special Interest (NOSI): Explainable Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Linked to Behavior	National Institutes of Health/DHHS	NOT-MH-23-110	07-Sep-2024	Not Specified
	Contact Name	Mauricio Rangel-Gomez, Ph.D.			
	Contact Telephone	301-435-6908			
	Contact Email	mauricio.rangel-gomez@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026			
	Synopsis	<p>This Notice of Special Interest (NOSI) solicits applications in the area of XAI applied to neuroscientific questions of encoding, decoding, and modulation of neural circuits linked to behavior. This NOSI encourages collaborations between computationally and experimentally focused investigators. This NOSI seeks the development of machine learning algorithms that are able to mechanistically explain how experimental manipulations affect cognitive, affective, or social processing in humans or animals. Proof-of-concept applications aimed at improving the current state of the technology that uses XAI to provide unbiased, hierarchical explanations of causal relationships between complex neural and behavioral data are also appropriate.</p>			
114857	Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-23-075	16-Oct-2024	200,000 USD
	Contact Name	James N. Coulombe, Ph.D.			
	Contact Telephone	301-451-1390			
	Contact Email	CoulombeJ@mail.nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025</p> <p>Synopsis The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. Kids First has established and continues to develop a Data Resource including a collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed.</p>				
115062	<p>Notice of Special Interest (NOSI): argeting the Endocannabinoid System for Brain Health and Acute and Chronic Diseases</p>	National Institutes of Health/DHHS	NOT-DA-22-048	07-Sep-2024	Not Specified
	<p>Contact Name Yu (Woody) Lin, PhD</p> <p>Contact Telephone 301-435-1318</p> <p>Contact Email ylin1@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 25-Sep-2024 , 05-Oct-2024 , 10-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 25-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 13-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 25-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 25-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis This Notice of Special Interest (NOSI) encourages studies of the endocannabinoid system (ECS) and its roles in brain health and acute and chronic disease, substance use, and substance use disorder (SUD). The desired outcomes of research will be a mechanistic understanding of how cannabinoids and manipulation of the ECS can elicit both therapeutic and deleterious effects as well as the role of cannabinoids and ECS in symptom management.</p>				
116487	<p>Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)</p>	National Institutes of Health/DHHS	PAR-23-131	16-Oct-2024	275,000 USD
	<p>Contact Name Katie M. Vance, Ph.D.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-435-6640</p> <p>Contact Email Katie.Vance@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.</p>				
117360	Notice of Special Interest (NOSI): Research to Address Vaccine Uptake and Implementation among Populations Experiencing Health Disparities	National Institutes of Health/DHHS	NOT-MD-23-008	05-Oct-2024	Not Specified
	<p>Contact Name Deborah E. Linares, Ph.D., M.A.</p> <p>Contact Telephone 301-402-2516</p> <p>Contact Email deborah.linares@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 07-Nov-2024 , 05-Feb-2025 , 16-Feb-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Feb-2026 , 16-Feb-2026 , 05-Jun-2026</p> <p>Synopsis This Notice of Special Interest (NOSI) highlights the need for research on strategies and interventions to increase vaccine uptake and implementation among populations experiencing health disparities in the United States (U.S.) and its territories. Research is needed to understand and address misinformation, uncertainty, distrust, and hesitancy regarding uptake of vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), varicella, tetanus, diphtheria, and pertussis [Tdap]) among individuals in the U.S. and its territories, especially in populations at increased risk for morbidity and mortality due to long-standing systemic health and social inequities, as well as chronic medical conditions. This NOSI is focused on individuals across the life span (i.e., all ages). The purpose of this NOSI is to solicit research that will: 1) understand and address barriers to increasing reach, access, and uptake of vaccinations among populations experiencing</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	health disparities; 2) evaluate organizational, local, state, and federal policies and initiatives that mitigate or exacerbate disparities in vaccine access, uptake, and series completion, and 3) evaluate community-engaged interventions (e.g., expand reach, address psychosocial barriers, and social determinants of health [SDOH]) to facilitate vaccination uptake in clinical and community contexts.				
119255	Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-208	16-Oct-2024	275,000 USD
	<p>Contact Name Laura M. Rowland, Ph.D.</p> <p>Contact Telephone 301-480-8335</p> <p>Contact Email laura.rowland@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026</p> <p>Synopsis The goal of this Notice of Funding Opportunity (NOFO) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This NOFO uses the R21 mechanism, while the companion PAR-23-207 uses the R01 grant mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism, while applicants with preliminary data who seek longer-term funding should apply using the R01 mechanism.</p>				
123347	Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-24-060	07-Sep-2024	450,000 USD
	<p>Contact Name Amy B. Goldstein, PhD</p> <p>Contact Telephone 301-827-4124</p> <p>Contact Email amy.goldstein@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of this notice of funding opportunity (NOFO) is to encourage theoretically driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. The latter may include pilot studies of strategies or approaches to intervention, and/or other service system-based research to address areas such as economics, funding, service quality and engagement. In addition to the prevention of substance use, misuse and disorder, other outcomes of interest for the research supported through this NOFO include a reduction in negative sequelae of use, such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.</p>			
105756	Investigator Initiated Research in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-255	16-Oct-2024	275,000 USD
	Contact Name	Daniel Gilchrist, Ph.D.			
	Contact Telephone				
	Contact Email	daniel.gilchrist@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Oct-2024			
	Synopsis	<p>The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research that develops innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems.</p>			
109792	Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-138	07-Sep-2024	275,000 USD
	Contact Name	Julia Zehr, Ph.D.			
	Contact Telephone	301-443-1617			
	Contact Email	Zehrj@mail.nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org). This FOA seeks shorter, higher-risk</p>				
109181	Notice of Special Interest (NOSI): Public Health Research on Cannabis	National Institutes of Health/DHHS	NOT-DA-22-003	07-Sep-2024	Not Specified
	<p>Contact Name Marsha Lopez, PhD</p> <p>Contact Telephone (301) 402-1846</p> <p>Contact Email (301) 402-1846</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025</p> <p>Synopsis The National Institute on Drug Abuse (NIDA) is issuing this notice to encourage grant applications on the effects of changing cannabis laws and policies in the US and globally on public health.</p>				
108357	Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-060	07-Sep-2024	375,000 USD
	<p>Contact Name Lisa Chadwick</p> <p>Contact Telephone 301-435-7275</p> <p>Contact Email lisa.chadwick@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p style="text-align: center;">Synopsis</p> <p>The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate or advanced science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the schools and colleges within the institution as a whole. Help determining the Organization Funding Level can be found here or https://grants.nih.gov/grants/funding/r15.htm.</p>				
110969	National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U19 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-22-144	25-Oct-2024	Not Specified

	Contact Name	Linda Brady, Ph.D.
	Contact Telephone	301-443-3563
	Contact Email	lbrady@mail.nih.gov
	Sponsor Website	
	Program URL	Link to program URL
	Deadline Dates (ALL)	25-Oct-2024 , 24-Feb-2025
Synopsis		<p>The purpose of this Funding Opportunity Announcement (FOA) is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies appropriate for this FOA will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders or alcohol use disorder (AUD); develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative candidates for mental disorders; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders or AUD. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or or AUD, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach should consider the companion FOA (PAR-22-143). This FOA will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including,</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral vector-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). This FOA supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.</p>				
114377	Notice of Special Interest (NOSI): Advancing Research for Tickborne Diseases (TBDs)	National Institutes of Health/DHHS	NOT-AI-23-013	05-Sep-2024	Not Specified
	<p>Contact Name Samuel Perdue, Ph.D. Contact Telephone 240-627-3341 Contact Email sperdue@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to announce that the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Mental Health (NIMH), and the National Institute of Neurological Disorders and Stroke (NINDS), encourage applications to advance research activities relevant to the five strategic priorities identified in the recently released NIH Strategic Plan for Tickborne Disease Research: Improve fundamental knowledge of Tickborne Diseases (TBDs) to understand the host, vector, and pathogen factors that drive TBD pathogenesis and transmission. Elucidate the host immune mechanisms in response to and exploited by TBD pathogens. Advance research to improve the diagnosis of TBDs using both host- and pathogen-targeted approaches, including research for rapid diagnostics and multiplex platform approaches that detect multiple tickborne pathogens. Accelerate research to improve TBD prevention by supporting science to design, develop, and evaluate vaccines, vector control strategies, and other prevention approaches. Promote research to improve treatment for all forms of TBDs, including studies to develop effective therapies to treat symptoms that persist after TBD treatment, therapies for non-infectious TBDs, and new antimicrobials. Support tools and resources to advance research in understanding, preventing, diagnosing, and treating TBDs, including repositories, genomic resources, animal models, and preclinical services to aid the development and assessment of diagnostic, vaccine, and therapeutic candidates.</p>				
111618	Notice of Special Interest (NOSI): Developing Academic Research Enhancement Award (AREA) and Research Enhancement Award Program (REAP) for Institutions	National Institutes of Health/DHHS	NOT-OD-22-136	07-Sep-2024	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[With an Emphasis On Down Syndrome Research \(R15 Clinical Trial Not Allowed\)](#)

	<p>Contact Name Sujata Barhan, Ph.D.</p> <p>Contact Telephone 301-435-0471</p> <p>Contact Email sujata.bardhan@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH support for development of Academic Research Enhancement Award (AREA) and Research Enhancement Award Program (REAP) applications to support small scale basic and translational research grants that meet programmatic objectives of the INCLUDE project at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate and/or graduate students and enhancing the research environment at applicant institutions. Eligible institutions must award NIH-relevant baccalaureate or advanced degrees in health professions and have received less than \$6 million per year of NIH support (total costs) in 4 of the last 7 fiscal years. In this FOA, a college is a stand-alone entity and not a component of a university system. The goal of this NOSI is also to build a pathway of meritorious undergraduate and graduate students engaged in Down syndrome research.</p>				
113804	<p>Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest</p>	National Institutes of Health/DHHS	NOT-HD-22-038	07-Sep-2024	Not Specified

	<p>Contact Name Elyse R. Grossman</p> <p>Contact Telephone 240-551-3628</p> <p>Contact Email elyse.grossman@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis This notice informs applicants of an expansion to the NOT-HD-22-038 "Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest" to include research priority areas for the National Institute on Drug Abuse (NIDA). The National Institute on Drug Abuse (NIDA) is issuing</p>				
--	--	--	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>this Notice of Special Interest (NOSI) to announce that research on the effects of: emerging and evolving public health crises; and/or policy changes on the health, development, and well-being of populations of interest to the NIDA is of high program priority. The NIDA populations of interest include neonates, infants, children, adolescents, young adults, adults, and older adults, people using or misusing substances, people with substance use disorders, as well as the families of these individuals. The NIDA supports research on the impact of policy in understanding and addressing substance use risk and behavior across the life span. For information on the NIDA Strategic Goals and Mission, see https://nida.nih.gov/about-nida/strategic-plan/nidas-mission.</p>				
114675	Notice of Special Interest (NOSI): Optimization of Data Storage and Utilization for the Sequence Read Archive (SRA)	National Institutes of Health/DHHS	NOT-GM-23-015	08-Aug-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Aug-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 08-Dec-2024 , 05-Jan-2025 , 07-Jan-2025 , 16-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 25-Feb-2025 , 05-Apr-2025 , 12-Apr-2025 , 07-May-2025 , 16-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 25-Jun-2025 , 08-Aug-2025 , 05-Sep-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 25-Oct-2025 , 08-Dec-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to inform the scientific community of the interest of NIGMS, NLM, and ODSS in supporting efficiency optimization and cost reduction for Sequence Read Archive (SRA) data storage and utilization.</p>				
103023	Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-166	05-Oct-2024	2,495,000 USD
	<p>Contact Name Miguel Ossandon MS</p> <p>Contact Telephone 240-276-5714</p> <p>Contact Email ossandom@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Nov-2024</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users.</p>			
106119	Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-21-313	07-Sep-2024	375,000 USD
	Contact Name	Katrina J. Serrano, Ph.D.			
	Contact Telephone	301-480-7855			
	Contact Email	katrina.serrano@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social sciences research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Human Genome Research Institute (NHGRI) or the National Institute of Biomedical Imaging and Bioengineering (NIBIB). New investigators at the time of award under this FOA will have had less than \$125,000 direct costs of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate transition to research independence. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	development of new research technology.																		
112904	Notice of Special Interest (NOSI): Research on the Health of Bisexual and Bisexual+ People	National Institutes of Health/DHHS	NOT-OD-22-166	07-Sep-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 10px;">Contact Name</td> <td>Christopher Barnhart, PhD</td> </tr> <tr> <td style="padding-right: 10px;">Contact Telephone</td> <td>301-594-8983</td> </tr> <tr> <td style="padding-right: 10px;">Contact Email</td> <td>christopher.barnhart@nih.gov</td> </tr> <tr> <td style="padding-right: 10px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 10px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 10px;">Deadline Dates (ALL)</td> <td>07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</td> </tr> <tr> <td style="padding-right: 10px;">Synopsis</td> <td>This Notice of Special Interest (NOSI) solicits research, research training, and research career development on the health and well-being of people who identify as bisexual or bisexual+. “Bisexual” or “bi” in this NOSI may describe those with the potential to be attracted, romantically and/or sexually, to people of more than one sex or gender, not necessarily at the same time, not necessarily in the same way, and not necessarily to the same degree. “Bisexual+” or “bi+” in this NOSI is an umbrella term that is intended to encompass non-monosexual identities, including but not limited to bisexual, pansexual, sexually fluid, and queer.</td> </tr> </table>					Contact Name	Christopher Barnhart, PhD	Contact Telephone	301-594-8983	Contact Email	christopher.barnhart@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025	Synopsis	This Notice of Special Interest (NOSI) solicits research, research training, and research career development on the health and well-being of people who identify as bisexual or bisexual+. “Bisexual” or “bi” in this NOSI may describe those with the potential to be attracted, romantically and/or sexually, to people of more than one sex or gender, not necessarily at the same time, not necessarily in the same way, and not necessarily to the same degree. “Bisexual+” or “bi+” in this NOSI is an umbrella term that is intended to encompass non-monosexual identities, including but not limited to bisexual, pansexual, sexually fluid, and queer.
Contact Name	Christopher Barnhart, PhD																		
Contact Telephone	301-594-8983																		
Contact Email	christopher.barnhart@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025																		
Synopsis	This Notice of Special Interest (NOSI) solicits research, research training, and research career development on the health and well-being of people who identify as bisexual or bisexual+. “Bisexual” or “bi” in this NOSI may describe those with the potential to be attracted, romantically and/or sexually, to people of more than one sex or gender, not necessarily at the same time, not necessarily in the same way, and not necessarily to the same degree. “Bisexual+” or “bi+” in this NOSI is an umbrella term that is intended to encompass non-monosexual identities, including but not limited to bisexual, pansexual, sexually fluid, and queer.																		
114765	Notice of Special Interest (NOSI): Firearm Injury and Mortality Prevention Research	National Institutes of Health/DHHS	NOT-OD-23-039	07-Sep-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 10px;">Contact Name</td> <td>Dara R. Blachman, Ph.D.</td> </tr> <tr> <td style="padding-right: 10px;">Contact Telephone</td> <td></td> </tr> <tr> <td style="padding-right: 10px;">Contact Email</td> <td>Dara.blachman-demner@nih.gov</td> </tr> <tr> <td style="padding-right: 10px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 10px;">Program URL</td> <td></td> </tr> <tr> <td style="padding-right: 10px;">Deadline Dates (ALL)</td> <td>07-Sep-2024 , 08-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026</td> </tr> <tr> <td style="padding-right: 10px;">Synopsis</td> <td>The purpose of this Notice is to highlight interest in research to improve understanding of the determinants of firearm injury, the identification of those at risk of firearm injury (including self- and other-directed, victims and perpetrators, accidental injury), the development, piloting, and testing of innovative interventions to prevent firearm injury and mortality, and the</td> </tr> </table>					Contact Name	Dara R. Blachman, Ph.D.	Contact Telephone		Contact Email	Dara.blachman-demner@nih.gov	Sponsor Website		Program URL		Deadline Dates (ALL)	07-Sep-2024 , 08-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026	Synopsis	The purpose of this Notice is to highlight interest in research to improve understanding of the determinants of firearm injury, the identification of those at risk of firearm injury (including self- and other-directed, victims and perpetrators, accidental injury), the development, piloting, and testing of innovative interventions to prevent firearm injury and mortality, and the
Contact Name	Dara R. Blachman, Ph.D.																		
Contact Telephone																			
Contact Email	Dara.blachman-demner@nih.gov																		
Sponsor Website																			
Program URL																			
Deadline Dates (ALL)	07-Sep-2024 , 08-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026																		
Synopsis	The purpose of this Notice is to highlight interest in research to improve understanding of the determinants of firearm injury, the identification of those at risk of firearm injury (including self- and other-directed, victims and perpetrators, accidental injury), the development, piloting, and testing of innovative interventions to prevent firearm injury and mortality, and the																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	examination of approaches to improve the implementation of existing, evidence-based interventions to prevent firearm injury and mortality.				
127139	Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	PAR-24-226	07-Sep-2024	Not Specified
	<p>Contact Name: Lanay M. Mudd, Ph.D., FACSM</p> <p>Contact Telephone: 301-594-9346</p> <p>Contact Email: lanay.mudd@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027</p> <p>Synopsis: The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) program is to support a cohort of early career, independent investigators from diverse backgrounds (for example, individuals from underrepresented groups) conducting research in NIH mission areas. The program has two components: an individual career transition award for postdoctoral scholars (K99/R00) and a research education cooperative agreement (UE5) awarded to organizations to provide these scholars with additional mentoring, networking and professional development activities to support their transition to and success in independent, tenure-track or equivalent research-intensive faculty careers. The MOSAIC program supports NIH's efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The goal of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds from their mentored postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The program is designed to support postdoctoral researchers who have demonstrated meaningful contributions and proposed compelling future plans to promote broad participation in the biomedical research workforce, such as activities that promote inclusive, supportive, and accessible biomedical research environments that support the success of trainees and scientists from all backgrounds, including individuals from underrepresented groups. This Notice of Funding Opportunity (NOFO) is designed specifically to support candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Candidates not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must work with their</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
institutions to apply to companion NOFO PAR-24-225.					
127245	FCO--Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE)	National Institutes of Health/DHHS	ARPA-H-SOL-24-111	31-Oct-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email GLIDE@arpa-h.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Oct-2024</p> <p>Synopsis The Advanced Research Projects Agency for Health (ARPA-H) is posting this DRAFT Innovative Solutions Opening (ISO) ARPA-H-SOL-24-111 for the Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) Program in order to help potential proposers prepare for Proposer's Day and plan for solution summary submission. The finalized ISO and related attachments will be posted at a later date.</p>				
122946	Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-24-092	07-Sep-2024	275,000 USD
	<p>Contact Name Ann Namkung, MPH</p> <p>Contact Telephone 301-496-6838</p> <p>Contact Email ann.namkung@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027</p> <p>Synopsis This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches. Proposed research must be consistent with the HIV/AIDS Research Priorities outlined by NIH s</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Office of AIDS Research (OAR) as described in NOT-OD-20-018.				
114250	Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-24-022	07-Sep-2024	400,000 USD
	Contact Name	Randy King, Ph.D.			
	Contact Telephone	301-451-0707			
	Contact Email	Randy.King@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Sep-2024 , 16-Oct-2024 , 16-Nov-2024 , 07-Jan-2025 , 16-Feb-2025 , 16-Mar-2025 , 07-May-2025 , 16-Jun-2025 , 16-Jul-2025 , 07-Sep-2025 , 16-Oct-2025 , 16-Nov-2025 , 07-Jan-2026			
	Synopsis	<p>This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators (https://grants.nih.gov/policy/early-investigators/index.htm) to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal. All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.</p>			
125253	Feasibility Trials of the NIH Music-based Interventions Toolkit for Brain Disorders of Aging (R34 Clinical Trial Required)	National Institutes of Health/DHHS	PAR-24-168	22-Sep-2024 [Optional][LOI/Pre-App]	450,000 USD
	Contact Name	Sekai Chideya, M.D., M.P..H			
	Contact Telephone	301-827-1916			
	Contact Email	Sekai.Chideya@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	22-Sep-2024 [Optional][LOI/Pre-App], 21-Oct-2024 , 19-Nov-2024			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis: The purpose of this Notice of Funding Opportunity (NOFO) is to resubmit PAR-23-256 “Feasibility Trials of the NIH Music-based Interventions Toolkit for Brain Disorders of Aging (R34 Clinical Trial Required)” in order to support proof-of-concept feasibility trials guided by the NIH Music-based Interventions (MBI) Toolkit for research on brain disorders of aging. These early phase clinical trials will generate evidence supporting the validity of the NIH MBI Toolkit’s guiding principles as well as the necessary pilot data to design a subsequent clinical efficacy or effectiveness study (or pragmatic clinical trial) using music-based interventions in the context of brain disorders of aging, including but not limited to Alzheimer’s disease and Alzheimer’s disease-related dementias, Parkinson’s disease, and stroke. The data collected should address gaps in scientific knowledge in order to facilitate development of a competitive large-scale clinical trial.</p>				
112325	Notice of Special Interest (NOSI): Research on Addressing Violence to Improve Health Outcomes	National Institutes of Health/DHHS	NOT-OD-22-167	07-Sep-2024	Not Specified
	<p>Contact Name: Dara R. Blachman, Ph.D. Contact Telephone: 301-496-8522 Contact Email: Dara.blachman-demner@nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 Synopsis: The purpose of this Notice is to highlight interest in addressing the role of violence in health outcomes and integrating violence-related screening and interventions into health care settings. This Notice is to encourage intervention research focused on addressing exposure to violence - including but not limited to child maltreatment, intimate partner violence/teen dating violence, elder mistreatment, peer violence/bullying, and community violence – to improve individual-level health processes and outcomes.</p>				
111641	Notice of Special Interest (NOSI): Climate Change and Health	National Institutes of Health/DHHS	NOT-ES-22-006	08-Aug-2024	Not Specified
	<p>Contact Name: Claudia L. Thompson Contact Telephone: 984-287-3330 Contact Email: thomps1@niehs.nih.gov Sponsor Website: Program URL: Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 08-Aug-2024 , 07-Sep-2024 , 25-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 21-Oct-2024 , 12-Nov-2024 , 15-Nov-2024 , 08-Dec-2024 , 09-Dec-2024 , 07-Jan-2025 , 25-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 19-Feb-2025 , 08-Apr-2025 , 07-May-2025</p> <p>Synopsis The National Institute of Environmental Health Science (NIEHS), in partnership with Fogarty International Center (FIC), National Institute of Minority Health and Health Disparities (NIMHD), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Heart Blood and Lung Institute (NHBLI) and National Institute of Allergy and Infectious Disease (NIAID) is leading an NIH-wide Climate Change and Health Initiative (CCHI) with the goals of: reducing the health threats posed by climate change across the lifespan; improving the health of people who are at increased risk from or disparately affected by climate change impacts; and building health resilience among individuals, communities, nations around the world, thereby increasing health equity. As a part of this CCHI, this NOSI encourages applications that address the impact of climate change on health and well-being over the life course, including the health implications of climate change in the United States and globally.</p>				
116940	<p>RFA-NS-24-005 -- BRAIN Initiative: Optimization of Instrumentation and Device Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed)</p>	National Institutes of Health/DHHS	RFA-NS-24-005	01-Oct-2024	Not Specified
	<p>Contact Name Grace M. Hwang, PhD</p> <p>Contact Telephone </p> <p>Contact Email BRAIN-FOAs@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024 , 03-Apr-2025 [Optional][LOI/Pre-App], 02-Jun-2025 , 21-Nov-2025 [Optional][LOI/Pre-App], 20-Jan-2026</p> <p>Synopsis This FOA seeks applications to optimize instrumentation and device technologies for recording and modulation of neural cells and circuits, to address major challenges and to enable transformative understanding of dynamic signaling in the central nervous system. It is expected that the proposed technologies and approaches have previously demonstrated their transformative potential through initial proof-of-concept testing, and are ready for accelerated refinement through iterative engineering and end-user feedback, appropriate for a path towards sustainable dissemination and user-friendly incorporation into routine neuroscience research. Applications may propose development of instrumentation hardware and/or devices and associated software. Approaches may utilize any modality such as optical, electrical, magnetic, or acoustic recording/manipulation, to target neuronal electrical signals or other forms of neural activity, including intracellular signaling and engagement of non-neuronal cells in circuit function. This FOA is a re-issue of RFA-NS-21-027, but unlike the previous</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

FOA the focus is narrowed to technologies associated with recording/manipulation instrumentation and devices, and excludes projects primarily focused on development of molecular reagents. Potential applicants primarily optimizing molecular constructs should consider RFA-MH-22-245, BRAIN Initiative: Engineering and optimization of molecular technologies for functional dissection of neural circuits (UM1 Clinical Trial Not Allowed). For projects at an earlier stage of development of molecular reagents, potential applicants should consider the companion FOA (RFA-NS-24-004) or alternative BRAIN Initiative announcements including RFA-MH-21-175 and RFA-EY-21-001. For this and the companion FOA, the aim of the proposed technologies should be to reduce major barriers to conducting neurobiological experiments, including considerations of cost and ease of access, and to enable new discoveries for understanding neural circuit function. Technologies should address major challenges associated with recording and modulating CNS activity, at cellular or circuit resolution, and should contribute to an overall ecosystem of technologies spanning multiple spatial and temporal scales in any region throughout the CNS. The approaches should be compatible with experiments in behaving animals, with an expectation that they will be validated with in vivo experiments during the course of the project. Proposed validation experiments must focus on demonstrating the capabilities and potential impact of the technology, rather than advancing the state of biological knowledge as the primary project goal. Applications are encouraged to integrate multiple approaches, and where appropriate, to leverage diverse domains of expertise from biological, chemical, and physical sciences, engineering, computational modeling, and statistical analysis. This FOA requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.

116939	RFA-NS-24-004 -- BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-NS-24-004	01-Oct-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Grace M. Hwang, PhD
Contact Telephone	
Contact Email	BRAIN-FOAs@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	01-Oct-2024 , 03-Apr-2025 [Optional][LOI/Pre-App], 02-Jun-2025 , 21-Nov-2025 [Optional][LOI/Pre-App], 20-Jan-2026
Synopsis	This FOA seeks applications for proof-of-concept testing and development of new technologies and novel approaches for recording and modulation of neural cells and circuits, to address major challenges and enable transformative understanding of dynamic signaling in the central nervous system. Preliminary feasibility data are not required, and it is expected that the proposed research may be high-risk, but if successful could profoundly change the course of neuroscience research. Applications may propose development of instrumentation hardware and/or devices and associated software,

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and/or molecular constructs for sensing and manipulating neural activity. Approaches may utilize any modality such as optical, electrical, magnetic, or acoustic recording/manipulation, to target neuronal electrical signals or other forms of neural activity, including intracellular signaling and engagement of non-neuronal cells in circuit function. A companion FOA (RFA-NS-24-005) is targeted to projects focused on optimization of instrumentation and devices that are later in the development cycle, where iterative optimization and end-user testing is needed. The companion FOA does not allow projects primarily focused on development or optimization of molecular constructs for recording and manipulating neural activity. Projects of this nature are supported by this FOA and other BRAIN Initiative announcements including RFA-MH-22-245, RFA-MH-21-175, and RFA-EY-21-001. For this and the companion FOA, the aim of the proposed technologies should be to reduce major barriers to conducting neurobiological experiments, including considerations of cost and ease of access, and to enable new discoveries for understanding neural circuit function. Technologies should address major challenges associated with recording and modulating CNS activity, at cellular or circuit resolution, and should contribute to an overall ecosystem of technologies spanning multiple spatial and temporal scales in any region throughout the CNS. The approaches should be compatible with experiments in behaving animals, with an expectation that they will be validated with in vivo experiments during the course of the project. Proposed validation experiments must focus on demonstrating the capabilities and potential impact of the technology, rather than advancing the state of biological knowledge as the primary project goal. Applications are encouraged to integrate multiple approaches, and where appropriate, to leverage diverse domains of expertise from biological, chemical, and physical sciences, engineering, computational modeling, and statistical analysis. This FOA requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.

113609	NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)	National Library of Medicine/NIH/DHHS	PAR-23-034	07-Sep-2024	1,000,000 USD
--------	--	---------------------------------------	------------	-------------	---------------

Contact Name	Meryl Sufian, PhD
Contact Telephone	301-496-4671
Contact Email	sufianm@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026
Synopsis	The National Library of Medicine (NLM) supports innovative research and development in biomedical informatics and data science. This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>personal wellness. The scope of NLM's interest in these research domains is broad, with emphasis on new and innovative methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, scalable, and reusable/reproducible approaches to discovery, curation, analysis, organization, and management of health-related digital objects.</p>				
115310	Notice of Special Interest (NOSI): Computational and Statistical Methods to Enhance Discovery from Health Data	National Library of Medicine/NIH/DHHS	NOT-LM-23-001	07-Sep-2024	Not Specified
	<p>Contact Name Meryl Sufian, PhD Contact Telephone 301-496-4671 Contact Email sufianm@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 Synopsis The National Library of Medicine is issuing this Notice to highlight its interest in receiving grant applications focused on research that aims to reduce or mitigate gaps and errors in health data sets.</p>				
113221	Notice of Special Interest (NOSI): Administrative Supplements for Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed)	Office of Dietary Supplements/NIH/DHHS	NOT-OD-22-202	15-Oct-2024	Not Specified
	<p>Contact Name Adam J. Kuszak, Ph.D. Contact Telephone 301-496-1795 Contact Email kuszakaj@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 15-Oct-2024 , 15-Jan-2025 , 15-Apr-2025 Synopsis The NIH Office of Dietary Supplements (ODS) within the Office of the Director Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) announces the availability of administrative supplements for the conduct of formal single-laboratory validation (SLV) studies of analytical methods for the identification and/or quantification of dietary ingredients and/or constituents (e.g., active or marker compounds, adulterants, contaminants), or metabolites thereof, in foods, dietary</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| supplements, their raw source materials, and/or clinical specimens (e.g., urine, plasma, tissue).

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
113926	Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research (R01)	Office of Research Infrastructure Programs/NIH/DHHS	PAR-23-040	05-Oct-2024	Not Specified

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Sige Zou, Ph.D. 301-435-0749 zous@mail.nih.gov Link to program URL 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 The Office of Research Infrastructure Programs (ORIP) encourages research project grant applications aimed at developing and implementing broadly applicable technologies, tools, and resources for validating animal models and enhancing rigor, reproducibility, and translatability of animal research. Research projects submitted under this Funding Opportunity Announcement (FOA) should be hypothesis driven with strong preliminary data. Proposed studies, models, resources, or technologies under this FOA must either address research interests of multiple NIH Institutes and Centers (ICs), explore multiple organ systems, or be applicable to diseases and processes that impact multiple organ systems in order to align with ORIP's NIH-wide mission and programs. Applications should aim to enhance the rigor, reproducibility, and translatability of animal research through the development and implementation of technologies, tools, and resources that have significant impact across a broad range of research areas using animal models. Applications must demonstrate how the proposed resources and technologies impact rigor and reproducibility of animal studies.
--	---

102835	Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)	Office of Research Infrastructure Programs/NIH/DHHS	PAR-21-167	07-Sep-2024	275,000 USD
--------	---	---	------------	-------------	-------------

Contact Name Contact Telephone Contact Email Sponsor Website	Sige Zou, Ph.D. 301-435-0749 zous@mail.nih.gov
---	---

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs' (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC, will be considered not acceptable to this FOA and will be withdrawn.</p>				
113710	<p>RFA-OD-22-028 -- The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional)</p>	Office of Research on Women's Health/NIH/DHHS	RFA-OD-22-028	23-Oct-2024 [Optional][LOI/Pre-App]	1,400,000 USD
	<p>Contact Name Chyren Hunter, Ph.D.</p> <p>Contact Telephone 301-496-7849</p> <p>Contact Email Huntermc@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Oct-2024 [Optional][LOI/Pre-App], 23-Nov-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications on the influence and intersection of sex and gender in health and disease, including: (1) research applications that examine sex and gender factors and their intersection in understanding health and disease; and (2) research that addresses one of the five objectives from Strategic Goal 1 of the 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women." The awards under this FOA will be administered by NIH ICs using funds that have been made available through the Office of Research on Women's Health (ORWH) and the scientific partnering Institutes and Centers across NIH</p>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
123333	ECosystem for Leading Innovation in Plasma Science and Engineering	National Science Foundation	PD-24-110Z	13-Aug-2024	Not Specified
	<p>Contact Name Raymond A. Adomaitis</p> <p>Contact Telephone 703-292-7519</p> <p>Contact Email eclipse@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Aug-2024 , 30-Sep-2024 , 01-Oct-2024 , 15-Oct-2024 , 31-Oct-2024 , 18-Nov-2024</p> <p>Synopsis Plasma science is a transdisciplinary field of research where fundamental studies in many disciplines, including plasma physics, plasma chemistry, materials science, and space science, come together to advance knowledge for discovery and technological innovation. The primary goal of the ECosystem for Leading Innovation in Plasma Science and Engineering (ECLIPSE) program is to identify and capitalize on opportunities for bringing fundamental plasma science investigations to bear on problems of societal and technological need within the scope of science and engineering supported by the participating NSF programs. The ECLIPSE meta-program has been created to foster an inclusive community of scientists and engineers, an ecosystem spanning multiple NSF Directorates, in the pursuit of translational research at the interface of fundamental plasma science and technological innovation. The ECLIPSE program builds on the long history of NSF leadership in supporting multi-disciplinary research in plasma science and engineering, and is intended to enhance organizational unity within NSF, and potentially with other funding agencies, in considering proposals and supporting projects that may otherwise struggle to find a natural home within the existing hierarchy of Directorates, Divisions, and programs within the Foundation.</p>				
125841	Dear Colleague Letter: Planning Proposals for Centers of Research Excellence in Science and Technology (CREST Centers) in Computer and Information Science and Engineering (CISE)	National Science Foundation	NSF 24-089	01-Oct-2024	200,000 USD
	<p>Contact Name Subrata Acharya</p> <p>Contact Telephone 703-292-5111</p> <p>Contact Email acharyas@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024</p> <p>Synopsis Consistent with the National Science Foundation's (NSF) efforts to increase institutional diversity within science, technology,</p>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>engineering and mathematics (STEM), the Directorate of STEM Education (EDU) and the Directorate for Computer and Information Science and Engineering (CISE) jointly encourage the submission of planning proposals for a future CREST center proposal with a focus on research in all areas of CISE to include the participation of the full spectrum of diverse talent in STEM.</p>			
126934	NSF EPSCoR Graduate Fellowship Program	National Science Foundation	24-588	02-Oct-2024	Not Specified
	<p>Contact Name Narcrisha S. Norman</p> <p>Contact Telephone 703-292-7965</p> <p>Contact Email nnorman@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Oct-2024 , 02-Jun-2025 , 01-Jun-2026</p>	<p>Synopsis The NSF EPSCoR Graduate Fellowship Program (EGFP) provides an opportunity for applicants who received the distinction of GRFP Honorable Mention no more than three years before the proposal due date to be named NSF EPSCoR Graduate Fellows and obtain financial support for their graduate education at an institution in an EPSCoR jurisdiction. EGFP aims to enhance the capacity and competitiveness of EPSCoR jurisdictions by providing funding to graduate degree-awarding institutions to support NSF EPSCoR Graduate Fellows as they pursue graduate degrees in the disciplines specified by the NSF Directorates and Office that are participating in the EGFP funding program. Fellows may pursue degrees in field that differ from the field or sub-field of study that the GRFP Honorable Mention recipients previously listed in their GRFP application. EGFP awards will be made to institutions in EPSCoR jurisdictions. Awards will provide three years of stipend and associated cost-of-education allowance for each NSF EPSCoR Graduate Fellow. Stipends must be budgeted at the level of \$37,000 per year per Fellow and cost-of-education allowances must be budgeted at the level of \$16,000 per year per Fellow. A total of three years of support must be budgeted per Fellow. Each Fellow must be given up to five years to utilize the support. Awardees will administer the awards such that the Fellows receive the full stipend amount and the institution retains the full cost-of-education allowance during the three years that each Fellow receives support. All submissions must request support for a minimum of three Fellows.</p>			
120776	Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science	National Science Foundation	23-614	03-Oct-2024	1,200,000 USD
	Contact Name Goli Yamini				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 703-292-5367</p> <p>Contact Email sch-correspondence@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Oct-2024 , 03-Oct-2025</p> <p>Synopsis The purpose of this interagency program solicitation is to support the development of transformative high-risk, high-reward advances in computer and information science, engineering, mathematics, statistics, behavioral and/or cognitive research to address pressing questions in the biomedical and public health communities. Transformations hinge on scientific and engineering innovations by interdisciplinary teams that develop novel methods to intuitively and intelligently collect, sense, connect, analyze and interpret data from individuals, devices and systems to enable discovery and optimize health. Solutions to these complex biomedical or public health problems demand the formation of interdisciplinary teams that are ready to address these issues, while advancing fundamental science and engineering.</p>				
122294	Research Experiences for Teachers (RET) in Engineering and Computer Science	National Science Foundation	24-503	09-Oct-2024	Not Specified
	<p>Contact Name Amelia S. Greer</p> <p>Contact Telephone 703-292-2552</p> <p>Contact Email agreer@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Oct-2024</p> <p>Synopsis The Research Experiences for Teachers (RET) in Engineering and Computer Science program supports authentic summer research experiences for K-14 educators to foster long-term collaborations between universities, community colleges, school districts, and industry partners. With this solicitation, the Directorates for Engineering (ENG) and Computer and Information Science and Engineering (CISE) focus on a reciprocal exchange of expertise between K-14 educators and research faculty and (when applicable) industry mentors. K-14 educators will enhance their scientific disciplinary knowledge in engineering or computer science and translate their research experiences into classroom activities and curricula to broaden their students' awareness of and participation in computing and engineering pathways. At the same time, the hosting research faculty will deepen their understanding of classroom practices, current curricula, pedagogy, and K-14 educational environments.</p>				
125690	Mathematical Foundations of Artificial Intelligence	National Science Foundation	24-569	10-Oct-	1,500,000

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Foundation		2024	USD
	<p>Contact Name Eyad Abed</p> <p>Contact Telephone 703-292-2303</p> <p>Contact Email eabed@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Oct-2024 , 10-Oct-2025 , 09-Oct-2026</p> <p>Synopsis The National Science Foundation Directorates for Mathematical and Physical Sciences (MPS), Computer and Information Science and Engineering (CISE), Engineering (ENG), and Social, Behavioral and Economic Sciences (SBE) will jointly sponsor research collaborations consisting of mathematicians, statisticians, computer scientists, engineers, and social and behavioral scientists focused on the mathematical and theoretical foundations of AI. Research activities should focus on the most challenging mathematical and theoretical questions aimed at understanding the capabilities, limitations, and emerging properties of AI methods as well as the development of novel, and mathematically grounded, design and analysis principles for the current and next generation of AI approaches.</p>				
123645	Campus Cyberinfrastructure	National Science Foundation	24-530	15-Oct-2024	Not Specified
	<p>Contact Name Kevin Thompson</p> <p>Contact Telephone 703-292-4220</p> <p>Contact Email kthompso@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Oct-2024</p> <p>Synopsis The Campus Cyberinfrastructure (CC*) program invests in coordinated campus-level cyberinfrastructure improvements, innovation, integration, and engineering for science applications and distributed research projects. Projects that help overcome disparities in cyber-connectivity associated with geographic location, and thereby advance the geography of innovation and enable populations based in these locales to become more nationally competitive in science, technology, engineering, and mathematics (STEM) research and education are particularly encouraged. Science-driven requirements are the primary motivation for any proposed activity.</p>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
127027	Graduate Research Fellowship Program (GRFP)	National Science Foundation	NSF 24-591	15-Oct-2024	Not Specified														
	<table border="0" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>866-673-4737</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>info@nsfgrfp.org</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>15-Oct-2024 , 16-Oct-2024 , 17-Oct-2024 , 18-Oct-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of the NSF Graduate Research Fellowship Program (GRFP) is to help ensure the quality, vitality, and diversity of the scientific and engineering workforce of the United States. The program recognizes and supports outstanding graduate students who are pursuing full-time research-based master's and doctoral degrees in science, technology, engineering, and mathematics (STEM) or in STEM education. The GRFP provides three years of support over a five-year fellowship period for the graduate education of individuals who have demonstrated their potential for significant research achievements in STEM or STEM education. NSF actively encourages submission of applications from the full spectrum of diverse talent that society has to offer which includes underrepresented and under-served communities. NSF GRFP was established to recruit and support individuals who demonstrate the potential to make significant contributions in STEM. NSF especially encourages applications from undergraduate seniors and Bachelor's degree-holders interested in pursuing research-based graduate study in STEM. First- and second-year graduate students in eligible STEM fields and degree programs are also encouraged to apply.</td> </tr> </table>					Contact Name		Contact Telephone	866-673-4737	Contact Email	info@nsfgrfp.org	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	15-Oct-2024 , 16-Oct-2024 , 17-Oct-2024 , 18-Oct-2024	Synopsis	The purpose of the NSF Graduate Research Fellowship Program (GRFP) is to help ensure the quality, vitality, and diversity of the scientific and engineering workforce of the United States. The program recognizes and supports outstanding graduate students who are pursuing full-time research-based master's and doctoral degrees in science, technology, engineering, and mathematics (STEM) or in STEM education. The GRFP provides three years of support over a five-year fellowship period for the graduate education of individuals who have demonstrated their potential for significant research achievements in STEM or STEM education. NSF actively encourages submission of applications from the full spectrum of diverse talent that society has to offer which includes underrepresented and under-served communities. NSF GRFP was established to recruit and support individuals who demonstrate the potential to make significant contributions in STEM. NSF especially encourages applications from undergraduate seniors and Bachelor's degree-holders interested in pursuing research-based graduate study in STEM. First- and second-year graduate students in eligible STEM fields and degree programs are also encouraged to apply.
Contact Name																			
Contact Telephone	866-673-4737																		
Contact Email	info@nsfgrfp.org																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	15-Oct-2024 , 16-Oct-2024 , 17-Oct-2024 , 18-Oct-2024																		
Synopsis	The purpose of the NSF Graduate Research Fellowship Program (GRFP) is to help ensure the quality, vitality, and diversity of the scientific and engineering workforce of the United States. The program recognizes and supports outstanding graduate students who are pursuing full-time research-based master's and doctoral degrees in science, technology, engineering, and mathematics (STEM) or in STEM education. The GRFP provides three years of support over a five-year fellowship period for the graduate education of individuals who have demonstrated their potential for significant research achievements in STEM or STEM education. NSF actively encourages submission of applications from the full spectrum of diverse talent that society has to offer which includes underrepresented and under-served communities. NSF GRFP was established to recruit and support individuals who demonstrate the potential to make significant contributions in STEM. NSF especially encourages applications from undergraduate seniors and Bachelor's degree-holders interested in pursuing research-based graduate study in STEM. First- and second-year graduate students in eligible STEM fields and degree programs are also encouraged to apply.																		
113761	Expanding AI Innovation through Capacity Building and Partnerships	National Science Foundation	23-506	18-Oct-2024	Not Specified														
	<table border="0" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>703-292-5111</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>ExpandAIProgram@nsf.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>18-Oct-2024 , 10-Mar-2025 , 23-Jun-2025</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The National Science Foundation and its partners support the continued growth of a broad and diverse interdisciplinary research community for the advancement of AI and AI-powered innovation, providing a unique opportunity to broadly</td> </tr> </table>					Contact Name		Contact Telephone	703-292-5111	Contact Email	ExpandAIProgram@nsf.gov	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	18-Oct-2024 , 10-Mar-2025 , 23-Jun-2025	Synopsis	The National Science Foundation and its partners support the continued growth of a broad and diverse interdisciplinary research community for the advancement of AI and AI-powered innovation, providing a unique opportunity to broadly
Contact Name																			
Contact Telephone	703-292-5111																		
Contact Email	ExpandAIProgram@nsf.gov																		
Sponsor Website	Link to sponsor website																		
Program URL	Link to program URL																		
Deadline Dates (ALL)	18-Oct-2024 , 10-Mar-2025 , 23-Jun-2025																		
Synopsis	The National Science Foundation and its partners support the continued growth of a broad and diverse interdisciplinary research community for the advancement of AI and AI-powered innovation, providing a unique opportunity to broadly																		

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

promote the NSF vision and core values, especially inclusion and collaboration. The Expanding AI Innovation through Capacity Building and Partnerships (ExpandAI) program aims to significantly broaden participation in AI research, education, and workforce development through capacity development projects and through partnerships within the National AI Research Institutes ecosystem.

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
115139	Special Emphasis Notice (SEN): Research on Climate Change and Healthcare	Agency for Healthcare Research and Quality/DHHS	NOT-HS-23-006	08-Aug-2024	Not Specified
	<p>Contact Name Brent Sandmeyer, MPH</p> <p>Contact Telephone 301-427-1441</p> <p>Contact Email Brent.sandmeyer@ahrq.hhs.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Aug-2024 , 12-Aug-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 26-Oct-2024 , 08-Dec-2024 , 12-Dec-2024 , 25-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 26-Feb-2025 , 08-Apr-2025 , 12-Apr-2025 , 25-May-2025 , 12-Jun-2025 , 08-Aug-2025 , 12-Aug-2025 , 25-Sep-2025 , 25-Sep-2025 , 12-Oct-2025 , 12-Dec-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027</p> <p>Synopsis This Special Emphasis Notice (SEN) announces AHRQ's interest in receiving health services research grant applications that address the intersection of climate change and healthcare.</p>				
109186	Notice of Special Interest (NOSI): Health Services Research on Health System and Healthcare Professional Responsiveness to COVID-19	Agency for Healthcare Research and Quality/DHHS	NOT-HS-22-010	25-Sep-2024	Not Specified
	<p>Contact Name Leeann Comfort, PhD, MPP</p> <p>Contact Telephone </p> <p>Contact Email Leeann.Comfort@ahrq.hhs.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Jan-2025 , 05-Feb-2025</p> <p>Synopsis This Special Emphasis Notice (SEN) informs the research community that the Agency for Healthcare Research and Quality (AHRQ) is interested in receiving health services research grant applications to develop models of care that improve access, quality, and outcomes of care related to COVID-19 and post-acute sequelae from COVID-19 (PASC).</p>				
123850	AHRQ Small Health Services Research Grant Program (R03)	Agency for Healthcare Research and Quality/DHHS	PA-24-155	16-Oct-2024	100,000 USD
	<p>Contact Name </p> <p>Contact Telephone 301-427-1025</p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email kathryn.woolridge@ahrq.hhs.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027 , 16-Feb-2028 , 16-Jun-2028 , 16-Oct-2028 , 16-Feb-2029 , 16-Jun-2029</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to seek health services research grant applications focused on AHRQ research priorities, including improving healthcare quality and patient safety, improving healthcare delivery and practice improvement, and enhancing whole-person healthcare delivery. AHRQ supports research in all healthcare settings, including the hospital, long-term care, ambulatory care, home healthcare, pharmacy, and care transitions between settings. Research may involve many partners and other groups, including patients, families, clinicians, non-clinical healthcare staff, policymakers, payers, healthcare organizations, providers and accreditors, local and State governments, the Federal Government, and others.</p>				
123849	AHRQ Health Services Research Projects (R01)	Agency for Healthcare Research and Quality/DHHS	PA-24-154	05-Oct-2024	2,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone 301-427-1025</p> <p>Contact Email kathryn.woolridge@ahrq.hhs.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027 , 05-Feb-2028 , 05-Jun-2028 , 05-Oct-2028 , 05-Feb-2029 , 05-Jun-2029</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to seek health services research grant applications focused on AHRQ research priorities, including improving healthcare quality and patient safety, improving healthcare delivery and practice improvement, and enhancing whole-person healthcare delivery. AHRQ supports research in all healthcare settings, including the hospital, long-term care, ambulatory care, home healthcare, pharmacy, and care transitions between settings. Research may involve many partners and other groups, including patients, families, clinicians, non-clinical healthcare staff, policymakers, payers, healthcare organizations, providers and accreditors, local and State governments, the Federal Government, and others.</p>				
114270	Special Emphasis Notice (SEN): Interest in Healthcare Associated Infections and	Agency for Healthcare Research and	NOT-HS-23-	25-Sep-	Not Specified

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Combating Antibiotic Resistant Bacteria Research	Quality/DHHS	003	2024	
	<p>Contact Name Leyi Lin, MD</p> <p>Contact Telephone 301-427-1333</p> <p>Contact Email leyi.lin@ahrq.hhs.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Sep-2024 , 05-Oct-2024 , 25-Jan-2025 , 05-Feb-2025 , 25-May-2025 , 05-Jun-2025 , 25-Sep-2025 , 25-Jan-2026 , 05-Feb-2026 , 25-May-2026 , 05-Jun-2026 , 25-Sep-2026 , 05-Oct-2026 , 05-Oct-2026</p> <p>Synopsis The purpose of this Special Emphasis Notice (SEN) is to inform the research community of the Agency for Healthcare Research and Quality (AHRQ) continued interest in, and available funding for, supporting innovative research seeking to reduce the burden of healthcare-associated infections (HAIs) and to address the growing threat posed by antimicrobial resistant organisms. HAIs continue to cause significant patient harm and are also associated with considerable financial consequences for healthcare facilities and for patients. Unfortunately, the COVID-19 pandemic has been associated with observed increases of several types of HAIs as well as increases in antimicrobial resistance, highlighting the importance of developing and studying resilient and adaptable countermeasures.</p>				
107009	Large Research Projects for Combating Antibiotic-Resistant Bacteria (CARB) (R01)	Agency for Healthcare Research and Quality/DHHS	PA-22-047	05-Oct-2024	2,500,000 USD
	<p>Contact Name James Cleeman, MD</p> <p>Contact Telephone 301-427-1330</p> <p>Contact Email james.cleeman@ahrq.hhs.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis Agency for Healthcare Research and Quality (AHRQ) invites applications to conduct Large Health Services Research Demonstration and Dissemination Projects (R18) focused on Combating Antibiotic-Resistant Bacteria (CARB). This FOA will use the R01 Research Project Grant award mechanism.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
043021	Research in Academic Pediatrics Initiative on Diversity (RAPID) Research Grants -- RAPID Scholar Awards	Academic Pediatric Association		01-Oct-2024	15,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Oct-2024 Synopsis RAPID's Scholar Awards awards target applicants (junior faculty and fellows in their last year of fellowship) who identify as underrepresented in medicine (UIM), or disabled. Selected proposals will receive up to \$15,000 in funding for a one-year project. Applicant Types Funding Limit 15,000.00 maximum Limited Submission No				
070333	Frederick V. Hunt Postdoctoral Research Fellowship in Acoustics	Acoustical Society of America		07-Oct-2024	70,000 USD
	Contact Name Contact Telephone 516-576-2360 Contact Email elaine@acousticalsociety.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 07-Oct-2024 Synopsis The F. V. Hunt Postdoctoral Research Fellowship was established by the Society to carry out Professor Hunt's wish that his estate be used to further the science of and education in acoustics. Fellows receive a stipend, provided jointly				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>by the Hunt estate and a fund established by the Acoustical Society, to support their research on a topic in acoustics at an institution of their choice. One Fellowship is usually awarded each year.</p> <p>70,000.00 see detail</p> <p>No</p>			
052818	Generic Call for Proposals	Agence Nationale de la Recherche (ANR)		15-Oct-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>+33 1 78 09 80 00</p> <p>contact-anr@anr.fr</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>15-Oct-2024</p> <p>The Generic Call for Proposals 2025 (AAPG 2025) is the French National Research Agency’s (ANR) main call. All scientific communities and all public and private actors involved in French research are concerned. It should allow researchers from different scientific fields to access, in addition to their recurrent funding allocated, co-funding on a large number of research themes, whether finalized or not.</p> <p>0.00 not provided</p> <p>No</p>			
020306	Grants Program	Alpha Foundation		01-Oct-2024	Not Specified
	Contact Name	Ashley Dyer			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 256-713-2277</p> <p>Contact Email info@alphafoundationhsv.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024</p> <p>Synopsis Since its formation in 1997, the Alpha Foundation has been dedicated to improving the human condition. To this end, Alpha will select organizations to which grants will be made that further this objective. An emphasis will be placed on grants to educational, scientific, and charitable organizations. A major focus of Alpha's support is biotechnology to aid in the discovery and cure of diseases.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 not provided</p> <p>Limited Submission No</p>				
004969	Faculty Development Award	American Academy of Allergy, Asthma, & Immunology (AAAAI)		21-Aug-2024 [LOI/Pre-App]	300,000 USD
	<p>Contact Name Katie Tetzlaff</p> <p>Contact Telephone 414-272-6071</p> <p>Contact Email ktetzlaff@aaaai.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Aug-2024 [LOI/Pre-App], 24-Oct-2024</p> <p>Synopsis This mentored award provides up to \$300,000 in funding over a three-year period and is intended to support the development of careers in Allergy and Immunology.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 300,000.00 maximum Limited Submission No				
120752	AAAAI/ Elliot and Roslyn Jaffe Third-Year Fellowship Food Allergy Research Award at Icahn School of Medicine at Mount Sinai	American Academy of Allergy, Asthma, & Immunology (AAAAI)		25-Oct-2024	65,000 USD
	Contact Name Katie Tetzlaff Contact Telephone 414-272-6071 Contact Email ktetzlaff@aaaai.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 25-Oct-2024 Synopsis The sponsor will support the development of an academic food allergy research career of a third or fourth-year allergy/immunology fellow-in-training or gastroenterology fellow-in-training in the specialty of food allergy and immunology at Icahn School of Medicine at Mount Sinai. Funding is to support education and research endeavors in food allergy. Applicants must conduct their research at Icahn School of Medicine at Mount Sinai. Applicant Types Funding Limit 65,000.00 maximum Limited Submission No				
120002	Drug Hypersensitivity Research Grant	American Academy of Allergy, Asthma, & Immunology (AAAAI)		14-Aug-2024 [LOI/Pre-App]	150,000 USD
	Contact Name				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 414-272-6071</p> <p>Contact Email info@aaaai.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Aug-2024 [LOI/Pre-App], 17-Oct-2024</p> <p>Synopsis This funding opportunity is to support up to three research grants to advance the state of knowledge, develop novel techniques, agents, methodologies, models or applications that could have a major impact on drug hypersensitivity research. This funding mechanism is designed to further research in drug allergy/hypersensitivity. For this opportunity, vaccines are not considered drugs and applications that focus on vaccine reactions will not be considered for this award. The awardee must attend the 2025 AAAAI Annual Meeting, in San Diego, CA.</p> <p>Applicant Types </p> <p>Funding Limit 150,000.00 maximum</p> <p>Limited Submission No</p>				
009566	Potamkin Prize for Research in Pick's, Alzheimer's and Related Diseases	American Academy of Neurology		31-Oct-2024	100,000 USD
	<p>Contact Name </p> <p>Contact Telephone 612-928-6000</p> <p>Contact Email science@aan.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Oct-2024</p> <p>Synopsis The Potamkin Prize for Research in Pick's, Alzheimer's, and Related Diseases recognizes major contributions to the understanding of the cause, prevention, treatment of, and ultimately the cure for Pick's, Alzheimer's, and related diseases.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 100,000.00 see detail Limited Submission No				
020307	AAP Foundation Fellowship to the ADEA/AAL Institute for Teaching & Learning in the Health Professions	American Academy of Periodontology Foundation		07-Oct-2024	3,500 USD
	Contact Name Contact Telephone 312-573-3254 Contact Email ariel@perio.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 07-Oct-2024 Synopsis AAP Foundation Fellowships are available to the Academy for Academic Leadership (AAL) Institute for Teaching and Learning in the Health Professions. Fellowships are available to cover full tuition to the Institute's Program for Dental School Faculty. Applicant Types Funding Limit 3,500.00 maximum Limited Submission No				
003686	Strategic Research Grant	American Academy of Sleep Medicine Foundation		21-Oct-2024 [LOI/Pre-App]	250,000 USD
	Contact Name Contact Telephone 630-737-9724 Contact Email foundation@aasm.org				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Oct-2024 [LOI/Pre-App], 10-Mar-2025</p> <p>Synopsis The AASM Foundation is committed to improving patient-centered diagnosis and care for all people with sleep disorders. To ensure that there is a continued advancement in effective diagnosis and care of people with sleep disorders, the AASM Foundation provides research funding through the Strategic Research Grant. This grant is investigator-initiated and supports high-impact research projects aimed at addressing gaps in knowledge that impact the ability to provide optimal, patient-centered, cost-effective diagnosis and care for people with sleep disorders.</p> <p>Applicant Types</p> <p>Funding Limit 250,000.00 see detail</p> <p>Limited Submission No</p>				
034933	Hench Post-Dissertation Fellowship	American Antiquarian Society		15-Oct-2024	Not Specified
	<p>Contact Name Nan Wolverton</p> <p>Contact Telephone 508-471-2119</p> <p>Contact Email nwolverton@mwa.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Oct-2024</p> <p>Synopsis Scholars who are no more than three years beyond receipt of the doctorate are eligible to apply for a special year-long residential fellowship at the American Antiquarian Society to revise their dissertation for publication. Any topic relevant to the Society's library collections and programmatic scope - that is, American history and culture through 1876 - is eligible.</p> <p>Applicant Types</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	0.00 maximum			
	Limited Submission	No			
126293	Fanconi Cancer Foundation - AACR NextGen Grant for Transformative Cancer Research	American Association for Cancer Research		02-Oct-2024	450,000 USD
	Contact Name				
	Contact Telephone	215-440-9300			
	Contact Email	grants@aacr.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	02-Oct-2024			
	Synopsis	The Fanconi Cancer Foundation-AACR NextGen Grant for Transformative Cancer Research to stimulate highly innovative research from young investigators currently working in the Fanconi anemia (FA) field as well as investigators with experience in other areas of cancer or biomedical research with an interest in studying FA-associated cancers. The grant provides \$450,000 over three years for expenses related to the research project.			
	Applicant Types				
	Funding Limit	450,000.00 maximum			
	Limited Submission	No			
104542	AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants	American Association for Cancer Research		01-Oct-2024	400,000 USD
	Contact Name				
	Contact Telephone	215-440-9300			
	Contact Email	grants@aacr.org			
	Sponsor Website	Link to sponsor website			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024</p> <p>Synopsis The AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants represents a joint effort to stimulate “high-risk, high-reward” research from early- to mid-career investigators. This novel grant mechanism is intended to promote and support creative, paradigm-shifting cancer research that might not be funded through conventional channels. It is expected that these grants will catalyze significant scientific discoveries that will advance our understanding of cancer and have a potentially transformative impact on future clinical practice.</p> <p>Applicant Types</p> <p>Funding Limit 400,000.00 maximum</p> <p>Limited Submission No</p>				
078944	AACR Immuno-oncology Research Fellowship	American Association for Cancer Research		08-Oct-2024	130,000 USD
	<p>Contact Name</p> <p>Contact Telephone 215-440-9300</p> <p>Contact Email grants@aacr.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Oct-2024</p> <p>Synopsis The AACR Immuno-oncology Research Fellowship provide two-year grants of \$130,000 to support the salary and benefits of the fellow while working on mentored immuno-oncology research. Proposed research projects may be basic, translational, clinical, or population sciences related research and must have direct applicability and relevance to immuno-oncology. Grants are anticipated to begin December 1, 2024.</p> <p>Applicant Types</p> <p>Funding Limit 130,000.00 maximum</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
077402	Kline Peripheral Nerve Research Award	American Association of Neurological Surgeons		14-Oct-2024	Not Specified
	Contact Name	Kristen Jones MD, Chair of Research and Awards Committee			
	Contact Telephone				
	Contact Email	kristen.jones@duke.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	14-Oct-2024			
	Synopsis	The Kline Peripheral Nerve Research Award is awarded to the most outstanding peripheral nerve research project to promote basic science or clinical research related to the peripheral nerves, and to provide a means of peer review to help improve the quality of the proposal and therefore enhance competitiveness for National Institutes of Health (NIH) funding.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
106678	Clinician Scientist Development Grant (CSDG)	American Cancer Society, Inc.		15-Oct-2024	135,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	grants@cancer.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 15-Oct-2024</p> <p>Synopsis Clinician Scientist Development Grants (CSDG) support protected time to allow junior faculty who see patients to be mentored and participate in research training, thus aiding their development as independent clinician scientists. These investigators pursue questions relevant to improving health across the cancer research continuum.</p> <p>Applicant Types</p> <p>Funding Limit 135,000.00 maximum</p> <p>Limited Submission No</p>				
015290	Research and Clinical Research Professor Grants	American Cancer Society, Inc.		15-Oct-2024	400,000 USD
	<p>Contact Name</p> <p>Contact Telephone 800-227-2345</p> <p>Contact Email lynne.elmore@cancer.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Oct-2024</p> <p>Synopsis The American Cancer Society offers a limited number of grants to investigators who have the rank of full professor and made seminal contributions in the area of cancer control that have changed the direction of clinical, psychosocial, behavioral, health policy, or epidemiologic cancer research. The award of up to \$80,000 per year can be budgeted at the recipient's discretion for creative pursuits in cancer research.</p> <p>Applicant Types</p> <p>Funding Limit 80,000.00 per year</p> <p>Limited Submission No</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																				
001310	Postdoctoral Fellowships	American Cancer Society, Inc.		15-Oct-2024	Not Specified																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>800-227-2345</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>grants@cancer.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>15-Oct-2024</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>Postdoctoral Fellowships (PF) support new investigators in research training programs to position them for independent careers in cancer research. As part of their evaluation, peer reviewers consider how well the fellowship will broaden the applicant’s research training and experience. Awards are for up to 3 years with recently increased progressive stipends of \$66,000, \$68,000, and \$70,000 a year.</td> </tr> <tr> <td style="border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>0.00 see detail</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>No</td> </tr> </table>						Contact Name		Contact Telephone	800-227-2345	Contact Email	grants@cancer.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	15-Oct-2024	Synopsis	Postdoctoral Fellowships (PF) support new investigators in research training programs to position them for independent careers in cancer research. As part of their evaluation, peer reviewers consider how well the fellowship will broaden the applicant’s research training and experience. Awards are for up to 3 years with recently increased progressive stipends of \$66,000, \$68,000, and \$70,000 a year.	Applicant Types		Funding Limit	0.00 see detail	Limited Submission	No
Contact Name																									
Contact Telephone	800-227-2345																								
Contact Email	grants@cancer.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	15-Oct-2024																								
Synopsis	Postdoctoral Fellowships (PF) support new investigators in research training programs to position them for independent careers in cancer research. As part of their evaluation, peer reviewers consider how well the fellowship will broaden the applicant’s research training and experience. Awards are for up to 3 years with recently increased progressive stipends of \$66,000, \$68,000, and \$70,000 a year.																								
Applicant Types																									
Funding Limit	0.00 see detail																								
Limited Submission	No																								
001054	Institutional Research Grants	American Cancer Society, Inc.		15-Oct-2024	Not Specified																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>800-227-2345</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>grants@cancer.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>15-Oct-2024</td> </tr> </table>						Contact Name		Contact Telephone	800-227-2345	Contact Email	grants@cancer.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	15-Oct-2024								
Contact Name																									
Contact Telephone	800-227-2345																								
Contact Email	grants@cancer.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	15-Oct-2024																								

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p style="text-align: right; margin-right: 20px;">Synopsis</p> <p>Institutional Research Grants are awarded to institutions as block grants, providing seed money for newly independent investigators to initiate cancer research projects. The intent is to support these junior faculty in initiating cancer research projects so they can obtain preliminary results that will enable them to compete successfully for national research grants.</p> <p style="text-align: right; margin-right: 20px;">Applicant Types</p> <p style="text-align: right; margin-right: 20px;">Funding Limit</p> <p style="text-align: right; margin-right: 20px;">Limited Submission</p>				
112975	Discovery Boost Grants (DBG)	American Cancer Society, Inc.		15-Oct-2024	270,000 USD
	<p style="text-align: right; margin-right: 20px;">Contact Name</p> <p style="text-align: right; margin-right: 20px;">Contact Telephone</p> <p style="text-align: right; margin-right: 20px;">Contact Email</p> <p style="text-align: right; margin-right: 20px;">Sponsor Website</p> <p style="text-align: right; margin-right: 20px;">Program URL</p> <p style="text-align: right; margin-right: 20px;">Deadline Dates (ALL)</p> <p style="text-align: right; margin-right: 20px;">Synopsis</p> <p style="text-align: right; margin-right: 20px;">Applicant Types</p> <p style="text-align: right; margin-right: 20px;">Funding Limit</p> <p style="text-align: right; margin-right: 20px;">Limited Submission</p>	<p>404-329-7558</p> <p>grants@cancer.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>15-Oct-2024</p> <p>Discovery Boost Grants (DBG) support high-risk, high-reward exploratory cancer research across the research continuum. Investigators may focus on developing research methodologies, establishing feasibility, or leading pilot tests. It is expected that preliminary data generated from a completed DBG will have the potential to secure additional grant funding to further the research and open new and highly innovative areas for investigation. Discovery Boost Grants are funded up to \$135,000 per year for up to 2 years, plus 10% indirect costs. The maximum allowable budget is \$297,000 for a 2-year project period.</p> <p>135,000.00 per year</p> <p>No</p>			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																				
116207	AHEAD (Advancing Health Equity and Addressing Cancer Disparities) Awards	American Cancer Society, Inc.		15-Oct-2024	270,000 USD																				
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td>Kimberly Clarke</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>404-329-7558</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>kimberly.clarke@cancer.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>15-Oct-2024</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>The American Cancer Society (ACS) is committed to improving the lives of cancer patients and their families by enhancing access to quality cancer care and ensuring that all people have an equal chance to prevent, detect, treat, and survive cancer. Toward this goal, ACS is announcing AHEAD (Advancing Health Equity and Addressing Cancer Disparities) Awards intended to fund pilot, first-in-field, innovative strategies that increase quality cancer screening, clinical trials—and cancer care closer to home.</td> </tr> <tr> <td style="border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>135,000.00 per year</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>No</td> </tr> </table>					Contact Name	Kimberly Clarke	Contact Telephone	404-329-7558	Contact Email	kimberly.clarke@cancer.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	15-Oct-2024	Synopsis	The American Cancer Society (ACS) is committed to improving the lives of cancer patients and their families by enhancing access to quality cancer care and ensuring that all people have an equal chance to prevent, detect, treat, and survive cancer. Toward this goal, ACS is announcing AHEAD (Advancing Health Equity and Addressing Cancer Disparities) Awards intended to fund pilot, first-in-field, innovative strategies that increase quality cancer screening, clinical trials—and cancer care closer to home.	Applicant Types		Funding Limit	135,000.00 per year	Limited Submission	No
Contact Name	Kimberly Clarke																								
Contact Telephone	404-329-7558																								
Contact Email	kimberly.clarke@cancer.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	15-Oct-2024																								
Synopsis	The American Cancer Society (ACS) is committed to improving the lives of cancer patients and their families by enhancing access to quality cancer care and ensuring that all people have an equal chance to prevent, detect, treat, and survive cancer. Toward this goal, ACS is announcing AHEAD (Advancing Health Equity and Addressing Cancer Disparities) Awards intended to fund pilot, first-in-field, innovative strategies that increase quality cancer screening, clinical trials—and cancer care closer to home.																								
Applicant Types																									
Funding Limit	135,000.00 per year																								
Limited Submission	No																								
014681	Mentoring Award	American Contact Dermatitis Society		15-Oct-2024	3,000 USD																				
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>414-918-9805</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>info@contactderm.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> </table>					Contact Name		Contact Telephone	414-918-9805	Contact Email	info@contactderm.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL										
Contact Name																									
Contact Telephone	414-918-9805																								
Contact Email	info@contactderm.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL)	15-Oct-2024
Synopsis	ACDS Mentoring Awards are granted for the purpose of assisting young dermatologists including dermatology residents, dermatology fellows, or dermatologist up to 5 years out of residency to become leaders/experts in the field of contact dermatitis by acquiring additional academic skills which may not be available at their training institutions. Funding may not exceed \$3,000 per applicant.
Applicant Types	
Funding Limit	3,000.00 maximum
Limited Submission	No

061455	Mid-Career Development Award	American Contact Dermatitis Society		15-Oct-2024	10,000 USD
--------	--	-------------------------------------	--	-------------	------------

Contact Name	
Contact Telephone	414-918-9805
Contact Email	info@contactderm.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	15-Oct-2024
Synopsis	The ACDS Mid Career Development Award provides financial support for ACDS members to defray the cost of acquiring specific skills and knowledge to enhance their professional development in some aspect of contact dermatitis and/or occupational dermatology. Up to \$10,000 in grants will be awarded each year. Preference will be given to budgets of \$4,000 or less.
Applicant Types	
Funding Limit	10,000.00 maximum
Limited Submission	No

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																				
041210	Outcomes Research Award	American Contact Dermatitis Society		15-Oct-2024	50,000 USD																				
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>414-918-9805</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>info@contactderm.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>15-Oct-2024</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>The American Contact Dermatitis Society is soliciting proposals for study of outcomes of dermatitis evaluation and management. Proposals may include investigators from single or multiple centers. The purpose is to establish the value of expert specialist evaluation and management of chronic dermatitis. Proposals are expected from established centers with availability of extended patch test series. Results from the research will be published in Dermatitis subject to editorial review. Grants of \$10,000-\$50,000 will be awarded for a study interval of up to 24 months.</td> </tr> <tr> <td style="border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>50,000.00 maximum</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>No</td> </tr> </table>					Contact Name		Contact Telephone	414-918-9805	Contact Email	info@contactderm.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	15-Oct-2024	Synopsis	The American Contact Dermatitis Society is soliciting proposals for study of outcomes of dermatitis evaluation and management. Proposals may include investigators from single or multiple centers. The purpose is to establish the value of expert specialist evaluation and management of chronic dermatitis. Proposals are expected from established centers with availability of extended patch test series. Results from the research will be published in Dermatitis subject to editorial review. Grants of \$10,000-\$50,000 will be awarded for a study interval of up to 24 months.	Applicant Types		Funding Limit	50,000.00 maximum	Limited Submission	No
Contact Name																									
Contact Telephone	414-918-9805																								
Contact Email	info@contactderm.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	15-Oct-2024																								
Synopsis	The American Contact Dermatitis Society is soliciting proposals for study of outcomes of dermatitis evaluation and management. Proposals may include investigators from single or multiple centers. The purpose is to establish the value of expert specialist evaluation and management of chronic dermatitis. Proposals are expected from established centers with availability of extended patch test series. Results from the research will be published in Dermatitis subject to editorial review. Grants of \$10,000-\$50,000 will be awarded for a study interval of up to 24 months.																								
Applicant Types																									
Funding Limit	50,000.00 maximum																								
Limited Submission	No																								
126693	Hevolution Foundation Postdoctoral Training in Geroscience (HF-PTG) Program	American Federation for Aging Research		30-Oct-2024	Not Specified																				
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>grants@afar.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> </table>					Contact Name		Contact Telephone		Contact Email	grants@afar.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL										
Contact Name																									
Contact Telephone																									
Contact Email	grants@afar.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 30-Oct-2024</p> <p>Synopsis Hevolution Foundation Postdoctoral Training in Geroscience (HF-PTG) Program will provide funding for PhD and MD/PhD students who want to pursue postdoctoral research training in the biology of aging or geroscience. The Hevolution Foundation will commit up to \$5M USD over a period of 4 years and anticipates funding 12-15 trainees in early 2025. Applicants must be doctoral students who have finished their PhD or MD/PhD studies prior to the start of the fellowship (earliest graduation date: May 2024, latest graduation date: March 2025). The HF-PTG Program will fund individuals for up to 4 years including salary and funds for consumables and a limited annual child allowance. Applicants must be current residents of the United States, Canada, UK, or Europe and must conduct their research projects in any of these countries.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
000680	Established Investigator Award	American Heart Association		02-Oct-2024 [LOI/Pre-App]	550,000 USD
	<p>Contact Name</p> <p>Contact Telephone 214-360-6107, option 1</p> <p>Contact Email apply@heart.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Oct-2024 [LOI/Pre-App], 08-Jan-2025</p> <p>Synopsis The Established Investigator Award supports established investigators in rapid career growth phase, with records of accomplishments and showing extraordinary promise. Candidates will have a demonstrated commitment to cardiovascular or cerebrovascular science disciplines that support the AHA's mission, as indicated by funding and</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>publication history and scientific accomplishments. Candidates should propose an innovative/novel research direction that challenges existing paradigms and employs novel concepts, approaches, or technologies.</p> <p>Applicant Types</p> <p>Funding Limit 110,000.00 per year</p> <p>Limited Submission No</p>				
017287	Scott Grundy Fellowship Award for Excellence in Metabolism Research	American Heart Association		09-Oct-2024	500 USD
	<p>Contact Name</p> <p>Contact Telephone 214-570-5935</p> <p>Contact Email professional.help@heart.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Oct-2024</p> <p>Synopsis The Fellowship Award for Excellence in Metabolism Research recognizes three outstanding abstracts submitted by young investigators to the EPI/Lifestyle Scientific Sessions. Up to three awards will be given for the abstracts achieving the highest average scores of all abstracts submitted in the categories of Diabetes/Metabolic Syndrome, Lipids/Lipoproteins, Metabolism, and Obesity and Adipose Tissue Distribution or Lipids and Lipoproteins. Acceptable entries for consideration include broad categories of study designs, including human or laboratory-based research, small metabolic studies, small clinical trials, and population-based studies. Each awardee will receive a cash prize of \$500 and a certificate.</p> <p>Applicant Types</p> <p>Funding Limit 500.00 see detail</p> <p>Limited Submission No</p>				
030379	ANMS Discovery Grants Program	American Neurogastroenterology and Motility Society		11-Oct-2024	30,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Shanthi Srinivasan
Contact Telephone	
Contact Email	ssrini2@emory.edu
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	11-Oct-2024
Synopsis	ANMS is accepting grant applications as part of the ANMS Discovery Grants Program. They will provide support for senior GI fellows, postdoctoral research fellows, or Instructor/Assistant Professor-level faculty who are pursuing research careers in the area of neurogastroenterology and GI motility. Up to two grants of up to \$30,000 each will be awarded in 2023 for qualified applicants including senior GI fellows, postdoctoral research fellows, or junior faculty (with no prior or current independent grant funding, i.e. PI status on an R level grant) pursuing projects spanning basic science, translational investigation, and clinical research pertaining to neurogastroenterology and GI motility.
Applicant Types	
Funding Limit	30,000.00 maximum
Limited Submission	No

022277	Biotechnology Division Student Excellence Award	American Oil Chemists' Society		14-Oct-2024	500 USD
--------	---	--------------------------------	--	-------------	---------

Contact Name	
Contact Telephone	
Contact Email	awards@aocs.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	14-Oct-2024

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis The Biotechnology Division Student Excellence Award recognizes graduate students presenting outstanding oral or poster presentations within the Biotechnology technical program at the AOCS Annual Meeting.</p> <p>Applicant Types </p> <p>Funding Limit 500.00 see detail</p> <p>Limited Submission No</p>				
022295	Health and Nutrition Division Student Excellence Award	American Oil Chemists' Society		14-Oct-2024	500 USD
	<p>Contact Name </p> <p>Contact Telephone </p> <p>Contact Email awards@aoocs.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Oct-2024</p> <p>Synopsis The Health and Nutrition Division Student Excellence Award recognizes graduate students presenting an outstanding oral or poster presentation within the Health and Nutrition technical program at the AOCS Annual Meeting.</p> <p>Applicant Types </p> <p>Funding Limit 500.00 see detail</p> <p>Limited Submission No</p>				
065572	ARRS Scholarship	American Roentgen Ray Society		07-Oct-2024	180,000 USD
	<p>Contact Name </p> <p>Contact Telephone 866-940-2777</p> <p>Contact Email scholarships@arrs.org</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 07-Oct-2024 Synopsis The ARRS Scholarship supports early-career faculty members in study/research in the radiologic sciences that has the possibility of changing the way radiology is practiced. The Scholarship is a two-year program, totaling \$180,000. Applicant Types Funding Limit 180,000.00 see detail Limited Submission Yes				
058656	Carl Koller Memorial Research Grant	American Society of Regional Anesthesia and Pain Medicine		01-Oct-2024 [LOI/Pre-App]	75,000 USD
	Contact Name Contact Telephone 412-471-2718 Contact Email asraassistant@asra.com Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Oct-2024 [LOI/Pre-App], 10-Jan-2025 Synopsis The Carl Koller Memorial Research Grant supports clinical and laboratory studies related to any aspect of regional anesthesia and analgesia and their application to surgery. The amount of the award will not exceed \$75,000. Applicant Types Funding Limit 75,000.00 maximum Limited Submission No				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																				
045646	Research Grants	Aplastic Anemia and MDS International Foundation, Inc.		31-Oct-2024	60,000 USD																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>800-747-2820</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>hok@aamds.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>31-Oct-2024</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>The Aplastic Anemia and MDS International Foundation, Inc. (AAMDSIF) offers research grants to investigators dedicated to studying bone marrow failure and advancing the understanding, prevention and treatment of bone marrow disorders in both pediatric and adult populations.</td> </tr> <tr> <td style="border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>30,000.00 per year</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>Yes</td> </tr> </table>						Contact Name		Contact Telephone	800-747-2820	Contact Email	hok@aamds.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	31-Oct-2024	Synopsis	The Aplastic Anemia and MDS International Foundation, Inc. (AAMDSIF) offers research grants to investigators dedicated to studying bone marrow failure and advancing the understanding, prevention and treatment of bone marrow disorders in both pediatric and adult populations.	Applicant Types		Funding Limit	30,000.00 per year	Limited Submission	Yes
Contact Name																									
Contact Telephone	800-747-2820																								
Contact Email	hok@aamds.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	31-Oct-2024																								
Synopsis	The Aplastic Anemia and MDS International Foundation, Inc. (AAMDSIF) offers research grants to investigators dedicated to studying bone marrow failure and advancing the understanding, prevention and treatment of bone marrow disorders in both pediatric and adult populations.																								
Applicant Types																									
Funding Limit	30,000.00 per year																								
Limited Submission	Yes																								
049880	Dr. David L. Epstein Award	Association for Research in Vision and Ophthalmology		01-Oct-2024	100,000 USD																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>240-221-2900</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>awards@arvo.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>01-Oct-2024</td> </tr> </table>						Contact Name		Contact Telephone	240-221-2900	Contact Email	awards@arvo.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	01-Oct-2024								
Contact Name																									
Contact Telephone	240-221-2900																								
Contact Email	awards@arvo.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	01-Oct-2024																								

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis The Dr. David L. Epstein Award was created by Dr. Epstein’s family to perpetuate and honor his commitment to the scientific understanding and cure of glaucoma through the support of promising clinician-scientists in exceptional research environments. It is the intent of the donors that this award further Dr. Epstein's long-standing determination and interest in solving the complex issues of glaucoma through well-conceived and executed scientific research focused on finding the causes and new treatments for the disease. The award consists of \$100,000.</p> <p>Applicant Types</p> <p>Funding Limit 100,000.00 maximum</p> <p>Limited Submission No</p>				
031426	Carl Camras Translational Research Awards	Association for Research in Vision and Ophthalmology		01-Oct-2024	12,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email arvo@arvo.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024</p> <p>Synopsis The Carl Camras Translational Research Award is intended for young investigators working in areas of translational research and honors Dr. Carl Camras, who is highly respected for his work as a glaucoma specialist and a research scientist. An award of \$12,000 will be presented.</p> <p>Applicant Types</p> <p>Funding Limit 12,000.00 maximum</p> <p>Limited Submission No</p>				
089931	PhD Fellowships	Boehringer Ingelheim Fonds		01-Oct-2024	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone +49 (0)6131 2750 80</p> <p>Contact Email secretariat@bifonds.de</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024</p> <p>Synopsis The Boehringer Ingelheim Fonds (BIF) awards PhD fellowships of 2 to 3.5 years to outstanding junior scientists worldwide who wish to pursue an ambitious PhD project in basic biomedical research in an internationally leading laboratory.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
099223	National Glaucoma Research Program -- Postdoctoral Fellowship Awards	BrightFocus Foundation		31-Oct-2024	150,000 USD
	<p>Contact Name</p> <p>Contact Telephone 1-800-437-2423</p> <p>Contact Email researchgrants@brightfocus.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Oct-2024</p> <p>Synopsis BrightFocus provides research funds for U.S. and international researchers pursuing pioneering research leading to greater understanding, prevention, and treatment of glaucoma. Postdoctoral fellowship awards are intended for young researchers in their final stages of mentored training. These awards fund projects in an established laboratory</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>that will serve as the basis for the applicant's own independent research career. This fellowship is available to researchers within four years of degree conferral or end of residency or fellowship. Exceptions to the above four-year eligibility period will be considered under unusual circumstances.</p> <p>Applicant Types</p> <p>Funding Limit 75,000.00 per year</p> <p>Limited Submission No</p>				
090492	Travel Awards	British Infection Association		31-Oct-2024	1,280 USD
	<p>Contact Name Profesor Thushan de Silva</p> <p>Contact Telephone</p> <p>Contact Email scientificresearch@britishinfection.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Oct-2024</p> <p>Synopsis The British Infection Association Travel Awards support registration and travel (if appropriate) to major national or international meetings (either in person or on-line), in particular, ASM, ICAAC, IDSA, and ECCMID to present original research, where the abstract is already accepted. Accommodation costs may also be included, up to the £1000 grant limit.</p> <p>Applicant Types</p> <p>Funding Limit 1,000.00 maximum</p> <p>Limited Submission No</p>				
013123	Career Awards for Medical Scientists (CAMS)	Burroughs Wellcome Fund		08-Oct-2024	700,000 USD
	Contact Name				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 919-991-5115 Contact Email lhaidar@bwfund.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 08-Oct-2024 Synopsis The Career Awards for Medical Scientists (CAMS) is a highly competitive program that provides \$700,000 awards over five years for physician-scientists, who are committed to an academic career, to bridge advanced postdoctoral/fellowship training and the early years of faculty service. Applicant Types Funding Limit 700,000.00 see detail Limited Submission No				
045538	Partnering Opportunity For Clinical Trial Stage Projects (CLIN2)	California Institute for Regenerative Medicine		30-Aug-2024	Not Specified
	Contact Name Contact Telephone 510-340-9101 Contact Email Clinical@cirm.ca.gov Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 30-Aug-2024 , 31-Oct-2024 , 29-Nov-2024 , 30-Dec-2024 , 31-Jan-2025 , 28-Feb-2025 , 31-Mar-2025 , 30-Apr-2025 , 30-May-2025 , 30-Jun-2025 Synopsis The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world. The objective of this funding opportunity is to support completion of a clinical trial for a regenerative medicine-based therapy (stem cell-based or genetic therapy) that addresses an unmet medical need. Under this program, CIRM will				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>act not only as a funding agency, but will also devote significant internal resources and leverage its external team of world-class subject matter experts to actively advance the project. The result of a successful application will be the formation of a true partnership that both accelerates the program and gives it the greatest opportunity for success.</p> <p>0.00 see detail</p> <p>No</p>			

045367	Partnering Opportunity for Late Stage Preclinical Projects (CLIN1)	California Institute for Regenerative Medicine		30-Aug-2024	6,000,000 USD
--------	--	--	--	-------------	---------------

Contact Name					
Contact Telephone	510-340-9101				
Contact Email	clinical@cirm.ca.gov				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	30-Aug-2024 , 31-Oct-2024 , 29-Nov-2024 , 30-Dec-2024 , 31-Jan-2025 , 28-Feb-2025 , 31-Mar-2025 , 30-Apr-2025 , 30-May-2025 , 30-Jun-2025				
Synopsis	<p>The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world. The objective of this program announcement is to support late-stage preclinical studies necessary to file and attain an active IND with the Food and Drug Administration (FDA) and initiate start-up activities to prepare for a clinical trial for a regenerative medicine therapy (stem cell-based or genetic therapy). Under this program, CIRM will act not only as a funding agency, but will also devote significant internal resources and leverage its external team of world-class subject matter experts to actively advance the project. The result of a successful application will be the formation of a true partnership that both accelerates the program and gives it the greatest opportunity for success.</p>				
Applicant Types					

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Funding Limit | 6,000,000.00 maximum
 Limited Submission | No

004422	Research Chairs	Canada Research Chairs		22-Oct-2024	1,008,000 USD
--------	---------------------------------	------------------------	--	-------------	------------------

Contact Name	Tamara Pyke
Contact Telephone	343-571-9650
Contact Email	tamara.pyke@chairs-chaire.gc.ca
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	22-Oct-2024
Synopsis	The Canada Research Chairs Program (CRCP) offers eligible Canadian degree-granting institutions the opportunity to nominate a diverse cadre of outstanding researchers for professorships in areas that will further the institution's strategic research plan and enable them to maximize their contributions as centres of research and research training. Eligible postsecondary institutions receive a set number of chair allocations based on the funding received by their researchers from the three federal research granting agencies: the Canadian Institutes for Health Research (CIHR); the Natural Sciences and Engineering Council (NSERC); and the Social Sciences and Humanities Research Council (SSHRC) (the agencies).
Applicant Types	
Funding Limit	200,000.00 per year
Limited Submission	No

098717	Doctoral Research Award: Vanier Canada Graduate Scholarships	Canadian Institutes of Health Research		30-Oct-2024	108,000 USD
--------	--	--	--	-------------	----------------

Contact Name |

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 613-941-2672</p> <p>Contact Email vanier@cihr-irsc.gc.ca</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Oct-2024</p> <p>Synopsis The Vanier Canada Graduate Scholarships (Vanier CGS) program attracts and retains world-class doctoral students and helps establish Canada as a global centre of excellence in research and higher learning. CIHR categorizes health research in four broad themes: 1. Biomedical Research; 2. Clinical Research; 3. Health Services Research; 4. Social, Cultural, Environmental and Population Health Research.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 per year</p> <p>Limited Submission No</p>				
072353	Research Grants		CARB-X	04-Oct-2024	Not Specified
	<p>Contact Name Genevieve Holmes</p> <p>Contact Telephone</p> <p>Contact Email carbopr@bu.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Oct-2024</p> <p>Synopsis The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today a funding solicitation with four distinct product themes.</p> <p>Applicant Types</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	0.00 not provided			
	Limited Submission	No			
098542	Conquer Cancer Foundation Career Development Award (CDA) in Palliative & Supportive Care	Conquer Cancer Foundation of ASCO		17-Oct-2024	200,000 USD
	Contact Name				
	Contact Telephone	571-483-1700			
	Contact Email	grants@conquer.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	17-Oct-2024			
	Synopsis	The Conquer Cancer Career Development Award (CDA) in Palliative & Supportive Care provides funding to clinical investigators who have received their initial faculty appointment to establish an independent clinical cancer research program with a focus on palliative and supportive care. This is a mentored award and the research project is conducted under the guidance of a scientific mentor. Applications in all areas of cancer research are accepted from U.S. and international applicants.			
	Applicant Types				
	Funding Limit	200,000.00 maximum			
	Limited Submission	No			
003893	Grants Program	Cummings (Frances L. & Edwin L.) Memorial Fund		01-Oct-2024	Not Specified
	Contact Name	Elizabeth H. Costas			
	Contact Telephone	212-286-1778			
	Contact Email	info@cummingsfund.org			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Oct-2024			
	Synopsis	The primary interest of the Frances L. & Edwin L. Cummings Memorial Fund is to support organizations operating in New York City and Northeastern New Jersey that provide programs and services in the areas of social welfare, education, and health. The Fund has a special interest in youth programs located in these regions.			
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	Yes			

002586	Grants Program	Cure Parkinsons Trust		21-Oct-2024	320,000 USD
--------	--------------------------------	-----------------------	--	-------------	----------------

Contact Name	Rosie Fuest, Research Manager				
Contact Telephone	0207 487 3892				
Contact Email	Rosie@cureparkinsons.org.uk				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	21-Oct-2024				
Synopsis	This programme primarily funds preclinical and clinical research focused on slowing, stopping, or reversing Parkinson's. For preclinical research, the sponsor funds grants up to £250,000 (GBP) and prioritise projects that are likely to lead to clinical trials in people with Parkinson's within 5 years. For clinical research, the sponsor funds clinical trials and sub-studies of trials in people with Parkinson's.				
Applicant Types					
Funding Limit	250,000.00 see detail				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
117011	Pathway and Pipeline Grant Program	CurePSP		03-Oct-2024	100,000 USD
	Contact Name	Jennifer Brummet			
	Contact Telephone	800-457-4777			
	Contact Email	brummet@curepsp.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-Oct-2024			
	Synopsis	Through the Pathway and Pipeline Grant program, CurePSP provides seed funding to investigators who have innovative ideas that need proof of concept or pilot studies in order to qualify for larger funding sources. CurePSP provides grants to scientists of up to \$100,000 for one- or two-year studies.			
	Applicant Types				
	Funding Limit	100,000.00 maximum			
	Limited Submission	No			
024444	Research Fellowship Awards	Cystic Fibrosis Canada		01-Oct-2024	64,800 USD
	Contact Name				
	Contact Telephone				
	Contact Email	research@cysticfibrosis.ca			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Oct-2024			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis Research Fellowship Awards are awarded to build capacity in CF research in Canada by supporting highly qualified fellows who are undertaking fulltime research training in areas relevant to cystic fibrosis.</p> <p>Applicant Types</p> <p>Funding Limit 45,000.00 per year</p> <p>Limited Submission No</p>				
020318	DFF-Research Project 2 - Medical Sciences	Danish Agency for Science and Higher Education		08-Oct-2024	602,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email DFF-opslag@ufm.dk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Oct-2024</p> <p>Synopsis To advance the quality of, and develop collaboration within Danish research, DFF offers funding for research projects carried out by multiple researchers (including postdoctoral candidates and PhD students) of up to 4.5 years in duration within a budget framework of between DKK 2,000,000 to DKK 4,300,000, excluding overhead/administration expenses. DFF Medical Sciences offers funding to researchers who work with all aspects of basic, translational, clinical and socio-medical research in relation to human health and disease.</p> <p>Applicant Types</p> <p>Funding Limit 4,300,000.00 maximum</p> <p>Limited Submission No</p>				
020313	Sapere Aude: DFF- Starting Grant	Danish Agency for Science and Higher Education		08-Oct-2024	602,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email DFF-opslag@ufm.dk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Oct-2024</p> <p>Synopsis The Danish Council for Independent Research (DFF) offers Starting Grants to younger researchers who have achieved outstanding research results in the field of Medical Sciences and gives them an opportunity to develop and strengthen their research ideas. DFF expects that a Sapere Aude: DFF–Starting Grant will help to enable the applicant to apply for an ERC Starting Grant/Consolidator Grant/Advanced Grant, or corresponding international programmes.</p> <p>Applicant Types</p> <p>Funding Limit 4,300,000.00 maximum</p> <p>Limited Submission No</p>				

020349	DFF-Research Project 2 – Humanities	Danish Agency for Science and Higher Education		08-Oct-2024	602,000 USD
--------	---	--	--	-------------	-------------

	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email DFF-opslag@ufm.dk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Oct-2024</p> <p>Synopsis To advance the quality of, and develop collaboration within Danish research in the Humanities, DFF offers funding for research projects carried out by multiple researchers (including postdoctoral candidates and PhD students) of up to</p>				
--	--	--	--	--	--

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit Limited Submission	4.5 years in duration within a budget framework of between DKK 2,000,000 to DKK 4,300,000, excluding overhead/administration expenses. 4,300,000.00 see detail No			
063107	Sarah K. deCoizart Perpetual Charitable Trust - Grants Program	deCoizart (Sarah K.) Perpetual Charitable Trust		01-Oct-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission	Lindsey Crane, Program Officer lindsey.s.crane@jpmorgan.com Link to sponsor website Link to program URL 01-Oct-2024 The Sarah K. de Coizart Perpetual Charitable Trust awards grants focusing on species conservation and blindness. Grants range in size from \$20,000 to \$75,000 per year. 0.00 see detail No			
009823	Research Career Development Award	Dermatology Foundation		15-Oct-2024	150,000 USD
	Contact Name Contact Telephone Contact Email	 847-328-2256 DFRAP@dermatologyfoundation.org			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	15-Oct-2024
Synopsis	The Research Career Development Award (CDA) assists an individual in the transition from fellowship to established investigator. It provides career development support in skin research for a junior investigator.
Applicant Types	
Funding Limit	75,000.00 per year
Limited Submission	No

065628	Science of Human Appearance Career Development Award	Dermatology Foundation		01-Oct-2024	75,000 USD
--------	--	------------------------	--	-------------	------------

Contact Name	
Contact Telephone	847-328-2256
Contact Email	dfrap@dermatologyfoundation.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	01-Oct-2024 , 01-Nov-2024
Synopsis	The Science of Human Appearance Career Development Award provides annual salary support for the career development of individuals who wish to understand the cell and molecular mechanisms of altered human appearance or of therapeutic interventions. This CDA recognizes the specialty's sizeable increase in focus on human appearance and the paucity of high quality research in the area. This award is intended to support research addressing human appearance issues caused by aging and/or environmental factors.
Applicant Types	
Funding Limit	75,000.00 per year
Limited Submission	No

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																				
020274	Dermatologist Investigator Research Fellowship	Dermatology Foundation		15-Oct-2024	35,000 USD																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; padding: 5px;">Contact Name</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">dfrap@dermatologyfoundation.org</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;">Link to sponsor website</td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">15-Oct-2024</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">The Dermatology Foundation offers a fellowship that is intended to advance the research careers of individuals in the early stages of career development. Each awarded fellowship, in the amount of \$35,000, provides an annual salary stipend and is not intended for faculty.</td> </tr> <tr> <td style="padding: 5px;">Applicant Types</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Funding Limit</td> <td style="padding: 5px;">35,000.00 per year</td> </tr> <tr> <td style="padding: 5px;">Limited Submission</td> <td style="padding: 5px;">No</td> </tr> </table>						Contact Name		Contact Telephone		Contact Email	dfrap@dermatologyfoundation.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	15-Oct-2024	Synopsis	The Dermatology Foundation offers a fellowship that is intended to advance the research careers of individuals in the early stages of career development. Each awarded fellowship, in the amount of \$35,000, provides an annual salary stipend and is not intended for faculty.	Applicant Types		Funding Limit	35,000.00 per year	Limited Submission	No
Contact Name																									
Contact Telephone																									
Contact Email	dfrap@dermatologyfoundation.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	15-Oct-2024																								
Synopsis	The Dermatology Foundation offers a fellowship that is intended to advance the research careers of individuals in the early stages of career development. Each awarded fellowship, in the amount of \$35,000, provides an annual salary stipend and is not intended for faculty.																								
Applicant Types																									
Funding Limit	35,000.00 per year																								
Limited Submission	No																								
009821	Research Grants Award	Dermatology Foundation		15-Oct-2024	25,000 USD																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; padding: 5px;">Contact Name</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">847-328-2256</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">DFRAP@dermatologyfoundation.org</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;">Link to sponsor website</td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">15-Oct-2024</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">The Foundation’s Research Grants provide an annual award of \$25,000 in financial support for research projects in dermatology and cutaneous biology that benefit the dermatology community at large.</td> </tr> <tr> <td style="padding: 5px;">Applicant Types</td> <td style="padding: 5px;"></td> </tr> </table>						Contact Name		Contact Telephone	847-328-2256	Contact Email	DFRAP@dermatologyfoundation.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	15-Oct-2024	Synopsis	The Foundation’s Research Grants provide an annual award of \$25,000 in financial support for research projects in dermatology and cutaneous biology that benefit the dermatology community at large.	Applicant Types					
Contact Name																									
Contact Telephone	847-328-2256																								
Contact Email	DFRAP@dermatologyfoundation.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	15-Oct-2024																								
Synopsis	The Foundation’s Research Grants provide an annual award of \$25,000 in financial support for research projects in dermatology and cutaneous biology that benefit the dermatology community at large.																								
Applicant Types																									

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Funding Limit | 25,000.00 per year
 Limited Submission | No

120954	Diversity, Equity, and Inclusion Career Development Award	Dermatology Foundation		15-Oct-2024	150,000 USD
--------	---	------------------------	--	-------------	-------------

Contact Name	
Contact Telephone	847-328-2256
Contact Email	dfrap@dermatologyfoundation.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	15-Oct-2024
Synopsis	The Dermatology Foundation announces a new Career Development Award to support research addressing issues impacting groups underrepresented or underserved in medicine, including, but not limited to: Racial and ethnic minorities; Sexual and gender minorities; and Underserved/disadvantaged populations. All Foundation-funded research must be conducted in the U.S. under the sponsorship of a department/division of dermatology that is ACGME-approved for training in dermatology.
Applicant Types	
Funding Limit	75,000.00 per year
Limited Submission	No

084748	Women's Health Career Development Award	Dermatology Foundation		15-Oct-2024	150,000 USD
--------	---	------------------------	--	-------------	-------------

Contact Name	
Contact Telephone	847-328-2256
Contact Email	dfrap@dermatologyfoundation.org

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Oct-2024 Synopsis The Women's Health Career Development Award is intended to focus on women's health issues where further research is needed. Career development awards (CDAs) may be renewed annually for up to a total of two years of funding. CDAs offer an annual salary stipend of \$75,000 that can be supplemented from institutional sources so that the salary received is commensurate with peers within the institution. Applicant Types Funding Limit 75,000.00 per year Limited Submission No				
069351	Clinical Career Development Award in Dermatologic Surgery	Dermatology Foundation		15-Oct-2024	Not Specified
	Contact Name Contact Telephone 847-328-2256 Contact Email dfrap@dermatologyfoundation.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Oct-2024 Synopsis The Dermatologic Surgery Career Development award supports a broad range of research projects that further the practice of dermatologic surgery and develops the teaching, research and/or leadership abilities of dermatologic surgeons. Projects may include but are not limited to: study of skin cancers, treatment outcomes, surgical management, Mohs micrographic surgery, Mohs laboratory techniques, reconstruction, wound healing, surgical complications, patient reported outcomes, laser surgery, and noninvasive imaging. Applicant Types				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	0.00 see detail			
	Limited Submission	No			
004728	Medical Dermatology Career Development Award	Dermatology Foundation		15-Oct-2024	165,000 USD
	Contact Name				
	Contact Telephone	847-328-2256			
	Contact Email	dfrap@dermatologyfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Oct-2024			
	Synopsis	The Medical Dermatology Career Development Award (CDA) provides funding for future intellectual leaders, educators, and clinical scholars in that aspect of the specialty that addresses severe dermatologic disease. The award fosters the careers of young dermatologists who will become the future role models and mentors for physicians diagnosing and treating complex skin disease.			
	Applicant Types				
	Funding Limit	55,000.00 per year			
	Limited Submission	No			
057701	Patient Directed Investigation Grant	Dermatology Foundation		15-Oct-2024	20,000 USD
	Contact Name				
	Contact Telephone	847-328-2256			
	Contact Email	dfrap@dermatologyfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 15-Oct-2024</p> <p>Synopsis The Dermatology Foundation's Patient Directed Investigation Grant exists to support translational studies that have the potential to benefit patients directly. Such studies may concern medical dermatology, dermatologic surgery, procedural dermatology, pediatric dermatology, or other aspects of the specialty that impact patient care.</p> <p>Applicant Types</p> <p>Funding Limit 20,000.00 per year</p> <p>Limited Submission No</p>				
084816	Patient Directed Investigation Grant	Dermatology Foundation		15-Oct-2024	25,000 USD
	<p>Contact Name</p> <p>Contact Telephone 847-328-2256</p> <p>Contact Email dfrap@dermatologyfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Oct-2024</p> <p>Synopsis The Patient Directed Investigation Grant exists to support translational studies that have the potential to benefit patients directly. Dermatology Foundation grants are annual awards of \$20,000.</p> <p>Applicant Types</p> <p>Funding Limit 25,000.00 maximum</p> <p>Limited Submission No</p>				
003290	Physician Scientist Career Development Award	Dermatology Foundation		15-Oct-2024	165,000 USD
	<p>Contact Name</p> <p>Contact Telephone 847-328-2256</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email dfrap@dermatologyfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Oct-2024</p> <p>Synopsis The Physician Scientist CDA supports the academic career of a physician scientist who is devoted to clinical dermatology, and assists in the transition from fellowship to established investigator. This award is intended for the academic investigator demonstrating significant creativity in clinically relevant research.</p> <p>Applicant Types</p> <p>Funding Limit 55,000.00 per year</p> <p>Limited Submission No</p>				

042778	Dermatopathology Research Career Development Award	Dermatology Foundation		15-Oct-2024	110,000 USD
--------	--	------------------------	--	-------------	-------------

Contact Name	
Contact Telephone	847-328-2256
Contact Email	dfrap@dermatologyfoundation.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	15-Oct-2024
Synopsis	The Dermatopathology Career Development Award (CDA) supports the academic career development of future intellectual leaders who demonstrate a strong commitment to advance the fields of dermatopathology and dermatology through research and/or education.
Applicant Types	
Funding Limit	55,000.00 per year

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
014221	Public Health Career Development Award	Dermatology Foundation		15-Oct-2024	75,000 USD
	Contact Name				
	Contact Telephone	847-328-2256			
	Contact Email	dfrap@dermatologyfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Oct-2024			
	Synopsis	The Public Health Career Development Award supports the establishment and/or development of careers in public health. Research proposals may concern health care policy, epidemiological research, outcome studies, comparative effectiveness research, information system development, teledermatology, or other topics relating to public health.			
	Applicant Types				
	Funding Limit	75,000.00 per year			
	Limited Submission	No			
121027	Type 1 Diabetes Research Grant Program	Diabetes Research Connection		15-Oct-2024	75,000 USD
	Contact Name				
	Contact Telephone	844-484-3372			
	Contact Email	research@diabetesresearchconnection.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Oct-2024			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Diabetes Research Connection gives early-career scientists the opportunity to perform innovative type 1 diabetes research in the broad areas of cure and care, including complications.			
	Applicant Types				
	Funding Limit	75,000.00 maximum			
	Limited Submission	No			
125923	Mission: A Soil Deal For Europe -- Living Labs in Urban Areas for Healthy Soils	European Commission	HORIZON-MISS-2024-SOIL-01-02	08-Oct-2024	13,080,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	See notes for contact information.			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Oct-2024			
	Synopsis	Proposals are invited against the following topic: HORIZON-MISS-2024-SOIL-01-02 - Living Labs in Urban Areas for Healthy Soils The topic is part of the call: Research and Innovation and other actions to support the implementation of Mission 'A Soil Deal for Europe' The call contributes to the EU Mission: A Soil Deal for Europe			
	Applicant Types				
	Funding Limit	12,000,000.00 on average			
	Limited Submission	No			
125920	Mission: A Soil Deal For Europe -- Co-Creating Solutions for Soil Health in Living Labs	European Commission	HORIZON-MISS-2024-SOIL-01-01	08-Oct-2024	13,080,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email See notes for contact information.</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Oct-2024</p> <p>Synopsis Proposals are invited against the following topic: HORIZON-MISS-2024-SOIL-01-01 - Co-Creating Solutions for Soil Health in Living Labs The topic is part of the call: Research and Innovation and other actions to support the implementation of Mission 'A Soil Deal for Europe' The call contributes to the EU Mission: A Soil Deal for Europe</p> <p>Applicant Types</p> <p>Funding Limit 12,000,000.00 on average</p> <p>Limited Submission No</p>				
125930	Mission: A Soil Deal For Europe -- Harnessing the Multifunctional Potential of Soil Biodiversity for Healthy Cropping Systems	European Commission		HORIZON-MISS-2024-SOIL-01-06 08-Oct-2024	8,720,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email See notes for contact information.</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Oct-2024</p> <p>Synopsis Proposals are invited against the following topic: HORIZON-MISS-2024-SOIL-01-06 - Harnessing the Multifunctional Potential of Soil Biodiversity for Healthy Cropping Systems The topic is part of the call: Research and Innovation and</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>other actions to support the implementation of Mission 'A Soil Deal for Europe' The call contributes to the EU Mission: A Soil Deal for Europe</p> <p>8,000,000.00 on average</p> <p>No</p>			
125926	Mission: A Soil Deal For Europe -- Systems To Quantify Nitrogen Fluxes and Uncertainties in European Landscapes	European Commission	HORIZON-MISS-2024-SOIL-01-04	08-Oct-2024	12,535,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>See notes for contact information.</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>08-Oct-2024</p> <p>Proposals are invited against the following topic: HORIZON-MISS-2024-SOIL-01-04 - Systems To Quantify Nitrogen Fluxes and Uncertainties in European Landscapes The topic is part of the call: Research and Innovation and other actions to support the implementation of Mission 'A Soil Deal for Europe' The call contributes to the EU Mission: A Soil Deal for Europe</p> <p>11,500,000.00 on average</p> <p>No</p>			
125869	Mission: A Soil Deal For Europe -- Assessment of Soil Health in Africa	European Commission	HORIZON-MISS-2024-SOIL-01-09	08-Oct-2024	7,630,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email See notes for contact information.</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Oct-2024</p> <p>Synopsis Proposals are invited against the following topic: HORIZON-MISS-2024-SOIL-01-09 - Assessment of Soil Health in Africa The topic is part of the call: Research and Innovation and other actions to support the implementation of Mission 'A Soil Deal for Europe' The call contributes to the EU Mission: A Soil Deal for Europe</p> <p>Applicant Types</p> <p>Funding Limit 7,000,000.00 on average</p> <p>Limited Submission No</p>				
126665	EU4Health Programme (EU4H) -- Call for Proposals to Increase Health Literacy for Cancer Prevention and Care - CR-g-24-39	European Commission	EU4H-2024-PJ-02-2	10-Oct-2024	1,090,000 USD

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email HADEA-HP-CALLS@ec.europa.eu</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Oct-2024</p> <p>Synopsis Proposals are invited against the following topic: EU4H-2024-PJ-02-2 -- Call for Proposals to Increase Health Literacy for Cancer Prevention and Care - CR-g-24-39 This topic is part of a call for proposals for EU action grants in the field of</p>

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	health under the EU4Health Programme (EU4H). The call is launched in accordance with the 2024 Work Programme and will be managed by the European Health and Digital Executive Agency, (HaDEA). Applicant Types Funding Limit 1,000,000.00 see detail Limited Submission No				
125928	Mission: A Soil Deal For Europe -- Soil Health, Pollinators and Key Ecosystem Functions	European Commission	HORIZON-MISS-2024-SOIL-01-05	08-Oct-2024	8,175,000 USD
	Contact Name Contact Telephone Contact Email See notes for contact information. Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 08-Oct-2024 Synopsis Proposals are invited against the following topic: HORIZON-MISS-2024-SOIL-01-05 - Soil Health, Pollinators and Key Ecosystem Functions The topic is part of the call: Research and Innovation and other actions to support the implementation of Mission 'A Soil Deal for Europe' The call contributes to the EU Mission: A Soil Deal for Europe Applicant Types Funding Limit 7,500,000.00 on average Limited Submission No				
126667	EU4Health Programme (EU4H) -- Call for Proposals on the Development of Social Services for Psychosocial Support and Rehabilitation for Children and Their Families in Paediatric Oncology	European Commission	EU4H-2024-PJ-02-3	10-Oct-2024	4,033,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[Clinics in Member States and Countries Associated to the EU4Health Programme - CR-g-24-43](#)

	Contact Name				
	Contact Telephone				
	Contact Email	HADEA-HP-CALLS@ec.europa.eu			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	10-Oct-2024			
	Synopsis	Proposals are invited against the following topic: EU4H-2024-PJ-02-3 -- Call for Proposals on the Development of Social Services for Psychosocial Support and Rehabilitation for Children and Their Families in Paediatric Oncology Clinics in Member States and Countries Associated to the EU4Health Programme - CR-g-24-43 This topic is part of a call for proposals for EU action grants in the field of health under the EU4Health Programme (EU4H). The call is launched in accordance with the 2024 Work Programme and will be managed by the European Health and Digital Executive Agency, (HaDEA).			
	Applicant Types				
	Funding Limit	3,700,000.00 see detail			
	Limited Submission	No			

126661	EU4Health Programme (EU4H) -- Call for Proposals on EU Network of Youth Cancer Survivors - CR-g-24-45	European Commission	EU4H-2024-PJ-02-4	10-Oct-2024	5,450,000 USD
--------	---	---------------------	-------------------	-------------	---------------

	Contact Name				
	Contact Telephone				
	Contact Email	HADEA-HP-CALLS@ec.europa.eu			
	Sponsor Website				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Oct-2024</p> <p>Synopsis Proposals are invited against the following topic: EU4H-2024-PJ-02-4 -- Call for Proposals on EU Network of Youth Cancer Survivors - CR-g-24-45 This topic is part of a call for proposals for EU action grants in the field of health under the EU4Health Programme (EU4H). The call is launched in accordance with the 2024 Work Programme and will be managed by the European Health and Digital Executive Agency, (HaDEA).</p> <p>Applicant Types</p> <p>Funding Limit 5,000,000.00 see detail</p> <p>Limited Submission No</p>				
126663	EU4Health Programme (EU4H) -- Call for Proposal to Support Integration of Cancer Images Into the Federated Pan-European Infrastructure to Foster Screening Programmes - CR-g-24-37	European Commission	EU4H-2024-PJ-02-1	10-Oct-2024	4,360,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email HADEA-HP-CALLS@ec.europa.eu</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Oct-2024</p> <p>Synopsis Proposals are invited against the following topic: EU4H-2024-PJ-02-1 - Call for Proposal to Support Integration of Cancer Images Into the Federated Pan-European Infrastructure to Foster Screening Programmes - CR-g-24-37 This topic is part of a call for proposals for EU action grants in the field of health under the EU4Health Programme (EU4H). The call is launched in accordance with the 2024 Work Programme and will be managed by the European Health and Digital Executive Agency, (HaDEA).</p> <p>Applicant Types</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit 4,000,000.00 see detail Limited Submission No				
019315	ESCMID Funded Observerships	European Society of Clinical Microbiology and Infectious Diseases		16-Oct-2024	Not Specified
	Contact Name Contact Telephone Contact Email info@escmid.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 16-Oct-2024 Synopsis ESCMID Funded Observerships provide participants with a fantastic opportunity to gain experience and exchange knowledge with colleagues across the fields of Clinical Microbiology (CM) and Infectious Diseases (ID). ESCMID gives out 100 observerships per year, hosted across our 123 ESCMID Collaborative Centres (ECCs). The funding, which can reach up to 2K EUR, financially supports the observer for a smooth journey. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
093882	Max Weber Fellowships	European University Institute		18-Oct-2024	Not Specified
	Contact Name Contact Telephone +39 055 4685 377 Contact Email applyfellow@eui.eu				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	18-Oct-2024			
	Synopsis	The Max Weber Programme (MWP) at the European University Institute (EUI) is a unique postdoctoral programme in the historical and social sciences in Europe. It is open to applicants who are within 5 years from the completion of their PhD, from anywhere in the world, regardless of nationality.			
	Applicant Types				
	Funding Limit	2,500.00 per month			
	Limited Submission	No			

010638	Central Fund Grants (October Round)	Finnish Cultural Foundation		31-Oct-2024	Not Specified
--------	---	-----------------------------	--	-------------	---------------

	Contact Name				
	Contact Telephone	+358 9 612 810			
	Contact Email	apurahainfo@skr.fi			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Oct-2024			
	Synopsis	The Finnish Cultural Foundation awards grants for scientific and artistic work as well as for projects and acquisitions from the October round of applications. In the October round of applications, it is possible to apply for a regular working and/or expenditure grant or a special purpose grant.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
014087	Small Research Grant	Fisheries Society of the British Isles		01-Oct-2024	9,600 USD		
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; vertical-align: top;"> <p>Contact Name</p> <p>Contact Telephone 02039253449</p> <p>Contact Email theteam@fsbi.org.uk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024</p> <p>Synopsis The FSBI funds a number of small research projects each year to support members of the Society to undertake novel research into any aspect of fish biology and fisheries science that is relevant to the Society’s objectives. The Small Research Grant scheme is open to bids for up to £7500 per project.</p> <p>Applicant Types</p> <p>Funding Limit 7,500.00 maximum</p> <p>Limited Submission No</p> </td> <td style="width: 75%;"></td> </tr> </table>						<p>Contact Name</p> <p>Contact Telephone 02039253449</p> <p>Contact Email theteam@fsbi.org.uk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024</p> <p>Synopsis The FSBI funds a number of small research projects each year to support members of the Society to undertake novel research into any aspect of fish biology and fisheries science that is relevant to the Society’s objectives. The Small Research Grant scheme is open to bids for up to £7500 per project.</p> <p>Applicant Types</p> <p>Funding Limit 7,500.00 maximum</p> <p>Limited Submission No</p>	
<p>Contact Name</p> <p>Contact Telephone 02039253449</p> <p>Contact Email theteam@fsbi.org.uk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024</p> <p>Synopsis The FSBI funds a number of small research projects each year to support members of the Society to undertake novel research into any aspect of fish biology and fisheries science that is relevant to the Society’s objectives. The Small Research Grant scheme is open to bids for up to £7500 per project.</p> <p>Applicant Types</p> <p>Funding Limit 7,500.00 maximum</p> <p>Limited Submission No</p>							
113739	Translational Research Acceleration Program (TRAP) Award	Foundation Fighting Blindness		17-Oct-2024	Not Specified		
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; vertical-align: top;"> <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grants@fightingblindness.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Oct-2024</p> <p>Synopsis The Foundation Fighting Blindness seeks proposals toward the Translational Research Acceleration Program (TRAP). The Translational Research Acceleration Program awards will accelerate the movement of preclinical research toward</p> </td> <td style="width: 75%;"></td> </tr> </table>						<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grants@fightingblindness.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Oct-2024</p> <p>Synopsis The Foundation Fighting Blindness seeks proposals toward the Translational Research Acceleration Program (TRAP). The Translational Research Acceleration Program awards will accelerate the movement of preclinical research toward</p>	
<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grants@fightingblindness.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Oct-2024</p> <p>Synopsis The Foundation Fighting Blindness seeks proposals toward the Translational Research Acceleration Program (TRAP). The Translational Research Acceleration Program awards will accelerate the movement of preclinical research toward</p>							

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

		an Investigational New Drug filing and into clinical trials to provide a robust and diverse pipeline of potential therapies to fight inherited retinal degenerations (IRD) and dry age-related macular degeneration.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			

025618	Traditional American Students Awards	Foundation for Educational Exchange Between Canada and the United States of America		01-Oct-2024	25,000 USD
--------	--	---	--	-------------	------------

	Contact Name				
	Contact Telephone	613-688-5540			
	Contact Email	info@fulbright.ca			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Oct-2024 , 08-Oct-2024			
	Synopsis	Traditional Fulbright Canada Student Awards are for American citizens who are graduate students, prospective graduate students, or promising young professionals who wish to enroll in graduate-level programs or conduct research in Canada. Awards may be held at any university, research center, think tank, or government agency in Canada. Explore a wide range of scholarly issues, including important contemporary issues that are relevant to Canada, the United States, and to the relationship between the two countries. Awards provide US\$25,000 for one academic year (9 months). Grants begin in September 2025.			
	Applicant Types				
	Funding Limit	25,000.00 maximum			
	Limited Submission	No			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
030560	Therapeutic Pipeline Program	Fox (Michael J.) Foundation for Parkinson's Research		03-Oct-2024	2,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone 212-509-0995</p> <p>Contact Email grants@michaeljfox.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Oct-2024</p> <p>Synopsis The Pre-clinical Therapeutics Pipeline Program seeks to advance therapeutic development through pre-clinical and/or clinical testing of approaches addressing unmet needs of people with Parkinson's disease (PD). The program is set up to benefit therapeutics with clear potential to prevent, stop, or delay disease progression or to reduce the burden of daily symptoms.</p> <p>Applicant Types</p> <p>Funding Limit 2,000,000.00 see detail</p> <p>Limited Submission No</p>				
000362	Parker B. Francis Fellowship Program	Francis Families Foundation		10-Oct-2024	225,000 USD
	<p>Contact Name</p> <p>Contact Telephone 816-531-0077</p> <p>Contact Email PBF@francisfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Oct-2024</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Synopsis	The Parker B. Francis Fellowship in Pulmonary Research is intended to support the development of outstanding investigators embarking on careers in pulmonary, critical care and sleep medicine. Parker B. Francis Fellowship grants are awarded to institutions for the purpose of providing stipends, fringe benefits, and modest travel expenses in support of qualified post-doctoral fellows or newly appointed faculty members.			
	Applicant Types				
	Funding Limit	75,000.00 per year			
	Limited Submission	Yes			
113771	Postdoctoral Research Award	Friedreich's Ataxia Research Alliance		15-Aug-2024 [LOI/Pre-App]	200,000 USD

	Contact Name				
	Contact Telephone	484-879-6160			
	Contact Email	info@curefa.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Aug-2024 [LOI/Pre-App], 15-Oct-2024			
	Synopsis	The Friedreich's Ataxia Research Alliance offers a Postdoctoral Research Award as a mechanism to expand and retain young investigators in the FA biomedical research space. The applicant may request a budget of up to \$100,000 per year for one or two years.			
	Applicant Types				
	Funding Limit	100,000.00 per year			
	Limited Submission	No			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																				
076236	General Research Grants	Friedreich's Ataxia Research Alliance		15-Aug-2024 [LOI/Pre-App]	250,000 USD																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>484-879-6160</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>grants@curefa.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>15-Aug-2024 [LOI/Pre-App], 15-Oct-2024</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>FARA supports research through funding competitive grants, promoting collaboration among scientists, advocating for public-private partnerships that support drug discovery, drug development and clinical research and hosting open forums for leading scientists to share their insights, ideas and challenges to advancing treatments for Friedreich's ataxia. The applicant may request a budget of up to \$125,000 per year for one or two years.</td> </tr> <tr> <td style="border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>125,000.00 per year</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>No</td> </tr> </table>						Contact Name		Contact Telephone	484-879-6160	Contact Email	grants@curefa.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	15-Aug-2024 [LOI/Pre-App], 15-Oct-2024	Synopsis	FARA supports research through funding competitive grants, promoting collaboration among scientists, advocating for public-private partnerships that support drug discovery, drug development and clinical research and hosting open forums for leading scientists to share their insights, ideas and challenges to advancing treatments for Friedreich's ataxia. The applicant may request a budget of up to \$125,000 per year for one or two years.	Applicant Types		Funding Limit	125,000.00 per year	Limited Submission	No
Contact Name																									
Contact Telephone	484-879-6160																								
Contact Email	grants@curefa.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	15-Aug-2024 [LOI/Pre-App], 15-Oct-2024																								
Synopsis	FARA supports research through funding competitive grants, promoting collaboration among scientists, advocating for public-private partnerships that support drug discovery, drug development and clinical research and hosting open forums for leading scientists to share their insights, ideas and challenges to advancing treatments for Friedreich's ataxia. The applicant may request a budget of up to \$125,000 per year for one or two years.																								
Applicant Types																									
Funding Limit	125,000.00 per year																								
Limited Submission	No																								
098050	Ignacio H. de Larramendi Research Grants	Fundación MAPFRE		07-Oct-2024	Not Specified																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>(+34) 91.581.23.45</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>becasyayudas@fundacionmapfre.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> </table>						Contact Name		Contact Telephone	(+34) 91.581.23.45	Contact Email	becasyayudas@fundacionmapfre.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL										
Contact Name																									
Contact Telephone	(+34) 91.581.23.45																								
Contact Email	becasyayudas@fundacionmapfre.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-Oct-2024</p> <p>Synopsis In 2024, Fundación MAPFRE has announced a call for research grants for a maximum total value of 265,000 euros, with the aim of financially supporting research projects in the following areas: Health Promotion: grants will be awarded up to a maximum gross value of 30,000 euros each. Insurance and Social Protection: grants will be awarded up to a maximum gross value of 15,000 euros per grant. This is a worldwide initiative.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
025936	Canada Gairdner International Awards	Gairdner Foundation		01-Oct-2024	72,000 USD
	<p>Contact Name Sarah Devonshire</p> <p>Contact Telephone</p> <p>Contact Email sarah@gairdner.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024</p> <p>Synopsis The Canada Gairdner International Award recognizes outstanding biomedical scientists who have made original contributions to medicine with the goal of contributing through research to increased understanding of human biology and disease. The prize is valued at \$100,000 CAD, and is for the personal use of recipients.</p> <p>Applicant Types</p> <p>Funding Limit 100,000.00 see detail</p> <p>Limited Submission No</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
126746	Call 8 -- Modelling Regulatory Sandbox Mechanisms and Enabling their Deployment to Support Breakthrough Innovation	Innovative Health Initiative (IHI)	HORIZON-JU-IHI-2024-08-03	10-Oct-2024 [LOI/Pre-App]	5,668,000 USD

Contact Name	
Contact Telephone	+32 (0)2 221 81 81
Contact Email	infodesk@ihi.europa.eu
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	10-Oct-2024 [LOI/Pre-App], 23-Apr-2025
Synopsis	Proposals are being accepted against the following topic: HORIZON-JU-IHI-2024-08-03 - Modelling Regulatory Sandbox Mechanisms and Enabling their Deployment to Support Breakthrough Innovation This topic is part of the Innovative Health Initiative 8th call for proposals.
Applicant Types	
Funding Limit	5,200,000.00 maximum
Limited Submission	No

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
126740	Call 8 -- Novel Endpoints for Osteoarthritis (OA) by Applying Big Data Analytics	Innovative Health Initiative (IHI)	HORIZON-JU-IHI-2024-08-02	10-Oct-2024 [LOI/Pre-App]	15,260,000 USD

Contact Name	
Contact Telephone	+32 (0)2 221 81 81
Contact Email	infodesk@ihi.europa.eu

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Oct-2024 [LOI/Pre-App], 23-Apr-2025</p> <p>Synopsis Proposals are being accepted against the following topic: HORIZON-JU-IHI-2024-08-02 - Novel Endpoints for Osteoarthritis (OA) by applying Big Data Analytics This topic is part of the Innovative Health Initiative 8th call for proposals.</p> <p>Applicant Types</p> <p>Funding Limit 14,000,000.00 maximum</p> <p>Limited Submission No</p>				
123485	<p>Call 6 -- Support Healthcare System Resilience Through a Focus on Persistency in the Treatment of Chronic Diseases</p>	Innovative Health Initiative (IHI)	HORIZON-JU-IHI-2024-06-01-two-stage	10-Oct-2024	12,317,000 USD
	<p>Contact Name</p> <p>Contact Telephone +32 (0)2 221 81 81</p> <p>Contact Email infodesk@ihi.europa.eu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Oct-2024</p> <p>Synopsis Proposals are being accepted against the following topic: HORIZON-JU-IHI-2024-06-01-two-stage -- Support healthcare system resilience through a focus on persistency in the treatment of chronic diseases This topic is part of the Innovative Health Initiative 6th call for proposals. The main outcome of this research collaboration is to better understand why significant advances in technology in recent years have not contributed to widespread improvements in healthcare systems, which still struggle to keep more than 50 % of people on chronic disease treatment for longer than 12 months. The goal is to develop and pilot innovative and multi-stakeholder approaches</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

leveraging social innovation activities and scalable technology to improve the health outcomes of people living with chronic diseases by supporting treatment persistency with a particular focus on diabetes, obesity, and cardiovascular disease. Persistency is part of drug adherence and is defined as the length of time between starting treatment and the last dose which immediately precedes discontinuation of medication. Although novel treatments are becoming more available with major improvements in convenience and efficacy, poor persistency to treatment is still a major challenge in the healthcare system. Insights from pilots under this topic will be shared with relevant stakeholders of the healthcare ecosystem to improve outcomes for people living with chronic diseases. The pilots should include cardiometabolic diseases, such as diabetes, obesity, and cardiovascular disease. Other chronic diseases may be considered in this collaboration if they contribute to the overall understanding of barriers and opportunities. Moreover, it is not the goal to develop new technologies and/or pharmaceutical drugs during the course of the project, but rather to address how insights and new approaches can be applied in clinical practice and implemented in guidelines and recommendations.

Applicant Types

Funding Limit 11,300,000.00 maximum

Limited Submission No

123482	Call 6 -- Support Healthcare System Resilience Through a Focus on Persistency in the Treatment of Chronic Diseases	Innovative Health Initiative (IHI)	HORIZON-JU-IHI-2024-06-01-two-stage	10-Oct-2024	12,317,000 USD
--------	--	------------------------------------	-------------------------------------	-------------	----------------

Contact Name

Contact Telephone +32 (0)2 221 81 81

Contact Email infodesk@ihi.europa.eu

Sponsor Website [Link to sponsor website](#)

Program URL [Link to program URL](#)

Deadline Dates (ALL) 10-Oct-2024

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p style="text-align: center;">Synopsis</p> <p>Proposals are being accepted against the following topic: HORIZON-JU-IHI-2024-06-01-two-stage -- Support healthcare system resilience through a focus on persistency in the treatment of chronic diseases This topic is part of the Innovative Health Initiative 6th call for proposals. The main outcome of this research collaboration is to better understand why significant advances in technology in recent years have not contributed to widespread improvements in healthcare systems, which still struggle to keep more than 50 % of people on chronic disease treatment for longer than 12 months. The goal is to develop and pilot innovative and multi-stakeholder approaches leveraging social innovation activities and scalable technology to improve the health outcomes of people living with chronic diseases by supporting treatment persistency with a particular focus on diabetes, obesity, and cardiovascular disease. Persistency is part of drug adherence and is defined as the length of time between starting treatment and the last dose which immediately precedes discontinuation of medication. Although novel treatments are becoming more available with major improvements in convenience and efficacy, poor persistency to treatment is still a major challenge in the healthcare system. Insights from pilots under this topic will be shared with relevant stakeholders of the healthcare ecosystem to improve outcomes for people living with chronic diseases. The pilots should include cardiometabolic diseases, such as diabetes, obesity, and cardiovascular disease. Other chronic diseases may be considered in this collaboration if they contribute to the overall understanding of barriers and opportunities. Moreover, it is not the goal to develop new technologies and/or pharmaceutical drugs during the course of the project, but rather to address how insights and new approaches can be applied in clinical practice and implemented in guidelines and recommendations.</p> <p style="text-align: center;">Applicant Types</p> <p style="text-align: center;">Funding Limit</p> <p style="text-align: center;">Limited Submission</p>				
126738	Call 8 -- Patient-Centred Clinical-Study Endpoints Derived Using Digital Health Technologies	Innovative Health Initiative (IHI)	HORIZON-JU-IHI-2024-08-04	10-Oct-2024 [LOI/Pre-App]	13,734,000 USD
	<p style="text-align: center;">Contact Name</p> <p style="text-align: center;">Contact Telephone</p> <p style="text-align: center;">Contact Email</p>	<p>+32 (0)2 221 81 81</p> <p>infodesk@ihi.europa.eu</p>			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	10-Oct-2024 [LOI/Pre-App], 23-Apr-2025			
	Synopsis	Proposals are being accepted against the following topic: HORIZON-JU-IHI-2024-08-04 - Patient-Centred Clinical-Study Endpoints Derived Using Digital Health Technologies This topic is part of the Innovative Health Initiative 8th call for proposals.			
	Applicant Types				
	Funding Limit	12,600,000.00 maximum			
	Limited Submission	No			

126739	Call 8 -- A City-Based Approach to Reducing Cardiovascular Mortality in Europe	Innovative Health Initiative (IHI)	HORIZON-JU-IHI-2024-08-01	10-Oct-2024 [LOI/Pre-App]	17,167,500 USD
--------	--	------------------------------------	---------------------------	---------------------------	----------------

Contact Name	
Contact Telephone	+32 (0)2 221 81 81
Contact Email	infodesk@ihi.europa.eu
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	10-Oct-2024 [LOI/Pre-App], 23-Apr-2025
Synopsis	Proposals are being accepted against the following topic: HORIZON-JU-IHI-2024-08-01 - A City-Based Approach to Reducing Cardiovascular Mortality in Europe This topic is part of the Innovative Health Initiative 8th call for proposals.
Applicant Types	
Funding Limit	15,750,000.00 maximum
Limited Submission	No

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																				
005262	School of Social Science Visiting Scholars	Institute for Advanced Study		15-Oct-2024	80,000 USD																				
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>609-734-8000</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>sssappqueries@ias.edu</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>15-Oct-2024</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>Each year, approximately 20 scholars are invited to the Institute for residential fellowships. About half of those invited are working in the year's designated theme, half on other projects. The School welcomes applications from junior and senior scholars across a wide range of fields in the social sciences and related disciplines. Members (as Institute fellows are known) have access to campus resources and facilities, including offices, libraries, subsidized dining services, and housing. The 2025-2026 theme is "Digital (In)Equality". Applications are not required to relate to the theme.</td> </tr> <tr> <td style="border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>80,000.00 see detail</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>No</td> </tr> </table>					Contact Name		Contact Telephone	609-734-8000	Contact Email	sssappqueries@ias.edu	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	15-Oct-2024	Synopsis	Each year, approximately 20 scholars are invited to the Institute for residential fellowships. About half of those invited are working in the year's designated theme, half on other projects. The School welcomes applications from junior and senior scholars across a wide range of fields in the social sciences and related disciplines. Members (as Institute fellows are known) have access to campus resources and facilities, including offices, libraries, subsidized dining services, and housing. The 2025-2026 theme is "Digital (In)Equality". Applications are not required to relate to the theme.	Applicant Types		Funding Limit	80,000.00 see detail	Limited Submission	No
Contact Name																									
Contact Telephone	609-734-8000																								
Contact Email	sssappqueries@ias.edu																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	15-Oct-2024																								
Synopsis	Each year, approximately 20 scholars are invited to the Institute for residential fellowships. About half of those invited are working in the year's designated theme, half on other projects. The School welcomes applications from junior and senior scholars across a wide range of fields in the social sciences and related disciplines. Members (as Institute fellows are known) have access to campus resources and facilities, including offices, libraries, subsidized dining services, and housing. The 2025-2026 theme is "Digital (In)Equality". Applications are not required to relate to the theme.																								
Applicant Types																									
Funding Limit	80,000.00 see detail																								
Limited Submission	No																								
083410	Fulbright Grants - Spain: English Teaching Assistant Award	Institute of International Education		08-Oct-2024	Not Specified																				
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>212-984-5396</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>FBstudent.EUR@iie.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> </table>					Contact Name		Contact Telephone	212-984-5396	Contact Email	FBstudent.EUR@iie.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL										
Contact Name																									
Contact Telephone	212-984-5396																								
Contact Email	FBstudent.EUR@iie.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 08-Oct-2024</p> <p>Synopsis The Fulbright English Teaching Assistant programs place grantees in schools overseas to supplement local English language instruction and to provide a native speaker presence in the classrooms. English Teaching Assistants assist teaching staff at the early childhood, elementary, middle school, high school, vocational and/or university level for up to 16 hours per week, with an additional two hours for planning and coordination meetings. Responsibilities include assistant-teaching, in English, subjects such as social studies, science and technology, art, physical education, and English language. Other activities include directing conversation groups, in some cases with school staff, and leading special programs such as Global Classrooms (Model UN) and Speak Truth to Power (STTP). ETAs are also expected to actively engage with their host community.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
112144	Fulbright Grants - U.K.: Fulbright/Imperial College London Award	Institute of International Education		08-Oct-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 312-254-3210</p> <p>Contact Email FBstudent.EUR@iie.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Oct-2024</p> <p>Synopsis The Fulbright U.S. Student Program offers the Fulbright Imperial College London Award that covers any one-year engineering, science or non-clinical medical studies master's degree offered by the institution.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
096729	Fulbright Grants - Italy: Fulbright/Casten Family Foundation Award at the University of Gastronomic Sciences	Institute of International Education		08-Oct-2024	Not Specified
	Contact Name				
	Contact Telephone	212-984-5396			
	Contact Email	bpizzella@fulbright.it			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Oct-2024			
	Synopsis	Two awards are available to attend the Master of Gastronomy: World Food Cultures and Mobility at the University of Gastronomic Sciences Pollenzo, Italy. The Master's program provides an advanced introduction to the world food cultures and systems with an emphasis on issues of food sustainability and food sovereignty. The program intends to train students to become holistic gastronomes, i.e. gastronomes who are able to understand and critically reflect upon food culture and history; food anthropology and ecology; and sensory and aesthetic features linked to local food production, gastronomies, and their attached sociabilities.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
000405	Christianson Fellowship	InterExchange Foundation		15-Oct-2024	10,000 USD
	Contact Name				
	Contact Telephone	212-924-0446			
	Contact Email	grants@interexchange.org			
	Sponsor Website	Link to sponsor website			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Oct-2024 , 15-Mar-2025</p> <p>Synopsis The InterExchange Foundation supports young Americans with a passion for improving the world by participating in meaningful projects abroad. Funding is available for impactful service projects abroad with up to \$10,000 in grant money to support motivated young Americans who are committed to perform meaningful service projects abroad. The volunteer project must be outside of the U.S. and conducted in-person at the host location.</p> <p>Applicant Types</p> <p>Funding Limit 10,000.00 maximum</p> <p>Limited Submission No</p>				
049952	IADR/AADOCR William J. Gies Award	International Association for Dental Research		01-Oct-2024	1,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email awards@iadr.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024</p> <p>Synopsis The William J. Gies Award is given for the best paper published in the Journal of Dental Research during the preceding year.</p> <p>Applicant Types</p> <p>Funding Limit 1,000.00 see detail</p> <p>Limited Submission No</p>				
022521	Grants Program	International Foundation		31-Oct-2024	50,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email info@intlfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Oct-2024</p> <p>Synopsis The International Foundation’s grants support the specific types of programs, in specific geographic regions, that we believe address the most pressing needs in the world today. Eligible organizations must have substantial experience in implementing projects with measurable results in one or more of the following categories: Agriculture Education Environment Health</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 maximum</p> <p>Limited Submission Yes</p>				

007873	ISSLS Prize for Lumbar Research	International Society for the Study of the Lumbar Spine		15-Oct-2024	20,000 USD
--------	---	---	--	-------------	------------

	<p>Contact Name</p> <p>Contact Telephone +61 3 8692 2036</p> <p>Contact Email ISSLS@asnevents.net.au</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Oct-2024</p>				
--	--	--	--	--	--

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>The ISSLS Prize program, sponsored by European Spine Journal, comprises three awards. Prizes are awarded competitively on the basis of scientific merit in one or more of the following areas: basic science, bioengineering science and clinical science.</p> <p>20,000.00 see detail</p> <p>No</p>			

100174	Postdoctoral Junior Leader Fellowships - Retaining	la Caixa Foundation		03-Oct-2024	348,909 USD
--------	--	---------------------	--	-------------	----------------

	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p>	<p>fellowships@contact.fundaciolacaixa.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>03-Oct-2024</p> <p>The "la Caixa" Foundation is offering 20 three-year postdoctoral fellowships to recruit experienced researchers to carry out their projects at any university or research centre of Spain or Portugal. The research must be carried out in the research areas of Science, Technology, Engineering and Mathematics (STEM), including Bio and Health Sciences. The call for applications is intended for researchers who finished their doctoral degree two to seven years prior to the application deadline and fulfil the requirements for mobility between countries. The fellow should start work at the host institution between 2nd May and 31st December 2025. In addition to the financial support, the fellowship includes a mixed training programme (face-to-face and online) on cross-cutting skills, innovation, and leadership. Attendance is mandatory for all fellows regardless of their discipline. The "la Caixa" Foundation will cover all costs for these sessions, as well as the fellows' accommodation and travel costs.</p>			
--	--	--	--	--	--

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	320,100.00 maximum			
	Limited Submission	No			
100173	Postdoctoral Junior Leader Fellowships - Incoming	la Caixa Foundation		03-Oct-2024	348,909 USD
	Contact Name				
	Contact Telephone				
	Contact Email	fellowships@contact.fundaciolacaixa.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-Oct-2024			
	Synopsis	"la Caixa" Foundation grants 20 postdoctoral fellowships for researchers of any nationality to carry out a research project in a STEM discipline at universities and research centres of accredited excellence. STEM disciplines include life sciences, experimental sciences, physics, chemistry, engineering, technology and mathematics.			
	Applicant Types				
	Funding Limit	320,100.00 maximum			
	Limited Submission	No			
005575	Career Development Program - Scholar	Leukemia and Lymphoma Society		18-Oct-2024 [LOI/Pre-App]	600,000 USD
	Contact Name				
	Contact Telephone	888-557-7177			
	Contact Email	researchprograms@lls.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 18-Oct-2024 [LOI/Pre-App], 01-Nov-2024 [LOI/Pre-App], 15-Nov-2024</p> <p>Synopsis The Leukemia & Lymphoma Society supports talented blood cancer researchers in the early phase of their careers through the Career Development Program. CDP continues to provide a pool of dedicated researchers to advance the understanding and diagnosis of blood cancer, as well as the development of treatment and prevention options that will ultimately lead to a higher quality of life for blood cancer patients. Scholar applicants are primarily basic and translational researchers.</p> <p>Applicant Types </p> <p>Funding Limit 120,000.00 per year</p> <p>Limited Submission No</p>				
009101	Career Development Program - Fellow	Leukemia and Lymphoma Society		18-Oct-2024 [LOI/Pre-App]	210,000 USD
	<p>Contact Name Senior Director of Research Administration</p> <p>Contact Telephone </p> <p>Contact Email researchprograms@lls.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Oct-2024 [LOI/Pre-App], 01-Nov-2024 [LOI/Pre-App], 15-Nov-2024</p> <p>Synopsis The Leukemia & Lymphoma Society supports talented blood cancer researchers in the early phase of their careers through the Career Development Program. CDP continues to provide a pool of dedicated researchers to advance the understanding and diagnosis of blood cancer, as well as the development of treatment and prevention options that will ultimately lead to a higher quality of life for blood cancer patients. CDP provides salary support to assist the awardee pursuing their research program.</p> <p>Applicant Types </p> <p>Funding Limit 70,000.00 per year</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
107290	Postdoctoral Training Award	Life Science Research Foundation		01-Oct-2024	231,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	admin@lsrf.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Oct-2024 , 01-Nov-2024			
	Synopsis	The Life Science Research Foundation (LSRF) provides support for exceptional postdoctoral researchers in all areas of basic life sciences discovery. The LSRF award provides three (3) years of support to a named postdoctoral researcher at a non-profit university or research institution.			
	Applicant Types				
	Funding Limit	231,000.00 maximum			
	Limited Submission	No			
001875	Postdoctoral Fellowship Program	Life Sciences Research Foundation		01-Oct-2024	231,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	apply@lsrf.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Oct-2024 , 01-Nov-2024			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>The LSRF award provides three (3) years of support to a named postdoctoral researcher at a non-profit university or research institution. The award is paid to the university or research institution where the researcher is carrying out their project and is solely for the benefit of the named researcher. The total award amount is \$231,000 (\$77,000 per year).</p> <p>231,000.00 see detail</p> <p>No</p>			
088576	Research Grants	Lumbar Spine Research Society		01-Oct-2024 [LOI/Pre-App]	20,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>608-770-8992</p> <p>LSRS@LSRS.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>01-Oct-2024 [LOI/Pre-App]</p> <p>The Lumbar Spine Research Society (LSRS) is awarding up to two research grants of up to \$20,000 to fund future, innovative projects. These awards are available to qualified principle investigators in the field of spine.</p> <p>20,000.00 maximum</p> <p>No</p>			
127250	Young Investigator Research Grant	Lumbar Spine Research Society		01-Oct-2024 [LOI/Pre-App]	10,000 USD
	<p>Contact Name</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 608-770-8992 Contact Email LSRS@LSRS.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Oct-2024 [LOI/Pre-App] Synopsis The Lumbar Spine Research Society (LSRS) is offering a young investigator research grants of up to \$10,000 for qualified young investigators in the field of spine. Applicant Types Funding Limit 10,000.00 maximum Limited Submission No				
089346	Research Grants Program	Lyme Disease Association, Inc.		31-Oct-2024	Not Specified
	Contact Name Contact Telephone 888-366-6611 Contact Email Lymeliter@aol.com Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 31-Oct-2024 Synopsis The Lyme Disease Association (LDA) provides research funding across the United States with a focus on Lyme and other tick-borne diseases. Applicant Types Funding Limit 0.00 not provided Limited Submission No				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																				
108503	Grant Program	Mathers (G.Harold and Leila Y.) Foundation		20-Sep-2024	Not Specified																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>grants@mathersfoundation.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>20-Sep-2024 , 04-Oct-2024 [LOI/Pre-App], 06-Dec-2024</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>The G. Harold and Leila Y. Mathers Foundation's mission is to advance knowledge in the life sciences by sponsoring scientific research that will benefit mankind. Basic scientific research, with potential translational application, is central to this goal, and fundamental to the Foundation's operating principles.</td> </tr> <tr> <td style="border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>0.00 not provided</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>Yes</td> </tr> </table>						Contact Name		Contact Telephone		Contact Email	grants@mathersfoundation.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	20-Sep-2024 , 04-Oct-2024 [LOI/Pre-App], 06-Dec-2024	Synopsis	The G. Harold and Leila Y. Mathers Foundation's mission is to advance knowledge in the life sciences by sponsoring scientific research that will benefit mankind. Basic scientific research, with potential translational application, is central to this goal, and fundamental to the Foundation's operating principles.	Applicant Types		Funding Limit	0.00 not provided	Limited Submission	Yes
Contact Name																									
Contact Telephone																									
Contact Email	grants@mathersfoundation.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	20-Sep-2024 , 04-Oct-2024 [LOI/Pre-App], 06-Dec-2024																								
Synopsis	The G. Harold and Leila Y. Mathers Foundation's mission is to advance knowledge in the life sciences by sponsoring scientific research that will benefit mankind. Basic scientific research, with potential translational application, is central to this goal, and fundamental to the Foundation's operating principles.																								
Applicant Types																									
Funding Limit	0.00 not provided																								
Limited Submission	Yes																								
012233	Anatomic and Clinical Pathology Residency (Minnesota)	Mayo Clinic College of Medicine and Science		15-Oct-2024	Not Specified																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>507-284-1196</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>pathologyeducation@mayo.edu</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>15-Oct-2024</td> </tr> </table>						Contact Name		Contact Telephone	507-284-1196	Contact Email	pathologyeducation@mayo.edu	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	15-Oct-2024								
Contact Name																									
Contact Telephone	507-284-1196																								
Contact Email	pathologyeducation@mayo.edu																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	15-Oct-2024																								

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The mission of the Anatomic and Clinical Pathology Residency at Mayo Clinic's campus in Rochester, Minnesota, is to provide outstanding education and practical experience in every aspect of laboratory medicine and pathology, in order to prepare graduates to excel in any practice setting. The program includes three program tracks: the Anatomic and Clinical Pathology Residency (AP/CP), the Anatomic and Neuropathology Pathology Pathway (AP/NP), and the Physician Scientist-Research Pathway.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
013056	Clinical Neurophysiology, Electroencephalography Fellowship (Minnesota)	Mayo Clinic College of Medicine and Science		01-Oct-2024	Not Specified
	Contact Name				
	Contact Telephone	507-284-8687			
	Contact Email	Bolduan.Paige@mayo.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Oct-2024			
	Synopsis	The one-year Clinical Neurophysiology Electroencephalography Fellowship at Mayo Clinic's campus in Rochester, Minnesota, prepares fellows for an academic career by providing them with experience in teaching, research and clinical activities. After completing their training, fellows will have the knowledge and experience necessary to establish and supervise a clinical neurophysiology laboratory in a teaching institution or clinical practice.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																			
012945	Adult Reconstructive Surgery Fellowship (Arizona)	Mayo Clinic College of Medicine and Science		31-Oct-2024	Not Specified																			
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;">Contact Name</td> <td></td> </tr> <tr> <td>Contact Telephone</td> <td>480-342-6202</td> </tr> <tr> <td>Contact Email</td> <td>stabler.eric@mayo.edu</td> </tr> <tr> <td>Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td>Program URL</td> <td>Link to program URL</td> </tr> <tr> <td>Deadline Dates (ALL)</td> <td>31-Oct-2024</td> </tr> <tr> <td>Synopsis</td> <td>The one-year Adult Reconstructive Surgery Fellowship at Mayo Clinic's campus in Phoenix/Scottsdale, Arizona, provides extensive exposure to, and experience in, the evaluation and management of complex hip and knee problems in adolescents and adults. The fellowship consists of four, three-month rotations in which fellows work one-on-one with faculty. Fellows perform preoperative consultations, participate actively in surgical procedures and are directly involved in postoperative patient management. Additionally, fellows are active in educational conferences and the development of research projects leading to presentation and publication.</td> </tr> <tr> <td>Applicant Types</td> <td></td> </tr> <tr> <td>Funding Limit</td> <td>0.00 see detail</td> </tr> <tr> <td>Limited Submission</td> <td>No</td> </tr> </table>	Contact Name		Contact Telephone	480-342-6202	Contact Email	stabler.eric@mayo.edu	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	31-Oct-2024	Synopsis	The one-year Adult Reconstructive Surgery Fellowship at Mayo Clinic's campus in Phoenix/Scottsdale, Arizona, provides extensive exposure to, and experience in, the evaluation and management of complex hip and knee problems in adolescents and adults. The fellowship consists of four, three-month rotations in which fellows work one-on-one with faculty. Fellows perform preoperative consultations, participate actively in surgical procedures and are directly involved in postoperative patient management. Additionally, fellows are active in educational conferences and the development of research projects leading to presentation and publication.	Applicant Types		Funding Limit	0.00 see detail	Limited Submission	No			
Contact Name																								
Contact Telephone	480-342-6202																							
Contact Email	stabler.eric@mayo.edu																							
Sponsor Website	Link to sponsor website																							
Program URL	Link to program URL																							
Deadline Dates (ALL)	31-Oct-2024																							
Synopsis	The one-year Adult Reconstructive Surgery Fellowship at Mayo Clinic's campus in Phoenix/Scottsdale, Arizona, provides extensive exposure to, and experience in, the evaluation and management of complex hip and knee problems in adolescents and adults. The fellowship consists of four, three-month rotations in which fellows work one-on-one with faculty. Fellows perform preoperative consultations, participate actively in surgical procedures and are directly involved in postoperative patient management. Additionally, fellows are active in educational conferences and the development of research projects leading to presentation and publication.																							
Applicant Types																								
Funding Limit	0.00 see detail																							
Limited Submission	No																							
013125	Obstetrics and Gynecology Residency (Minnesota)	Mayo Clinic College of Medicine and Science		01-Oct-2024	Not Specified																			
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;">Contact Name</td> <td></td> </tr> <tr> <td>Contact Telephone</td> <td>507-266-3262</td> </tr> <tr> <td>Contact Email</td> <td>obgeduc@mayo.edu</td> </tr> <tr> <td>Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td>Program URL</td> <td>Link to program URL</td> </tr> </table>	Contact Name		Contact Telephone	507-266-3262	Contact Email	obgeduc@mayo.edu	Sponsor Website	Link to sponsor website	Program URL	Link to program URL													
Contact Name																								
Contact Telephone	507-266-3262																							
Contact Email	obgeduc@mayo.edu																							
Sponsor Website	Link to sponsor website																							
Program URL	Link to program URL																							

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL) 01-Oct-2024 Synopsis The Obstetrics and Gynecology Residency at Mayo Clinic's campus in Rochester, Minnesota, provides an unprecedented experience in a collegial training setting that emphasizes a unique blend of traditional didactics and mentorship coupled with state-of-the-art learning utilizing simulation labs and interactive computer-based learning. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
012858	Neurosurgery - Neurologic Surgery Residency (Minnesota)	Mayo Clinic College of Medicine and Science		31-Oct-2024	Not Specified
	Contact Name Contact Telephone 507-538-6545 Contact Email rstnseduc@mayo.edu Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 31-Oct-2024 Synopsis The seven-year Neurologic Surgery Residency provides a rigorous, comprehensive surgical training experience designed to produce the highest caliber academic and clinical neurosurgeons. While the emphasis is on training academic neurosurgeons, the Neurologic Surgery Residency offers the versatility required for a career in either academia or private practice. The program provides residents with a solid foundation in basic neuroscience and preparation for both written and oral neurosurgery board examinations, as well as opportunities for laboratory and clinical research alike, including the option to pursue an advanced degree in neuroscience and neurosurgery or clinical and translational research. Applicant Types Funding Limit 0.00 see detail				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
013211	General Surgery Residency (Minnesota)	Mayo Clinic College of Medicine and Science		01-Oct-2024	Not Specified
	Contact Name				
	Contact Telephone	507-284-8240			
	Contact Email	mgs.m.roch.mn.surgery@mayo.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Oct-2024			
	Synopsis	Mayo Clinic's campus in Rochester, Minnesota, offers a dynamic and robust five-year categorical General Surgery Residency. The General Surgery Residency at Mayo Clinic's campus in Rochester, Minnesota, is accredited by the ACGME and is approved for 10 categorical positions each year.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
013210	General Surgery Residency (Florida)	Mayo Clinic College of Medicine and Science		01-Oct-2024	Not Specified
	Contact Name				
	Contact Telephone	904-953-0424			
	Contact Email	rodriguez.erin@mayo.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Oct-2024			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis The General Surgery Residency at Mayo Clinic's campus in Jacksonville, Florida, integrates extensive exposure to all aspects of current general surgery with a firm grounding in underlying scientific principles, methods of clinical investigation and controversies in management.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
013187	Urology Residency (Arizona)	Mayo Clinic College of Medicine and Science		01-Oct-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 480-342-2839</p> <p>Contact Email moore.cassandra@mayo.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024</p> <p>Synopsis The five-year Urology Residency at Mayo Clinic's campus in Phoenix, Arizona, provides a well-rounded clinical and research experience with exposure to all aspects of urology. The program is accredited by the Accreditation Council for Graduate Medical Education. After successfully completing the program, residents are eligible to take the certification examination offered by the American Board of Urology.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
012227	Otolaryngology - Head and Neck Surgery Residency (Arizona)	Mayo Clinic College of Medicine and Science		31-Oct-2024	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 480-342-2812</p> <p>Contact Email rangel.evangelina@mayo.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Oct-2024</p> <p>Synopsis The Otolaryngology - Head and Neck Surgery Residency at Mayo Clinic in Phoenix/Scottsdale, Arizona, provides superior surgical and medical training in all areas of otolaryngology and head and neck surgery. This five-year residency prepares graduates for either private practice or academic medicine through education and training with board-certified and fellowship-trained staff that teach management concepts in: Head and neck oncology Neurotology Laryngology Rhinology and endoscopic skull base surgery Facial plastic and reconstructive surgery Pediatric otolaryngology Facial trauma Microvascular free tissue transfer The Otolaryngology Residency uses a unique apprenticeship system in which residents are assigned to one or two Mayo Clinic staff consultants for three-month periods. This system gives residents graduated responsibility and close supervision and interaction.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
013216	Preliminary Surgery Residency (Minnesota)	Mayo Clinic College of Medicine and Science		01-Oct-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 507-284-4710</p> <p>Contact Email mgsm.roch.mn.surgery@mayo.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 01-Oct-2024</p> <p>Synopsis The Mayo Clinic in Rochester offers 12 non-designated preliminary surgery positions at the PGY-1 level each year. This residency offers a wide variety of surgical experiences to residents who have not yet chosen a surgical subspecialty. The program provides one year of general surgery training before residents go on to the military, public health or other professional interest.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
013042	Adult Neurology Residency (Arizona)	Mayo Clinic College of Medicine and Science		01-Oct-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 480-301-6884</p> <p>Contact Email warfield.linda@mayo.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024</p> <p>Synopsis The Adult Neurology Residency at Mayo Clinic’s campus in Arizona provides training for excellent clinician scientists and educators who will be leaders in the field of neurology.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
013166	Orthopedic Surgery Residency (Minnesota)	Mayo Clinic College of Medicine and Science		01-Oct-2024	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 507-266-4512</p> <p>Contact Email cole.channon@mayo.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024</p> <p>Synopsis The Department of Orthopedic Surgery at Mayo Clinic's campus in Rochester, Minnesota offers an Orthopedic Surgery Residency with rotations in all subspecialty areas over a five year period.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
002648	Geriatric Medicine Fellowship (Minnesota)	Mayo Clinic College of Medicine and Science		31-Oct-2024	Not Specified
	<p>Contact Name Linda Ferrie, Education Coordinator</p> <p>Contact Telephone 507-538-0498</p> <p>Contact Email ferrie.linda@mayo.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Oct-2024</p> <p>Synopsis The goal of the Geriatric Medicine Fellowship at the Mayo Clinic campus in Rochester, Minnesota, is to train the next generation of leaders in geriatric medicine. The fellowship offers a robust curriculum of unique clinical and academic experiences across the care continuum.</p> <p>Applicant Types</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit 0.00 see detail Limited Submission No				
013222	Surgery Specialties - Plastic Surgery Integrated Residency (Arizona)	Mayo Clinic College of Medicine and Science		15-Oct-2024	Not Specified
	Contact Name Contact Telephone 480-342-0584 Contact Email hansalia.rita@mayo.edu Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Oct-2024 Synopsis The Plastic Surgery Integrated Residency at Mayo Clinic's campus in Phoenix/Scottsdale, Arizona, is open to medical school graduates interested in specializing in plastic surgery. The program is six years long and offers one position each year. The program is accredited by the Accreditation Council for Graduate Medical Education. After successfully completing the program, residents are eligible to take the written examination offered by the American Board of Plastic Surgery. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
012164	Anesthesiology Residency (Minnesota)	Mayo Clinic College of Medicine and Science		01-Oct-2024	Not Specified
	Contact Name Contact Telephone 507-255-1246 Contact Email lmanderson@mayo.edu				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024</p> <p>Synopsis Mayo Clinic's Anesthesiology Residency in Rochester, Minnesota, aims to craft the next leaders field of anesthesiology and perioperative medicine by providing an outstanding clinical anesthesia experience tailored to each individual trainee. Within a three-year program following a transitional internship year, Mayo Clinic anesthesiology residents are immersed in a program comprising two hospitals with more than 109 operating rooms, servicing more than 40,000 anesthetics per year in some of the most advanced facilities and cutting-edge medical procedures in the world.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
003413	Medical Scientist Training Program	Mayo Graduate School		01-Oct-2024	40,000 USD
	<p>Contact Name Lisa Hurley, Program Manager</p> <p>Contact Telephone 507-284-4356</p> <p>Contact Email mayoclinicmdphd@mayo.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024 , 15-Oct-2024</p> <p>Synopsis The Mayo Clinic M.D.-Ph.D. Program educates students to meet the demands of a career as a physician-scientist. By combining M.D. and Ph.D. training, we prepare our graduates to be leaders in both clinical medicine and in scientific research to significantly impact the future of medicine and science.</p> <p>Applicant Types</p> <p>Funding Limit 40,000.00 see detail</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
044094	General Research Grants	McGovern (Jack) Coats Disease Foundation (JMCFD)		01-Oct-2024	35,000 USD
	Contact Name				
	Contact Telephone	888-314-8853			
	Contact Email	deborahmarron@curecoats.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Oct-2024			
	Synopsis	The General Research Grant is offered by the Jack McGovern Coats' Disease Foundation to support medical research specific to Coats' Disease and other retinal diseases, which may lead to a cure or improve treatments and understanding of the pathophysiology for Coats' Disease. Annual Grants will be up to \$35,000.			
	Applicant Types				
	Funding Limit	35,000.00 maximum			
	Limited Submission	No			
057820	Investigator Studies Program (MISP) -- Rotavirus	Merck		07-Aug-2024	Not Specified
	Contact Name	Lindsay O'Connell			
	Contact Telephone	267-305-9775			
	Contact Email	lindsay.oconnell@msd.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Aug-2024 , 23-Oct-2024			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>The Company Investigator Studies Program (MISP) aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented, and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications. The Rotavirus Investigator Studies Program Review Committee (MISP-RC) will accept protocol submissions within the current Areas of Interest (AoI).</p> <p>0.00 not provided</p> <p>No</p>			
057824	Investigator Studies Program (MISP) -- Measles, Mumps, Rubella & Varicella	Merck		07-Aug-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>Lindsay O’Connell</p> <p>267-305-9775</p> <p>lindsay.oconnell@msd.com</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>07-Aug-2024 , 23-Oct-2024</p> <p>The Investigator Studies Program aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications. The Measles, Mumps, Rubella & Varicella Investigator Studies Program (MISP) Committee will accept proposals within the current areas of interest.</p> <p>0.00 not provided</p> <p>No</p>			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																				
066292	Richard Lounsbery Award	National Academy of Sciences		07-Oct-2024	75,000 USD																				
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>202-334-2000</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>awards@nas.edu</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>07-Oct-2024</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>The Richard Lounsbery Award is intended to stimulate research and to encourage reciprocal scientific exchanges between the United States and France. A \$75,000 prize is given.</td> </tr> <tr> <td style="border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>75,000.00 maximum</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>No</td> </tr> </table>					Contact Name		Contact Telephone	202-334-2000	Contact Email	awards@nas.edu	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	07-Oct-2024	Synopsis	The Richard Lounsbery Award is intended to stimulate research and to encourage reciprocal scientific exchanges between the United States and France. A \$75,000 prize is given.	Applicant Types		Funding Limit	75,000.00 maximum	Limited Submission	No
Contact Name																									
Contact Telephone	202-334-2000																								
Contact Email	awards@nas.edu																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	07-Oct-2024																								
Synopsis	The Richard Lounsbery Award is intended to stimulate research and to encourage reciprocal scientific exchanges between the United States and France. A \$75,000 prize is given.																								
Applicant Types																									
Funding Limit	75,000.00 maximum																								
Limited Submission	No																								
051065	Center for Regulatory Excellence (CRE) Grant Program	National Council of State Boards of Nursing		04-Oct-2024	300,000 USD																				
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>312-525-3600</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>CRE@ncsbn.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>04-Oct-2024</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>The Center for Regulatory Excellence (CRE) grant program provides funding for scientific research projects that advance the science of nursing policy and regulation and build regulatory expertise worldwide. Investigators may apply for grants up to \$300,000.</td> </tr> </table>					Contact Name		Contact Telephone	312-525-3600	Contact Email	CRE@ncsbn.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	04-Oct-2024	Synopsis	The Center for Regulatory Excellence (CRE) grant program provides funding for scientific research projects that advance the science of nursing policy and regulation and build regulatory expertise worldwide. Investigators may apply for grants up to \$300,000.						
Contact Name																									
Contact Telephone	312-525-3600																								
Contact Email	CRE@ncsbn.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	04-Oct-2024																								
Synopsis	The Center for Regulatory Excellence (CRE) grant program provides funding for scientific research projects that advance the science of nursing policy and regulation and build regulatory expertise worldwide. Investigators may apply for grants up to \$300,000.																								

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 300,000.00 maximum Limited Submission No				
091597	Grants Program	National Operating Committee on Standards for Athletic Equipment		31-Oct-2024	Not Specified
	Contact Name Kim D. Barber Foss, PhD ATC Contact Telephone Contact Email Research@nocsae.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 31-Oct-2024 Synopsis The mission of the National Operating Committee on Standards for Athletic Equipment (NOCSAE) is to commission research in sports medicine and science and, where feasible, establish standards for athletic equipment. Accordingly, the intent of the NOCSAE grant program is to commission investigator-initiated research and to provide support for education, health, and safety research and development. The NOCSAE research plan proposed by the applicant must be related to NOCSAE's stated program interests. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
075482	Research for Novel Approaches in Sustainable Agriculture Grant	Northeast Region Sustainable Agriculture Research and Education Program		06-Aug-2024 [LOI/Pre-App]	200,000 USD
	Contact Name				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email northeastcare@uvm.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Aug-2024 [LOI/Pre-App], 29-Oct-2024</p> <p>Synopsis The Research for Novel Approaches in Sustainable Agriculture Grant Program funds “proof of concept” projects intended to confirm the benefit and/or feasibility of new practices and approaches that have high potential for adoption by farmers.</p> <p>Applicant Types</p> <p>Funding Limit 200,000.00 see detail</p> <p>Limited Submission No</p>				

018771	Department of Medicine - Physician-Scientist Training Program	Northwestern University Feinberg School of Medicine		04-Oct-2024	75,000 USD
--------	---	---	--	-------------	------------

Contact Name	Benjamin Singer, MD, Program Director-Physician Scientist Training Program				
Contact Telephone					
Contact Email	benjamin-singer@northwestern.edu				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	04-Oct-2024				
Synopsis	The Department of Medicine’s Physician-Scientist Training Program at the Feinberg School of Medicine focuses on the transition period from graduation with an MD or combined MD/PhD degree to appointment to a full-time academic position as a physician-scientist. Beyond training in the Categorical Internal Medicine Training Program at the McGaw Medical Center of Northwestern University and the Northwestern University Feinberg School of Medicine, trainees				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>accepted into the program will be guaranteed a position in the fellowship program of any of the 12 clinical divisions in the Department of Medicine and a minimum of \$75,000 of support during clinical and research training.</p> <p>Applicant Types</p> <p>Funding Limit 75,000.00 minimum</p> <p>Limited Submission No</p>				
081429	OREF/RJOS Diversity, Equity, Inclusion and Disparities in Orthopaedic Health Care Research Grant	Orthopaedic Research & Education Foundation (OREF)		12-Aug-2024 [LOI/Pre-App]	150,000 USD
	<p>Contact Name</p> <p>Contact Telephone 847-698-9980</p> <p>Contact Email grants@oref.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Aug-2024 [LOI/Pre-App], 14-Oct-2024</p> <p>Synopsis The Orthopaedic Research and Education Foundation in collaboration with J. Robert Gladden Society (JRGOS)the OREF encourage investigators to conduct research in the area of diversity, equity, inclusion, and disparities in Orthopaedic Surgery health care. Maximum funding will be a total of \$150,000 over a two -year grant period is available.</p> <p>Applicant Types</p> <p>Funding Limit 150,000.00 maximum</p> <p>Limited Submission Yes</p>				
038084	Seed Grants	Pablove Foundation		08-Oct-2024	Not Specified
	Contact Name				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 323-657-5557</p> <p>Contact Email grants@pablove.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Oct-2024</p> <p>Synopsis The Pablove Foundation invites pediatric cancer researchers to apply for our Powered by Pablove Seed Grant Program, which provides funds to conduct innovative, cutting edge investigations, with preferences going toward less common childhood cancers. In addition, projects that focus on Opsoclonus-Myoclonus Syndrome (OMS) will be considered. The seed grants serve to advance the work of researchers to qualify for larger grants, federal funding and clinical trial.</p> <p>Applicant Types </p> <p>Funding Limit 50,000.00 per year</p> <p>Limited Submission No</p>				
102065	<p>Medical Education Grant: Local Level Educational Grants Program to Increase Awareness & Understanding of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)</p>	Pfizer Pharmaceuticals		15-Oct-2024	20,000 USD
	<p>Contact Name Amanda Stein, Grant Officer</p> <p>Contact Telephone </p> <p>Contact Email amanda.j.stein@pfizer.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Oct-2024</p> <p>Synopsis Pfizer is issuing this Request for Proposals (RFP) to encourage organizations to submit grant applications for local level educational activities focused on healthcare professionals involved in the treatment of heart failure patients at risk</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>for TTR Amyloidosis. Potential applicants are encouraged to identify and address the educational needs of healthcare professionals to increase awareness of heart failure patients at risk for TTR Amyloidosis and enable appropriate and early patient identification through an evidence-based approach. Individual projects requesting up to \$10,000 will be considered for small local/community programs. Individual projects requesting up to \$20,000 will be considered for large local/community programs.</p> <p>20,000.00 maximum</p> <p>No</p>			
126231	American Headache Society & Pfizer Quality Improvement Competitive Grant Program	Pfizer Pharmaceuticals		05-Aug-2024 [LOI/Pre-App]	375,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p>	<p>Angelo Carter, Grant Officer</p> <p>Angelo.Carter@pfizer.com</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>30-Oct-2024</p> <p>Pfizer and the American Headache Society are issuing this Request for Proposals (RFP) for projects that will address quality gaps in headache medicine, with a goal of producing information or tools that can be widely used in the field and lead to measurable improvements in healthcare services for individuals with headache. Projects should also contribute to the core goal of the American Headache Society (AHS) – improving the lives of people impacted by migraine and other headache disorders. Individual projects requesting up to \$375,000 total over two (2) years will be considered.</p> <p>375,000.00 maximum</p>			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
016536	Garite Mini-Sabbatical Grants	Pregnancy Foundation		01-Oct-2024	Not Specified
	Contact Name				
	Contact Telephone	202-517-7068			
	Contact Email	foundation@smfm.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Oct-2024 , 01-Apr-2025			
	Synopsis	The Garite Mini-Sabbatical Grant allows recipients to gain or expand skills in clinical practice or research under the guidance of experts in the field of maternal-fetal medicine. Up to \$20,000 in grant funds are available annually.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
076667	Research Projects - Basic and Clinical Research	Propionic Acidemia Foundation		01-Oct-2024	100,000 USD
	Contact Name				
	Contact Telephone	1-877-720-2192			
	Contact Email	research@pafoundation.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Oct-2024			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis The Propionic Acidemia Foundation's Research Projects program funds research in the areas of basic and clinical science, supporting projects designed to understand the molecular basis of the PA pathology and explore possible therapeutic avenues for the treatment of this condition.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 per year</p> <p>Limited Submission No</p>				
065095	Fellows Program	Propionic Acidemia Foundation		01-Oct-2024	50,000 USD
	<p>Contact Name</p> <p>Contact Telephone 877-720-2192</p> <p>Contact Email research@pafoundation.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024</p> <p>Synopsis The Propionic Acidemia Foundation's Post-Doctoral Fellows Program provides financial support up to \$50,000 per one year for a metabolic/genetic fellow working on a research project in propionic acidemia (PA). This salary is intended to supplement any existing institutional support.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 maximum</p> <p>Limited Submission No</p>				
125268	Targeted Call for Applications: Improving Understanding of Disease Mechanisms of PTEN Hamartoma Tumour Syndrome (PHTS)	PTEN Research Foundation		04-Oct-2024	281,600 USD
	Contact Name				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email research@ptenresearch.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Oct-2024</p> <p>Synopsis Grants awarded through this call are intended primarily for non-clinical research projects that aim to directly advance understanding of the disease mechanisms underlying PTEN hamartoma tumour syndrome (PHTS) and facilitate the development of new therapeutic options for PHTS. Specifically encouraged are proposals that not only have translational potential but also incorporate the use of recently generated PHTS patient-derived induced pluripotent stem cells (iPSCs) that will be available through a US-based biorepository later in 2024.</p> <p>Applicant Types</p> <p>Funding Limit 220,000.00 maximum</p> <p>Limited Submission No</p>				

001567	Radcliffe Fellowship Program	Radcliffe Institute for Advanced Study		12-Sep-2024	83,000 USD
--------	--	--	--	-------------	------------

Contact Name					
Contact Telephone	617-495-8212				
Contact Email	fellowships@radcliffe.harvard.edu				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	12-Sep-2024 , 03-Oct-2024				
Synopsis	Radcliffe fellows are exceptional scientists, writers, scholars, public intellectuals, and artists whose work is making a difference in their professional fields and in the larger world. The Radcliffe Fellowship Program awards 50 fellowships				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>each academic year. Applications are accepted in the disciplines of humanities, social sciences, creative arts, science, engineering, and mathematics.</p> <p>Applicant Types</p> <p>Funding Limit 83,000.00 see detail</p> <p>Limited Submission No</p>				
003582	Career Development Bridge Funding Award: K Bridge	Rheumatology Research Foundation		01-Oct-2024	75,000 USD
	<p>Contact Name</p> <p>Contact Telephone 404-365-1373</p> <p>Contact Email Foundation@rheumatology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024</p> <p>Synopsis The mission of the Rheumatology Research Foundation is to advance research and training to improve the health of people with rheumatic diseases. The purpose of this award is to provide bridge funding for promising investigators as they are revising outstanding individual career development award applications (i.e., applications for NIH K series awards, VA CDA-2 awards, or any equivalent career development awards). Through this bridge funding award, the Foundation will support young faculty members so that they have the highest likelihood of achieving success in obtaining longer term career development awards.</p> <p>Applicant Types</p> <p>Funding Limit 75,000.00 maximum</p> <p>Limited Submission No</p>				
014227	Sir Peter Tizard Research Bursary	Royal College of Paediatrics and Child Health		21-Oct-2024	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 020 7092 6174</p> <p>Contact Email bpsu@rcpch.ac.uk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Oct-2024</p> <p>Synopsis The Sir Peter Tizard Research bursary covers the full economic cost of including a study on the Orange Reporting Card and a training stipend for professional development.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				

124475	Individual Investigator Research Grant Awards	RYR-1 Foundation	19-Oct-2024		120,000 USD
--------	---	------------------	-------------	--	----------------

<p>Contact Name Patricia Raffaele</p> <p>Contact Telephone</p> <p>Contact Email patricia@ryr1.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Oct-2024</p> <p>Synopsis The RYR-1 Foundation actively funds research in RYR-1-related diseases (RYR-1-RD). The RYR-1 Foundation is currently funding almost \$600,000 of RYR-1-RD research, and since their inception, the sponsor has funded over \$1.5 million in research. Individual Investigator Research Grant Awards are designed to concentrate research in areas that will have the greatest potential to move towards treatments and cures for RYR-1-RD. As appropriate, applicants are</p>				
--	--	--	--	--

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types encouraged to use one or more of RYR-1-RD murine models currently available from commercial, corporate, academic, and other sources, including recently developed animal models. Recently developed murine models of RYR-1-RD demonstrating moderate-severe myopathy phenotypes, including mice with mutations on exons 34 and 96.</p> <p>Funding Limit 120,000.00 maximum</p> <p>Limited Submission No</p>				
002055	Grants-in-Aid of Research	Sigma Xi		01-Oct-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 919-549-4691</p> <p>Contact Email gjar@sigmaxi.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Oct-2024</p> <p>Synopsis Sigma Xi, The Scientific Research Honor Society is the international honor society of science and engineering. The Sigma Xi Grants in Aid of Research (GIAR) program has provided undergraduate and graduate students with valuable educational experiences. By encouraging close working relationships between students and mentors, the program promotes scientific excellence and achievement through hands-on learning. Undergraduate and graduate students and students in the health professions currently enrolled in degree seeking programs may apply.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
104938	Dermatology Research Award	Skin of Color Society (SOCS)		15-Oct-2024	20,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 630-578-3991</p> <p>Contact Email info@skinofcolorsociety.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Oct-2024</p> <p>Synopsis The SOCS Dermatology Research Award will provide annual research grants (each up to \$20,000) to promote dermatology research within the field of skin of color. Two of the awards will be given to those applications that focus on inflammatory dermatologic diseases in skin of color.</p> <p>Applicant Types</p> <p>Funding Limit 20,000.00 maximum</p> <p>Limited Submission No</p>				
104942	Career Development Award	Skin of Color Society (SOCS)		15-Oct-2024	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone 630-578-3991</p> <p>Contact Email info@skinofcolorsociety.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Oct-2024</p> <p>Synopsis The Skin of Color Society (SOCS) offers a Career Development Award of up to \$100,000 which can be used over a two-year period. This award should have a research focus on inflammatory dermatologic diseases in skin of color in areas where further clinical, translational, and basic research is needed.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 100,000.00 maximum Limited Submission No				
066849	Mentored Clinical Scientist Research Career Development Award (K08)	Society for Vascular Surgery		12-Oct-2024	Not Specified
	Contact Name Contact Telephone 800-258-7188 Contact Email svsfoundation@vascularsociety.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 12-Oct-2024 , 12-Nov-2024 Synopsis The Mentored Clinical Scientist Research Career Development Award (K08) will prepare clinically trained individuals for careers that have a significant impact on the health-related research needs of the Nation. This program provides support and protected time for an intensive, supervised research career development experience in the fields of biomedical, behavioral, or clinical research, including translational research. Applicant Types Funding Limit 50,000.00 per year Limited Submission No				
120119	Drotar-Crawford Postdoctoral Fellowship Research Grant in Pediatric Psychology	Society of Pediatric Psychology		15-Oct-2024	10,000 USD
	Contact Name Megan Cohen Contact Telephone 202-336-5500 Contact Email Megan.Cohen@nemours.org				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Oct-2024</p> <p>Synopsis This \$10,000 grant is given to a postdoctoral fellow to support research in pediatric psychology while they are enrolled in a postdoctoral fellowship. The research project must be conducted under the supervision of a faculty advisor in an area of research specific to pediatric psychology. The budget may span up to two years (e.g. \$10,000 in total for up to two years). Up to \$1000 of the award may be allocated for travel related to research training, collaborations, or for presentation of research findings. Funds are not provided for indirect costs, stipends of the fellow or costs associated with manuscript preparation.</p> <p>Applicant Types</p> <p>Funding Limit 10,000.00 maximum</p> <p>Limited Submission No</p>				
120121	Mary Jo Kupst Trainee Grant for Research in Resilience	Society of Pediatric Psychology		15-Oct-2024	1,000 USD
	<p>Contact Name Megan Cohen</p> <p>Contact Telephone 202-336-5500</p> <p>Contact Email Megan.Cohen@nemours.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Oct-2024</p> <p>Synopsis This award is designed to help facilitate trainee research that will provide a novel contribution and advance the field of pediatric psychology specifically in the area of resilience. A yearly award of \$1,000 will be made to a trainee who proposes a research project examining resilience and/or family functioning with a pediatric psychology population. The award is available to any graduate student, intern or postdoctoral fellow who is a member of SPP and involved in a program involving substantial training in pediatric psychology. The research project for which funding is requested</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>must be conducted under the supervision of a faculty advisor and may include work leading to a master’s or doctoral degree or may be an independent study.</p> <p>1,000.00 maximum</p> <p>No</p>			
016605	Marion and Donald Routh Student Research Grant	Society of Pediatric Psychology		15-Oct-2024	5,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>Megan.Cohen@nemours.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>15-Oct-2024</p> <p>This grant is designed to enable a student member of the Society of Pediatric Psychology to pursue research scholarship. Funding is available up to \$5,000. Up to \$500 of the award amount can be budgeted for convention and meeting travel. Funds may not be used for indirect costs of the University, stipends of principal investigators or costs associated with manuscript preparation. Up to \$1,000 will also be provided to the runner-up to support their proposed research.</p> <p>5,000.00 maximum</p> <p>No</p>			
068302	Arnold J. Lehman Award	Society of Toxicology		09-Oct-2024	Not Specified
	Contact Name				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email sothq@toxicology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Oct-2024</p> <p>Synopsis The Arnold J. Lehman Award is presented to recognize an individual who has made a major contribution to risk assessment and/or the regulation of chemical agents, including pharmaceuticals. The contribution may have resulted from the application of sound scientific principles to regulation and/or from research activities that have significantly influenced the regulatory process. This award consists of a plaque that is presented at the SOT Annual Meeting Awards Ceremony and a cash stipend.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
016133	Founders Award (for Outstanding Leadership in Toxicology)	Society of Toxicology		09-Oct-2024	Not Specified

Contact Name					
Contact Telephone	703-438-3115				
Contact Email	sothq@toxicology.org				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	09-Oct-2024				
Synopsis	The SOT Founders Award is presented to a Full, Emeritus or Retired Full member of the Society of Toxicology who has demonstrated outstanding leadership in fostering the role of toxicological sciences in safety decision-making through				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types the development and/or application of state-of-the-art approaches that elucidate, with a high degree of confidence, the distinctions for humans between safe and unsafe levels of exposures to chemical and physical agents.</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
016141	Perry J. Gehring Student Diversity Travel Award	Society of Toxicology		15-Oct-2024	Not Specified
	<p>Contact Name </p> <p>Contact Telephone 703-438-3115</p> <p>Contact Email jenna@toxicology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Oct-2024</p> <p>Synopsis The Perry J. Gehring Diversity Student Award recognizes an undergraduate or graduate student who was previously selected to participate in the SOT Undergraduate Diversity Program, who is from a racial/ethnic group underrepresented in toxicology (for example, African American, Hispanic, Native American or Pacific Islander), and who is presenting a paper at the upcoming Society of Toxicology Annual Meeting. The recipient will receive a plaque and travel stipend to assist in defraying expenses for travel, lodging, and meals at the meeting. The award recipient is selected by the Committee on Diversity Initiatives and will be recognized during the SOT Undergraduate Diversity Program.</p> <p>Applicant Types </p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
067066	Translational/Bridging Travel Award	Society of Toxicology		09-Oct-2024	2,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 703-438-3115</p> <p>Contact Email sothq@toxicology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Oct-2024</p> <p>Synopsis The SOT Awards Committee offers this award, intended to assist with travel to the SOT Annual Meeting, to either a mid- or senior-level scientist or clinician, with at least ten years postdoctoral research or clinical practice experience and who has an active research program, or currently is active either in the practice of clinical toxicology, medical toxicology, disease prevention, or in the application of translational toxicology.</p> <p>Applicant Types</p> <p>Funding Limit 2,000.00 see detail</p> <p>Limited Submission No</p>				
001193	E.W. Al Thrasher Awards	Thrasher Research Fund		22-Oct-2024	Not Specified

Contact Name

Contact Telephone 801-240-4753

Contact Email MartinezAF@ThrasherResearch.org

Sponsor Website [Link to sponsor website](#)

Program URL [Link to program URL](#)

Deadline Dates (ALL) 22-Oct-2024

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis The purpose of the E.W. "Al" Thrasher Awards is to improve children's health through medical research, with an emphasis on projects that have the potential to translate into clinically meaningful results within a few years. The Fund awards grants two times per year, with no fixed number of awards given in each funding cycle or in each year.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
091400	Early Career Awards	Thrasher Research Fund		05-Sep-2024 [LOI/Pre-App]	25,000 USD
	<p>Contact Name Brittni Smith, PhD</p> <p>Contact Telephone 801-240-4720</p> <p>Contact Email SmithBA@ThrasherResearch.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Sep-2024 [LOI/Pre-App], 29-Oct-2024</p> <p>Synopsis The Fund recognizes that young investigators may find it difficult to remain in pediatric research because of a lack of funding. Therefore, the purpose of this program is to encourage the development of medical research in child health by awarding small grants to new researchers, helping them gain a foothold in this important area. The goal is to fund applicants who will go on to be independent investigators.</p> <p>Applicant Types</p> <p>Funding Limit 25,000.00 see detail</p> <p>Limited Submission No</p>				
019127	Hyland R. Johns Grant Program	TREE Fund		15-Sep-2024 [LOI/Pre-App]	25,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 630-369-8300</p> <p>Contact Email treefund@treefund.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Sep-2024 [LOI/Pre-App], 01-Oct-2024</p> <p>Synopsis The Hyland R. Johns Grant Program funds longer-term research and technology transfer projects that have the potential of benefiting the everyday work of arborists. Projects are expected to be completed within three to five years, with a maximum award value of \$25,000. No project may receive more than one award from this program.</p> <p>Applicant Types</p> <p>Funding Limit 25,000.00 maximum</p> <p>Limited Submission No</p>				

020491	John Z. Duling Grant Program	TREE Fund		15-Sep-2024 [LOI/Pre-App]	25,000 USD
--------	--	-----------	--	---------------------------	------------

	<p>Contact Name</p> <p>Contact Telephone 630-369-8300</p> <p>Contact Email treefund@treefund.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Sep-2024 [LOI/Pre-App], 01-Oct-2024</p> <p>Synopsis The John Z. Duling Grant Program is awarded to provide start-up or seed funding to support innovative research and technology transfer projects that have the potential of benefiting the everyday work of arborists. Projects are expected to be completed within one to three years with a maximum grant award of \$25,000.</p>				
--	--	--	--	--	--

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Applicant Types	
Funding Limit	25,000.00 maximum
Limited Submission	No

075116	Dickson Prize in Medicine	University of Pittsburgh School of Medicine		25-Oct-2024	50,000 USD
--------	---	---	--	-------------	------------

Contact Name	
Contact Telephone	412-383-7382
Contact Email	healthsciences@pitt.edu
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	25-Oct-2024
Synopsis	The Dickson Prize in Medicine is awarded annually to a leading American investigator who is engaged in innovative, paradigm-shifting biomedical research.
Applicant Types	
Funding Limit	50,000.00 see detail
Limited Submission	No

059984	V ESS/Medtronic Vascular Resident Research Award	Vascular and Endovascular Surgery Society		04-Oct-2024	12,500 USD
--------	--	---	--	-------------	------------

Contact Name	
Contact Telephone	978-927-7800
Contact Email	vess@administrare.com
Sponsor Website	Link to sponsor website

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Oct-2024</p> <p>Synopsis The VESS/Medtronic Resident Research Award is designed to help residents in training initiate projects during protected academic development time that will lead to future academic potential toward extramural funding for basic or clinical research. One \$12,500 grant for basic/translational science, educational, clinical or health outcomes research will be awarded during the VESS annual winter meeting.</p> <p>Applicant Types</p> <p>Funding Limit 12,500.00 see detail</p> <p>Limited Submission No</p>				
003009	Vatican Film Library Mellon Fellowship Program	Vatican Microfilm Library		01-Oct-2024	4,500 USD

Contact Name	
Contact Telephone	314-977-3096
Contact Email	vfl@slu.edu
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	01-Oct-2024
Synopsis	Short-term research fellowships are available for periods between two and eight weeks in length to support research utilizing the collections of the Vatican Film Library. Applications must demonstrate need to consult the primary source materials of the library. All topics will be considered that are served by the collections, such as history, philosophy, theology, literature, art, science, paleography, codicology, illumination, text editing, library history, etc.
Applicant Types	
Funding Limit	2,250.00 per month
Limited Submission	No

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
059105	E-Team Program	VentureWell		02-Oct-2024	25,000 USD		
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; vertical-align: top;"> Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission </td> <td style="border-left: 1px solid black; padding-left: 10px;"> 413-587-2172 swharmby@venturewell.org Link to sponsor website Link to program URL 02-Oct-2024 The E-Team Program, part of the VentureWell Accelerator, supports student ventures as you embark down the path you're likely to take as an innovator and entrepreneur. We help you advance your invention through a powerful mix of up to \$25,000 in grant funding, entrepreneurship training, mentorship by dedicated staff, national recognition, and networking with peers and industry experts. 25,000.00 see detail No </td> </tr> </table>					Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission	413-587-2172 swharmby@venturewell.org Link to sponsor website Link to program URL 02-Oct-2024 The E-Team Program, part of the VentureWell Accelerator, supports student ventures as you embark down the path you're likely to take as an innovator and entrepreneur. We help you advance your invention through a powerful mix of up to \$25,000 in grant funding, entrepreneurship training, mentorship by dedicated staff, national recognition, and networking with peers and industry experts. 25,000.00 see detail No
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission	413-587-2172 swharmby@venturewell.org Link to sponsor website Link to program URL 02-Oct-2024 The E-Team Program, part of the VentureWell Accelerator, supports student ventures as you embark down the path you're likely to take as an innovator and entrepreneur. We help you advance your invention through a powerful mix of up to \$25,000 in grant funding, entrepreneurship training, mentorship by dedicated staff, national recognition, and networking with peers and industry experts. 25,000.00 see detail No						
009730	Grants-in-Aid	Whitehall Foundation, Inc.		02-Sep-2024	30,000 USD		
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; vertical-align: top;"> Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis </td> <td style="border-left: 1px solid black; padding-left: 10px;"> 561-655-4474 email@whitehall.org Link to sponsor website Link to program URL 02-Sep-2024 , 01-Oct-2024 [LOI/Pre-App] The Whitehall Foundation, through its program of grants and grants-in-aid, assists scholarly research in the life sciences. It is the Foundation's policy to assist those dynamic areas of basic biological research that are not heavily </td> </tr> </table>					Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	 561-655-4474 email@whitehall.org Link to sponsor website Link to program URL 02-Sep-2024 , 01-Oct-2024 [LOI/Pre-App] The Whitehall Foundation, through its program of grants and grants-in-aid, assists scholarly research in the life sciences. It is the Foundation's policy to assist those dynamic areas of basic biological research that are not heavily
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	 561-655-4474 email@whitehall.org Link to sponsor website Link to program URL 02-Sep-2024 , 01-Oct-2024 [LOI/Pre-App] The Whitehall Foundation, through its program of grants and grants-in-aid, assists scholarly research in the life sciences. It is the Foundation's policy to assist those dynamic areas of basic biological research that are not heavily						

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>supported by Federal Agencies or other foundations with specialized missions. The Foundation is currently interested in basic research in neurobiology. The Grants-in-Aid program is designed for researchers at the assistant professor level who experience difficulty in competing for research funds because they have not yet become firmly established. Grants-in-Aid can also be made to senior scientists. All applications will be judged on the scientific merit and innovative aspects of the proposal, as well as on past performance and evidence of the applicant’s continued productivity. Grants-in-Aid are awarded for a one-year period and do not exceed \$30,000.</p> <p>30,000.00 maximum</p> <p>No</p>			
001018	Research Grants	Whitehall Foundation, Inc.		01-Sep-2024	300,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>561-655-4474</p> <p>email@whitehall.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>01-Sep-2024 , 01-Oct-2024 [LOI/Pre-App]</p> <p>The Whitehall Foundation is focused exclusively on assisting basic research in vertebrate (excluding clinical) and invertebrate neurobiology. They offer research grants to established scientists of all ages working at accredited institutions in the United States. Research grants of up to three years are available. A renewal grant with a maximum of two years is possible, but it will be awarded on a competitive basis.</p> <p>100,000.00 per year</p> <p>No</p>			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------